Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6119773,distribution half-life,"Following the i.v. dose, ranitidine plasma concentrations fell biexponentially with a distribution half-life of 6.1 +/- 0.9 min and a terminal elimination half-life of 1.9 +/- 0.1 h.",Pharmacokinetic and gastric secretory studies of ranitidine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),min,6.1,260,DB00501,Cimetidine
,6119773,terminal elimination half-life,"Following the i.v. dose, ranitidine plasma concentrations fell biexponentially with a distribution half-life of 6.1 +/- 0.9 min and a terminal elimination half-life of 1.9 +/- 0.1 h.",Pharmacokinetic and gastric secretory studies of ranitidine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),h,1.9,261,DB00501,Cimetidine
,6119773,volume of distribution,The volume of distribution was 115 +/- 7 1 and the systemic plasma clearance 709 +/- 62 ml/min.,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),1,115,262,DB00501,Cimetidine
,6119773,systemic plasma clearance,The volume of distribution was 115 +/- 7 1 and the systemic plasma clearance 709 +/- 62 ml/min.,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),[ml] / [min],709,263,DB00501,Cimetidine
,6119773,systemic availability,After 20 mg oral doses the systemic availability was high (88 +/- 10%).,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),%,88,264,DB00501,Cimetidine
,6119773,Renal excretion,Renal excretion of unchanged ranitidine was between 50 and 70% and a further 1-3% was excreted as desmethylranitidine.,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),%,50 and 70,265,DB00501,Cimetidine
,6119773,Renal excretion,Renal excretion of unchanged ranitidine was between 50 and 70% and a further 1-3% was excreted as desmethylranitidine.,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),%,1-3,266,DB00501,Cimetidine
,3932043,serum protein binding,The serum protein binding of the free acid metabolite of misoprostol was similar in young (81-88%) and elderly (81-89%) people.,Metabolism and pharmacokinetic studies of misoprostol. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932043/),%,81-88,993,DB00501,Cimetidine
,3932043,serum protein binding,The serum protein binding of the free acid metabolite of misoprostol was similar in young (81-88%) and elderly (81-89%) people.,Metabolism and pharmacokinetic studies of misoprostol. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932043/),%,81-89,994,DB00501,Cimetidine
,3792438,peak plasma oxaprozin concentration,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[μg] / [ml],86,1264,DB00501,Cimetidine
,3792438,volume of distribution,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[l] / [kg],0.23,1265,DB00501,Cimetidine
,3792438,time of peak concentration,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),h,3.7,1266,DB00501,Cimetidine
,3792438,elimination half-life,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),h,54,1267,DB00501,Cimetidine
,3792438,oral clearance,"Oxaprozin oral clearance was significantly lower (by 20%) during both the cimetidine and ranitidine trials versus control (0.047 vs 0.047 vs 0.059 ml/min/kg), but clearance during acetaminophen was not significantly different from control.","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[ml] / [kg·min],0.047,1268,DB00501,Cimetidine
,3792438,oral clearance,"Oxaprozin oral clearance was significantly lower (by 20%) during both the cimetidine and ranitidine trials versus control (0.047 vs 0.047 vs 0.059 ml/min/kg), but clearance during acetaminophen was not significantly different from control.","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[ml] / [kg·min],0.059,1269,DB00501,Cimetidine
,2866097,spectral dissociation constant (Ks),"Cimetidine induced binding changes with a spectral dissociation constant (Ks) of 0.87 mM, whereas famotidine produced no measurable spectral alteration in concentrations up to 4 mM.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),mM,0.87,1804,DB00501,Cimetidine
,2866097,elimination half-life (t1/2,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,45.6,1805,DB00501,Cimetidine
,2866097,total plasma clearance (CL,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [kg·min],0.28,1806,DB00501,Cimetidine
,2866097,t1/2,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,39.0,1807,DB00501,Cimetidine
,2866097,CL,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [kg·min],0.31,1808,DB00501,Cimetidine
,2866097,t1/2,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,2.9,1809,DB00501,Cimetidine
,2866097,t1/2,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,3.0,1810,DB00501,Cimetidine
,2866097,renal clearance (CLR),"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],436,1811,DB00501,Cimetidine
,2866097,renal clearance (CLR),"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],443,1812,DB00501,Cimetidine
,2866097,CLR,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],195,1813,DB00501,Cimetidine
,2866097,CLR,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],212,1814,DB00501,Cimetidine
,1958451,AUC,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[μg] / [l],105,2145,DB00501,Cimetidine
,1958451,AUC,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[h·μg] / [l],111,2146,DB00501,Cimetidine
,1958451,AUC,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[h·μg] / [l],211,2147,DB00501,Cimetidine
,1958451,Cmax,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[μg] / [l],33,2148,DB00501,Cimetidine
,1958451,Cmax,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[μg] / [l],39,2149,DB00501,Cimetidine
,1958451,Cmax,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[μg] / [l],76,2150,DB00501,Cimetidine
,7185539,t 1/2 beta,"Mean theophylline t 1/2 beta increased significantly during cimetidine treatment from 5.9 +/- 1.0 to 7.3 +/- 1.5 hr, and CLtot decreased significantly from 0.065 +/- 0.010 to 0.049 +/- 0.012 liter/hr/kg.",Impact of cimetidine on the pharmacokinetics of theophylline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185539/),h,5.9,4081,DB00501,Cimetidine
,7185539,t 1/2 beta,"Mean theophylline t 1/2 beta increased significantly during cimetidine treatment from 5.9 +/- 1.0 to 7.3 +/- 1.5 hr, and CLtot decreased significantly from 0.065 +/- 0.010 to 0.049 +/- 0.012 liter/hr/kg.",Impact of cimetidine on the pharmacokinetics of theophylline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185539/),h,7.3,4082,DB00501,Cimetidine
,7185539,CLtot,"Mean theophylline t 1/2 beta increased significantly during cimetidine treatment from 5.9 +/- 1.0 to 7.3 +/- 1.5 hr, and CLtot decreased significantly from 0.065 +/- 0.010 to 0.049 +/- 0.012 liter/hr/kg.",Impact of cimetidine on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185539/),[l] / [h·kg],0.065,4083,DB00501,Cimetidine
,7185539,CLtot,"Mean theophylline t 1/2 beta increased significantly during cimetidine treatment from 5.9 +/- 1.0 to 7.3 +/- 1.5 hr, and CLtot decreased significantly from 0.065 +/- 0.010 to 0.049 +/- 0.012 liter/hr/kg.",Impact of cimetidine on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185539/),[l] / [h·kg],0.049,4084,DB00501,Cimetidine
,7904983,elimination half-life,"Surprisingly, a significantly shorter elimination half-life was found after 20 days on cimetidine (from 5.1 +/- 0.4 h to 4.4 +/- 0.5 h).",The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7904983/),h,5.1,4806,DB00501,Cimetidine
,7904983,elimination half-life,"Surprisingly, a significantly shorter elimination half-life was found after 20 days on cimetidine (from 5.1 +/- 0.4 h to 4.4 +/- 0.5 h).",The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7904983/),h,4.4,4807,DB00501,Cimetidine
,2355107,Peak serum cimetidine concentration,Peak serum cimetidine concentration was 2.0 +/- 0.5 mg/L for the intravenous dose and 1.5 +/- 0.3 mg/L for the oral dose (P = .001).,Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2355107/),[mg] / [l],2.0,4889,DB00501,Cimetidine
,2355107,Peak serum cimetidine concentration,Peak serum cimetidine concentration was 2.0 +/- 0.5 mg/L for the intravenous dose and 1.5 +/- 0.3 mg/L for the oral dose (P = .001).,Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2355107/),[mg] / [l],1.5,4890,DB00501,Cimetidine
,2355107,Area under the curve (AUC),Area under the curve (AUC) of cimetidine concentration was 3.81 +/- 1.1 mg/hr/L for the intravenous dose and 4.19 +/- 1.22 mg/hr/L for the oral dose (P greater than .30).,Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2355107/),[mg] / [h·l],3.81,4891,DB00501,Cimetidine
,2355107,Area under the curve (AUC),Area under the curve (AUC) of cimetidine concentration was 3.81 +/- 1.1 mg/hr/L for the intravenous dose and 4.19 +/- 1.22 mg/hr/L for the oral dose (P greater than .30).,Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2355107/),[mg] / [h·l],4.19,4892,DB00501,Cimetidine
,2355107,Bioavailability (AUCpo/AUCiv),"Bioavailability (AUCpo/AUCiv) was 1.13 +/- 0.25, demonstrating complete oral absorption.",Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2355107/),,1.13,4893,DB00501,Cimetidine
,2355107,time,"The time during a 6-hour dosing interval that the gastric pH remained above 3.0 was 3.3 +/- 2.1 hours for the intravenous dose and 2.5 +/- 2.3 hours for the oral dose, P = .171).",Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2355107/),h,3.3,4894,DB00501,Cimetidine
,2355107,time,"The time during a 6-hour dosing interval that the gastric pH remained above 3.0 was 3.3 +/- 2.1 hours for the intravenous dose and 2.5 +/- 2.3 hours for the oral dose, P = .171).",Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2355107/),h,2.5,4895,DB00501,Cimetidine
,2355107,time that the serum cimetidine,The time that the serum cimetidine concentration remained above 0.5 mg/L was 2.0 +/- 0.9 hours for the intravenous dose and 2.7 +/- 1.0 hours for the oral dose (P = .055).,Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2355107/),h,2.0,4896,DB00501,Cimetidine
,2355107,time that the serum cimetidine,The time that the serum cimetidine concentration remained above 0.5 mg/L was 2.0 +/- 0.9 hours for the intravenous dose and 2.7 +/- 1.0 hours for the oral dose (P = .055).,Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2355107/),h,2.7,4897,DB00501,Cimetidine
,1976775,AUC,"The AUC of DDS in the presence of cimetidine (1018.8 +/- 267.8 micrograms min mL-1) was almost three-fold higher than control (345.0 +/- 68.1 micrograms min mL-1, P less than 0.01).",Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976775/),[min·μg] / [ml],1018.8,5676,DB00501,Cimetidine
,1976775,AUC,"The AUC of DDS in the presence of cimetidine (1018.8 +/- 267.8 micrograms min mL-1) was almost three-fold higher than control (345.0 +/- 68.1 micrograms min mL-1, P less than 0.01).",Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976775/),[min·μg] / [ml],345.0,5677,DB00501,Cimetidine
,1976775,half-life,"The half-life of DDS was also prolonged by cimetidine compared with control (117.0 +/- 48.2 min vs 51.2 +/- 22.9, P less than 0.05).",Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976775/),min,117.0,5678,DB00501,Cimetidine
,1976775,half-life,"The half-life of DDS was also prolonged by cimetidine compared with control (117.0 +/- 48.2 min vs 51.2 +/- 22.9, P less than 0.05).",Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976775/),,51.2,5679,DB00501,Cimetidine
,1976775,clearance,The clearance of DDS (3.0 +/- 0.55 mL min-1) was greatly reduced in the presence of cimetidine (1.03 +/- 0.26 mL min-1 P less than 0.01).,Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976775/),[ml] / [min],3.0,5680,DB00501,Cimetidine
,1976775,clearance,The clearance of DDS (3.0 +/- 0.55 mL min-1) was greatly reduced in the presence of cimetidine (1.03 +/- 0.26 mL min-1 P less than 0.01).,Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976775/),[ml] / [min],1.03,5681,DB00501,Cimetidine
,1976775,AUC0-3h,"The AUC0-3h for DDS-NOH (28.3 +/- 21.2 micrograms min mL-1) was significantly reduced by cimetidine (8.1 +/- 3.40 micrograms min mL-1, P less than 0.01).",Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976775/),[min·μg] / [ml],28.3,5682,DB00501,Cimetidine
,1976775,AUC0-3h,"The AUC0-3h for DDS-NOH (28.3 +/- 21.2 micrograms min mL-1) was significantly reduced by cimetidine (8.1 +/- 3.40 micrograms min mL-1, P less than 0.01).",Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976775/),[min·μg] / [ml],8.1,5683,DB00501,Cimetidine
,1976775,AUC0-3h,"In contrast, there was a marked increase in the AUC0-3h for MADDS (32.7 +/- 25.8 micrograms min mL-1) in the presence of cimetidine (166.0 +/- 26.5 micrograms min mL-1 P less than 0.01).",Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976775/),[min·μg] / [ml],32.7,5684,DB00501,Cimetidine
,1976775,AUC0-3h,"In contrast, there was a marked increase in the AUC0-3h for MADDS (32.7 +/- 25.8 micrograms min mL-1) in the presence of cimetidine (166.0 +/- 26.5 micrograms min mL-1 P less than 0.01).",Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976775/),[min·μg] / [ml],166.0,5685,DB00501,Cimetidine
,2903807,t 1/2,"All 'old' and 'new' H2-receptor blockers are eliminated relatively rapidly (t 1/2 ranges from 1.5 to 4 hours), mainly by the renal route (glomerular filtration and tubular secretion).",Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903807/),h,1.5 to 4,6283,DB00501,Cimetidine
,8512758,elimination half-life,2. The mean elimination half-life of naproxen was 24.7 +/- 6.4 h (range 7 to 36 h).,"The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),h,24.7,6398,DB00501,Cimetidine
,8512758,plasma binding,"5. The extents of plasma binding of the unconjugated compounds were 98% (naproxen) and 100% (O-desmethylnaproxen), while naproxen acyl glucuronide binding was 92%; that of its isomer isoglucuronide 66%.","The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),%,98,6399,DB00501,Cimetidine
,8512758,plasma binding,"5. The extents of plasma binding of the unconjugated compounds were 98% (naproxen) and 100% (O-desmethylnaproxen), while naproxen acyl glucuronide binding was 92%; that of its isomer isoglucuronide 66%.","The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),%,100,6400,DB00501,Cimetidine
,8512758,plasma binding,"5. The extents of plasma binding of the unconjugated compounds were 98% (naproxen) and 100% (O-desmethylnaproxen), while naproxen acyl glucuronide binding was 92%; that of its isomer isoglucuronide 66%.","The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),%,92,6401,DB00501,Cimetidine
,8512758,plasma binding,"5. The extents of plasma binding of the unconjugated compounds were 98% (naproxen) and 100% (O-desmethylnaproxen), while naproxen acyl glucuronide binding was 92%; that of its isomer isoglucuronide 66%.","The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),%,66,6402,DB00501,Cimetidine
,8512758,binding,"5. The extents of plasma binding of the unconjugated compounds were 98% (naproxen) and 100% (O-desmethylnaproxen), while naproxen acyl glucuronide binding was 92%; that of its isomer isoglucuronide 66%.","The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),%,92,6403,DB00501,Cimetidine
,8512758,binding,"5. The extents of plasma binding of the unconjugated compounds were 98% (naproxen) and 100% (O-desmethylnaproxen), while naproxen acyl glucuronide binding was 92%; that of its isomer isoglucuronide 66%.","The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),%,66,6404,DB00501,Cimetidine
,8512758,t1/2,6. Cimetidine (400 mg twice daily) decreased the t1/2 of naproxen by 39-60% (mean 47.3 +/- 11.5%; P = 0.0014) from 24.7 +/- 6.4 h to 13.2 +/- 1.0 h.,"The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),h,24.7,6405,DB00501,Cimetidine
,8512758,t1/2,6. Cimetidine (400 mg twice daily) decreased the t1/2 of naproxen by 39-60% (mean 47.3 +/- 11.5%; P = 0.0014) from 24.7 +/- 6.4 h to 13.2 +/- 1.0 h.,"The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),h,13.2,6406,DB00501,Cimetidine
,2979275,area under the curve,"In the chronic dosing study, the area under the curve for metoprolol was also significantly higher on cimetidine (1796 ng h/ml; P less than 0.001) whereas the area under the curve on ranitidine (1258 ng h/ml) was comparable to that on placebo (1183 ng h/ml).",The effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979275/),[h·ng] / [ml],1796,6425,DB00501,Cimetidine
,2979275,area under the curve,"In the chronic dosing study, the area under the curve for metoprolol was also significantly higher on cimetidine (1796 ng h/ml; P less than 0.001) whereas the area under the curve on ranitidine (1258 ng h/ml) was comparable to that on placebo (1183 ng h/ml).",The effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979275/),[h·ng] / [ml],1258,6426,DB00501,Cimetidine
,2979275,area under the curve,"In the chronic dosing study, the area under the curve for metoprolol was also significantly higher on cimetidine (1796 ng h/ml; P less than 0.001) whereas the area under the curve on ranitidine (1258 ng h/ml) was comparable to that on placebo (1183 ng h/ml).",The effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979275/),[h·ng] / [ml],1183,6427,DB00501,Cimetidine
,2897462,AUC0-infinity,"Comparison of the pharmacokinetic parameters of propranolol between etintidine and the placebo groups indicates that etintidine significantly increased the AUC0-infinity values (573.5 vs. 146.4 ng.hr/ml, p = 0.0001) and prolonged the elimination half-life (4.61 vs. 2.33 hr) of propranolol.",Etintidine-propranolol interaction study in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),[h·ng] / [ml],573.5,6731,DB00501,Cimetidine
,2897462,AUC0-infinity,"Comparison of the pharmacokinetic parameters of propranolol between etintidine and the placebo groups indicates that etintidine significantly increased the AUC0-infinity values (573.5 vs. 146.4 ng.hr/ml, p = 0.0001) and prolonged the elimination half-life (4.61 vs. 2.33 hr) of propranolol.",Etintidine-propranolol interaction study in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),[h·ng] / [ml],146.4,6732,DB00501,Cimetidine
,2897462,elimination half-life,"Comparison of the pharmacokinetic parameters of propranolol between etintidine and the placebo groups indicates that etintidine significantly increased the AUC0-infinity values (573.5 vs. 146.4 ng.hr/ml, p = 0.0001) and prolonged the elimination half-life (4.61 vs. 2.33 hr) of propranolol.",Etintidine-propranolol interaction study in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),h,4.61,6733,DB00501,Cimetidine
,2897462,elimination half-life,"Comparison of the pharmacokinetic parameters of propranolol between etintidine and the placebo groups indicates that etintidine significantly increased the AUC0-infinity values (573.5 vs. 146.4 ng.hr/ml, p = 0.0001) and prolonged the elimination half-life (4.61 vs. 2.33 hr) of propranolol.",Etintidine-propranolol interaction study in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),h,2.33,6734,DB00501,Cimetidine
,2897462,AUC0-24,"Statistical evaluation of the pharmacokinetic parameters of 4-hydroxypropranolol indicates that etintidine also increased the AUC0-24 values (43.8 vs. 16.4 ng.hr/ml, p = 0.0028) and prolonged the elimination half-life (4.87 vs. 1.97 hr) of 4-hydroxypropranolol.",Etintidine-propranolol interaction study in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),[h·ng] / [ml],43.8,6735,DB00501,Cimetidine
,2897462,AUC0-24,"Statistical evaluation of the pharmacokinetic parameters of 4-hydroxypropranolol indicates that etintidine also increased the AUC0-24 values (43.8 vs. 16.4 ng.hr/ml, p = 0.0028) and prolonged the elimination half-life (4.87 vs. 1.97 hr) of 4-hydroxypropranolol.",Etintidine-propranolol interaction study in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),[h·ng] / [ml],16.4,6736,DB00501,Cimetidine
,2897462,elimination half-life,"Statistical evaluation of the pharmacokinetic parameters of 4-hydroxypropranolol indicates that etintidine also increased the AUC0-24 values (43.8 vs. 16.4 ng.hr/ml, p = 0.0028) and prolonged the elimination half-life (4.87 vs. 1.97 hr) of 4-hydroxypropranolol.",Etintidine-propranolol interaction study in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),h,4.87,6737,DB00501,Cimetidine
,2897462,elimination half-life,"Statistical evaluation of the pharmacokinetic parameters of 4-hydroxypropranolol indicates that etintidine also increased the AUC0-24 values (43.8 vs. 16.4 ng.hr/ml, p = 0.0028) and prolonged the elimination half-life (4.87 vs. 1.97 hr) of 4-hydroxypropranolol.",Etintidine-propranolol interaction study in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),h,1.97,6738,DB00501,Cimetidine
,6322709,elimination half-life,"Cimetidine, 1,200 mg/day, significantly decreased theophylline clearance by 36% (range, 22% to 49%) and increased the mean elimination half-life from 5.7 hours (control) to 9.2 hours.",Inhibition of theophylline clearance by cimetidine but not ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322709/),h,5.7,8319,DB00501,Cimetidine
,6322709,elimination half-life,"Cimetidine, 1,200 mg/day, significantly decreased theophylline clearance by 36% (range, 22% to 49%) and increased the mean elimination half-life from 5.7 hours (control) to 9.2 hours.",Inhibition of theophylline clearance by cimetidine but not ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322709/),h,9.2,8320,DB00501,Cimetidine
,7286040,neutralising capacity,"In 8 healthy subjects the absorption of cimetidine was investigated when given alone, together with 60 ml aluminium/magnesium hydroxide containing antacid (neutralising capacity 26 mmol HCl/10 ml), and together with liquid metoclopramide 14 mg.",Impaired cimetidine absorption due to antacids and metoclopramide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286040/),[hcl·mM] / [10·ml],26,11176,DB00501,Cimetidine
,3392231,elimination half-life,The mean elimination half-life of propranolol was 6.3 hours during all three treatments.,The effect of cimetidine dose timing on oral propranolol kinetics in adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392231/),h,6.3,11709,DB00501,Cimetidine
,2933205,steady-state plasma concentration,Cimetidine significantly increased the mean (+/- SD) steady-state plasma concentration of midazolam from 56.7 +/- 7.8 to 71.3 +/- 19.6 ng/ml (P = 0.004).,Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933205/),[ng] / [ml],56.7,12601,DB00501,Cimetidine
,2933205,steady-state plasma concentration,Cimetidine significantly increased the mean (+/- SD) steady-state plasma concentration of midazolam from 56.7 +/- 7.8 to 71.3 +/- 19.6 ng/ml (P = 0.004).,Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933205/),[ng] / [ml],71.3,12602,DB00501,Cimetidine
,2933205,steady-state midazolam concentration,"In contrast, the steady-state midazolam concentration after ranitidine dosing (61.8 +/- 6.8 ng/ml) did not differ significantly from that after placebo.",Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933205/),[ng] / [ml],61.8,12603,DB00501,Cimetidine
,2439789,absolute bioavailability,Bisoprolol exhibits a high absolute bioavailability (90%) because of its nearly complete absorption (greater than 90%) and small first-pass effect (10%).,Balanced pharmacokinetics and metabolism of bisoprolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439789/),%,90,13263,DB00501,Cimetidine
,2439789,plasma-elimination half-life,A long plasma-elimination half-life (10-11h) allows a once-a-day dose regimen.,Balanced pharmacokinetics and metabolism of bisoprolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439789/),h,10-11,13264,DB00501,Cimetidine
,28603935,bioavailability,Oral tramadol bioavailability was low (2.6%).,The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),%,2.6,15349,DB00501,Cimetidine
,28603935,bioavailability,"Ketoconazole and cimetidine significantly increased tramadol bioavailability to 18.2% and 20.3%, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),%,18.2,15350,DB00501,Cimetidine
,28603935,bioavailability,"Ketoconazole and cimetidine significantly increased tramadol bioavailability to 18.2% and 20.3%, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),%,20.3,15351,DB00501,Cimetidine
,28603935,maximum plasma concentration,"The mean maximum plasma concentration of tramadol alone was 22.9 ng/ml, and increased to 109.9 and 143.2 μg/ml with ketoconazole and cimetidine, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[ng] / [ml],22.9,15352,DB00501,Cimetidine
,28603935,maximum plasma concentration,"The mean maximum plasma concentration of tramadol alone was 22.9 ng/ml, and increased to 109.9 and 143.2 μg/ml with ketoconazole and cimetidine, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[μg] / [ml],109.9,15353,DB00501,Cimetidine
,28603935,maximum plasma concentration,"The mean maximum plasma concentration of tramadol alone was 22.9 ng/ml, and increased to 109.9 and 143.2 μg/ml with ketoconazole and cimetidine, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[μg] / [ml],143.2,15354,DB00501,Cimetidine
,28603935,minimum concentration,"However, measured tramadol plasma concentrations were below the minimum concentration considered effective in humans (228 μg/ml).",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[μg] / [ml],228,15355,DB00501,Cimetidine
,11259329,maximum inactivation rate constant,"The maximum inactivation rate constant and the apparent inactivation constant of EM on MDZ metabolism were 0.0665 min(-1) and 81.8 microM, respectively.","Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259329/),1/[min],0.0665,16036,DB00501,Cimetidine
,11259329,apparent inactivation constant,"The maximum inactivation rate constant and the apparent inactivation constant of EM on MDZ metabolism were 0.0665 min(-1) and 81.8 microM, respectively.","Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259329/),μM,81.8,16037,DB00501,Cimetidine
,9342502,oral bioavailability,Nefazodone undergoes significant first-pass metabolism resulting in an oral bioavailability of approximately 20%.,Clinical pharmacokinetics of nefazodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342502/),%,20,16638,DB00501,Cimetidine
,2369810,t1/2,"In group 1, ciprofloxacin administration resulted in a significant decrease in antipyrine elimination (t1/2, 9.45 +/- 3.74 vs. 14.92 +/- 3.32 hr).",Metabolic interactions of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),h,9.45,16811,DB00501,Cimetidine
,2369810,t1/2,"In group 1, ciprofloxacin administration resulted in a significant decrease in antipyrine elimination (t1/2, 9.45 +/- 3.74 vs. 14.92 +/- 3.32 hr).",Metabolic interactions of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),h,14.92,16812,DB00501,Cimetidine
,2369810,clearance,The average decrease in antipyrine clearance was 35% (0.85 +/- 0.45 vs. 0.52 +/- 0.24 ml/min/kg).,Metabolic interactions of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),[ml] / [kg·min],0.85,16813,DB00501,Cimetidine
,2369810,clearance,The average decrease in antipyrine clearance was 35% (0.85 +/- 0.45 vs. 0.52 +/- 0.24 ml/min/kg).,Metabolic interactions of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),[ml] / [kg·min],0.52,16814,DB00501,Cimetidine
,2369810,t1/2,"In group 2, the change in antipyrine kinetics was less pronounced (t1/2, 9.79 +/- 3.06 vs. 11.22 +/- 2.64 hr).",Metabolic interactions of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),h,9.79,16815,DB00501,Cimetidine
,2369810,t1/2,"In group 2, the change in antipyrine kinetics was less pronounced (t1/2, 9.79 +/- 3.06 vs. 11.22 +/- 2.64 hr).",Metabolic interactions of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),h,11.22,16816,DB00501,Cimetidine
,2369810,clearance,Antipyrine clearance was decreased by only 10% (0.77 +/- 0.13 vs. 0.70 +/- 0.14 ml/min/kg).,Metabolic interactions of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),[ml] / [kg·min],0.77,16817,DB00501,Cimetidine
,2369810,clearance,Antipyrine clearance was decreased by only 10% (0.77 +/- 0.13 vs. 0.70 +/- 0.14 ml/min/kg).,Metabolic interactions of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),[ml] / [kg·min],0.70,16818,DB00501,Cimetidine
,11421376,Cmax,Cmax was 0.21+/-0.14 mg/L after 5 mg/kg and 0.39+/-0.19 mg/L after 30 mg/kg albendazole (P = 0.217).,Effect of dose increase or cimetidine co-administration on albendazole bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421376/),[mg] / [l],0.21,17083,DB00501,Cimetidine
,11421376,Cmax,Cmax was 0.21+/-0.14 mg/L after 5 mg/kg and 0.39+/-0.19 mg/L after 30 mg/kg albendazole (P = 0.217).,Effect of dose increase or cimetidine co-administration on albendazole bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421376/),[mg] / [l],0.39,17084,DB00501,Cimetidine
,11421376,elimination half-life,Cimetidine tended to decrease Cmax by 52% (P = 0.109) and significantly inhibited ABZSX breakdown as indicated by the prolongation of ABZSX elimination half-life from 7.4+/-3.3 hr to 19.0+/-11.7 hr (P = 0.028).,Effect of dose increase or cimetidine co-administration on albendazole bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421376/),h,7.4,17085,DB00501,Cimetidine
,11421376,elimination half-life,Cimetidine tended to decrease Cmax by 52% (P = 0.109) and significantly inhibited ABZSX breakdown as indicated by the prolongation of ABZSX elimination half-life from 7.4+/-3.3 hr to 19.0+/-11.7 hr (P = 0.028).,Effect of dose increase or cimetidine co-administration on albendazole bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421376/),h,19.0,17086,DB00501,Cimetidine
,2407090,apparent volume of distribution,"The drug has a large apparent volume of distribution (approximately 4 liters/kg), exhibits extensive plasma protein binding (approximately 95%) and produces at least 30 metabolites.",Clinical pharmacokinetics of moricizine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),[l] / [kg],4,17631,DB00501,Cimetidine
,2407090,plasma protein binding,"The drug has a large apparent volume of distribution (approximately 4 liters/kg), exhibits extensive plasma protein binding (approximately 95%) and produces at least 30 metabolites.",Clinical pharmacokinetics of moricizine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),%,95,17632,DB00501,Cimetidine
,2407090,elimination half-life,"The elimination half-life of moricizine is 2 to 6 hours, but its duration of antiarrhythmic action is much longer suggesting active metabolites.",Clinical pharmacokinetics of moricizine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),h,2 to 6,17633,DB00501,Cimetidine
,7356903,bioavailability,The bioavailability of tetracycline from tablets and suspension was found to be similar (31.2% and 36.9% of the dose excreted in the urine over 72 h).,Effect of cimetidine on the absorption of orally administered tetracycline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7356903/),%,31.2,18670,DB00501,Cimetidine
,7356903,bioavailability,The bioavailability of tetracycline from tablets and suspension was found to be similar (31.2% and 36.9% of the dose excreted in the urine over 72 h).,Effect of cimetidine on the absorption of orally administered tetracycline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7356903/),%,36.9,18671,DB00501,Cimetidine
,7356903,renal clearance,The mean renal clearance of tetracycline was 83.8 ml/min (95% confidence interval +/- 9.2 ml/min) and was unaltered by cimetidine treatment.,Effect of cimetidine on the absorption of orally administered tetracycline. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7356903/),[ml] / [min],83.8,18672,DB00501,Cimetidine
,9812177,peak concentrations (Cmax),Mean peak concentrations (Cmax) of 2.86 to 6.50 mg/L were achieved within 1.22 to 2.75 hours of administration.,Clinical pharmacokinetics of nimesulide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[mg] / [l],2.86 to 6.50,18714,DB00501,Cimetidine
,9812177,bioavailability,"When nimesulide was administered in the suppository form, the Cmax was lower and occurred later than after oral administration; the bioavailability of nimesulide via suppository ranged from 54 to 64%, relative to that of orally administered formulations.",Clinical pharmacokinetics of nimesulide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),%,54 to 64,18715,DB00501,Cimetidine
,9812177,apparent volume of distribution,Nimesulide is rapidly distributed and has an apparent volume of distribution ranging between 0.18 and 0.39 L/kg.,Clinical pharmacokinetics of nimesulide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[l] / [kg],0.18 and 0.39,18716,DB00501,Cimetidine
,9812177,unbound fraction,It is extensively bound to albumin; the unbound fraction in plasma was 1%.,Clinical pharmacokinetics of nimesulide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),%,1,18717,DB00501,Cimetidine
,9812177,terminal elimination half-life,The estimated mean terminal elimination half-life varied from 1.80 to 4.73 hours.,Clinical pharmacokinetics of nimesulide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),h,1.80 to 4.73,18718,DB00501,Cimetidine
,9812177,total plasma clearance,"The total plasma clearance of nimesulide, was 31.02 to 106.16 ml/h/kg, reflecting almost exclusive metabolic clearance.",Clinical pharmacokinetics of nimesulide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[ml] / [h·kg],31.02 to 106.16,18719,DB00501,Cimetidine
,9812177,extraction ratio,"The drug has a low extraction ratio, close to 0.1.",Clinical pharmacokinetics of nimesulide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),,0.1,18720,DB00501,Cimetidine
,2307399,clearance,The control group had a colchicine clearance of 77.33 ml/min.,The effect of liver dysfunction on colchicine pharmacokinetics in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2307399/),[ml] / [min],77.33,19267,DB00501,Cimetidine
,2307399,half-life,"kg, a half-life of 16.68 min +/- 0.97 min and a volume of distribution of 1.84 L/kg +/- 0.15 L/kg.",The effect of liver dysfunction on colchicine pharmacokinetics in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2307399/),min,16.68,19268,DB00501,Cimetidine
,2307399,volume of distribution,"kg, a half-life of 16.68 min +/- 0.97 min and a volume of distribution of 1.84 L/kg +/- 0.15 L/kg.",The effect of liver dysfunction on colchicine pharmacokinetics in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2307399/),[l] / [kg],1.84,19269,DB00501,Cimetidine
,2307399,terminal half-life,"At 48 hr after bile duct ligation, colchicine clearance decreased by 84% (p less than 0.05), terminal half-life increased to 513.7 min +/- 106.6 min (p less than 0.05) and volume of distribution increased by 175% (p less than 0.05).",The effect of liver dysfunction on colchicine pharmacokinetics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2307399/),min,513.7,19270,DB00501,Cimetidine
,9799054,AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[h·mg] / [l],292,20854,DB00501,Cimetidine
,9799054,Cmax/AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[h·mg] / [l],287,20855,DB00501,Cimetidine
,9799054,Cmax/AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[l] / [h],0.0150,20856,DB00501,Cimetidine
,9799054,Cmax/AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[l] / [h],0.0144,20857,DB00501,Cimetidine
,9799054,rate characteristic,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[l] / [h],0.0144,20858,DB00501,Cimetidine
,3768247,apparent oral clearance,"After cimetidine pretreatment there was a significant reduction in the apparent oral clearance of quinine, from 0.182 +/- 0.063 (mean +/- s.d.) to 0.133 +/- 0.055 1 h-1 kg-1 (P less than 0.05).",Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768247/),[1] / [h·kg],0.182,21822,DB00501,Cimetidine
,3768247,apparent oral clearance,"After cimetidine pretreatment there was a significant reduction in the apparent oral clearance of quinine, from 0.182 +/- 0.063 (mean +/- s.d.) to 0.133 +/- 0.055 1 h-1 kg-1 (P less than 0.05).",Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768247/),[1] / [h·kg],0.133,21823,DB00501,Cimetidine
,3768247,elimination half-life,This was reflected in a 49% (range 17 to 90%) increase in the mean elimination half-life from 7.6 +/- 1.3 to 11.3 +/- 3.7 h (P less than 0.05).,Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768247/),h,7.6,21824,DB00501,Cimetidine
,3768247,elimination half-life,This was reflected in a 49% (range 17 to 90%) increase in the mean elimination half-life from 7.6 +/- 1.3 to 11.3 +/- 3.7 h (P less than 0.05).,Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768247/),h,11.3,21825,DB00501,Cimetidine
,3323258,apparent oral clearance rate,"The apparent oral clearance rate of chloroquine was reduced from 0.49 +/- 0.04 L/d/kg in the control group to 0.23 +/- 0.02 L/d/kg in the test group, and the elimination half-life was prolonged from 3.11 days in the control group to 4.62 days in the test group.",Chloroquine elimination in humans: effect of low-dose cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323258/),[l] / [d·kg],0.49,24302,DB00501,Cimetidine
,3323258,apparent oral clearance rate,"The apparent oral clearance rate of chloroquine was reduced from 0.49 +/- 0.04 L/d/kg in the control group to 0.23 +/- 0.02 L/d/kg in the test group, and the elimination half-life was prolonged from 3.11 days in the control group to 4.62 days in the test group.",Chloroquine elimination in humans: effect of low-dose cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323258/),[l] / [d·kg],0.23,24303,DB00501,Cimetidine
,3323258,elimination half-life,"The apparent oral clearance rate of chloroquine was reduced from 0.49 +/- 0.04 L/d/kg in the control group to 0.23 +/- 0.02 L/d/kg in the test group, and the elimination half-life was prolonged from 3.11 days in the control group to 4.62 days in the test group.",Chloroquine elimination in humans: effect of low-dose cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323258/),d,3.11,24304,DB00501,Cimetidine
,3323258,elimination half-life,"The apparent oral clearance rate of chloroquine was reduced from 0.49 +/- 0.04 L/d/kg in the control group to 0.23 +/- 0.02 L/d/kg in the test group, and the elimination half-life was prolonged from 3.11 days in the control group to 4.62 days in the test group.",Chloroquine elimination in humans: effect of low-dose cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323258/),d,4.62,24305,DB00501,Cimetidine
,3323258,apparent volume of distribution at steady state,The apparent volume of distribution at steady state was increased from 0.46 +/- 0.07 L/kg in the control group to 0.72 +/- 0.10 L/kg in the test group.,Chloroquine elimination in humans: effect of low-dose cimetidine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323258/),[l] / [kg],0.46,24306,DB00501,Cimetidine
,3323258,apparent volume of distribution at steady state,The apparent volume of distribution at steady state was increased from 0.46 +/- 0.07 L/kg in the control group to 0.72 +/- 0.10 L/kg in the test group.,Chloroquine elimination in humans: effect of low-dose cimetidine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323258/),[l] / [kg],0.72,24307,DB00501,Cimetidine
,10741624,apparent oral clearance,"Concomitant administration of cimetidine significantly increased the area under the plasma concentration-time curve of pilsicainide by a mean of 33%, prolonged elimination half-life by a mean of 24% (from 5 to 6.2 hours), reduced apparent oral clearance by a mean of 26% (from 14.7 +/- 0.1 to 10.8 +/- 0.8 L/h) and reduced renal clearance by a mean of 28% (from 196.8 +/- 53.9 to 141.8 +/- 25.9 mL/min).",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[l] / [h],14.7,24634,DB00501,Cimetidine
,10741624,apparent oral clearance,"Concomitant administration of cimetidine significantly increased the area under the plasma concentration-time curve of pilsicainide by a mean of 33%, prolonged elimination half-life by a mean of 24% (from 5 to 6.2 hours), reduced apparent oral clearance by a mean of 26% (from 14.7 +/- 0.1 to 10.8 +/- 0.8 L/h) and reduced renal clearance by a mean of 28% (from 196.8 +/- 53.9 to 141.8 +/- 25.9 mL/min).",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[l] / [h],10.8,24635,DB00501,Cimetidine
,10741624,renal clearance,"Concomitant administration of cimetidine significantly increased the area under the plasma concentration-time curve of pilsicainide by a mean of 33%, prolonged elimination half-life by a mean of 24% (from 5 to 6.2 hours), reduced apparent oral clearance by a mean of 26% (from 14.7 +/- 0.1 to 10.8 +/- 0.8 L/h) and reduced renal clearance by a mean of 28% (from 196.8 +/- 53.9 to 141.8 +/- 25.9 mL/min).",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[ml] / [min],196.8,24636,DB00501,Cimetidine
,10741624,renal clearance,"Concomitant administration of cimetidine significantly increased the area under the plasma concentration-time curve of pilsicainide by a mean of 33%, prolonged elimination half-life by a mean of 24% (from 5 to 6.2 hours), reduced apparent oral clearance by a mean of 26% (from 14.7 +/- 0.1 to 10.8 +/- 0.8 L/h) and reduced renal clearance by a mean of 28% (from 196.8 +/- 53.9 to 141.8 +/- 25.9 mL/min).",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[ml] / [min],141.8,24637,DB00501,Cimetidine
,10741624,net renal clearance by tubular secretion,"The net renal clearance by tubular secretion was significantly reduced by a mean value of 38%, from 151.4 +/- 62.9 to 93.0 +/- 31.1 mL/min.",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[ml] / [min],151.4,24638,DB00501,Cimetidine
,10741624,net renal clearance by tubular secretion,"The net renal clearance by tubular secretion was significantly reduced by a mean value of 38%, from 151.4 +/- 62.9 to 93.0 +/- 31.1 mL/min.",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[ml] / [min],93.0,24639,DB00501,Cimetidine
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,2.6,25394,DB00501,Cimetidine
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,68,25395,DB00501,Cimetidine
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,40,25396,DB00501,Cimetidine
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,60,25397,DB00501,Cimetidine
,28499878,Km,"Moreover, the uptake of sulpiride by human hepatocytes was diminished by tetraethylammonium, and saturable with Km of 18 μM.","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,18,25398,DB00501,Cimetidine
,4019663,total analysis time,The total analysis time was approximately 11 min.,Determination of cimetidine and metabolites in plasma by reversed-phase high-performance liquid chromatographic radial compression technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019663/),min,11,25686,DB00501,Cimetidine
,7586949,milk/serum ratio,"In vitro measurements, including skim to whole milk concentration ratio, milk pH, and free fractions in serum and milk were used for a diffusion model prediction of milk to serum concentration ratio of cimetidine; the mean milk/serum ratio (+/- SD) was 1.05 +/- 0.18.",Active transport of cimetidine into human milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586949/),,1.05,26720,DB00501,Cimetidine
,7586949,milk/serum ratio,The observed milk/serum ratio (5.77 +/- 1.24) was 5.5 times higher than the milk/serum ratio predicted by diffusion.,Active transport of cimetidine into human milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586949/),,5.77,26721,DB00501,Cimetidine
,7586949,Time of peak concentration (tmax),Time of peak concentration (tmax) in milk (3.3 +/- 0.7 hours) displayed a delay compared with serum tmax (1.7 +/- 0.6 hours).,Active transport of cimetidine into human milk. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586949/),h,3.3,26722,DB00501,Cimetidine
,7586949,serum tmax,Time of peak concentration (tmax) in milk (3.3 +/- 0.7 hours) displayed a delay compared with serum tmax (1.7 +/- 0.6 hours).,Active transport of cimetidine into human milk. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586949/),h,1.7,26723,DB00501,Cimetidine
,7586949,Oral clearance,"Oral clearance for 1200 mg cimetidine dose (0.47 +/- 0.11 L/hr/kg) was significantly lower compared with oral clearance values for 100 and 600 mg cimetidine doses (0.59 +/- 0.11 and 0.57 +/- 0.13 L/hr/kg, respectively).",Active transport of cimetidine into human milk. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586949/),[l] / [h·kg],0.47,26724,DB00501,Cimetidine
,7586949,oral clearance,"Oral clearance for 1200 mg cimetidine dose (0.47 +/- 0.11 L/hr/kg) was significantly lower compared with oral clearance values for 100 and 600 mg cimetidine doses (0.59 +/- 0.11 and 0.57 +/- 0.13 L/hr/kg, respectively).",Active transport of cimetidine into human milk. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586949/),[l] / [h·kg],0.59,26725,DB00501,Cimetidine
,7586949,oral clearance,"Oral clearance for 1200 mg cimetidine dose (0.47 +/- 0.11 L/hr/kg) was significantly lower compared with oral clearance values for 100 and 600 mg cimetidine doses (0.59 +/- 0.11 and 0.57 +/- 0.13 L/hr/kg, respectively).",Active transport of cimetidine into human milk. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586949/),[l] / [h·kg],0.57,26726,DB00501,Cimetidine
,2864251,AUC0- infinity,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[h·μg] / [ml],38.1,26778,DB00501,Cimetidine
,2864251,AUC0- infinity,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[h·μg] / [ml],38.8,26779,DB00501,Cimetidine
,2864251,systemic clearance,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[l] / [h·kg],0.11,26780,DB00501,Cimetidine
,2864251,systemic clearance,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[l] / [h·kg],0.16,26781,DB00501,Cimetidine
,2864251,half-life,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),h,2.8,26782,DB00501,Cimetidine
,2864251,half-life,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),h,2.0,26783,DB00501,Cimetidine
,2864251,volume of distribution,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[l] / [kg],0.39,26784,DB00501,Cimetidine
,2864251,volume of distribution,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[l] / [kg],0.41,26785,DB00501,Cimetidine
,9020396,fractional excretion of paraquat (FEpq),The fractional excretion of paraquat (FEpq) decreased from 2.1+/-0.01 to 1.2+/-0.03 as the plasma concentration rose from 0.4+/-0.02 to 21.2+/-1.6 microM.,The mechanism of excretion of paraquat in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9020396/),,2.1,27289,DB00501,Cimetidine
,9020396,fractional excretion of paraquat (FEpq),The fractional excretion of paraquat (FEpq) decreased from 2.1+/-0.01 to 1.2+/-0.03 as the plasma concentration rose from 0.4+/-0.02 to 21.2+/-1.6 microM.,The mechanism of excretion of paraquat in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9020396/),,1.2,27290,DB00501,Cimetidine
,9020396,Km,"The excretion of PQ was dependent predominantly on the glomerular filtration rate with a small secretory component (Km = 8.5+/-3.1 microM, Vmax = 114+/-19 nmol/kg per min).",The mechanism of excretion of paraquat in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9020396/),μM,8.5,27291,DB00501,Cimetidine
,9020396,Vmax,"The excretion of PQ was dependent predominantly on the glomerular filtration rate with a small secretory component (Km = 8.5+/-3.1 microM, Vmax = 114+/-19 nmol/kg per min).",The mechanism of excretion of paraquat in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9020396/),[nM] / [kg·min],114,27292,DB00501,Cimetidine
,8220911,Kis,6. Sulphaphenazole competitively inhibits the 7- and in some samples partly (up to 50%) the 6-hydroxylation of S-warfarin as well as the 7-hydroxylation of R- and S-acenocoumarol and the 6-hydroxylation of S-acenocoumarol (Kis ranging from 0.5-1.3 microM).,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,0.5-1.3,27727,DB00501,Cimetidine
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,99,27728,DB00501,Cimetidine
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,117,27729,DB00501,Cimetidine
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,219,27730,DB00501,Cimetidine
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,7.2,27731,DB00501,Cimetidine
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,6.1,27732,DB00501,Cimetidine
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,7.7,27733,DB00501,Cimetidine
,6148361,plasma clearance,"The mean (+/- S.D.) plasma clearance by the spectrophotometric method was 7.48 +/- 2.07 (control), 7.15 +/- 3.07 (ranitidine), and 6.88 +/- 1.35 ml/min/kg (cimetidine).",Lack of effect of histamine H2-receptor antagonists on indocyanine green disposition measured by two methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148361/),[ml] / [kg·min],7.48,27879,DB00501,Cimetidine
,6148361,plasma clearance,"The mean (+/- S.D.) plasma clearance by the spectrophotometric method was 7.48 +/- 2.07 (control), 7.15 +/- 3.07 (ranitidine), and 6.88 +/- 1.35 ml/min/kg (cimetidine).",Lack of effect of histamine H2-receptor antagonists on indocyanine green disposition measured by two methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148361/),[ml] / [kg·min],7.15,27880,DB00501,Cimetidine
,6148361,plasma clearance,"The mean (+/- S.D.) plasma clearance by the spectrophotometric method was 7.48 +/- 2.07 (control), 7.15 +/- 3.07 (ranitidine), and 6.88 +/- 1.35 ml/min/kg (cimetidine).",Lack of effect of histamine H2-receptor antagonists on indocyanine green disposition measured by two methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148361/),[ml] / [kg·min],6.88,27881,DB00501,Cimetidine
,15286096,CL(T),"The GFR and Vd remained unchanged, but significant reductions in CL(T) (655 vs. 486 mL/min, p < 0.001) and CL(sec) (410 vs. 311 mL/min, p = 0.001) were observed.",Renal interaction between itraconazole and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286096/),[ml] / [min],655,28392,DB00501,Cimetidine
,15286096,CL(T),"The GFR and Vd remained unchanged, but significant reductions in CL(T) (655 vs. 486 mL/min, p < 0.001) and CL(sec) (410 vs. 311 mL/min, p = 0.001) were observed.",Renal interaction between itraconazole and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286096/),[ml] / [min],486,28393,DB00501,Cimetidine
,15286096,CL(sec),"The GFR and Vd remained unchanged, but significant reductions in CL(T) (655 vs. 486 mL/min, p < 0.001) and CL(sec) (410 vs. 311 mL/min, p = 0.001) were observed.",Renal interaction between itraconazole and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286096/),[ml] / [min],410,28394,DB00501,Cimetidine
,15286096,CL(sec),"The GFR and Vd remained unchanged, but significant reductions in CL(T) (655 vs. 486 mL/min, p < 0.001) and CL(sec) (410 vs. 311 mL/min, p = 0.001) were observed.",Renal interaction between itraconazole and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286096/),[ml] / [min],311,28395,DB00501,Cimetidine
,3292102,body clearance,"In healthy subjects given captopril intravenously, the body clearance of captopril and steady-state volume of distribution were about 0.7 L/h/kg and 0.8 L/kg, respectively.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),[l] / [h·kg],0.7,28702,DB00501,Cimetidine
,3292102,steady-state volume of distribution,"In healthy subjects given captopril intravenously, the body clearance of captopril and steady-state volume of distribution were about 0.7 L/h/kg and 0.8 L/kg, respectively.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),[l] / [kg],0.8,28703,DB00501,Cimetidine
,3292102,elimination half-life,The elimination half-life of unchanged captopril was approximately 2 hours.,Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),h,2,28704,DB00501,Cimetidine
,3292102,bioavailability,"In healthy subjects, about 70 to 75% of an oral dose is absorbed and the bioavailability of captopril is approximately 65%.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),%,65,28705,DB00501,Cimetidine
,6785475,Rates of infusion,Rates of infusion of CT ranged from 38 to 56.3 mg/hr.,Cimetidine and parenteral nutrition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6785475/),[mg] / [h],38 to 56.3,28739,DB00501,Cimetidine
,6785475,serum concentrations (C88),Average serum concentrations (C88) of CT at steady state ranged from 0.6 to 1.0 microgram/ml.,Cimetidine and parenteral nutrition. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6785475/),[μg] / [ml],0.6 to 1.0,28740,DB00501,Cimetidine
,16129921,CD(50),"Astemizole (1 mg/kg) did not affect the threshold for aminophylline-induced seizures, but when administered at a dose of 2 mg/kg, it significantly reduced the CD(50) value of aminophylline from 249 mg/kg to 211 mg/kg (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),[mg] / [kg],249,29195,DB00501,Cimetidine
,16129921,CD(50),"Astemizole (1 mg/kg) did not affect the threshold for aminophylline-induced seizures, but when administered at a dose of 2 mg/kg, it significantly reduced the CD(50) value of aminophylline from 249 mg/kg to 211 mg/kg (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),[mg] / [kg],211,29196,DB00501,Cimetidine
,16129921,latency to,"Furthermore, astemizole (2 mg/kg) decreased latency to the clonic phase of aminophylline-induced convulsions from 51.1 +/- 4.5 to 32.1 +/- 4.3 min (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),min,51.1,29197,DB00501,Cimetidine
,16129921,latency to,"Furthermore, astemizole (2 mg/kg) decreased latency to the clonic phase of aminophylline-induced convulsions from 51.1 +/- 4.5 to 32.1 +/- 4.3 min (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),min,32.1,29198,DB00501,Cimetidine
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.7,31995,DB00501,Cimetidine
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],9.0,31996,DB00501,Cimetidine
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.5,31997,DB00501,Cimetidine
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.1,31998,DB00501,Cimetidine
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.6,31999,DB00501,Cimetidine
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.2,32000,DB00501,Cimetidine
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,19.6,32001,DB00501,Cimetidine
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,26.2,32002,DB00501,Cimetidine
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,13.3,32003,DB00501,Cimetidine
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,18.4,32004,DB00501,Cimetidine
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,13.2,32005,DB00501,Cimetidine
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,19.0,32006,DB00501,Cimetidine
,4020559,t1/2,"Cimetidine disposition was best described by a biphasic elimination curve with t1/2 values for cimetidine, cimetidine sulfoxide, and hydroxymethyl cimetidine of 1.39, 2.6, and 4.7 hours, respectively.",Pharmacokinetics and pharmacodynamics of cimetidine and metabolites in critically ill children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020559/),h,1.39,33749,DB00501,Cimetidine
,4020559,t1/2,"Cimetidine disposition was best described by a biphasic elimination curve with t1/2 values for cimetidine, cimetidine sulfoxide, and hydroxymethyl cimetidine of 1.39, 2.6, and 4.7 hours, respectively.",Pharmacokinetics and pharmacodynamics of cimetidine and metabolites in critically ill children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020559/),h,2.6,33750,DB00501,Cimetidine
,4020559,t1/2,"Cimetidine disposition was best described by a biphasic elimination curve with t1/2 values for cimetidine, cimetidine sulfoxide, and hydroxymethyl cimetidine of 1.39, 2.6, and 4.7 hours, respectively.",Pharmacokinetics and pharmacodynamics of cimetidine and metabolites in critically ill children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020559/),h,4.7,33751,DB00501,Cimetidine
greater,4020559,plasma concentrations,Cimetidine plasma concentrations were maintained at greater than or equal to 0.5 microgram/ml for a significantly longer time in patients who received greater than or equal to 20 mg/kg/day.,Pharmacokinetics and pharmacodynamics of cimetidine and metabolites in critically ill children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020559/),,0.5,33752,DB00501,Cimetidine
,4020559,apparent volume of distribution,"The mean apparent volume of distribution and total body clearance for cimetidine were 1.23 L/kg and 10.4 ml/min/kg, respectively.",Pharmacokinetics and pharmacodynamics of cimetidine and metabolites in critically ill children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020559/),[l] / [kg],1.23,33753,DB00501,Cimetidine
,4020559,total body clearance,"The mean apparent volume of distribution and total body clearance for cimetidine were 1.23 L/kg and 10.4 ml/min/kg, respectively.",Pharmacokinetics and pharmacodynamics of cimetidine and metabolites in critically ill children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020559/),[ml] / [kg·min],10.4,33754,DB00501,Cimetidine
,4020559,steady-state plasma cimetidine concentrations,"On the basis of our data, a cimetidine dosage of 20 to 30 mg/kg/day administered in six divided doses should provide for average steady-state plasma cimetidine concentrations of 1.3 to 2.0 micrograms/ml.",Pharmacokinetics and pharmacodynamics of cimetidine and metabolites in critically ill children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020559/),[μg] / [ml],1.3 to 2.0,33755,DB00501,Cimetidine
,6720687,total body clearance,"Cimetidine pharmacokinetics were similar to those in patients with end-stage renal failure, with a total body clearance of 3.3 +/- 1.0 mL/min/kg and a half-life of 4.1 hours.",Rebound following hemodialysis of cimetidine and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6720687/),[ml] / [kg·min],3.3,34238,DB00501,Cimetidine
,6720687,half-life,"Cimetidine pharmacokinetics were similar to those in patients with end-stage renal failure, with a total body clearance of 3.3 +/- 1.0 mL/min/kg and a half-life of 4.1 hours.",Rebound following hemodialysis of cimetidine and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6720687/),h,4.1,34239,DB00501,Cimetidine
,6720687,clearances,"Dialysis clearances, as calculated from extraction ratios, were 83 +/- 15, 90 +/- 16, 93 +/- 24, and 126 +/- 23 mL/min for cimetidine, hydroxymethyl, sulfoxide, and creatinine, respectively.",Rebound following hemodialysis of cimetidine and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6720687/),[ml] / [min],83,34240,DB00501,Cimetidine
,6720687,clearances,"Dialysis clearances, as calculated from extraction ratios, were 83 +/- 15, 90 +/- 16, 93 +/- 24, and 126 +/- 23 mL/min for cimetidine, hydroxymethyl, sulfoxide, and creatinine, respectively.",Rebound following hemodialysis of cimetidine and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6720687/),[ml] / [min],90,34241,DB00501,Cimetidine
,6720687,clearances,"Dialysis clearances, as calculated from extraction ratios, were 83 +/- 15, 90 +/- 16, 93 +/- 24, and 126 +/- 23 mL/min for cimetidine, hydroxymethyl, sulfoxide, and creatinine, respectively.",Rebound following hemodialysis of cimetidine and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6720687/),[ml] / [min],93,34242,DB00501,Cimetidine
,6720687,clearances,"Dialysis clearances, as calculated from extraction ratios, were 83 +/- 15, 90 +/- 16, 93 +/- 24, and 126 +/- 23 mL/min for cimetidine, hydroxymethyl, sulfoxide, and creatinine, respectively.",Rebound following hemodialysis of cimetidine and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6720687/),[ml] / [min],126,34243,DB00501,Cimetidine
,6720687,extraction ratios,"Dialysis clearances, as calculated from extraction ratios, were 83 +/- 15, 90 +/- 16, 93 +/- 24, and 126 +/- 23 mL/min for cimetidine, hydroxymethyl, sulfoxide, and creatinine, respectively.",Rebound following hemodialysis of cimetidine and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6720687/),[ml] / [min],83,34244,DB00501,Cimetidine
,6720687,extraction ratios,"Dialysis clearances, as calculated from extraction ratios, were 83 +/- 15, 90 +/- 16, 93 +/- 24, and 126 +/- 23 mL/min for cimetidine, hydroxymethyl, sulfoxide, and creatinine, respectively.",Rebound following hemodialysis of cimetidine and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6720687/),[ml] / [min],90,34245,DB00501,Cimetidine
,6720687,extraction ratios,"Dialysis clearances, as calculated from extraction ratios, were 83 +/- 15, 90 +/- 16, 93 +/- 24, and 126 +/- 23 mL/min for cimetidine, hydroxymethyl, sulfoxide, and creatinine, respectively.",Rebound following hemodialysis of cimetidine and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6720687/),[ml] / [min],93,34246,DB00501,Cimetidine
,6720687,extraction ratios,"Dialysis clearances, as calculated from extraction ratios, were 83 +/- 15, 90 +/- 16, 93 +/- 24, and 126 +/- 23 mL/min for cimetidine, hydroxymethyl, sulfoxide, and creatinine, respectively.",Rebound following hemodialysis of cimetidine and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6720687/),[ml] / [min],126,34247,DB00501,Cimetidine
,8593491,inhibition constant (Ki),"Cimetidine showed competitive inhibition of theophylline elimination in vivo, with an inhibition constant (Ki) of 28.5 microM.","Drug interactions between theophylline and H2-antagonists, roxatidine acetate hydrochloride and cimetidine: pharmacokinetic analysis in rats in vivo. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593491/),μM,28.5,34910,DB00501,Cimetidine
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],7.76,35040,DB00501,Cimetidine
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],11.50,35041,DB00501,Cimetidine
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],73.0,35042,DB00501,Cimetidine
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],91.5,35043,DB00501,Cimetidine
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],101,35044,DB00501,Cimetidine
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],123,35045,DB00501,Cimetidine
,9692688,first pass metabolism,"Following food, and with ethanol taken in the form of beer, mean first pass metabolism of ethanol was 58% (range 34-78%).","Omeprazole, ranitidine, and cimetidine have no effect on peak blood ethanol concentrations, first pass metabolism or area under the time-ethanol curve under 'real-life' drinking conditions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692688/),%,58,37226,DB00501,Cimetidine
,3061720,systemic bioavailability,"It is well absorbed after oral administration, but systemic bioavailability is only 12% after a 300-mg dose.",Propafenone: a new antiarrhythmic agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),%,12,37633,DB00501,Cimetidine
,3061720,elimination half-life,"Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers.",Propafenone: a new antiarrhythmic agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),h,5.5,37634,DB00501,Cimetidine
,3061720,elimination half-life,"Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers.",Propafenone: a new antiarrhythmic agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),h,17.2,37635,DB00501,Cimetidine
,3968854,elimination half-life,"The elimination half-life of cimetidine in burned patients was significantly reduced (2.2 v 1.5 hours), and total clearance significantly increased (8.2 v 13.3 mL/min/kg).",Increased cimetidine clearance in burn patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3968854/),h,2.2,37671,DB00501,Cimetidine
,3968854,elimination half-life,"The elimination half-life of cimetidine in burned patients was significantly reduced (2.2 v 1.5 hours), and total clearance significantly increased (8.2 v 13.3 mL/min/kg).",Increased cimetidine clearance in burn patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3968854/),h,1.5,37672,DB00501,Cimetidine
,3968854,total clearance,"The elimination half-life of cimetidine in burned patients was significantly reduced (2.2 v 1.5 hours), and total clearance significantly increased (8.2 v 13.3 mL/min/kg).",Increased cimetidine clearance in burn patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3968854/),[ml] / [kg·min],8.2,37673,DB00501,Cimetidine
,3968854,total clearance,"The elimination half-life of cimetidine in burned patients was significantly reduced (2.2 v 1.5 hours), and total clearance significantly increased (8.2 v 13.3 mL/min/kg).",Increased cimetidine clearance in burn patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3968854/),[ml] / [kg·min],13.3,37674,DB00501,Cimetidine
,1690458,milk/plasma ratios,The milk/plasma ratios far exceeded the theoretical milk/plasma ratio of 2.0.,Excretion of high concentrations of cimetidine and ranitidine into rat milk and their effects on milk composition and mammary gland nucleic acid content. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1690458/),,2.0,39354,DB00501,Cimetidine
,1690458,milk/plasma ratio,The milk/plasma ratios far exceeded the theoretical milk/plasma ratio of 2.0.,Excretion of high concentrations of cimetidine and ranitidine into rat milk and their effects on milk composition and mammary gland nucleic acid content. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1690458/),,2.0,39355,DB00501,Cimetidine
less,2613393,metabolic ratio (MR),"In PM on rifampicin, the debrisoquine metabolic ratio (MR) was significantly reduced, even reaching a value less than 12.6 in 2 subjects but on phenobarbital and cimetidine, the MR was not significantly modified.","Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2613393/),,12,39596,DB00501,Cimetidine
,7937553,elimination half-life,From the terminal phase of the curves it is possible to calculate the elimination half-life: 2.69 apolisychrons for theophylline when it is administered alone and 3.86 apolisychrons when it is administered in combination with cimetidine.,Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: interspecies scaling in pharmacokinetic interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937553/),,2.69,41037,DB00501,Cimetidine
,7937553,elimination half-life,From the terminal phase of the curves it is possible to calculate the elimination half-life: 2.69 apolisychrons for theophylline when it is administered alone and 3.86 apolisychrons when it is administered in combination with cimetidine.,Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: interspecies scaling in pharmacokinetic interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937553/),,3.86,41038,DB00501,Cimetidine
,3345623,elimination half-life (t1/2),"After intravenous infusion, elimination half-life (t1/2) was 4.0 +/- 2.3 hours, systemic clearance (CL) was 0.83 +/- 0.17 L/min, and volume of distribution was 1.6 +/- 0.6 L/kg.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),h,4.0,42272,DB00501,Cimetidine
,3345623,systemic clearance (CL),"After intravenous infusion, elimination half-life (t1/2) was 4.0 +/- 2.3 hours, systemic clearance (CL) was 0.83 +/- 0.17 L/min, and volume of distribution was 1.6 +/- 0.6 L/kg.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),[l] / [min],0.83,42273,DB00501,Cimetidine
,3345623,volume of distribution,"After intravenous infusion, elimination half-life (t1/2) was 4.0 +/- 2.3 hours, systemic clearance (CL) was 0.83 +/- 0.17 L/min, and volume of distribution was 1.6 +/- 0.6 L/kg.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),[l] / [kg],1.6,42274,DB00501,Cimetidine
,3345623,t1/2,"After oral nisoldipine, t1/2 was 3.8 +/- 1.3 hours and systemic availability was 3.9% +/- 3.5%.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),h,3.8,42275,DB00501,Cimetidine
,3345623,systemic availability,"After oral nisoldipine, t1/2 was 3.8 +/- 1.3 hours and systemic availability was 3.9% +/- 3.5%.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),%,3.9,42276,DB00501,Cimetidine
,3345623,Systemic availability,Systemic availability increased to 5.7% +/- 2.8%.,Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),%,5.7,42277,DB00501,Cimetidine
,1527712,half-life,"After oral carbaryl administration to normal subjects, plasma concentrations rapidly rose to a peak, then declined with a half-life of 0.79 +/- 0.47 hr.",Cimetidine-carbaryl interaction in humans: evidence for an active metabolite of carbaryl. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527712/),h,0.79,42887,DB00501,Cimetidine
,1527712,clearance,Oral carbaryl clearance was 5.4 +/- 2.0 l/min.,Cimetidine-carbaryl interaction in humans: evidence for an active metabolite of carbaryl. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527712/),[l] / [min],5.4,42888,DB00501,Cimetidine
,1527712,terminal half-life,The terminal half-life for the dynamic response was 2.6 +/- 1.5 hr.,Cimetidine-carbaryl interaction in humans: evidence for an active metabolite of carbaryl. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527712/),h,2.6,42889,DB00501,Cimetidine
,1527712,clearance,"After pretreatment with cimetidine, peak plasma carbaryl concentrations doubled and clearance was reduced (to 2.5 +/- 1.5 l/min) (P less than .05).",Cimetidine-carbaryl interaction in humans: evidence for an active metabolite of carbaryl. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527712/),[l] / [min],2.5,42890,DB00501,Cimetidine
,20347037,clearance,"Clofarabine clearance was significantly reduced upon co-administration with, cimetidine (0.83+/-0.22-->0.32+/-0.058mL/min).",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [min],0.83,43396,DB00501,Cimetidine
,20347037,clearance,"Clofarabine clearance was significantly reduced upon co-administration with, cimetidine (0.83+/-0.22-->0.32+/-0.058mL/min).",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [min],0.32,43397,DB00501,Cimetidine
,20347037,clearance,"In vivo data correlated with IPK results as clofarabine clearance decreased 61% (20.2-7.80mL/min/kg), upon co-administration with cimetidine in rats.",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [kg·min],20.2-7.80,43398,DB00501,Cimetidine
,15083216,volume of distribution (Vd),"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),[l] / [kg],0.77,43855,DB00501,Cimetidine
,15083216,elimination rate constant (Ke),"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),1/[h],0.027,43856,DB00501,Cimetidine
,15083216,CL,"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),[l] / [h·kg],0.019,43857,DB00501,Cimetidine
,15083216,t0.5,"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),,30.7,43858,DB00501,Cimetidine
,15083216,Css level,"In view of the results and practical considerations, initial dosage regimen to attain a TH Css level within the therapeutic range (6-12 ug/ml) was suggested: LD 6-7 mg/kg, MD 1.5 - 2.0 mg/kg/12 hours.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),[ug] / [ml],6-12,43859,DB00501,Cimetidine
,2938614,plasma half-life,Cimetidine caused a significant increase in the mean plasma half-life of R warfarin (from 47.8 h to 57.8 h) and a significant decrease in its mean plasma clearance (from 2.3 to 1.7 ml h-1 kg-1) (P less than 0.02).,Stereoselective interaction between the R enantiomer of warfarin and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2938614/),h,47.8,45288,DB00501,Cimetidine
,2938614,plasma half-life,Cimetidine caused a significant increase in the mean plasma half-life of R warfarin (from 47.8 h to 57.8 h) and a significant decrease in its mean plasma clearance (from 2.3 to 1.7 ml h-1 kg-1) (P less than 0.02).,Stereoselective interaction between the R enantiomer of warfarin and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2938614/),h,57.8,45289,DB00501,Cimetidine
,2938614,plasma clearance,Cimetidine caused a significant increase in the mean plasma half-life of R warfarin (from 47.8 h to 57.8 h) and a significant decrease in its mean plasma clearance (from 2.3 to 1.7 ml h-1 kg-1) (P less than 0.02).,Stereoselective interaction between the R enantiomer of warfarin and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2938614/),[ml] / [h·kg],2.3,45290,DB00501,Cimetidine
,2938614,plasma clearance,Cimetidine caused a significant increase in the mean plasma half-life of R warfarin (from 47.8 h to 57.8 h) and a significant decrease in its mean plasma clearance (from 2.3 to 1.7 ml h-1 kg-1) (P less than 0.02).,Stereoselective interaction between the R enantiomer of warfarin and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2938614/),[ml] / [h·kg],1.7,45291,DB00501,Cimetidine
,1673880,oral bioavailability,The mean oral bioavailability for the H2-antagonists ranges from 50 to 70%.,Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),%,50 to 70,45683,DB00501,Cimetidine
,1673880,terminal half-life,"All of the H2-antagonists are eliminated quite rapidly, with a terminal half-life of 1 to 3h and a total body clearance of 24 to 48 L/h.",Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),h,1 to 3,45684,DB00501,Cimetidine
,1673880,total body clearance,"All of the H2-antagonists are eliminated quite rapidly, with a terminal half-life of 1 to 3h and a total body clearance of 24 to 48 L/h.",Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),[l] / [h],24 to 48,45685,DB00501,Cimetidine
,1673880,renal clearances,"Elimination is mainly attributable to renal excretion, with renal clearances ranging from 13.8 to 30 L/h.",Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),[l] / [h],13.8 to 30,45686,DB00501,Cimetidine
,1839532,trough drug concentration at steady state (CSSmin),"Dose-corrected, trough drug concentration at steady state (CSSmin) and dose-corrected AUC24h were significantly higher in the patients with liver diseases than in the control subjects [3.4 vs 1.5 ng.",Pharmacokinetics of paroxetine in patients with cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1839532/),ng,3.4,46531,DB00501,Cimetidine
,1839532,dose-corrected AUC24h,"Dose-corrected, trough drug concentration at steady state (CSSmin) and dose-corrected AUC24h were significantly higher in the patients with liver diseases than in the control subjects [3.4 vs 1.5 ng.",Pharmacokinetics of paroxetine in patients with cirrhosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1839532/),ng,1.5,46532,DB00501,Cimetidine
,1839532,elimination t1/2,"The elimination t1/2 was prolonged [83 vs 36 h], but the difference was not statistically significant, and the cirrhotic patients were still able to clear almost all the paroxetine by metabolism.",Pharmacokinetics of paroxetine in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1839532/),h,83,46533,DB00501,Cimetidine
,1839532,elimination t1/2,"The elimination t1/2 was prolonged [83 vs 36 h], but the difference was not statistically significant, and the cirrhotic patients were still able to clear almost all the paroxetine by metabolism.",Pharmacokinetics of paroxetine in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1839532/),h,36,46534,DB00501,Cimetidine
,6734697,total plasma clearance,"Compared to a control group of 10 healthy volunteers, the total renal and nonrenal clearance was significantly reduced in the cirrhotic patients; (total plasma clearance mean +/- SD) 356 +/- 181 vs 789 +/- 262 ml/min (p less than 0.01); renal clearance (Clr) 296 +/- 100 vs 588 +/- 181 ml/min (p less than 0.01) and nonrenal clearance ( Clnr ) 97 +/- 111 vs 205 +/- 89 ml/min (p less than 0.05).",Pharmacokinetics of cimetidine in advanced cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734697/),[ml] / [min],356,47011,DB00501,Cimetidine
,6734697,total plasma clearance,"Compared to a control group of 10 healthy volunteers, the total renal and nonrenal clearance was significantly reduced in the cirrhotic patients; (total plasma clearance mean +/- SD) 356 +/- 181 vs 789 +/- 262 ml/min (p less than 0.01); renal clearance (Clr) 296 +/- 100 vs 588 +/- 181 ml/min (p less than 0.01) and nonrenal clearance ( Clnr ) 97 +/- 111 vs 205 +/- 89 ml/min (p less than 0.05).",Pharmacokinetics of cimetidine in advanced cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734697/),[ml] / [min],789,47012,DB00501,Cimetidine
,6734697,renal clearance (Clr),"Compared to a control group of 10 healthy volunteers, the total renal and nonrenal clearance was significantly reduced in the cirrhotic patients; (total plasma clearance mean +/- SD) 356 +/- 181 vs 789 +/- 262 ml/min (p less than 0.01); renal clearance (Clr) 296 +/- 100 vs 588 +/- 181 ml/min (p less than 0.01) and nonrenal clearance ( Clnr ) 97 +/- 111 vs 205 +/- 89 ml/min (p less than 0.05).",Pharmacokinetics of cimetidine in advanced cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734697/),[ml] / [min],296,47013,DB00501,Cimetidine
,6734697,renal clearance (Clr),"Compared to a control group of 10 healthy volunteers, the total renal and nonrenal clearance was significantly reduced in the cirrhotic patients; (total plasma clearance mean +/- SD) 356 +/- 181 vs 789 +/- 262 ml/min (p less than 0.01); renal clearance (Clr) 296 +/- 100 vs 588 +/- 181 ml/min (p less than 0.01) and nonrenal clearance ( Clnr ) 97 +/- 111 vs 205 +/- 89 ml/min (p less than 0.05).",Pharmacokinetics of cimetidine in advanced cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734697/),[ml] / [min],588,47014,DB00501,Cimetidine
,6734697,nonrenal clearance ( Clnr ),"Compared to a control group of 10 healthy volunteers, the total renal and nonrenal clearance was significantly reduced in the cirrhotic patients; (total plasma clearance mean +/- SD) 356 +/- 181 vs 789 +/- 262 ml/min (p less than 0.01); renal clearance (Clr) 296 +/- 100 vs 588 +/- 181 ml/min (p less than 0.01) and nonrenal clearance ( Clnr ) 97 +/- 111 vs 205 +/- 89 ml/min (p less than 0.05).",Pharmacokinetics of cimetidine in advanced cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734697/),[ml] / [min],97,47015,DB00501,Cimetidine
,6734697,nonrenal clearance ( Clnr ),"Compared to a control group of 10 healthy volunteers, the total renal and nonrenal clearance was significantly reduced in the cirrhotic patients; (total plasma clearance mean +/- SD) 356 +/- 181 vs 789 +/- 262 ml/min (p less than 0.01); renal clearance (Clr) 296 +/- 100 vs 588 +/- 181 ml/min (p less than 0.01) and nonrenal clearance ( Clnr ) 97 +/- 111 vs 205 +/- 89 ml/min (p less than 0.05).",Pharmacokinetics of cimetidine in advanced cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734697/),[ml] / [min],205,47016,DB00501,Cimetidine
,6734697,volume of distribution (Vd beta),"A significant reduction in volume of distribution (Vd beta) was found, from 2.1 +/- 0.1 l/kg in controls to 1.0 +/- 0.4 l/kg, and in the patient group there was a significant correlation between Vd beta and total plasma clearance (r = 0.72, p less than 0.05).",Pharmacokinetics of cimetidine in advanced cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734697/),[l] / [kg],2.1,47017,DB00501,Cimetidine
,6734697,volume of distribution (Vd beta),"A significant reduction in volume of distribution (Vd beta) was found, from 2.1 +/- 0.1 l/kg in controls to 1.0 +/- 0.4 l/kg, and in the patient group there was a significant correlation between Vd beta and total plasma clearance (r = 0.72, p less than 0.05).",Pharmacokinetics of cimetidine in advanced cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734697/),[l] / [kg],1.0,47018,DB00501,Cimetidine
,6734697,Bioavailability,"Bioavailability, estimated by AUC-measurement, showed considerable patient variability (21-143%), with a mean of 70 +/- 39%.",Pharmacokinetics of cimetidine in advanced cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734697/),%,70,47019,DB00501,Cimetidine
,6734697,bioavailability,"In contrast, measurement of urinary excretion showed higher bioavailability in the patients (66 +/- 23 vs 51 +/- 8%).",Pharmacokinetics of cimetidine in advanced cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734697/),%,66,47020,DB00501,Cimetidine
,6734697,bioavailability,"In contrast, measurement of urinary excretion showed higher bioavailability in the patients (66 +/- 23 vs 51 +/- 8%).",Pharmacokinetics of cimetidine in advanced cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734697/),%,51,47021,DB00501,Cimetidine
,6143815,peak plasma concentration,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),[ng] / [ml],560,47687,DB00501,Cimetidine
,6143815,peak plasma concentration,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),[ng] / [ml],498,47688,DB00501,Cimetidine
,6143815,time of peak concentration,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),h,2.0,47689,DB00501,Cimetidine
,6143815,time of peak concentration,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),h,2.1,47690,DB00501,Cimetidine
,6143815,volume of distribution,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),[l] / [kg],1.30,47691,DB00501,Cimetidine
,6143815,volume of distribution,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),[l] / [kg],1.39,47692,DB00501,Cimetidine
,6143815,elimination half-life,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),h,9.9,47693,DB00501,Cimetidine
,6143815,elimination half-life,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),h,11.4,47694,DB00501,Cimetidine
,6143815,total clearance,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),[ml] / [kg·min],1.59,47695,DB00501,Cimetidine
,6143815,total clearance,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),[ml] / [kg·min],1.60,47696,DB00501,Cimetidine
,6143815,free fraction,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),%,4.1,47697,DB00501,Cimetidine
,6143815,free fraction,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),%,3.8,47698,DB00501,Cimetidine
,3169118,Control half-life,Control half-life of tolbutamide 6.29 h was not significantly altered by cimetidine (6.93 h) or ranitidine (6.97 h).,Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),h,6.29,51051,DB00501,Cimetidine
,3169118,Control half-life,Control half-life of tolbutamide 6.29 h was not significantly altered by cimetidine (6.93 h) or ranitidine (6.97 h).,Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),h,6.93,51052,DB00501,Cimetidine
,3169118,Control half-life,Control half-life of tolbutamide 6.29 h was not significantly altered by cimetidine (6.93 h) or ranitidine (6.97 h).,Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),h,6.97,51053,DB00501,Cimetidine
,3169118,apparent oral clearance,"The corresponding apparent oral clearance (ml.min-1.kg-1) were not significantly different: 0.26 (control), 0.24 (cimetidine) and 0.25 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[ml] / [kg·min],0.26,51054,DB00501,Cimetidine
,3169118,apparent oral clearance,"The corresponding apparent oral clearance (ml.min-1.kg-1) were not significantly different: 0.26 (control), 0.24 (cimetidine) and 0.25 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[ml] / [kg·min],0.24,51055,DB00501,Cimetidine
,3169118,apparent oral clearance,"The corresponding apparent oral clearance (ml.min-1.kg-1) were not significantly different: 0.26 (control), 0.24 (cimetidine) and 0.25 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[ml] / [kg·min],0.25,51056,DB00501,Cimetidine
,3169118,Apparent volume of distribution,"Apparent volume of distribution was also unaltered 0.140 l.kg-1 (control), 0.141 l.kg-1 (cimetidine) and 0.146 l.kg-1 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[l] / [kg],0.140,51057,DB00501,Cimetidine
,3169118,Apparent volume of distribution,"Apparent volume of distribution was also unaltered 0.140 l.kg-1 (control), 0.141 l.kg-1 (cimetidine) and 0.146 l.kg-1 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[l] / [kg],0.141,51058,DB00501,Cimetidine
,3169118,Apparent volume of distribution,"Apparent volume of distribution was also unaltered 0.140 l.kg-1 (control), 0.141 l.kg-1 (cimetidine) and 0.146 l.kg-1 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[l] / [kg],0.146,51059,DB00501,Cimetidine
,8101096,AUC,The AUC of carebastine was not affected by cimetidine coadministration (4049 +/- 985 ng ml-1 h after cimetidine vs 3795 +/- 959 ng ml-1 h after placebo; 95% confidence interval of the difference: -412 to 919).,Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8101096/),[h·ng] / [ml],4049,52760,DB00501,Cimetidine
,8101096,AUC,The AUC of carebastine was not affected by cimetidine coadministration (4049 +/- 985 ng ml-1 h after cimetidine vs 3795 +/- 959 ng ml-1 h after placebo; 95% confidence interval of the difference: -412 to 919).,Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8101096/),[h·ng] / [ml],3795,52761,DB00501,Cimetidine
,6194997,area under the procainamide plasma concentration-time curve,The area under the procainamide plasma concentration-time curve was increased by cimetidine by an average of 35% from 27.0 +/- 0.3 micrograms/ml X h to 36.5 +/- 3.4 micrograms/ml X h.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),[μg] / [h·ml],27.0,53667,DB00501,Cimetidine
,6194997,area under the procainamide plasma concentration-time curve,The area under the procainamide plasma concentration-time curve was increased by cimetidine by an average of 35% from 27.0 +/- 0.3 micrograms/ml X h to 36.5 +/- 3.4 micrograms/ml X h.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),[μg] / [h·ml],36.5,53668,DB00501,Cimetidine
,6194997,elimination half-life,The elimination half-life increased from an harmonic mean of 2.92 to 3.68 h.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),h,2.92,53669,DB00501,Cimetidine
,6194997,elimination half-life,The elimination half-life increased from an harmonic mean of 2.92 to 3.68 h.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),h,3.68,53670,DB00501,Cimetidine
,6194997,renal clearance,The renal clearance of procainamide was reduced by cimetidine from 347 +/- 46 ml/min to 196 +/- 11 ml/min.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),[ml] / [min],347,53671,DB00501,Cimetidine
,6194997,renal clearance,The renal clearance of procainamide was reduced by cimetidine from 347 +/- 46 ml/min to 196 +/- 11 ml/min.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),[ml] / [min],196,53672,DB00501,Cimetidine
,6194997,renal clearance,The area under the plasma concentration-time curve for n-acetylprocainamide was increased by a mean of 25% by cimetidine due to a significant (p less than 0.016) reduction in renal clearance from 258 +/- 60 ml/min to 197 +/- 59 ml/min.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),[ml] / [min],258,53673,DB00501,Cimetidine
,6194997,renal clearance,The area under the plasma concentration-time curve for n-acetylprocainamide was increased by a mean of 25% by cimetidine due to a significant (p less than 0.016) reduction in renal clearance from 258 +/- 60 ml/min to 197 +/- 59 ml/min.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),[ml] / [min],197,53674,DB00501,Cimetidine
,3741720,tmax,Six days pretreatment with cimetidine induced the following changes in flecainide kinetic parameters: average tmax was prolonged from 1.8 h to 3.6 h and total AUC increased significantly from 4779 to 6131 ng ml-1 h.,Altered pharmacokinetics of oral flecainide by cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741720/),h,1.8,53955,DB00501,Cimetidine
,3741720,tmax,Six days pretreatment with cimetidine induced the following changes in flecainide kinetic parameters: average tmax was prolonged from 1.8 h to 3.6 h and total AUC increased significantly from 4779 to 6131 ng ml-1 h.,Altered pharmacokinetics of oral flecainide by cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741720/),h,3.6,53956,DB00501,Cimetidine
,3741720,total AUC,Six days pretreatment with cimetidine induced the following changes in flecainide kinetic parameters: average tmax was prolonged from 1.8 h to 3.6 h and total AUC increased significantly from 4779 to 6131 ng ml-1 h.,Altered pharmacokinetics of oral flecainide by cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741720/),[h·ng] / [ml],4779,53957,DB00501,Cimetidine
,3741720,total AUC,Six days pretreatment with cimetidine induced the following changes in flecainide kinetic parameters: average tmax was prolonged from 1.8 h to 3.6 h and total AUC increased significantly from 4779 to 6131 ng ml-1 h.,Altered pharmacokinetics of oral flecainide by cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741720/),[h·ng] / [ml],6131,53958,DB00501,Cimetidine
,6858908,apparent oral clearance,Cimetidine reduced the mean apparent oral clearance of quinidine (+/- standard error of the mean) from 25.5 +/- 2.7 to 16.2 +/- 1.4 liters/h (p less than 0.05).,Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6858908/),[l] / [h],25.5,54585,DB00501,Cimetidine
,6858908,apparent oral clearance,Cimetidine reduced the mean apparent oral clearance of quinidine (+/- standard error of the mean) from 25.5 +/- 2.7 to 16.2 +/- 1.4 liters/h (p less than 0.05).,Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6858908/),[l] / [h],16.2,54586,DB00501,Cimetidine
,6858908,half-life,This was reflected in a 55% (range 30 to 109) increase in the mean half-life from 5.8 +/- 0.2 to 9.0 +/- 0.6 hours (p less than 0.05).,Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6858908/),h,5.8,54587,DB00501,Cimetidine
,6858908,half-life,This was reflected in a 55% (range 30 to 109) increase in the mean half-life from 5.8 +/- 0.2 to 9.0 +/- 0.6 hours (p less than 0.05).,Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6858908/),h,9.0,54588,DB00501,Cimetidine
,3998201,half-life,"Cimetidine did not significantly affect acetaminophen half-life, 2.38 hours (A), 2.65 hours (A + C), and 2.50 hours (A + C*).",Cimetidine--acetaminophen interaction in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),h,2.38,57103,DB00501,Cimetidine
,3998201,half-life,"Cimetidine did not significantly affect acetaminophen half-life, 2.38 hours (A), 2.65 hours (A + C), and 2.50 hours (A + C*).",Cimetidine--acetaminophen interaction in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),h,2.65,57104,DB00501,Cimetidine
,3998201,half-life,"Cimetidine did not significantly affect acetaminophen half-life, 2.38 hours (A), 2.65 hours (A + C), and 2.50 hours (A + C*).",Cimetidine--acetaminophen interaction in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),h,2.50,57105,DB00501,Cimetidine
,3998201,clearance,Acetaminophen clearance was minimally affected by cimetidine; the mean clearance of acetaminophen ranged from 4.16 (A + C*) to 5.57 mL/min/kg (A).,Cimetidine--acetaminophen interaction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),[ml] / [kg·min],4.16,57106,DB00501,Cimetidine
,3998201,clearance,Acetaminophen clearance was minimally affected by cimetidine; the mean clearance of acetaminophen ranged from 4.16 (A + C*) to 5.57 mL/min/kg (A).,Cimetidine--acetaminophen interaction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),[ml] / [kg·min],5.57,57107,DB00501,Cimetidine
,3998201,Area under the ace,"Area under the acetaminophen plasma concentration-time curve was slightly increased by cimetidine, 35.4 (A), 41.6 (A + C), and 47.6 micrograms/mL/h (A + C*).",Cimetidine--acetaminophen interaction in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),[μg] / [h·ml],35.4,57108,DB00501,Cimetidine
,3998201,Area under the ace,"Area under the acetaminophen plasma concentration-time curve was slightly increased by cimetidine, 35.4 (A), 41.6 (A + C), and 47.6 micrograms/mL/h (A + C*).",Cimetidine--acetaminophen interaction in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),[μg] / [h·ml],41.6,57109,DB00501,Cimetidine
,3998201,Area under the ace,"Area under the acetaminophen plasma concentration-time curve was slightly increased by cimetidine, 35.4 (A), 41.6 (A + C), and 47.6 micrograms/mL/h (A + C*).",Cimetidine--acetaminophen interaction in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),[μg] / [h·ml],47.6,57110,DB00501,Cimetidine
,7460483,clearance,"No differences were observed in cimetidine clearance between the group with peptic ulcer (556 +/- 44 ml/min, mean +/- SEM) and the group with cirrhosis (606 +/- 64 ml/min).",Cimetidine clearance and bioavailability in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460483/),[ml] / [min],556,58399,DB00501,Cimetidine
,7460483,clearance,"No differences were observed in cimetidine clearance between the group with peptic ulcer (556 +/- 44 ml/min, mean +/- SEM) and the group with cirrhosis (606 +/- 64 ml/min).",Cimetidine clearance and bioavailability in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460483/),[ml] / [min],606,58400,DB00501,Cimetidine
,7460483,bioavailability,The bioavailability of cimetidine was unchanged (84 +/- 4% and 97 +/- 7%).,Cimetidine clearance and bioavailability in hepatic cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460483/),%,84,58401,DB00501,Cimetidine
,7460483,bioavailability,The bioavailability of cimetidine was unchanged (84 +/- 4% and 97 +/- 7%).,Cimetidine clearance and bioavailability in hepatic cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460483/),%,97,58402,DB00501,Cimetidine
,4018106,total body clearance,"Compared with a group of adults, the children had a higher total body clearance (11.6 +/- 3.4 versus 7.0 +/- 2.5 ml/min per kg; P less than 0.005), a larger apparent volume of distribution (1.24 +/- 0.40 versus 0.80 +/- 0.24 l/kg; P less than 0.005) and a shorter elimination half-life (83 +/- 26 versus 122 +/- 16 min; P less than 0.001) of cimetidine.",Cimetidine pharmacokinetics and dosage requirements in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018106/),[ml] / [kg·min],11.6,59378,DB00501,Cimetidine
,4018106,total body clearance,"Compared with a group of adults, the children had a higher total body clearance (11.6 +/- 3.4 versus 7.0 +/- 2.5 ml/min per kg; P less than 0.005), a larger apparent volume of distribution (1.24 +/- 0.40 versus 0.80 +/- 0.24 l/kg; P less than 0.005) and a shorter elimination half-life (83 +/- 26 versus 122 +/- 16 min; P less than 0.001) of cimetidine.",Cimetidine pharmacokinetics and dosage requirements in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018106/),[ml] / [kg·min],7.0,59379,DB00501,Cimetidine
,4018106,apparent volume of distribution,"Compared with a group of adults, the children had a higher total body clearance (11.6 +/- 3.4 versus 7.0 +/- 2.5 ml/min per kg; P less than 0.005), a larger apparent volume of distribution (1.24 +/- 0.40 versus 0.80 +/- 0.24 l/kg; P less than 0.005) and a shorter elimination half-life (83 +/- 26 versus 122 +/- 16 min; P less than 0.001) of cimetidine.",Cimetidine pharmacokinetics and dosage requirements in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018106/),[l] / [kg],1.24,59380,DB00501,Cimetidine
,4018106,apparent volume of distribution,"Compared with a group of adults, the children had a higher total body clearance (11.6 +/- 3.4 versus 7.0 +/- 2.5 ml/min per kg; P less than 0.005), a larger apparent volume of distribution (1.24 +/- 0.40 versus 0.80 +/- 0.24 l/kg; P less than 0.005) and a shorter elimination half-life (83 +/- 26 versus 122 +/- 16 min; P less than 0.001) of cimetidine.",Cimetidine pharmacokinetics and dosage requirements in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018106/),[l] / [kg],0.80,59381,DB00501,Cimetidine
,4018106,elimination half-life,"Compared with a group of adults, the children had a higher total body clearance (11.6 +/- 3.4 versus 7.0 +/- 2.5 ml/min per kg; P less than 0.005), a larger apparent volume of distribution (1.24 +/- 0.40 versus 0.80 +/- 0.24 l/kg; P less than 0.005) and a shorter elimination half-life (83 +/- 26 versus 122 +/- 16 min; P less than 0.001) of cimetidine.",Cimetidine pharmacokinetics and dosage requirements in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018106/),min,83,59382,DB00501,Cimetidine
,4018106,elimination half-life,"Compared with a group of adults, the children had a higher total body clearance (11.6 +/- 3.4 versus 7.0 +/- 2.5 ml/min per kg; P less than 0.005), a larger apparent volume of distribution (1.24 +/- 0.40 versus 0.80 +/- 0.24 l/kg; P less than 0.005) and a shorter elimination half-life (83 +/- 26 versus 122 +/- 16 min; P less than 0.001) of cimetidine.",Cimetidine pharmacokinetics and dosage requirements in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018106/),min,122,59383,DB00501,Cimetidine
,4018106,Renal clearance,"Renal clearance in children comprised 70% of total body clearance, more than double that of adults (9.0 +/- 1.9 versus 4.2 +/- 2.1 ml/min per kg; P less than 0.001).",Cimetidine pharmacokinetics and dosage requirements in children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018106/),[ml] / [kg·min],9.0,59384,DB00501,Cimetidine
,4018106,Renal clearance,"Renal clearance in children comprised 70% of total body clearance, more than double that of adults (9.0 +/- 1.9 versus 4.2 +/- 2.1 ml/min per kg; P less than 0.001).",Cimetidine pharmacokinetics and dosage requirements in children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018106/),[ml] / [kg·min],4.2,59385,DB00501,Cimetidine
,8126258,clearance,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),[ml] / [kg·min],0.702,60985,DB00501,Cimetidine
,8126258,clearance,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),[ml] / [kg·min],0.641,60986,DB00501,Cimetidine
,8126258,clearance,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),[ml] / [kg·min],0.542,60987,DB00501,Cimetidine
,8126258,half-life,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),h,7.58,60988,DB00501,Cimetidine
,8126258,half-life,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),h,8.59,60989,DB00501,Cimetidine
,8126258,half-life,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),h,10.08,60990,DB00501,Cimetidine
,18330245,AUC,"The AUC of oxymatrine and oxymatrine-phospholipid complex were 4.52 mg x mL(-1) x h(-1) and 6.21 mg x mL(-1) x h(-1), respectively.",[Study on bioavilability of oxymatrine-phospholipid complex in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330245/),[mg] / [h·ml],4.52,61288,DB00501,Cimetidine
,18330245,AUC,"The AUC of oxymatrine and oxymatrine-phospholipid complex were 4.52 mg x mL(-1) x h(-1) and 6.21 mg x mL(-1) x h(-1), respectively.",[Study on bioavilability of oxymatrine-phospholipid complex in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330245/),[mg] / [h·ml],6.21,61289,DB00501,Cimetidine
,2262900,steady-state plasma concentrations,Sixteen sheep were administered both cimetidine and ranitidine in random order by a combination of bolus and i.v. infusion to achieve steady-state plasma concentrations of 1000 to 2000 ng/ml.,Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262900/),[ng] / [ml],1000 to 2000,61425,DB00501,Cimetidine
,2262900,renal clearance,Maternal renal clearance of cimetidine (0.51 +/- 0.18 l/min) and ranitidine (0.54 +/- 0.14 l/min) were not correlated with the period of gestation.,Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262900/),[l] / [min],0.51,61426,DB00501,Cimetidine
,2262900,renal clearance,Maternal renal clearance of cimetidine (0.51 +/- 0.18 l/min) and ranitidine (0.54 +/- 0.14 l/min) were not correlated with the period of gestation.,Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262900/),[l] / [min],0.54,61427,DB00501,Cimetidine
,2262900,renal clearance ratios,"Cimetidine/creatinine and ranitidine/creatinine renal clearance ratios were higher than unity being 5.48 +/- 1.91 and 5.65 +/- 1.18, respectively.",Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262900/),,5.48,61428,DB00501,Cimetidine
,2262900,renal clearance ratios,"Cimetidine/creatinine and ranitidine/creatinine renal clearance ratios were higher than unity being 5.48 +/- 1.91 and 5.65 +/- 1.18, respectively.",Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262900/),,5.65,61429,DB00501,Cimetidine
,2262900,renal clearance ratios,"At 80 days, cimetidine/creatinine and ranitidine/creatinine renal clearance ratios (3.0 and 4.4, respectively) were higher than unity and did not increase further during the remainder of gestation.",Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262900/),,3.0,61430,DB00501,Cimetidine
,2262900,renal clearance ratios,"At 80 days, cimetidine/creatinine and ranitidine/creatinine renal clearance ratios (3.0 and 4.4, respectively) were higher than unity and did not increase further during the remainder of gestation.",Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262900/),,4.4,61431,DB00501,Cimetidine
,2905991,elimination half-life,The elimination half-life of ibuprofen on placebo was 2.04 h.,Do nizatidine and cimetidine interact with ibuprofen? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905991/),h,2.04,61733,DB00501,Cimetidine
,2905991,elimination half-life,The elimination half-life of nizatidine on ibuprofen was 1.72 h and that of cimetidine was 3.54 h.,Do nizatidine and cimetidine interact with ibuprofen? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905991/),h,1.72,61734,DB00501,Cimetidine
,2905991,elimination half-life,The elimination half-life of nizatidine on ibuprofen was 1.72 h and that of cimetidine was 3.54 h.,Do nizatidine and cimetidine interact with ibuprofen? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905991/),h,3.54,61735,DB00501,Cimetidine
,3987177,ratio,"Cimetidine reduced the mean (+/- SD) ratio of prednisone dose to the plasma prednisolone AUC (16.6 +/- 2.9 L/hr) below that ratio after ranitidine (19.2 +/- 4.2 L/hr) and placebo (19.3 +/- 2.8 L/hr), and resulted in the lowest fractional excretion of prednisolone in the urine (5.2% +/- 2.2%, 9.8% +/- 4.5%, and 12.4% +/- 4.9%, respectively).",Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987177/),[l] / [h],16.6,62253,DB00501,Cimetidine
,3987177,ratio,"Cimetidine reduced the mean (+/- SD) ratio of prednisone dose to the plasma prednisolone AUC (16.6 +/- 2.9 L/hr) below that ratio after ranitidine (19.2 +/- 4.2 L/hr) and placebo (19.3 +/- 2.8 L/hr), and resulted in the lowest fractional excretion of prednisolone in the urine (5.2% +/- 2.2%, 9.8% +/- 4.5%, and 12.4% +/- 4.9%, respectively).",Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987177/),[l] / [h],19.2,62254,DB00501,Cimetidine
,6849776,trough levels,"3 During cimetidine treatment trough levels of theophylline increased 34% (6.4 +/- 0.8 to 8.6 +/- 1.0 micrograms/ml, P less than 0.05), half-life increased 48% (6.5 +/- 0.6 to 9.6 +/- 0.8 h, P less than 0.001), and total plasma clearance decreased 33% (3.88 +/- 0.46 to 2.59 +/- 0.33 l/h, P less than 0.001), without a significant change in volume of distribution or protein binding.",Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849776/),[μg] / [ml],6.4,66558,DB00501,Cimetidine
,6849776,trough levels,"3 During cimetidine treatment trough levels of theophylline increased 34% (6.4 +/- 0.8 to 8.6 +/- 1.0 micrograms/ml, P less than 0.05), half-life increased 48% (6.5 +/- 0.6 to 9.6 +/- 0.8 h, P less than 0.001), and total plasma clearance decreased 33% (3.88 +/- 0.46 to 2.59 +/- 0.33 l/h, P less than 0.001), without a significant change in volume of distribution or protein binding.",Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849776/),[μg] / [ml],8.6,66559,DB00501,Cimetidine
,6849776,half-life,"3 During cimetidine treatment trough levels of theophylline increased 34% (6.4 +/- 0.8 to 8.6 +/- 1.0 micrograms/ml, P less than 0.05), half-life increased 48% (6.5 +/- 0.6 to 9.6 +/- 0.8 h, P less than 0.001), and total plasma clearance decreased 33% (3.88 +/- 0.46 to 2.59 +/- 0.33 l/h, P less than 0.001), without a significant change in volume of distribution or protein binding.",Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849776/),h,6.5,66560,DB00501,Cimetidine
,6849776,half-life,"3 During cimetidine treatment trough levels of theophylline increased 34% (6.4 +/- 0.8 to 8.6 +/- 1.0 micrograms/ml, P less than 0.05), half-life increased 48% (6.5 +/- 0.6 to 9.6 +/- 0.8 h, P less than 0.001), and total plasma clearance decreased 33% (3.88 +/- 0.46 to 2.59 +/- 0.33 l/h, P less than 0.001), without a significant change in volume of distribution or protein binding.",Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849776/),h,9.6,66561,DB00501,Cimetidine
,6849776,total plasma clearance,"3 During cimetidine treatment trough levels of theophylline increased 34% (6.4 +/- 0.8 to 8.6 +/- 1.0 micrograms/ml, P less than 0.05), half-life increased 48% (6.5 +/- 0.6 to 9.6 +/- 0.8 h, P less than 0.001), and total plasma clearance decreased 33% (3.88 +/- 0.46 to 2.59 +/- 0.33 l/h, P less than 0.001), without a significant change in volume of distribution or protein binding.",Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849776/),[l] / [h],3.88,66562,DB00501,Cimetidine
,6849776,total plasma clearance,"3 During cimetidine treatment trough levels of theophylline increased 34% (6.4 +/- 0.8 to 8.6 +/- 1.0 micrograms/ml, P less than 0.05), half-life increased 48% (6.5 +/- 0.6 to 9.6 +/- 0.8 h, P less than 0.001), and total plasma clearance decreased 33% (3.88 +/- 0.46 to 2.59 +/- 0.33 l/h, P less than 0.001), without a significant change in volume of distribution or protein binding.",Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849776/),[l] / [h],2.59,66563,DB00501,Cimetidine
,6144699,elimination half-life,"Cimetidine likewise did not alter the elimination half-life of oxazepam (9.4 hours) or lorazepam (11.6 hours), and did not change total AUC for lorazepam.","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),h,9.4,66643,DB00501,Cimetidine
,6144699,elimination half-life,"Cimetidine likewise did not alter the elimination half-life of oxazepam (9.4 hours) or lorazepam (11.6 hours), and did not change total AUC for lorazepam.","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),h,11.6,66644,DB00501,Cimetidine
,6144699,elimination half-life,"In contrast, cimetidine prolonged desalkylflurazepam elimination half-life (141 vs. 94 hours, P less than 0.1) and increased AUC an average of 65 per cent (P less than 0.05).","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),h,141,66645,DB00501,Cimetidine
,6144699,elimination half-life,"In contrast, cimetidine prolonged desalkylflurazepam elimination half-life (141 vs. 94 hours, P less than 0.1) and increased AUC an average of 65 per cent (P less than 0.05).","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),h,94,66646,DB00501,Cimetidine
,6144699,AUC,"In contrast, cimetidine prolonged desalkylflurazepam elimination half-life (141 vs. 94 hours, P less than 0.1) and increased AUC an average of 65 per cent (P less than 0.05).","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),-1,65,66647,DB00501,Cimetidine
,4044466,peak time,The mean peak time was 1 h 29 min (after lag-time).,Pharmacokinetics of vibunazole (BAY n 7133) administered orally to healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4044466/),h,1,67075,DB00501,Cimetidine
,4044466,peak time,The mean peak time was 1 h 29 min (after lag-time).,Pharmacokinetics of vibunazole (BAY n 7133) administered orally to healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4044466/),min,29,67076,DB00501,Cimetidine
,4044466,lag-time,The mean peak time was 1 h 29 min (after lag-time).,Pharmacokinetics of vibunazole (BAY n 7133) administered orally to healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4044466/),min,29,67077,DB00501,Cimetidine
,4044466,peak concentration,The mean peak concentration was 2.76 mg/l.,Pharmacokinetics of vibunazole (BAY n 7133) administered orally to healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4044466/),[mg] / [l],2.76,67078,DB00501,Cimetidine
,4044466,elimination half-life,The mean elimination half-life of vibunazole was 2 h 22 min.,Pharmacokinetics of vibunazole (BAY n 7133) administered orally to healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4044466/),h,2,67079,DB00501,Cimetidine
,4044466,elimination half-life,The mean elimination half-life of vibunazole was 2 h 22 min.,Pharmacokinetics of vibunazole (BAY n 7133) administered orally to healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4044466/),min,22,67080,DB00501,Cimetidine
,4044466,absorption lag-time,"The mean absorption lag-time was 30 min, with considerable variation.",Pharmacokinetics of vibunazole (BAY n 7133) administered orally to healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4044466/),min,30,67081,DB00501,Cimetidine
,6128298,clearance,"In control experiments (no other drug present), antipyrine clearance was 32.5 +/- 0.9 ml per hr.",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],32.5,67082,DB00501,Cimetidine
,6128298,clearance,"This was greatly reduced in the presence of cimetidine (clearance = 10.1 +/- 0.8 and 5.8 +/- 1.5 ml per hr after 1 and 5 mg doses, p less than 0.01) and burimamide (4.5 +/- 0.6 and 3.0 +/- 1.7 ml per hr, p less than 0.001).",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],10.1,67083,DB00501,Cimetidine
,6128298,clearance,"This was greatly reduced in the presence of cimetidine (clearance = 10.1 +/- 0.8 and 5.8 +/- 1.5 ml per hr after 1 and 5 mg doses, p less than 0.01) and burimamide (4.5 +/- 0.6 and 3.0 +/- 1.7 ml per hr, p less than 0.001).",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],5.8,67084,DB00501,Cimetidine
,6128298,clearance,"This was greatly reduced in the presence of cimetidine (clearance = 10.1 +/- 0.8 and 5.8 +/- 1.5 ml per hr after 1 and 5 mg doses, p less than 0.01) and burimamide (4.5 +/- 0.6 and 3.0 +/- 1.7 ml per hr, p less than 0.001).",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],4.5,67085,DB00501,Cimetidine
,6128298,clearance,"This was greatly reduced in the presence of cimetidine (clearance = 10.1 +/- 0.8 and 5.8 +/- 1.5 ml per hr after 1 and 5 mg doses, p less than 0.01) and burimamide (4.5 +/- 0.6 and 3.0 +/- 1.7 ml per hr, p less than 0.001).",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],3.0,67086,DB00501,Cimetidine
,2882883,peak serum bromazepam concentrations,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ng] / [ml],132,67537,DB00501,Cimetidine
,2882883,peak serum bromazepam concentrations,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ng] / [ml],82,67538,DB00501,Cimetidine
,2882883,volume of distribution,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[l] / [kg],0.88,67539,DB00501,Cimetidine
,2882883,volume of distribution,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[l] / [kg],1.44,67540,DB00501,Cimetidine
,2882883,oral clearance,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ml] / [kg·min],0.41,67541,DB00501,Cimetidine
,2882883,oral clearance,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ml] / [kg·min],0.76,67542,DB00501,Cimetidine
,2882883,serum free fraction,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),,34,67543,DB00501,Cimetidine
,2882883,serum free fraction,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),,28.8,67544,DB00501,Cimetidine
,2882883,clearance,Coadministration of cimetidine (1.2 gm daily) significantly reduced bromazepam clearance (0.41 vs. 0.82 ml/min/kg) and prolonged elimination half-life (29 vs. 23 hours).,"Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ml] / [kg·min],0.41,67545,DB00501,Cimetidine
,2882883,clearance,Coadministration of cimetidine (1.2 gm daily) significantly reduced bromazepam clearance (0.41 vs. 0.82 ml/min/kg) and prolonged elimination half-life (29 vs. 23 hours).,"Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ml] / [kg·min],0.82,67546,DB00501,Cimetidine
,2882883,elimination half-life,Coadministration of cimetidine (1.2 gm daily) significantly reduced bromazepam clearance (0.41 vs. 0.82 ml/min/kg) and prolonged elimination half-life (29 vs. 23 hours).,"Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),h,29,67547,DB00501,Cimetidine
,2882883,elimination half-life,Coadministration of cimetidine (1.2 gm daily) significantly reduced bromazepam clearance (0.41 vs. 0.82 ml/min/kg) and prolonged elimination half-life (29 vs. 23 hours).,"Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),h,23,67548,DB00501,Cimetidine
,2882883,half-life,"Propranolol (160 mg daily) significantly prolonged bromazepam half-life (28 vs. 23 hours), but the reduction in clearance associated with propranolol (0.65 vs. 0.82 ml/min/kg) did not reach significance.","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),h,28,67549,DB00501,Cimetidine
,2882883,half-life,"Propranolol (160 mg daily) significantly prolonged bromazepam half-life (28 vs. 23 hours), but the reduction in clearance associated with propranolol (0.65 vs. 0.82 ml/min/kg) did not reach significance.","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),h,23,67550,DB00501,Cimetidine
,2882883,clearance,"Propranolol (160 mg daily) significantly prolonged bromazepam half-life (28 vs. 23 hours), but the reduction in clearance associated with propranolol (0.65 vs. 0.82 ml/min/kg) did not reach significance.","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ml] / [kg·min],0.65,67551,DB00501,Cimetidine
,2882883,clearance,"Propranolol (160 mg daily) significantly prolonged bromazepam half-life (28 vs. 23 hours), but the reduction in clearance associated with propranolol (0.65 vs. 0.82 ml/min/kg) did not reach significance.","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ml] / [kg·min],0.82,67552,DB00501,Cimetidine
,2882883,half-life,Bromazepam has the pharmacokinetic characteristics of benzodiazepines with half-life values between 20 and 30 hours.,"Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),h,20 and 30,67553,DB00501,Cimetidine
,8738810,TSc,"The median TSc decreased from 0.71 mumol/min (range, -0.24 to 5.90) in CP-1 to 0.30 mumol/min (range, -0.18 to 0.64) in CP-2 (P < 0.05).",Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738810/),[μM] / [min],0.71,67595,DB00501,Cimetidine
,8738810,TSc,"The median TSc decreased from 0.71 mumol/min (range, -0.24 to 5.90) in CP-1 to 0.30 mumol/min (range, -0.18 to 0.64) in CP-2 (P < 0.05).",Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738810/),[μM] / [min],0.30,67596,DB00501,Cimetidine
,8513649,peak plasma concentration,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[μg] / [l],12 to 22,68577,DB00501,Cimetidine
,8513649,volume of distribution,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[l] / [kg],0.8 to 1.3,68578,DB00501,Cimetidine
,8513649,elimination half-life,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),h,9 to 16,68579,DB00501,Cimetidine
,8513649,clearance,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[ml] / [kg·min],0.7 to 1.5,68580,DB00501,Cimetidine
,8513649,Absolute bioavailability,Absolute bioavailability of oral alprazolam averages 80 to 100%.,Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),%,80 to 100,68581,DB00501,Cimetidine
,8513649,steady-state plasma alpra,"Although a therapeutic concentration range is not clearly established, some studies indicate that optimal reduction of anxiety associated with panic disorder occurs at steady-state plasma alprazolam concentrations of 20 to 40 micrograms/L.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[μg] / [l],20 to 40,68582,DB00501,Cimetidine
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],547,69199,DB00501,Cimetidine
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],531,69200,DB00501,Cimetidine
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],563,69201,DB00501,Cimetidine
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],529,69202,DB00501,Cimetidine
more,84204,trough-concentrations,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/84204/),[μg] / [ml],1.25,69320,DB00501,Cimetidine
,84204,cerebrospinal fluid: serum ratio,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/84204/),,0.24,69321,DB00501,Cimetidine
,4006366,absorption t1/2,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,0.20,69837,DB00501,Cimetidine
,4006366,absorption t1/2,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,0.61,69838,DB00501,Cimetidine
,4006366,time to peak mexi,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,1.13,69839,DB00501,Cimetidine
,4006366,time to peak mexi,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,1.88,69840,DB00501,Cimetidine
,4006366,plasma concentration,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),mg,0.74,69841,DB00501,Cimetidine
,4006366,plasma concentration,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),mg,0.59,69842,DB00501,Cimetidine
,3858978,binding,"The binding is lower in the dog and rat (90 and 87%, respectively).",Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3858978/),%,90,71897,DB00501,Cimetidine
,3858978,binding,"The binding is lower in the dog and rat (90 and 87%, respectively).",Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3858978/),%,87,71898,DB00501,Cimetidine
,3858978,elimination half-life,"The mean elimination half-life in man and in the dog is about 1 hour, whereas half-lives in the range of 5 to 15 minutes have been recorded in the mouse.",Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3858978/),h,1,71899,DB00501,Cimetidine
,3858978,half-lives,"The mean elimination half-life in man and in the dog is about 1 hour, whereas half-lives in the range of 5 to 15 minutes have been recorded in the mouse.",Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3858978/),min,5 to 15,71900,DB00501,Cimetidine
,3858978,total body clearance,"In two studies in man, the mean total body clearance was 880 and 1097 ml X min-1, indicating that omeprazole belongs to the group of high clearance drugs.",Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3858978/),[ml] / [min],880,71901,DB00501,Cimetidine
,3858978,total body clearance,"In two studies in man, the mean total body clearance was 880 and 1097 ml X min-1, indicating that omeprazole belongs to the group of high clearance drugs.",Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3858978/),[ml] / [min],1097,71902,DB00501,Cimetidine
,3858978,total body clearance,"In the dog, too, the drug appears to be rapidly cleared from the blood, the mean total body clearance being about 10.5 ml X min-1 X kg-1.",Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3858978/),[ml] / [kg·min],10.5,71903,DB00501,Cimetidine
,2882837,half-lives,"Taxol disappearance from plasma was biphasic; half-lives of the first and second phases after a 275 mg/m2 dose were 0.32 and 8.6 h, respectively.",Phase I clinical and pharmacokinetic study of taxol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882837/),h,0.32,72315,DB00501,Cimetidine
,2882837,half-lives,"Taxol disappearance from plasma was biphasic; half-lives of the first and second phases after a 275 mg/m2 dose were 0.32 and 8.6 h, respectively.",Phase I clinical and pharmacokinetic study of taxol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882837/),h,8.6,72316,DB00501,Cimetidine
,2882837,apparent volume of distribution,"The apparent volume of distribution was 55 liters/m2, and the peak plasma concentration with a dose of 275 mg/m2, which occurred immediately postinfusion, was approximately 8 microM.",Phase I clinical and pharmacokinetic study of taxol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882837/),[l] / [m2],55,72317,DB00501,Cimetidine
,2882837,peak plasma concentration,"The apparent volume of distribution was 55 liters/m2, and the peak plasma concentration with a dose of 275 mg/m2, which occurred immediately postinfusion, was approximately 8 microM.",Phase I clinical and pharmacokinetic study of taxol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882837/),μM,8,72318,DB00501,Cimetidine
,23468261,Cmax,"The bioavailability parameters were found as: Cmax 1508.79 ± 37.95 ng/ml, Tmax 3.67 ± 0.17 h and AUC 14366.19 ± 377.64 ng h /mL.",Pharmacokinetic study of hydroxypropylmethylcellulose microparticles loaded with cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23468261/),[ng] / [ml],1508.79,72321,DB00501,Cimetidine
,23468261,Tmax,"The bioavailability parameters were found as: Cmax 1508.79 ± 37.95 ng/ml, Tmax 3.67 ± 0.17 h and AUC 14366.19 ± 377.64 ng h /mL.",Pharmacokinetic study of hydroxypropylmethylcellulose microparticles loaded with cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23468261/),h,3.67,72322,DB00501,Cimetidine
,23468261,AUC,"The bioavailability parameters were found as: Cmax 1508.79 ± 37.95 ng/ml, Tmax 3.67 ± 0.17 h and AUC 14366.19 ± 377.64 ng h /mL.",Pharmacokinetic study of hydroxypropylmethylcellulose microparticles loaded with cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23468261/),[h·ng] / [ml],14366.19,72323,DB00501,Cimetidine
,10628898,absolute bioavailability,The absolute bioavailability of the active metabolite from orally administered oseltamivir is 80%.,Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10628898/),%,80,74584,DB00501,Cimetidine
,10628898,apparent half-life,"After peak plasma concentrations are attained, the concentration of the active metabolite declines with an apparent half-life of 6 to 10 hours.",Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10628898/),h,6 to 10,74585,DB00501,Cimetidine
,6108390,recovery,The assay is linear (r2 = 0.99) and the recovery is 97.6 +/- 6.38% over a concentration range of 0.050-5.00 microgram/mL.,"Quantitative high-performance liquid chromatography determination of ICI 125,211 in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108390/),%,97.6,75601,DB00501,Cimetidine
,6108390,whole blood/plasma ratio,The whole blood/plasma ratio averages 0.97 +/- .073 for dog blood (N = 5).,"Quantitative high-performance liquid chromatography determination of ICI 125,211 in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108390/),,0.97,75602,DB00501,Cimetidine
,6108390,elimination half-life,Pharmacokinetic data gathered for two dogs dosed orally with an HPMC-TWEEN 80 suspension of (I) at 40 mg/kg gave elimination half-life values of 4.3 and 7.4 hours.,"Quantitative high-performance liquid chromatography determination of ICI 125,211 in plasma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108390/),h,4.3,75603,DB00501,Cimetidine
,6108390,elimination half-life,Pharmacokinetic data gathered for two dogs dosed orally with an HPMC-TWEEN 80 suspension of (I) at 40 mg/kg gave elimination half-life values of 4.3 and 7.4 hours.,"Quantitative high-performance liquid chromatography determination of ICI 125,211 in plasma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108390/),h,7.4,75604,DB00501,Cimetidine
,29551575,renal clearance,"Insulin treated diabetic animals showed higher renal clearance compared to control (vehicle + GAB: 0.25 [0.18-0.30] L/h·kg; DM + GAB + insulin: 0.55 [0.45-1.43] L/h·kg), which was attributed to the diabetes-induced glomerular hyperfiltration.","The role of organic cation transporter 2 inhibitor cimetidine, experimental diabetes mellitus and metformin on gabapentin pharmacokinetics in rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29551575/),[l] / [h·kg],0.25,77927,DB00501,Cimetidine
,29551575,renal clearance,"Insulin treated diabetic animals showed higher renal clearance compared to control (vehicle + GAB: 0.25 [0.18-0.30] L/h·kg; DM + GAB + insulin: 0.55 [0.45-1.43] L/h·kg), which was attributed to the diabetes-induced glomerular hyperfiltration.","The role of organic cation transporter 2 inhibitor cimetidine, experimental diabetes mellitus and metformin on gabapentin pharmacokinetics in rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29551575/),[l] / [h·kg],0.55,77928,DB00501,Cimetidine
greater,2895125,basal secretion,"Nizatidine was studied in six high-acid-secretor (basal secretion, greater than or equal to 5 mEq/hr) male volunteers in a randomized, double-blind, nonbalanced, cross-over, placebo and standard drug-controlled study.",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [h],5,79356,DB00501,Cimetidine
,2895125,Nocturnal,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,36,79357,DB00501,Cimetidine
,2895125,Nocturnal,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,36,79358,DB00501,Cimetidine
,2895125,Nocturnal,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,43,79359,DB00501,Cimetidine
,2895125,acid output,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,36,79360,DB00501,Cimetidine
,2895125,acid output,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,36,79361,DB00501,Cimetidine
,2895125,acid output,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,26,79362,DB00501,Cimetidine
,2895125,acid output,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,43,79363,DB00501,Cimetidine
,2895125,acid output,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,101,79364,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],14,79365,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],9,79366,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],5,79367,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),m,50,79368,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),m,57,79369,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),m,50,79370,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],65,79371,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],78,79372,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],71,79373,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],25,79374,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],27,79375,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],31,79376,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],81,79377,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],76,79378,DB00501,Cimetidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],66,79379,DB00501,Cimetidine
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],378,80807,DB00501,Cimetidine
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],309,80808,DB00501,Cimetidine
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],66.7,80809,DB00501,Cimetidine
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],48,80810,DB00501,Cimetidine
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],42.9,80811,DB00501,Cimetidine
,4064467,peak serum ibuprofen concentration,"Compared with the control state, cimetidine increased the peak serum ibuprofen concentration (64 vs. 56 micrograms/ml), but the value during ranitidine dosing (57 micrograms/ml) was indistinguishable from the control value.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[μg] / [ml],64,80890,DB00501,Cimetidine
,4064467,peak serum ibuprofen concentration,"Compared with the control state, cimetidine increased the peak serum ibuprofen concentration (64 vs. 56 micrograms/ml), but the value during ranitidine dosing (57 micrograms/ml) was indistinguishable from the control value.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[μg] / [ml],56,80891,DB00501,Cimetidine
,4064467,peak serum ibuprofen concentration,"Compared with the control state, cimetidine increased the peak serum ibuprofen concentration (64 vs. 56 micrograms/ml), but the value during ranitidine dosing (57 micrograms/ml) was indistinguishable from the control value.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[μg] / [ml],57,80892,DB00501,Cimetidine
,4064467,elimination t1/2,"There were no significant differences between control, cimetidine, and ranitidine conditions in ibuprofen elimination t1/2 (2.1, 2.1, and 2.0 hours, respectively).",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),h,2.1,80893,DB00501,Cimetidine
,4064467,elimination t1/2,"There were no significant differences between control, cimetidine, and ranitidine conditions in ibuprofen elimination t1/2 (2.1, 2.1, and 2.0 hours, respectively).",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),h,2.0,80894,DB00501,Cimetidine
,4064467,oral clearance,"Overall there was a significant difference among the control, cimetidine, and ranitidine conditions in ibuprofen oral clearance (52.8, 48.3, and 54.1 ml/min, respectively), but individual differences in cimetidine vs. control and between ranitidine vs. control were not statistically significant.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[ml] / [min],52.8,80895,DB00501,Cimetidine
,4064467,oral clearance,"Overall there was a significant difference among the control, cimetidine, and ranitidine conditions in ibuprofen oral clearance (52.8, 48.3, and 54.1 ml/min, respectively), but individual differences in cimetidine vs. control and between ranitidine vs. control were not statistically significant.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[ml] / [min],48.3,80896,DB00501,Cimetidine
,4064467,oral clearance,"Overall there was a significant difference among the control, cimetidine, and ranitidine conditions in ibuprofen oral clearance (52.8, 48.3, and 54.1 ml/min, respectively), but individual differences in cimetidine vs. control and between ranitidine vs. control were not statistically significant.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[ml] / [min],54.1,80897,DB00501,Cimetidine
,16120067,t(1/2),"Co-administration with cimetidine caused a moderate increase in the systemic exposure [AUC0, infinity] to escitalopram (geometric mean ratio = 1.72, [95% CI 1.34, 2.21]) and a small increase in t(1/2) from 23.7 to 29.0 h (5.24 h [3.75, 6.70]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,23.7,81356,DB00501,Cimetidine
,16120067,t(1/2),"Co-administration with cimetidine caused a moderate increase in the systemic exposure [AUC0, infinity] to escitalopram (geometric mean ratio = 1.72, [95% CI 1.34, 2.21]) and a small increase in t(1/2) from 23.7 to 29.0 h (5.24 h [3.75, 6.70]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,29.0,81357,DB00501,Cimetidine
,16120067,t(1/2),"Co-administration with cimetidine caused a moderate increase in the systemic exposure [AUC0, infinity] to escitalopram (geometric mean ratio = 1.72, [95% CI 1.34, 2.21]) and a small increase in t(1/2) from 23.7 to 29.0 h (5.24 h [3.75, 6.70]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,5.24,81358,DB00501,Cimetidine
,16120067,"AUC(0, infinity)","Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),,1.51,81359,DB00501,Cimetidine
,16120067,t(1/2),"Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,26.5,81360,DB00501,Cimetidine
,16120067,t(1/2),"Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,34.8,81361,DB00501,Cimetidine
,16120067,t(1/2),"Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,8.3,81362,DB00501,Cimetidine
,1602396,systemic disease (CL),"Nursing rabbits and suckling offspring exhibited similar pharmacokinetics with a mean systemic disease (CL) in the adults and pups of 22.0 +/- 5.2 and 30.4 +/- 8.9 ml/min/kg, respectively.",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),[ml] / [kg·min],22.0,81855,DB00501,Cimetidine
,1602396,systemic disease (CL),"Nursing rabbits and suckling offspring exhibited similar pharmacokinetics with a mean systemic disease (CL) in the adults and pups of 22.0 +/- 5.2 and 30.4 +/- 8.9 ml/min/kg, respectively.",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),[ml] / [kg·min],30.4,81856,DB00501,Cimetidine
,1602396,distribution,"Cimetidine exhibited a distributional time lag and a prolonged T 1/2 in milk compared to serum (70 +/- 15 vs. 33 +/- 5 min), resulting in a time-dependent milk to serum (M/S) drug concentration ratio.",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),min,70,81857,DB00501,Cimetidine
,1602396,T 1/2,"Cimetidine exhibited a distributional time lag and a prolonged T 1/2 in milk compared to serum (70 +/- 15 vs. 33 +/- 5 min), resulting in a time-dependent milk to serum (M/S) drug concentration ratio.",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),min,70,81858,DB00501,Cimetidine
,1602396,T 1/2,"Cimetidine exhibited a distributional time lag and a prolonged T 1/2 in milk compared to serum (70 +/- 15 vs. 33 +/- 5 min), resulting in a time-dependent milk to serum (M/S) drug concentration ratio.",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),min,33,81859,DB00501,Cimetidine
,1602396,M/S ratio,The ratio of the area under the time curve of cimetidine in serum and milk was 1.49 +/- 0.37 and was comparable to a diffusional model predicted M/S ratio of 1.16 +/- 0.11.,Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),,1.16,81860,DB00501,Cimetidine
,1602396,Unbound CL,"Unbound CL after a high cimetidine infusion regimen (16.6 +/- 7.3 ml/min/kg) was significantly less than that after two lower infusion rates (26.2 +/- 4.9 and 29.4 +/- 12.3 ml/min/kg, respectively).",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),[ml] / [kg·min],16.6,81861,DB00501,Cimetidine
,1602396,Unbound CL,"Unbound CL after a high cimetidine infusion regimen (16.6 +/- 7.3 ml/min/kg) was significantly less than that after two lower infusion rates (26.2 +/- 4.9 and 29.4 +/- 12.3 ml/min/kg, respectively).",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),[ml] / [kg·min],26.2,81862,DB00501,Cimetidine
,1602396,Unbound CL,"Unbound CL after a high cimetidine infusion regimen (16.6 +/- 7.3 ml/min/kg) was significantly less than that after two lower infusion rates (26.2 +/- 4.9 and 29.4 +/- 12.3 ml/min/kg, respectively).",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),[ml] / [kg·min],29.4,81863,DB00501,Cimetidine
,1602396,M/S,"M/S determined at increasing steady-state serum concentrations were 1.03, 1.08 and 1.08, respectively, which agreed well with the corresponding predicted M/S (1.06, 1.14 and 1.13, respectively).",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),,1.03,81864,DB00501,Cimetidine
,1602396,M/S,"M/S determined at increasing steady-state serum concentrations were 1.03, 1.08 and 1.08, respectively, which agreed well with the corresponding predicted M/S (1.06, 1.14 and 1.13, respectively).",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),,1.08,81865,DB00501,Cimetidine
,1602396,M/S,"M/S determined at increasing steady-state serum concentrations were 1.03, 1.08 and 1.08, respectively, which agreed well with the corresponding predicted M/S (1.06, 1.14 and 1.13, respectively).",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),,1.06,81866,DB00501,Cimetidine
,1602396,M/S,"M/S determined at increasing steady-state serum concentrations were 1.03, 1.08 and 1.08, respectively, which agreed well with the corresponding predicted M/S (1.06, 1.14 and 1.13, respectively).",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),,1.14,81867,DB00501,Cimetidine
,1602396,M/S,"M/S determined at increasing steady-state serum concentrations were 1.03, 1.08 and 1.08, respectively, which agreed well with the corresponding predicted M/S (1.06, 1.14 and 1.13, respectively).",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),,1.13,81868,DB00501,Cimetidine
,1602396,CL,"Cimetidine was also administered to lactating rats and resulted in a concentration-dependent decrease in CL (11.2 +/- 1.5, 10.8 +/- 2.7 and 7.30 +/- 1.0 ml/min, respectively) after three increasing infusion rates.",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),[ml] / [min],11.2,81869,DB00501,Cimetidine
,1602396,CL,"Cimetidine was also administered to lactating rats and resulted in a concentration-dependent decrease in CL (11.2 +/- 1.5, 10.8 +/- 2.7 and 7.30 +/- 1.0 ml/min, respectively) after three increasing infusion rates.",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),[ml] / [min],10.8,81870,DB00501,Cimetidine
,1602396,CL,"Cimetidine was also administered to lactating rats and resulted in a concentration-dependent decrease in CL (11.2 +/- 1.5, 10.8 +/- 2.7 and 7.30 +/- 1.0 ml/min, respectively) after three increasing infusion rates.",Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),[ml] / [min],7.30,81871,DB00501,Cimetidine
,1602396,steady-state M/S ratio,The steady-state M/S ratio decreased slightly from 31.9 +/- 9.0 to 26.5 +/- 9.5 and 24.6 +/- 6.4 with the increasing infusion rate.,Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),,31.9,81872,DB00501,Cimetidine
,1602396,steady-state M/S ratio,The steady-state M/S ratio decreased slightly from 31.9 +/- 9.0 to 26.5 +/- 9.5 and 24.6 +/- 6.4 with the increasing infusion rate.,Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),,26.5,81873,DB00501,Cimetidine
,1602396,steady-state M/S ratio,The steady-state M/S ratio decreased slightly from 31.9 +/- 9.0 to 26.5 +/- 9.5 and 24.6 +/- 6.4 with the increasing infusion rate.,Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),,24.6,81874,DB00501,Cimetidine
,1602396,M/S,Steady-state M/S values were 6-fold higher than the predicted M/S value (4.19).,Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1602396/),,4.19,81875,DB00501,Cimetidine
,3792426,t 1/2,Cimetidine preadministration statistically prolonged imipramine t 1/2 compared to ranitidine (22.7 vs. 13.0 h) or placebo (10.8 h).,The effect of ranitidine and cimetidine on imipramine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),h,22.7,82118,DB00501,Cimetidine
,3792426,t 1/2,Cimetidine preadministration statistically prolonged imipramine t 1/2 compared to ranitidine (22.7 vs. 13.0 h) or placebo (10.8 h).,The effect of ranitidine and cimetidine on imipramine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),h,13.0,82119,DB00501,Cimetidine
,3792426,t 1/2,Cimetidine preadministration statistically prolonged imipramine t 1/2 compared to ranitidine (22.7 vs. 13.0 h) or placebo (10.8 h).,The effect of ranitidine and cimetidine on imipramine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),h,10.8,82120,DB00501,Cimetidine
,3792426,area under the curve (AUC),Mean imipramine area under the curve (AUC) following cimetidine pretreatment was more than double that following placebo (2.633 vs. 0.966 micrograms X h X ml-1) or ranitidine (1.14 micrograms X h X ml-1) pretreatment.,The effect of ranitidine and cimetidine on imipramine disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),[h·μg] / [ml],2.633,82121,DB00501,Cimetidine
,3792426,area under the curve (AUC),Mean imipramine area under the curve (AUC) following cimetidine pretreatment was more than double that following placebo (2.633 vs. 0.966 micrograms X h X ml-1) or ranitidine (1.14 micrograms X h X ml-1) pretreatment.,The effect of ranitidine and cimetidine on imipramine disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),[h·μg] / [ml],0.966,82122,DB00501,Cimetidine
,3792426,area under the curve (AUC),Mean imipramine area under the curve (AUC) following cimetidine pretreatment was more than double that following placebo (2.633 vs. 0.966 micrograms X h X ml-1) or ranitidine (1.14 micrograms X h X ml-1) pretreatment.,The effect of ranitidine and cimetidine on imipramine disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),[h·μg] / [ml],1.14,82123,DB00501,Cimetidine
,7141756,Oral bioavailability,Oral bioavailability of cimetidine was about 94% compared to that of the i.v. route.,Oral and intravenous pharmacokinetics of cimetidine in liver cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7141756/),%,94,82176,DB00501,Cimetidine
,20519552,K(m),In vitro studies conducted to characterize the transporters involved demonstrated PNU-288034 uptake by human organic anion transporter 3 (OAT3; K(m) = 44 +/- 5 microM) and human multidrug and toxin extrusion protein 1 (hMATE1; K(m) = 340 +/- 55 microM).,Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20519552/),μM,44,83674,DB00501,Cimetidine
,20519552,K(m),In vitro studies conducted to characterize the transporters involved demonstrated PNU-288034 uptake by human organic anion transporter 3 (OAT3; K(m) = 44 +/- 5 microM) and human multidrug and toxin extrusion protein 1 (hMATE1; K(m) = 340 +/- 55 microM).,Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20519552/),μM,340,83675,DB00501,Cimetidine
,7259925,overall rates of healing,The overall rates of healing were 63% and 79% of patients after 3 and after 6 months of treatment respectively.,Cimetidine-a clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7259925/),%,63,84555,DB00501,Cimetidine
,7259925,overall rates of healing,The overall rates of healing were 63% and 79% of patients after 3 and after 6 months of treatment respectively.,Cimetidine-a clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7259925/),%,79,84556,DB00501,Cimetidine
,7259925,elimination half-life,"4 Pharmacokinetic studies showed the mean elimination half-life of cimetidine to be 100 +/- 25 min, the total body cimetidine clearance 652 +/- 223 ml/min, the mean volume of distribution at steady state 65 +/- 181 and the overall bioavailability 78%.",Cimetidine-a clinical and pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7259925/),min,100,84557,DB00501,Cimetidine
,7259925,total body cime,"4 Pharmacokinetic studies showed the mean elimination half-life of cimetidine to be 100 +/- 25 min, the total body cimetidine clearance 652 +/- 223 ml/min, the mean volume of distribution at steady state 65 +/- 181 and the overall bioavailability 78%.",Cimetidine-a clinical and pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7259925/),[ml] / [min],652,84558,DB00501,Cimetidine
,7259925,volume of distribution at steady state,"4 Pharmacokinetic studies showed the mean elimination half-life of cimetidine to be 100 +/- 25 min, the total body cimetidine clearance 652 +/- 223 ml/min, the mean volume of distribution at steady state 65 +/- 181 and the overall bioavailability 78%.",Cimetidine-a clinical and pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7259925/),,65,84559,DB00501,Cimetidine
,7259925,overall bioavailability,"4 Pharmacokinetic studies showed the mean elimination half-life of cimetidine to be 100 +/- 25 min, the total body cimetidine clearance 652 +/- 223 ml/min, the mean volume of distribution at steady state 65 +/- 181 and the overall bioavailability 78%.",Cimetidine-a clinical and pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7259925/),%,78,84560,DB00501,Cimetidine
,6780369,elimination half-life,"Cimetidine significantly impaired (p = 0.03) the elimination of desmethyldiazepam, as shown prolongation of its elimination half-life from 51.7 +/- 21.9 h to 72.6 +/- 39.4 h (mean +/- SD), and a decrease in total plasma clearance from 12.0 +/- 2.7 ml/min to 8.6 +/- 3.3 ml/min.",Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780369/),h,51.7,85671,DB00501,Cimetidine
,6780369,elimination half-life,"Cimetidine significantly impaired (p = 0.03) the elimination of desmethyldiazepam, as shown prolongation of its elimination half-life from 51.7 +/- 21.9 h to 72.6 +/- 39.4 h (mean +/- SD), and a decrease in total plasma clearance from 12.0 +/- 2.7 ml/min to 8.6 +/- 3.3 ml/min.",Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780369/),h,72.6,85672,DB00501,Cimetidine
,6780369,total plasma clearance,"Cimetidine significantly impaired (p = 0.03) the elimination of desmethyldiazepam, as shown prolongation of its elimination half-life from 51.7 +/- 21.9 h to 72.6 +/- 39.4 h (mean +/- SD), and a decrease in total plasma clearance from 12.0 +/- 2.7 ml/min to 8.6 +/- 3.3 ml/min.",Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780369/),[ml] / [min],12.0,85673,DB00501,Cimetidine
,6780369,total plasma clearance,"Cimetidine significantly impaired (p = 0.03) the elimination of desmethyldiazepam, as shown prolongation of its elimination half-life from 51.7 +/- 21.9 h to 72.6 +/- 39.4 h (mean +/- SD), and a decrease in total plasma clearance from 12.0 +/- 2.7 ml/min to 8.6 +/- 3.3 ml/min.",Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780369/),[ml] / [min],8.6,85674,DB00501,Cimetidine
,7897151,area under the curve,"When hydroxyzine was administered with cimetidine, the partial hydroxyzine area under the curve increased significantly (p < 0.05) to 303 +/- 92 ng/ml/hr from 227 +/- 77 ng/ml/hr after administration of hydroxyzine alone, and the concentration of cetirizine arising from hydroxyzine was lower.",Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7897151/),[ng] / [h·ml],303,87715,DB00501,Cimetidine
,7897151,area under the curve,"When hydroxyzine was administered with cimetidine, the partial hydroxyzine area under the curve increased significantly (p < 0.05) to 303 +/- 92 ng/ml/hr from 227 +/- 77 ng/ml/hr after administration of hydroxyzine alone, and the concentration of cetirizine arising from hydroxyzine was lower.",Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7897151/),[ng] / [h·ml],227,87716,DB00501,Cimetidine
,7154136,half-life,Her serum acetaminophen concentration at 22 h was 485 micrograms/mL and declined with an unusually long half-life of 14 h.,Massive intoxication with acetaminophen and propoxyphene: unexpected survival and unusual pharmacokinetics of acetaminophen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7154136/),h,14,87767,DB00501,Cimetidine
,6364798,Elimination half-life,Elimination half-life was not different between obese and control subjects (2.23 versus 2.08 h).,Cimetidine disposition in obesity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6364798/),h,2.23,88669,DB00501,Cimetidine
,6364798,Elimination half-life,Elimination half-life was not different between obese and control subjects (2.23 versus 2.08 h).,Cimetidine disposition in obesity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6364798/),h,2.08,88670,DB00501,Cimetidine
,6364798,Apparent volume of distribution,"Apparent volume of distribution was also similar between subject groups (120 versus 106), as was total metabolic clearance (616 versus 579 ml/min).",Cimetidine disposition in obesity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6364798/),,120,88671,DB00501,Cimetidine
,6364798,Apparent volume of distribution,"Apparent volume of distribution was also similar between subject groups (120 versus 106), as was total metabolic clearance (616 versus 579 ml/min).",Cimetidine disposition in obesity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6364798/),,106,88672,DB00501,Cimetidine
,6364798,total metabolic clearance,"Apparent volume of distribution was also similar between subject groups (120 versus 106), as was total metabolic clearance (616 versus 579 ml/min).",Cimetidine disposition in obesity. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6364798/),[ml] / [min],616,88673,DB00501,Cimetidine
,6364798,total metabolic clearance,"Apparent volume of distribution was also similar between subject groups (120 versus 106), as was total metabolic clearance (616 versus 579 ml/min).",Cimetidine disposition in obesity. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6364798/),[ml] / [min],579,88674,DB00501,Cimetidine
,6538427,half-life,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),h,12.7,90690,DB00501,Cimetidine
,6538427,half-life,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),h,15.5,90691,DB00501,Cimetidine
,6538427,total plasma clearance,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),[ml] / [min],40.9,90692,DB00501,Cimetidine
,6538427,total plasma clearance,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),[ml] / [min],33.9,90693,DB00501,Cimetidine
,11510628,time to reach maximum observed plasma concentration,"In pharmacokinetic studies in humans, quetiapine was rapidly absorbed after oral administration, with median time to reach maximum observed plasma concentration ranging from 1 to 2 hours.",Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,1 to 2,91263,DB00501,Cimetidine
,11510628,terminal half-life,The drug is eliminated with a mean terminal half-life of approximately 7 hours.,Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,7,91264,DB00501,Cimetidine
,9350255,plasma clearance (Cl),The median (range) plasma clearance (Cl) was 8.20 (4.96-10.2) mL/min.,Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350255/),[ml] / [min],8.20,92144,DB00501,Cimetidine
,9350255,steady-state volume of distribution (Vdss),"kg of body weight, that of the steady-state volume of distribution (Vdss) was 0.771 (0.521-1.15) L/kg bw, and that of the terminal elimination half-life (t1/2 beta) was 92.4 (70.6-125) minutes.",Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350255/),[l] / [bw·kg],0.771,92145,DB00501,Cimetidine
,9350255,terminal elimination half-life (t1/2 beta),"kg of body weight, that of the steady-state volume of distribution (Vdss) was 0.771 (0.521-1.15) L/kg bw, and that of the terminal elimination half-life (t1/2 beta) was 92.4 (70.6-125) minutes.",Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350255/),min,92.4,92146,DB00501,Cimetidine
,9350255,renal clearance,The median (range) renal clearance of cimetidine was 4.08 (2.19-6.23) mL/min.kg bw or 55.4 (36.3-81.8)% of the corresponding plasma clearance.,Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350255/),[ml] / [bw·kg·min],4.08,92147,DB00501,Cimetidine
,9350255,renal clearance,The median (range) renal clearance of cimetidine was 4.08 (2.19-6.23) mL/min.kg bw or 55.4 (36.3-81.8)% of the corresponding plasma clearance.,Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350255/),,55.,92148,DB00501,Cimetidine
,9350255,bioavailability,The median (range) extent of intragastric bioavailability was 14.4 (6.82-21.8)% and the maximum plasma concentration after intragastric administration was 0.31 (0.24-0.50) microgram/mL.,Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350255/),%,14.4,92149,DB00501,Cimetidine
,9350255,maximum plasma concentration,The median (range) extent of intragastric bioavailability was 14.4 (6.82-21.8)% and the maximum plasma concentration after intragastric administration was 0.31 (0.24-0.50) microgram/mL.,Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350255/),[μg] / [ml],0.31,92150,DB00501,Cimetidine
,6883944,bioavailability,The bioavailability of cimetidine was not significantly different between the two groups (78 +/- 15% in patients with SIRF and 62 +/- 17% in the NRF subjects).,Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883944/),%,78,92158,DB00501,Cimetidine
,6883944,bioavailability,The bioavailability of cimetidine was not significantly different between the two groups (78 +/- 15% in patients with SIRF and 62 +/- 17% in the NRF subjects).,Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883944/),%,62,92159,DB00501,Cimetidine
,6883944,serum half-life (t1/2),"In subjects with NRF, a mean of 50.4% of the i.v. dose was excreted renally as unchanged drug and the mean serum half-life (t1/2) was 2.00 hours.",Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883944/),h,2.00,92160,DB00501,Cimetidine
,6883944,total body,"The mean total body and renal clearances were 710.0 and 370.7 ml/min, respectively.",Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883944/),[ml] / [min],710.0,92161,DB00501,Cimetidine
,6883944,renal clearances,"The mean total body and renal clearances were 710.0 and 370.7 ml/min, respectively.",Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883944/),[ml] / [min],370.7,92162,DB00501,Cimetidine
,6883944,t1/2,"In the SIRF group, a mean of 1.7% of the i.v. dose was excreted renally unchanged, and the mean t1/2 was 12.71 hours.",Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883944/),h,12.71,92163,DB00501,Cimetidine
,6883944,total body,"The total body and renal clearances were 147.1 and 2.5 ml/min, respectively.",Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883944/),[ml] / [min],147.1,92164,DB00501,Cimetidine
,6883944,renal clearances,"The total body and renal clearances were 147.1 and 2.5 ml/min, respectively.",Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883944/),[ml] / [min],2.5,92165,DB00501,Cimetidine
,8558221,overall response proportion,"The overall response proportion (CRs plus PRs) was 54% (95% confidence interval, 37% to 71%).",Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558221/),%,54,92272,DB00501,Cimetidine
,8558221,time to response,"The median time to response was 12 weeks (range, 3 to 15) and the median duration was 26 weeks (range, 10 to 58+).",Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558221/),weeks,12,92273,DB00501,Cimetidine
,8558221,duration,"The median time to response was 12 weeks (range, 3 to 15) and the median duration was 26 weeks (range, 10 to 58+).",Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558221/),weeks,26,92274,DB00501,Cimetidine
,6319067,elimination t1/2,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.6,94730,DB00501,Cimetidine
,6319067,elimination t1/2,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.5,94731,DB00501,Cimetidine
,6319067,volume of distribution (Vd),"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.77,94732,DB00501,Cimetidine
,6319067,volume of distribution (Vd),"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.75,94733,DB00501,Cimetidine
,6319067,total clearance,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.77,94734,DB00501,Cimetidine
,6319067,total clearance,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.75,94735,DB00501,Cimetidine
,6319067,t1/2,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,32.3,94736,DB00501,Cimetidine
,6319067,t1/2,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,28.9,94737,DB00501,Cimetidine
,6319067,Vd,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.42,94738,DB00501,Cimetidine
,6319067,Vd,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.39,94739,DB00501,Cimetidine
,6319067,total clearance,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.42,94740,DB00501,Cimetidine
,6319067,total clearance,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.39,94741,DB00501,Cimetidine
,6319067,t1/2,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.7,94742,DB00501,Cimetidine
,6319067,t1/2,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.3,94743,DB00501,Cimetidine
,6319067,Vd,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.52,94744,DB00501,Cimetidine
,6319067,total clearance,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.52,94745,DB00501,Cimetidine
,6319067,total clearance,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.65,94746,DB00501,Cimetidine
,16296697,absolute bioavailability,Amlodipine is absorbed gradually after oral administration (peak plasma levels 6-12 h postdose) and has an absolute bioavailability of 64%.,Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16296697/),%,64,95655,DB00501,Cimetidine
,4028631,t1/2,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),h,3.60,95919,DB00501,Cimetidine
,4028631,t1/2,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),h,4.30,95920,DB00501,Cimetidine
,4028631,volume of distribution,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[l] / [kg],5.8,95921,DB00501,Cimetidine
,4028631,volume of distribution,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[l] / [kg],6.6,95922,DB00501,Cimetidine
,4028631,total clearance,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ml] / [kg·min],19.2,95923,DB00501,Cimetidine
,4028631,total clearance,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ml] / [kg·min],18.4,95924,DB00501,Cimetidine
,4028631,t1/2,"After oral doses, the t1/2 (4.25 +/- 0.57 vs.",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),,4.25,95925,DB00501,Cimetidine
,4028631,plasma AUC,"4.60 +/- 0.70 hours), plasma AUC (585 +/- 113 vs. 506 +/- 82 ng/ml X hr) and absolute bioavailability (35% +/- 7% vs. 30% +/- 5%) did not differ between control and cimetidine trials, respectively.",Lack of interaction between verapamil and cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ng] / [h·ml],585,95926,DB00501,Cimetidine
,4028631,plasma AUC,"4.60 +/- 0.70 hours), plasma AUC (585 +/- 113 vs. 506 +/- 82 ng/ml X hr) and absolute bioavailability (35% +/- 7% vs. 30% +/- 5%) did not differ between control and cimetidine trials, respectively.",Lack of interaction between verapamil and cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ng] / [h·ml],506,95927,DB00501,Cimetidine
,4028631,absolute bioavailability,"4.60 +/- 0.70 hours), plasma AUC (585 +/- 113 vs. 506 +/- 82 ng/ml X hr) and absolute bioavailability (35% +/- 7% vs. 30% +/- 5%) did not differ between control and cimetidine trials, respectively.",Lack of interaction between verapamil and cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),%,35,95928,DB00501,Cimetidine
,4028631,absolute bioavailability,"4.60 +/- 0.70 hours), plasma AUC (585 +/- 113 vs. 506 +/- 82 ng/ml X hr) and absolute bioavailability (35% +/- 7% vs. 30% +/- 5%) did not differ between control and cimetidine trials, respectively.",Lack of interaction between verapamil and cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),%,30,95929,DB00501,Cimetidine
,4028631,clearance,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ml] / [min],665,95930,DB00501,Cimetidine
,4028631,clearance,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ml] / [min],527,95931,DB00501,Cimetidine
,4028631,t1/2,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),h,1.81,95932,DB00501,Cimetidine
,4028631,t1/2,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),h,2.44,95933,DB00501,Cimetidine
,4028631,volume of distribution,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[l] / [kg],1.77,95934,DB00501,Cimetidine
,4028631,volume of distribution,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[l] / [kg],1.99,95935,DB00501,Cimetidine
,4028631,heart rate,A decrease in mean arterial pressure (8 +/- 1 vs. 9 +/- 2 mm Hg) and a reflex increase in heart rate (14 +/- 3 vs. 17 +/- 2 bpm) were no different in the control and cimetidine trials.,Lack of interaction between verapamil and cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),bpm,14,95936,DB00501,Cimetidine
,4028631,heart rate,A decrease in mean arterial pressure (8 +/- 1 vs. 9 +/- 2 mm Hg) and a reflex increase in heart rate (14 +/- 3 vs. 17 +/- 2 bpm) were no different in the control and cimetidine trials.,Lack of interaction between verapamil and cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),bpm,17,95937,DB00501,Cimetidine
,2359015,area under the plasma concentration vs. time curve,Coadministration of cimetidine led to a significant increase in the area under the plasma concentration vs. time curve of S-verapamil (29.2 +/- 31.8 min x nmol x ml-1 vs. 41.2 +/- 33.7 min x nmol x ml-1; P less than .003) and R-verapamil (124.7 +/- 112.2 min x nmol x ml-1 vs. 156.8 +/- 105.0 min x nmol x ml-1; P less than .01).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[min·nM] / [ml],29.2,96485,DB00501,Cimetidine
,2359015,area under the plasma concentration vs. time curve,Coadministration of cimetidine led to a significant increase in the area under the plasma concentration vs. time curve of S-verapamil (29.2 +/- 31.8 min x nmol x ml-1 vs. 41.2 +/- 33.7 min x nmol x ml-1; P less than .003) and R-verapamil (124.7 +/- 112.2 min x nmol x ml-1 vs. 156.8 +/- 105.0 min x nmol x ml-1; P less than .01).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[min·nM] / [ml],41.2,96486,DB00501,Cimetidine
,2359015,area under the plasma concentration vs. time curve,Coadministration of cimetidine led to a significant increase in the area under the plasma concentration vs. time curve of S-verapamil (29.2 +/- 31.8 min x nmol x ml-1 vs. 41.2 +/- 33.7 min x nmol x ml-1; P less than .003) and R-verapamil (124.7 +/- 112.2 min x nmol x ml-1 vs. 156.8 +/- 105.0 min x nmol x ml-1; P less than .01).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[min·nM] / [ml],124.7,96487,DB00501,Cimetidine
,2359015,area under the plasma concentration vs. time curve,Coadministration of cimetidine led to a significant increase in the area under the plasma concentration vs. time curve of S-verapamil (29.2 +/- 31.8 min x nmol x ml-1 vs. 41.2 +/- 33.7 min x nmol x ml-1; P less than .003) and R-verapamil (124.7 +/- 112.2 min x nmol x ml-1 vs. 156.8 +/- 105.0 min x nmol x ml-1; P less than .01).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[min·nM] / [ml],156.8,96488,DB00501,Cimetidine
,2359015,Tu,Tubular secretion of S-D-617 was inhibited by cimetidine (342 +/- 104 vs. 238 +/- 52 ml x min-1; P less than .05) whereas secretion of the R-enantiomer remained unchanged (276 +/- 91 vs. 222 +/- 43 ml x min-1).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[ml] / [min],342,96489,DB00501,Cimetidine
,2359015,secretion,Tubular secretion of S-D-617 was inhibited by cimetidine (342 +/- 104 vs. 238 +/- 52 ml x min-1; P less than .05) whereas secretion of the R-enantiomer remained unchanged (276 +/- 91 vs. 222 +/- 43 ml x min-1).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[ml] / [min],342,96490,DB00501,Cimetidine
,2359015,secretion,Tubular secretion of S-D-617 was inhibited by cimetidine (342 +/- 104 vs. 238 +/- 52 ml x min-1; P less than .05) whereas secretion of the R-enantiomer remained unchanged (276 +/- 91 vs. 222 +/- 43 ml x min-1).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[ml] / [min],238,96491,DB00501,Cimetidine
,2359015,secretion,Tubular secretion of S-D-617 was inhibited by cimetidine (342 +/- 104 vs. 238 +/- 52 ml x min-1; P less than .05) whereas secretion of the R-enantiomer remained unchanged (276 +/- 91 vs. 222 +/- 43 ml x min-1).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[ml] / [min],276,96492,DB00501,Cimetidine
,2359015,secretion,Tubular secretion of S-D-617 was inhibited by cimetidine (342 +/- 104 vs. 238 +/- 52 ml x min-1; P less than .05) whereas secretion of the R-enantiomer remained unchanged (276 +/- 91 vs. 222 +/- 43 ml x min-1).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[ml] / [min],222,96493,DB00501,Cimetidine
,6780813,area under the plasma level curve,"The area under the plasma level curve as a measure for bioavailability was significantly increased in the two gastrectomy groups (17% and 23%, resp.).",[Bioavailability of cimetidine after partial gastrectomy (author's transl)]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780813/),%,17,96879,DB00501,Cimetidine
,6780813,area under the plasma level curve,"The area under the plasma level curve as a measure for bioavailability was significantly increased in the two gastrectomy groups (17% and 23%, resp.).",[Bioavailability of cimetidine after partial gastrectomy (author's transl)]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780813/),%,23,96880,DB00501,Cimetidine
,6780813,bioavailability,"The area under the plasma level curve as a measure for bioavailability was significantly increased in the two gastrectomy groups (17% and 23%, resp.).",[Bioavailability of cimetidine after partial gastrectomy (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780813/),%,17,96881,DB00501,Cimetidine
,6780813,bioavailability,"The area under the plasma level curve as a measure for bioavailability was significantly increased in the two gastrectomy groups (17% and 23%, resp.).",[Bioavailability of cimetidine after partial gastrectomy (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780813/),%,23,96882,DB00501,Cimetidine
above,6780813,effective plasma concentrations,"In addition, the duration of effective plasma concentrations above 0.5 microgram/ml was significantly prolonged in the two groups.",[Bioavailability of cimetidine after partial gastrectomy (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780813/),[μg] / [ml],0.5,96883,DB00501,Cimetidine
<,28615288,Ktapp,"In this study, we determined the Jmax and apparent Michaelis constant (Ktapp) values for six structurally distinct OCT2 substrates and found a strong correlation between Jmax and Ktapp; high-affinity substrates [Ktapp values <50 µM, including 1-methyl-4-phenylpyridinium, or 1-methyl-4-phenylpyridinium (MPP), and cimetidine] displayed systematically lower Jmax values (<50 pmol cm-2 min-1) than did low-affinity substrates (Ktapp >200 µM, including choline and metformin).",Correlation between Apparent Substrate Affinity and OCT2 Transport Turnover. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28615288/),μM,50,97592,DB00501,Cimetidine
<,28615288,Jmax,"In this study, we determined the Jmax and apparent Michaelis constant (Ktapp) values for six structurally distinct OCT2 substrates and found a strong correlation between Jmax and Ktapp; high-affinity substrates [Ktapp values <50 µM, including 1-methyl-4-phenylpyridinium, or 1-methyl-4-phenylpyridinium (MPP), and cimetidine] displayed systematically lower Jmax values (<50 pmol cm-2 min-1) than did low-affinity substrates (Ktapp >200 µM, including choline and metformin).",Correlation between Apparent Substrate Affinity and OCT2 Transport Turnover. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28615288/),[pM] / [(cm)^2·min],50,97593,DB00501,Cimetidine
>,28615288,Ktapp,"In this study, we determined the Jmax and apparent Michaelis constant (Ktapp) values for six structurally distinct OCT2 substrates and found a strong correlation between Jmax and Ktapp; high-affinity substrates [Ktapp values <50 µM, including 1-methyl-4-phenylpyridinium, or 1-methyl-4-phenylpyridinium (MPP), and cimetidine] displayed systematically lower Jmax values (<50 pmol cm-2 min-1) than did low-affinity substrates (Ktapp >200 µM, including choline and metformin).",Correlation between Apparent Substrate Affinity and OCT2 Transport Turnover. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28615288/),μM,200,97594,DB00501,Cimetidine
,25795100,Absolute bioavailability,Absolute bioavailability after 24 h transdermal delivery is 37 % of the applied rotigotine dose.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),%,37,99596,DB00501,Cimetidine
>,25795100,apparent volume of distribution,The drug shows a high apparent volume of distribution (>2500 L) and a total body clearance of 300-600 L/h.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),l,2500,99597,DB00501,Cimetidine
,25795100,total body clearance,The drug shows a high apparent volume of distribution (>2500 L) and a total body clearance of 300-600 L/h.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),[l] / [h],300-600,99598,DB00501,Cimetidine
,29920736,renal clearance,"Mean (standard deviation) renal clearance of mirogabalin (l h-1 ) was substantially slower after probenecid [6.67 (1.53)] or cimetidine [7.17 (1.68)] coadministration, compared with mirogabalin alone [11.3 (2.39)].","Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29920736/),[l] / [h],6.67,100144,DB00501,Cimetidine
,29920736,renal clearance,"Mean (standard deviation) renal clearance of mirogabalin (l h-1 ) was substantially slower after probenecid [6.67 (1.53)] or cimetidine [7.17 (1.68)] coadministration, compared with mirogabalin alone [11.3 (2.39)].","Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29920736/),[l] / [h],7.17,100145,DB00501,Cimetidine
,29920736,renal clearance,"Mean (standard deviation) renal clearance of mirogabalin (l h-1 ) was substantially slower after probenecid [6.67 (1.53)] or cimetidine [7.17 (1.68)] coadministration, compared with mirogabalin alone [11.3 (2.39)].","Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29920736/),[l] / [h],11.3,100146,DB00501,Cimetidine
,29920736,apparent total body clearance,"Coadministration of probenecid or cimetidine decreased mirogabalin mean (standard deviation) apparent total body clearance [10.5 (2.33) and 12.8 (2.67) l h-1 , respectively, vs. 18.4 (3.93) for mirogabalin alone].","Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29920736/),[l] / [h],10.5,100147,DB00501,Cimetidine
,29920736,apparent total body clearance,"Coadministration of probenecid or cimetidine decreased mirogabalin mean (standard deviation) apparent total body clearance [10.5 (2.33) and 12.8 (2.67) l h-1 , respectively, vs. 18.4 (3.93) for mirogabalin alone].","Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29920736/),[l] / [h],12.8,100148,DB00501,Cimetidine
,29920736,apparent total body clearance,"Coadministration of probenecid or cimetidine decreased mirogabalin mean (standard deviation) apparent total body clearance [10.5 (2.33) and 12.8 (2.67) l h-1 , respectively, vs. 18.4 (3.93) for mirogabalin alone].","Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29920736/),,18.4,100149,DB00501,Cimetidine
,15801548,"CLr,u/GFR ratio","In rhesus monkeys, renal elimination of compound A also involved tubular secretion, with a CLr,u/GFR ratio of about 30.",Renal elimination of a novel and potent alphavbeta3 integrin antagonist in animals. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801548/),,30,103091,DB00501,Cimetidine
,15801548,renal secretion,The renal secretion of compound A was not affected by either cimetidine (about 120 microM) or PAH (about 80 microM).,Renal elimination of a novel and potent alphavbeta3 integrin antagonist in animals. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801548/),μM,120,103092,DB00501,Cimetidine
,15801548,Km,"In an uptake study using rOAT1 and rOAT3 transfected HEK cell lines, compound A was shown to be a substrate for rat OAT3 (Km= 15 microM), but not rat OAT1.",Renal elimination of a novel and potent alphavbeta3 integrin antagonist in animals. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801548/),μM,15,103093,DB00501,Cimetidine
,3244614,clearance,"The clearance of inulin was 2.02 +/- 0.22 microliters/min, which is in excellent agreement with the CSF production rate of 2.2 microliters/min in anesthetized rats.",Cimetidine elimination from the cerebrospinal fluid of the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244614/),[μl] / [min],2.02,103174,DB00501,Cimetidine
,3244614,production rate,"The clearance of inulin was 2.02 +/- 0.22 microliters/min, which is in excellent agreement with the CSF production rate of 2.2 microliters/min in anesthetized rats.",Cimetidine elimination from the cerebrospinal fluid of the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244614/),[μl] / [min],2.2,103175,DB00501,Cimetidine
,3244614,clearance,"The clearance of cimetidine from the CSF following the administration of a low dose was 11.8 +/- 3.1 microliters/min, which is in good agreement with the cimetidine CSF clearance in the rat obtained previously in studies using the technique of ventriculocisternal perfusion.",Cimetidine elimination from the cerebrospinal fluid of the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3244614/),[μl] / [min],11.8,103176,DB00501,Cimetidine
,6877447,absorption fraction,"The absorption fraction was found to be 0.75 (range 0.61-0.86), the terminal half-life in plasma between 138 and 238 min, the total body clearance (Cltotal) between 178 and 337 ml/min, and the apparent volume of distribution about 1 l/kg.",Pharmacokinetics of cimetidine in patients undergoing hemodialysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6877447/),,0.75,103657,DB00501,Cimetidine
,6877447,terminal half-life,"The absorption fraction was found to be 0.75 (range 0.61-0.86), the terminal half-life in plasma between 138 and 238 min, the total body clearance (Cltotal) between 178 and 337 ml/min, and the apparent volume of distribution about 1 l/kg.",Pharmacokinetics of cimetidine in patients undergoing hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6877447/),min,138 and 238,103658,DB00501,Cimetidine
,6877447,total body clearance (Cltotal),"The absorption fraction was found to be 0.75 (range 0.61-0.86), the terminal half-life in plasma between 138 and 238 min, the total body clearance (Cltotal) between 178 and 337 ml/min, and the apparent volume of distribution about 1 l/kg.",Pharmacokinetics of cimetidine in patients undergoing hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6877447/),[ml] / [min],178 and 337,103659,DB00501,Cimetidine
,6877447,apparent volume of distribution,"The absorption fraction was found to be 0.75 (range 0.61-0.86), the terminal half-life in plasma between 138 and 238 min, the total body clearance (Cltotal) between 178 and 337 ml/min, and the apparent volume of distribution about 1 l/kg.",Pharmacokinetics of cimetidine in patients undergoing hemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6877447/),[l] / [kg],1,103660,DB00501,Cimetidine
,6877447,steady state concentration,"Based on the Cltotal obtained in this study, dosage schemes producing a 24-hours mean steady state concentration from 0.60 (2.38) to 1.20 (4.76) mg/l (mumol/l) are suggested.",Pharmacokinetics of cimetidine in patients undergoing hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6877447/),[mg] / [l],0.60,103661,DB00501,Cimetidine
,6877447,steady state concentration,"Based on the Cltotal obtained in this study, dosage schemes producing a 24-hours mean steady state concentration from 0.60 (2.38) to 1.20 (4.76) mg/l (mumol/l) are suggested.",Pharmacokinetics of cimetidine in patients undergoing hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6877447/),[μM] / [l],1.20,103662,DB00501,Cimetidine
,2871051,elimination half-life,"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),h,72,106430,DB00501,Cimetidine
,2871051,elimination half-life,"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),h,55,106431,DB00501,Cimetidine
,2871051,total area under the curve (AUC),"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],11.8,106432,DB00501,Cimetidine
,2871051,total area under the curve (AUC),"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],9.8,106433,DB00501,Cimetidine
,2871051,total clearance,"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[ml] / [kg·min],0.20,106434,DB00501,Cimetidine
,2871051,total clearance,"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[ml] / [kg·min],0.28,106435,DB00501,Cimetidine
,2871051,AUC,"Seven-day AUC for desmethyldiazepam also increased (4.6 vs 3.8 hr-micrograms/mL, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],4.6,106436,DB00501,Cimetidine
,2871051,AUC,"Seven-day AUC for desmethyldiazepam also increased (4.6 vs 3.8 hr-micrograms/mL, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],3.8,106437,DB00501,Cimetidine
,2871051,elimination half-life,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),h,53,106438,DB00501,Cimetidine
,2871051,elimination half-life,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),h,55,106439,DB00501,Cimetidine
,2871051,total AUC,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],9.5,106440,DB00501,Cimetidine
,2871051,total AUC,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],9.8,106441,DB00501,Cimetidine
,2871051,total clearance,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[ml] / [kg·min],0.28,106442,DB00501,Cimetidine
,2871051,AUC,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],3.9,106443,DB00501,Cimetidine
,2871051,AUC,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],3.8,106444,DB00501,Cimetidine
,8612382,area under the curve (AUC),"Coingestion of a ferrous sulfate tablet with cimetidine (300 mg) was associated with little reduction in serum cimetidine area under the curve (AUC) (mean versus mean, 20.8 versus 23.4 mumol.hr/L; mean percentage difference, -11%; 95% confidence interval [CI] of percentage difference, -26% to 4.2%) or peak concentration (Cmax) (mean versus mean, 5.1 versus 6.1 mumol/L; mean percentage difference, -16%; CI of percentage difference, -36% to 4%).",Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612382/),[h·μM] / [l],20.8,108097,DB00501,Cimetidine
,8612382,area under the curve (AUC),"Coingestion of a ferrous sulfate tablet with cimetidine (300 mg) was associated with little reduction in serum cimetidine area under the curve (AUC) (mean versus mean, 20.8 versus 23.4 mumol.hr/L; mean percentage difference, -11%; 95% confidence interval [CI] of percentage difference, -26% to 4.2%) or peak concentration (Cmax) (mean versus mean, 5.1 versus 6.1 mumol/L; mean percentage difference, -16%; CI of percentage difference, -36% to 4%).",Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612382/),[h·μM] / [l],23.4,108098,DB00501,Cimetidine
,8612382,peak,"Coingestion of a ferrous sulfate tablet with cimetidine (300 mg) was associated with little reduction in serum cimetidine area under the curve (AUC) (mean versus mean, 20.8 versus 23.4 mumol.hr/L; mean percentage difference, -11%; 95% confidence interval [CI] of percentage difference, -26% to 4.2%) or peak concentration (Cmax) (mean versus mean, 5.1 versus 6.1 mumol/L; mean percentage difference, -16%; CI of percentage difference, -36% to 4%).",Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612382/),,5,108099,DB00501,Cimetidine
,8612382,peak,"Coingestion of a ferrous sulfate tablet with cimetidine (300 mg) was associated with little reduction in serum cimetidine area under the curve (AUC) (mean versus mean, 20.8 versus 23.4 mumol.hr/L; mean percentage difference, -11%; 95% confidence interval [CI] of percentage difference, -26% to 4.2%) or peak concentration (Cmax) (mean versus mean, 5.1 versus 6.1 mumol/L; mean percentage difference, -16%; CI of percentage difference, -36% to 4%).",Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612382/),,6,108100,DB00501,Cimetidine
,2877885,peak plasma levels (Cssmax),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [ml],55.5,108453,DB00501,Cimetidine
,2877885,area under the plasma level-time curve (AUC tau),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [h·ml],597,108454,DB00501,Cimetidine
,2877885,total body clearance (CL),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[l] / [h],15.8,108455,DB00501,Cimetidine
,2877885,elimination half-lives (t1/2 beta),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),h,10.1,108456,DB00501,Cimetidine
,2877885,Cssmax,"Co-administration of rifampicin resulted in a decrease in Cssmax (43.0 +/- 6.9 ng/ml), AUC tau (397 +/- 54 ng/ml X h) and t1/2 beta (6.2 +/- 0.4 h).",Interaction of bisoprolol with cimetidine and rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [ml],43.0,108457,DB00501,Cimetidine
,2877885,AUC tau,"Co-administration of rifampicin resulted in a decrease in Cssmax (43.0 +/- 6.9 ng/ml), AUC tau (397 +/- 54 ng/ml X h) and t1/2 beta (6.2 +/- 0.4 h).",Interaction of bisoprolol with cimetidine and rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [h·ml],397,108458,DB00501,Cimetidine
,2877885,t1/2 beta,"Co-administration of rifampicin resulted in a decrease in Cssmax (43.0 +/- 6.9 ng/ml), AUC tau (397 +/- 54 ng/ml X h) and t1/2 beta (6.2 +/- 0.4 h).",Interaction of bisoprolol with cimetidine and rifampicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),h,6.2,108459,DB00501,Cimetidine
,2877885,total body clearance,"Accordingly, total body clearance increased to 23.8 +/- 2.5 l/h (p less than 0.05).",Interaction of bisoprolol with cimetidine and rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[l] / [h],23.8,108460,DB00501,Cimetidine
,8061850,terminal half-life,"After intravenous infusion, the disposition of spirapril is monophasic with a terminal half-life of 20-50 minutes.",Spirapril: pharmacokinetic properties and drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),min,20-50,108588,DB00501,Cimetidine
,8061850,Plasma clearance,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],56,108589,DB00501,Cimetidine
,8061850,renal clearance,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],11,108590,DB00501,Cimetidine
,8061850,volume of distribution,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),l,28,108591,DB00501,Cimetidine
,8061850,half-lives,"After intravenous infusion of spiraprilat, the disposition was biphasic with half-lives of 2 hours and 35 hours, respectively.",Spirapril: pharmacokinetic properties and drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),h,2,108592,DB00501,Cimetidine
,8061850,half-lives,"After intravenous infusion of spiraprilat, the disposition was biphasic with half-lives of 2 hours and 35 hours, respectively.",Spirapril: pharmacokinetic properties and drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),h,35,108593,DB00501,Cimetidine
,8061850,Plasma clearance,"Plasma clearance of spiraprilat was 10 l/h, of which 7.6 l/h was cleared by the kidneys.",Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],10,108594,DB00501,Cimetidine
,8061850,Plasma clearance,"Plasma clearance of spiraprilat was 10 l/h, of which 7.6 l/h was cleared by the kidneys.",Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],7.6,108595,DB00501,Cimetidine
,8061850,volume of distribution,The volume of distribution was 43 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),l,43,108596,DB00501,Cimetidine
,8061850,bioavailability,The bioavailability of orally administered spirapril was 50% whereas the bioavailability of orally administered spiraprilat was virtually zero.,Spirapril: pharmacokinetic properties and drug interactions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),%,50,108597,DB00501,Cimetidine
,1972124,half-life,"Beyond the peak, decrease in roxatidine concentrations was slow, as expected from a known 6-h half-life.",[Plasma pharmacokinetics of roxatidine in the healthy man: correlation with gastric antisecretory effect]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1972124/),h,6,109468,DB00501,Cimetidine
,1517687,fractional clearance,"The fractional clearance (relative to inulin) of creatinine was also higher during the night: normal subjects, 1.28 +/- 0.02 versus 1.10 +/- 0.02; patients, 1.78 +/- 0.08 versus 1.45 +/- 0.05 (p less than 0.005).",Discrepancy between circadian rhythms of inulin and creatinine clearance. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517687/),,1.28,109638,DB00501,Cimetidine
,1517687,fractional clearance,"The fractional clearance (relative to inulin) of creatinine was also higher during the night: normal subjects, 1.28 +/- 0.02 versus 1.10 +/- 0.02; patients, 1.78 +/- 0.08 versus 1.45 +/- 0.05 (p less than 0.005).",Discrepancy between circadian rhythms of inulin and creatinine clearance. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517687/),,1.10,109639,DB00501,Cimetidine
,1517687,fractional clearance,"The fractional clearance (relative to inulin) of creatinine was also higher during the night: normal subjects, 1.28 +/- 0.02 versus 1.10 +/- 0.02; patients, 1.78 +/- 0.08 versus 1.45 +/- 0.05 (p less than 0.005).",Discrepancy between circadian rhythms of inulin and creatinine clearance. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517687/),,1.78,109640,DB00501,Cimetidine
,1517687,fractional clearance,"The fractional clearance (relative to inulin) of creatinine was also higher during the night: normal subjects, 1.28 +/- 0.02 versus 1.10 +/- 0.02; patients, 1.78 +/- 0.08 versus 1.45 +/- 0.05 (p less than 0.005).",Discrepancy between circadian rhythms of inulin and creatinine clearance. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517687/),,1.45,109641,DB00501,Cimetidine
,6813365,half-life,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),h,16.4,109996,DB00501,Cimetidine
,6813365,half-life,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),h,11.0,109997,DB00501,Cimetidine
,6813365,metabolic clearance,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),[ml] / [kg·min],0.48,109998,DB00501,Cimetidine
,6813365,metabolic clearance,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),[ml] / [kg·min],0.72,109999,DB00501,Cimetidine
,6813365,half-life,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,150,110000,DB00501,Cimetidine
,6813365,half-life,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,153,110001,DB00501,Cimetidine
,6813365,metabolic clearance,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,79,110002,DB00501,Cimetidine
,6813365,metabolic clearance,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,69,110003,DB00501,Cimetidine
,6813365,half-life,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,175,110004,DB00501,Cimetidine
,6813365,half-life,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,164,110005,DB00501,Cimetidine
,6813365,metabolic clearance,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,51,110006,DB00501,Cimetidine
,6813365,metabolic clearance,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,65,110007,DB00501,Cimetidine
,22072731,plasma unbound concentrations,"They were 95 to 146 μM for hOCT2, providing at most 10% inhibition based on its clinically reported plasma unbound concentrations (3.6-7.8 μM).","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),μM,3.6-7.8,112143,DB00501,Cimetidine
,22072731,K(i),"In contrast, cimetidine is a potent inhibitor of MATE1 and MATE2-K with K(i) values (μM) of 1.1 to 3.8 and 2.1 to 6.9, respectively.","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),μM,1.1 to 3.8,112144,DB00501,Cimetidine
,22072731,K(i),"In contrast, cimetidine is a potent inhibitor of MATE1 and MATE2-K with K(i) values (μM) of 1.1 to 3.8 and 2.1 to 6.9, respectively.","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),μM,2.1 to 6.9,112145,DB00501,Cimetidine
,22072731,plasma unbound concentration,"Cimetidine was administered to mice by a constant infusion to achieve a plasma unbound concentration of 21.6 μM to examine its effect on the renal disposition of Mate1 probes (metformin, TEA, and cephalexin) in vivo.","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),μM,21.6,112146,DB00501,Cimetidine
,22072731,renal clearance,"Cimetidine also increased the kidney-to-plasma ratio of TEA and cephalexin 8.0- and 3.3-fold compared with a control and decreased the renal clearance from 49 to 23 and 11 to 6.6 ml/min/kg, respectively.","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),[ml] / [kg·min],49,112147,DB00501,Cimetidine
,22072731,renal clearance,"Cimetidine also increased the kidney-to-plasma ratio of TEA and cephalexin 8.0- and 3.3-fold compared with a control and decreased the renal clearance from 49 to 23 and 11 to 6.6 ml/min/kg, respectively.","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),[ml] / [kg·min],23,112148,DB00501,Cimetidine
,22072731,renal clearance,"Cimetidine also increased the kidney-to-plasma ratio of TEA and cephalexin 8.0- and 3.3-fold compared with a control and decreased the renal clearance from 49 to 23 and 11 to 6.6 ml/min/kg, respectively.","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),[ml] / [kg·min],11,112149,DB00501,Cimetidine
,22072731,renal clearance,"Cimetidine also increased the kidney-to-plasma ratio of TEA and cephalexin 8.0- and 3.3-fold compared with a control and decreased the renal clearance from 49 to 23 and 11 to 6.6 ml/min/kg, respectively.","Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072731/),[ml] / [kg·min],6.6,112150,DB00501,Cimetidine
,22968103,maximal concentration,"The serum concentration of glucose did not change significantly after pentamidine infusion at 7.5mg/kg, while it increased with pentamidine at 15 mg/kg, and the maximal concentration of glucose was 167 ± 36 mg/dl, 30 min after the start of pentamidine infusion.",Effect of cimetidine on pentamidine induced hyperglycemia in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968103/),[mg] / [dl],167,112792,DB00501,Cimetidine
,22968103,maximal concentration,Cimetidine (50mg/kg) enhanced the pentamidine-induced elevation of glucose concentration and the maximal concentration of glucose was 208 ± 33 mg/dl in the pentamidine 15 mg/kg treated group.,Effect of cimetidine on pentamidine induced hyperglycemia in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968103/),[mg] / [dl],208,112793,DB00501,Cimetidine
,10589372,bioavailability,"Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%.",Clinical pharmacokinetics of mexiletine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),%,90,113401,DB00501,Cimetidine
,10589372,volume of distribution,Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals.,Clinical pharmacokinetics of mexiletine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),[l] / [kg],5 to 9,113402,DB00501,Cimetidine
,10589372,elimination half-life,Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours).,Clinical pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),h,10,113403,DB00501,Cimetidine
,8096710,clearance,DMAc clearance was 2.20 ml min-1 at a medium concentration of about 36 microM.,Toxicokinetics of dimethylacetamide (DMAc) in rat isolated perfused liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8096710/),[ml] / [min],2.20,113443,DB00501,Cimetidine
,3311552,fractional excretion,"The renal clearance of cimetidine was unchanged by the dietary restriction; however, the fractional excretion of cimetidine increased from 3.06 to 3.94 (P less than 0.05), indicating an apparent increase in net tubular secretion of cimetidine during the restricted diet.",The effect of dietary protein-calorie restriction on the renal elimination of cimetidine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311552/),,3.06,116828,DB00501,Cimetidine
,3311552,fractional excretion,"The renal clearance of cimetidine was unchanged by the dietary restriction; however, the fractional excretion of cimetidine increased from 3.06 to 3.94 (P less than 0.05), indicating an apparent increase in net tubular secretion of cimetidine during the restricted diet.",The effect of dietary protein-calorie restriction on the renal elimination of cimetidine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311552/),,3.94,116829,DB00501,Cimetidine
,9570004,Plasma clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],198,117110,DB00501,Cimetidine
,9570004,Plasma clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],119,117111,DB00501,Cimetidine
,9570004,renal clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],104,117112,DB00501,Cimetidine
,9570004,renal clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],54,117113,DB00501,Cimetidine
,9570004,renal clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],89,117114,DB00501,Cimetidine
,9570004,Basolateral transport,"Basolateral transport was reduced (from 18.4 +/- 7.8 to 13.6 +/- 10.3 min-1 by cimetidine and 3.9 +/- 3.1 min-1 by probenecid), whereas no effect on brush-border exit was found.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),1/[min],18.4,117115,DB00501,Cimetidine
,9570004,Basolateral transport,"Basolateral transport was reduced (from 18.4 +/- 7.8 to 13.6 +/- 10.3 min-1 by cimetidine and 3.9 +/- 3.1 min-1 by probenecid), whereas no effect on brush-border exit was found.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),1/[min],13.6,117116,DB00501,Cimetidine
,9570004,Basolateral transport,"Basolateral transport was reduced (from 18.4 +/- 7.8 to 13.6 +/- 10.3 min-1 by cimetidine and 3.9 +/- 3.1 min-1 by probenecid), whereas no effect on brush-border exit was found.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),1/[min],3.9,117117,DB00501,Cimetidine
,9570004,inhibition constants,"Estimated inhibition constants of cimetidine and probenecid were 62 and 4 micrograms mL-1, respectively.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[μg] / [ml],62,117118,DB00501,Cimetidine
,9570004,inhibition constants,"Estimated inhibition constants of cimetidine and probenecid were 62 and 4 micrograms mL-1, respectively.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[μg] / [ml],4,117119,DB00501,Cimetidine
,6144486,clearance,Concomitant cimetidine administration produced a decrease in carbamazepine clearance (liters/hr/kg) (0.68 +/- 0.037 vs. 0.41 +/- 0.091; p less than 0.002) which was accompanied by an increase in carbamazepine half-life (hr) (1.1 +/- 0.16 vs. 2.0 +/- 0.37; p less than 0.003).,Inhibition of carbamazepine metabolism by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),[l] / [h·kg],0.68,118368,DB00501,Cimetidine
,6144486,clearance,Concomitant cimetidine administration produced a decrease in carbamazepine clearance (liters/hr/kg) (0.68 +/- 0.037 vs. 0.41 +/- 0.091; p less than 0.002) which was accompanied by an increase in carbamazepine half-life (hr) (1.1 +/- 0.16 vs. 2.0 +/- 0.37; p less than 0.003).,Inhibition of carbamazepine metabolism by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),[l] / [h·kg],0.41,118369,DB00501,Cimetidine
,6144486,half-life,Concomitant cimetidine administration produced a decrease in carbamazepine clearance (liters/hr/kg) (0.68 +/- 0.037 vs. 0.41 +/- 0.091; p less than 0.002) which was accompanied by an increase in carbamazepine half-life (hr) (1.1 +/- 0.16 vs. 2.0 +/- 0.37; p less than 0.003).,Inhibition of carbamazepine metabolism by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),h,1.1,118370,DB00501,Cimetidine
,6144486,half-life,Concomitant cimetidine administration produced a decrease in carbamazepine clearance (liters/hr/kg) (0.68 +/- 0.037 vs. 0.41 +/- 0.091; p less than 0.002) which was accompanied by an increase in carbamazepine half-life (hr) (1.1 +/- 0.16 vs. 2.0 +/- 0.37; p less than 0.003).,Inhibition of carbamazepine metabolism by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),h,2.0,118371,DB00501,Cimetidine
,6144486,volume of distribution at steady-state,No cimetidine-induced alterations in the volume of distribution at steady-state (liters/kg) occurred (1.1 +/- 0.14 vs. 1.2 +/- 0.04; NS).,Inhibition of carbamazepine metabolism by cimetidine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),[l] / [kg],1.1,118372,DB00501,Cimetidine
,6144486,volume of distribution at steady-state,No cimetidine-induced alterations in the volume of distribution at steady-state (liters/kg) occurred (1.1 +/- 0.14 vs. 1.2 +/- 0.04; NS).,Inhibition of carbamazepine metabolism by cimetidine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),[l] / [kg],1.2,118373,DB00501,Cimetidine
,6144486,area under the plasma concentration-time curve,"A reduction in the partial area under the plasma concentration-time curve for carbamazepine-10, 11-epoxide (mg X hr/liter) (28 +/- 2.5 vs. 18 +/- 3.7; p less than 0.002) with cimetidine treatment suggests that a portion of the reduction in carbamazepine clearance may be the result of cimetidine-induced inhibition of epoxide formation.",Inhibition of carbamazepine metabolism by cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),[h·mg] / [l],28,118374,DB00501,Cimetidine
,6144486,area under the plasma concentration-time curve,"A reduction in the partial area under the plasma concentration-time curve for carbamazepine-10, 11-epoxide (mg X hr/liter) (28 +/- 2.5 vs. 18 +/- 3.7; p less than 0.002) with cimetidine treatment suggests that a portion of the reduction in carbamazepine clearance may be the result of cimetidine-induced inhibition of epoxide formation.",Inhibition of carbamazepine metabolism by cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),[h·mg] / [l],18,118375,DB00501,Cimetidine
,9314090,half-life,"Cefaclor is not metabolized to a significant degree, but it degrades chemically in the body with an approximate half-life of 2 hours.",Pharmacokinetic profile of cefaclor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9314090/),h,2,120289,DB00501,Cimetidine
,9314090,serum half-life,"Most of the drug is excreted unchanged in the urine, the serum half-life after oral administration is 0.5-0.7 hours.",Pharmacokinetic profile of cefaclor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9314090/),h,0.5-0.7,120290,DB00501,Cimetidine
,3311444,half-life,"The elimination rate of melphalan from plasma was significantly increased by cimetidine (P less than 0.05), the half-life being reduced from 1.94 +/- 0.55 h to 1.57 +/- 0.53 h.",Interaction of cimetidine with oral melphalan. A pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311444/),h,1.94,122237,DB00501,Cimetidine
,3311444,half-life,"The elimination rate of melphalan from plasma was significantly increased by cimetidine (P less than 0.05), the half-life being reduced from 1.94 +/- 0.55 h to 1.57 +/- 0.53 h.",Interaction of cimetidine with oral melphalan. A pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311444/),h,1.57,122238,DB00501,Cimetidine
,8314361,t1/2 beta,The mean t1/2 beta of naproxen in 6 subjects was 25.7 +/- 5.4 h (range 16 to 36).,"The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,25.7,124746,DB00501,Cimetidine
,8314361,t1/2 beta,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,25,124747,DB00501,Cimetidine
,8314361,t1/2 beta,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,13,124748,DB00501,Cimetidine
,8314361,t1/2 alpha,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,4.0,124749,DB00501,Cimetidine
,8314361,t1/2 alpha,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,1.1,124750,DB00501,Cimetidine
,6109588,elimination rates,The elimination rates for both drugs did not differ; they were both approximately 2 to 3 hr.,Tiotidine and cimetidine--kinetics and dynamics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6109588/),h,2 to 3,125342,DB00501,Cimetidine
,3958924,clearance,The addition of cimetidine resulted in a 37% decrease in pentoxifylline clearance (23.8 +/- 7.5 versus 15.0 +/- 3.2 mL/min; p less than 0.03).,Inhibition of pentoxifylline clearance by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958924/),[ml] / [min],23.8,125913,DB00501,Cimetidine
,3958924,clearance,The addition of cimetidine resulted in a 37% decrease in pentoxifylline clearance (23.8 +/- 7.5 versus 15.0 +/- 3.2 mL/min; p less than 0.03).,Inhibition of pentoxifylline clearance by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958924/),[ml] / [min],15.0,125914,DB00501,Cimetidine
,9144740,Renal clearance,"Renal clearance was 2.56 +/- 0.42 ml/min in control, which accounted for 34% of the total body clearance.",Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9144740/),[ml] / [min],2.56,126164,DB00501,Cimetidine
,9144740,Renal clearance,"Renal clearance was significantly decreased to 0.83 +/- 0.25 ml/min by cimetidine (p < .05), corresponding to 32% of the control value.",Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9144740/),[ml] / [min],0.83,126165,DB00501,Cimetidine
,9144740,clearance ratio,"The clearance ratio of levofloxacin, which was calculated by renal clearance divided by the plasma unbound fraction and the glomerular filtration rate, was 1.60 +/- 0.38 in the control and it was decreased to 0.68 +/- 0.17 and 1.11 +/- 0.22 by cimetidine and tetraethylammonium, respectively.",Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9144740/),,1.60,126166,DB00501,Cimetidine
,9144740,clearance ratio,"The clearance ratio of levofloxacin, which was calculated by renal clearance divided by the plasma unbound fraction and the glomerular filtration rate, was 1.60 +/- 0.38 in the control and it was decreased to 0.68 +/- 0.17 and 1.11 +/- 0.22 by cimetidine and tetraethylammonium, respectively.",Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9144740/),,0.68,126167,DB00501,Cimetidine
,9144740,clearance ratio,"The clearance ratio of levofloxacin, which was calculated by renal clearance divided by the plasma unbound fraction and the glomerular filtration rate, was 1.60 +/- 0.38 in the control and it was decreased to 0.68 +/- 0.17 and 1.11 +/- 0.22 by cimetidine and tetraethylammonium, respectively.",Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9144740/),,1.11,126168,DB00501,Cimetidine
,8521677,absolute bio-availability,Zolpidem is approximately 92% bound to plasma proteins; absolute bio-availability of zolpidem is about 70%.,Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),%,70,127592,DB00501,Cimetidine
,8521677,peak plasma concentration,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[μg] / [l],192 to 324,127593,DB00501,Cimetidine
,8521677,terminal elimination half-line,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),h,1.5 to 3.2,127594,DB00501,Cimetidine
,8521677,total clearance,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[ml] / [kg·min],0.24 to 0.27,127595,DB00501,Cimetidine
,9551707,Cmax (the maximum concentration),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),[eq·ng] / [ml],5.11,128283,DB00501,Cimetidine
,9551707,Cmax (the maximum concentration),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),[eq·ng] / [ml],4.54,128284,DB00501,Cimetidine
,9551707,tmax (the time to reach maximum concentration),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),h,2.2,128285,DB00501,Cimetidine
,9551707,tmax (the time to reach maximum concentration),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),h,1.3,128286,DB00501,Cimetidine
,9551707,AUC0-24 (area under the concentration-time curve from time 0 h to 24 h),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),[eq·h·ng] / [ml],58.6,128287,DB00501,Cimetidine
,9551707,AUC0-24 (area under the concentration-time curve from time 0 h to 24 h),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),[eq·h·ng] / [ml],58.5,128288,DB00501,Cimetidine
,9551707,t1/2 (terminal half-life),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),h,10.1,128289,DB00501,Cimetidine
,9551707,t1/2 (terminal half-life),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),h,17.0,128290,DB00501,Cimetidine
above,2737228,steady-state plasma cimetidine concentrations,"In an additional four patients the effects of cimetidine on gastric pH were studied during a continuous infusion of cimetidine, which maintained steady-state plasma cimetidine concentrations above 0.5 microgram.",Alteration by burn injury of the pharmacokinetics and pharmacodynamics of cimetidine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737228/),μg,0.5,128831,DB00501,Cimetidine
,2737228,clearance,The mean (SEM) clearance of cimetidine in burned children was 16.22 ml.kg-1 and cimetidine half-life was 1.06 h.,Alteration by burn injury of the pharmacokinetics and pharmacodynamics of cimetidine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737228/),[ml] / [kg],16.22,128832,DB00501,Cimetidine
,2737228,half-life,The mean (SEM) clearance of cimetidine in burned children was 16.22 ml.kg-1 and cimetidine half-life was 1.06 h.,Alteration by burn injury of the pharmacokinetics and pharmacodynamics of cimetidine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737228/),h,1.06,128833,DB00501,Cimetidine
,2737228,clearance,"The cimetidine clearance and half-life values were significantly higher in burned children compared with our previously reported values for normal adult patients, 8.2 ml.min.kg-1 and 2.21 h respectively.",Alteration by burn injury of the pharmacokinetics and pharmacodynamics of cimetidine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737228/),[min·ml] / [kg],8.2,128834,DB00501,Cimetidine
,2737228,half-life,"The cimetidine clearance and half-life values were significantly higher in burned children compared with our previously reported values for normal adult patients, 8.2 ml.min.kg-1 and 2.21 h respectively.",Alteration by burn injury of the pharmacokinetics and pharmacodynamics of cimetidine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737228/),h,2.21,128835,DB00501,Cimetidine
,2773455,Tmax,"The pharmacokinetic analysis revealed a slower resorption of cimetidine in the patients who had taken the drug in the evening (Tmax = 2 h, resp. 1.67 h) and a lowered Cmax (1.96 micrograms/ml, resp. 2.79 micrograms/ml) in comparison with the patients who had taken the drug in the morning.",[Chronopharmacokinetics of the preparation biomet400 in patients with duodenal ulcer]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773455/),h,2,130000,DB00501,Cimetidine
,2773455,Tmax,"The pharmacokinetic analysis revealed a slower resorption of cimetidine in the patients who had taken the drug in the evening (Tmax = 2 h, resp. 1.67 h) and a lowered Cmax (1.96 micrograms/ml, resp. 2.79 micrograms/ml) in comparison with the patients who had taken the drug in the morning.",[Chronopharmacokinetics of the preparation biomet400 in patients with duodenal ulcer]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773455/),h,1.67,130001,DB00501,Cimetidine
,2773455,Cmax,"The pharmacokinetic analysis revealed a slower resorption of cimetidine in the patients who had taken the drug in the evening (Tmax = 2 h, resp. 1.67 h) and a lowered Cmax (1.96 micrograms/ml, resp. 2.79 micrograms/ml) in comparison with the patients who had taken the drug in the morning.",[Chronopharmacokinetics of the preparation biomet400 in patients with duodenal ulcer]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773455/),[μg] / [ml],1.96,130002,DB00501,Cimetidine
,2773455,Cmax,"The pharmacokinetic analysis revealed a slower resorption of cimetidine in the patients who had taken the drug in the evening (Tmax = 2 h, resp. 1.67 h) and a lowered Cmax (1.96 micrograms/ml, resp. 2.79 micrograms/ml) in comparison with the patients who had taken the drug in the morning.",[Chronopharmacokinetics of the preparation biomet400 in patients with duodenal ulcer]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773455/),[μg] / [ml],2.79,130003,DB00501,Cimetidine
,2773455,apparent volume of distribution,"In the patients who had taken the drug in the evening the apparent volume of distribution is statistically significantly higher (242 l, resp. 124 l by the morning administration) and a tendency toward a slower elimination than by the morning administration is found (t1/2 = 4.41 h, resp. 3.89 h).",[Chronopharmacokinetics of the preparation biomet400 in patients with duodenal ulcer]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773455/),l,242,130004,DB00501,Cimetidine
,2773455,apparent volume of distribution,"In the patients who had taken the drug in the evening the apparent volume of distribution is statistically significantly higher (242 l, resp. 124 l by the morning administration) and a tendency toward a slower elimination than by the morning administration is found (t1/2 = 4.41 h, resp. 3.89 h).",[Chronopharmacokinetics of the preparation biomet400 in patients with duodenal ulcer]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773455/),l,124,130005,DB00501,Cimetidine
,2773455,t1/2,"In the patients who had taken the drug in the evening the apparent volume of distribution is statistically significantly higher (242 l, resp. 124 l by the morning administration) and a tendency toward a slower elimination than by the morning administration is found (t1/2 = 4.41 h, resp. 3.89 h).",[Chronopharmacokinetics of the preparation biomet400 in patients with duodenal ulcer]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773455/),h,4.41,130006,DB00501,Cimetidine
,2773455,t1/2,"In the patients who had taken the drug in the evening the apparent volume of distribution is statistically significantly higher (242 l, resp. 124 l by the morning administration) and a tendency toward a slower elimination than by the morning administration is found (t1/2 = 4.41 h, resp. 3.89 h).",[Chronopharmacokinetics of the preparation biomet400 in patients with duodenal ulcer]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773455/),h,3.89,130007,DB00501,Cimetidine
,2773455,Clr,"In the patients who had taken the drug in the morning the elimination is mainly by renal excretion (Clr = 405 ml/min, resp. 3.29 ml/min for the evening administration) while in the patients with evening administration the nonrenal clearance prevails (Clnr = 534 ml/min, resp. 339 ml/min).",[Chronopharmacokinetics of the preparation biomet400 in patients with duodenal ulcer]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773455/),[ml] / [min],405,130008,DB00501,Cimetidine
,2773455,Clr,"In the patients who had taken the drug in the morning the elimination is mainly by renal excretion (Clr = 405 ml/min, resp. 3.29 ml/min for the evening administration) while in the patients with evening administration the nonrenal clearance prevails (Clnr = 534 ml/min, resp. 339 ml/min).",[Chronopharmacokinetics of the preparation biomet400 in patients with duodenal ulcer]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773455/),[ml] / [min],3.29,130009,DB00501,Cimetidine
,2773455,Clnr,"In the patients who had taken the drug in the morning the elimination is mainly by renal excretion (Clr = 405 ml/min, resp. 3.29 ml/min for the evening administration) while in the patients with evening administration the nonrenal clearance prevails (Clnr = 534 ml/min, resp. 339 ml/min).",[Chronopharmacokinetics of the preparation biomet400 in patients with duodenal ulcer]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773455/),[ml] / [min],534,130010,DB00501,Cimetidine
,2773455,Clnr,"In the patients who had taken the drug in the morning the elimination is mainly by renal excretion (Clr = 405 ml/min, resp. 3.29 ml/min for the evening administration) while in the patients with evening administration the nonrenal clearance prevails (Clnr = 534 ml/min, resp. 339 ml/min).",[Chronopharmacokinetics of the preparation biomet400 in patients with duodenal ulcer]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773455/),[ml] / [min],339,130011,DB00501,Cimetidine
,10434239,steady-state concentration,This was a concentration-controlled drug interaction study in which the subjects were administered a dose of SR theophylline every 12 hours to provide a mean steady-state concentration between 8 and 15 micrograms/ml.,The effect of low-dose cimetidine (200 mg twice daily) on the pharmacokinetics of theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434239/),[μg] / [ml],8 and 15,131955,DB00501,Cimetidine
,6679515,peak plasma concentration,"The peak plasma concentration of cimetidine (2.13 +/- 0.17 micrograms/ml vs 1.43 +/- 0.04 micrograms/ml), the area under the plasma concentration curve (A.U.C.) between 0 to 8 hours after cimetidine (8.49 +/- 0.29 micrograms/ml/h vs 5.83 +/- 0.25 micrograms/ml/h), and the time span in which cimetidine was above 0.5 micrograms/ml (I.C.50) (401 +/- 8.86 min vs 296 +/- 20 min) were all found to be greater in responding patients than in non-responders to the therapy.",Pharmacokinetics of cimetidine in patients with unresponsive duodenal ulcer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6679515/),[μg] / [ml],2.13,132195,DB00501,Cimetidine
,6679515,peak plasma concentration,"The peak plasma concentration of cimetidine (2.13 +/- 0.17 micrograms/ml vs 1.43 +/- 0.04 micrograms/ml), the area under the plasma concentration curve (A.U.C.) between 0 to 8 hours after cimetidine (8.49 +/- 0.29 micrograms/ml/h vs 5.83 +/- 0.25 micrograms/ml/h), and the time span in which cimetidine was above 0.5 micrograms/ml (I.C.50) (401 +/- 8.86 min vs 296 +/- 20 min) were all found to be greater in responding patients than in non-responders to the therapy.",Pharmacokinetics of cimetidine in patients with unresponsive duodenal ulcer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6679515/),[μg] / [ml],1.43,132196,DB00501,Cimetidine
,6679515,area under the plasma concentration curve (A.U.C.) between 0 to 8 hours,"The peak plasma concentration of cimetidine (2.13 +/- 0.17 micrograms/ml vs 1.43 +/- 0.04 micrograms/ml), the area under the plasma concentration curve (A.U.C.) between 0 to 8 hours after cimetidine (8.49 +/- 0.29 micrograms/ml/h vs 5.83 +/- 0.25 micrograms/ml/h), and the time span in which cimetidine was above 0.5 micrograms/ml (I.C.50) (401 +/- 8.86 min vs 296 +/- 20 min) were all found to be greater in responding patients than in non-responders to the therapy.",Pharmacokinetics of cimetidine in patients with unresponsive duodenal ulcer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6679515/),[μg] / [h·ml],8.49,132197,DB00501,Cimetidine
,6679515,area under the plasma concentration curve (A.U.C.) between 0 to 8 hours,"The peak plasma concentration of cimetidine (2.13 +/- 0.17 micrograms/ml vs 1.43 +/- 0.04 micrograms/ml), the area under the plasma concentration curve (A.U.C.) between 0 to 8 hours after cimetidine (8.49 +/- 0.29 micrograms/ml/h vs 5.83 +/- 0.25 micrograms/ml/h), and the time span in which cimetidine was above 0.5 micrograms/ml (I.C.50) (401 +/- 8.86 min vs 296 +/- 20 min) were all found to be greater in responding patients than in non-responders to the therapy.",Pharmacokinetics of cimetidine in patients with unresponsive duodenal ulcer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6679515/),[μg] / [h·ml],5.83,132198,DB00501,Cimetidine
,6679515,time span,"The peak plasma concentration of cimetidine (2.13 +/- 0.17 micrograms/ml vs 1.43 +/- 0.04 micrograms/ml), the area under the plasma concentration curve (A.U.C.) between 0 to 8 hours after cimetidine (8.49 +/- 0.29 micrograms/ml/h vs 5.83 +/- 0.25 micrograms/ml/h), and the time span in which cimetidine was above 0.5 micrograms/ml (I.C.50) (401 +/- 8.86 min vs 296 +/- 20 min) were all found to be greater in responding patients than in non-responders to the therapy.",Pharmacokinetics of cimetidine in patients with unresponsive duodenal ulcer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6679515/),min,401,132199,DB00501,Cimetidine
,6679515,time span,"The peak plasma concentration of cimetidine (2.13 +/- 0.17 micrograms/ml vs 1.43 +/- 0.04 micrograms/ml), the area under the plasma concentration curve (A.U.C.) between 0 to 8 hours after cimetidine (8.49 +/- 0.29 micrograms/ml/h vs 5.83 +/- 0.25 micrograms/ml/h), and the time span in which cimetidine was above 0.5 micrograms/ml (I.C.50) (401 +/- 8.86 min vs 296 +/- 20 min) were all found to be greater in responding patients than in non-responders to the therapy.",Pharmacokinetics of cimetidine in patients with unresponsive duodenal ulcer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6679515/),min,296,132200,DB00501,Cimetidine
,6137021,total metabolic clearance,"For alprazolam, which has a low hepatic clearance and low extraction ratio, cimetidine significantly impaired total metabolic clearance (1.05 versus 1.66 ml/min/kg, P less than 0.005), resulting in significantly prolonged elimination half-life (16.6 versus 12.4 h, P less than 0.005).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),[ml] / [kg·min],1.05,132679,DB00501,Cimetidine
,6137021,total metabolic clearance,"For alprazolam, which has a low hepatic clearance and low extraction ratio, cimetidine significantly impaired total metabolic clearance (1.05 versus 1.66 ml/min/kg, P less than 0.005), resulting in significantly prolonged elimination half-life (16.6 versus 12.4 h, P less than 0.005).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),[ml] / [kg·min],1.66,132680,DB00501,Cimetidine
,6137021,elimination half-life,"For alprazolam, which has a low hepatic clearance and low extraction ratio, cimetidine significantly impaired total metabolic clearance (1.05 versus 1.66 ml/min/kg, P less than 0.005), resulting in significantly prolonged elimination half-life (16.6 versus 12.4 h, P less than 0.005).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),h,16.6,132681,DB00501,Cimetidine
,6137021,elimination half-life,"For alprazolam, which has a low hepatic clearance and low extraction ratio, cimetidine significantly impaired total metabolic clearance (1.05 versus 1.66 ml/min/kg, P less than 0.005), resulting in significantly prolonged elimination half-life (16.6 versus 12.4 h, P less than 0.005).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),h,12.4,132682,DB00501,Cimetidine
,6137021,total clearance,"For triazolam, which has higher hepatic clearance and an intermediate extraction ratio, total clearance was reduced by cimetidine (3.9 versus 5.9 ml/min/kg), causing a significant increase in total area under the plasma concentration curve (25 versus 38 ng/ml X h, P less than 0.02).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),[ml] / [kg·min],3.9,132683,DB00501,Cimetidine
,6137021,total clearance,"For triazolam, which has higher hepatic clearance and an intermediate extraction ratio, total clearance was reduced by cimetidine (3.9 versus 5.9 ml/min/kg), causing a significant increase in total area under the plasma concentration curve (25 versus 38 ng/ml X h, P less than 0.02).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),[ml] / [kg·min],5.9,132684,DB00501,Cimetidine
,6137021,total area under the plasma concentration curve,"For triazolam, which has higher hepatic clearance and an intermediate extraction ratio, total clearance was reduced by cimetidine (3.9 versus 5.9 ml/min/kg), causing a significant increase in total area under the plasma concentration curve (25 versus 38 ng/ml X h, P less than 0.02).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),[ng] / [h·ml],25,132685,DB00501,Cimetidine
,6137021,total area under the plasma concentration curve,"For triazolam, which has higher hepatic clearance and an intermediate extraction ratio, total clearance was reduced by cimetidine (3.9 versus 5.9 ml/min/kg), causing a significant increase in total area under the plasma concentration curve (25 versus 38 ng/ml X h, P less than 0.02).",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),[ng] / [h·ml],38,132686,DB00501,Cimetidine
,6137021,elimination half-life,"However, elimination half-life of triazolam was not influenced by cimetidine (3.3 versus 3.2 h), indicating that the reduction in clearance was manifested as increased systemic availability.",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),h,3.3,132687,DB00501,Cimetidine
,6137021,elimination half-life,"However, elimination half-life of triazolam was not influenced by cimetidine (3.3 versus 3.2 h), indicating that the reduction in clearance was manifested as increased systemic availability.",Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137021/),h,3.2,132688,DB00501,Cimetidine
more,2191442,oral bioavailability,"The pharmacokinetic profile of fluconazole clearly distinguishes it from other antifungal agents; oral bioavailability is more than 90%, and plasma protein binding is 12%.",The clinical pharmacology of fluconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),%,90,132916,DB00501,Cimetidine
,2191442,plasma protein binding,"The pharmacokinetic profile of fluconazole clearly distinguishes it from other antifungal agents; oral bioavailability is more than 90%, and plasma protein binding is 12%.",The clinical pharmacology of fluconazole. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),%,12,132917,DB00501,Cimetidine
,2191442,elimination half-life,The mean elimination half-life is approximately 30 hours.,The clinical pharmacology of fluconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),h,30,132918,DB00501,Cimetidine
,4066561,terminal half-lives,"The mean terminal half-lives in serum were 0.97 and 0.94 h, respectively.","Pharmacokinetics of clavulanic acid, given in combination with amoxycillin, in volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4066561/),h,0.97,133492,DB00501,Cimetidine
,4066561,terminal half-lives,"The mean terminal half-lives in serum were 0.97 and 0.94 h, respectively.","Pharmacokinetics of clavulanic acid, given in combination with amoxycillin, in volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4066561/),h,0.94,133493,DB00501,Cimetidine
,4066561,Total serum clearance,Total serum clearance was 248 +/- 55 ml/min X 1.73 m2.,"Pharmacokinetics of clavulanic acid, given in combination with amoxycillin, in volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4066561/),[ml] / [1.73·m2·min],248,133494,DB00501,Cimetidine
,4066561,Renal clearance,Renal clearance was 108 +/- 20 and 115 +/- 18 ml/min X 1.73 m2 after intravenous and peroral administration.,"Pharmacokinetics of clavulanic acid, given in combination with amoxycillin, in volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4066561/),[ml] / [1.73·m2·min],108,133495,DB00501,Cimetidine
,4066561,Renal clearance,Renal clearance was 108 +/- 20 and 115 +/- 18 ml/min X 1.73 m2 after intravenous and peroral administration.,"Pharmacokinetics of clavulanic acid, given in combination with amoxycillin, in volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4066561/),[ml] / [1.73·m2·min],115,133496,DB00501,Cimetidine
,4066561,Urinary recovery,Urinary recovery over 12 h was 49.4 +/- 8.7% of the intravenous and 35.7 +/- 13.0% of the oral dose.,"Pharmacokinetics of clavulanic acid, given in combination with amoxycillin, in volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4066561/),%,49.4,133497,DB00501,Cimetidine
,4066561,Urinary recovery,Urinary recovery over 12 h was 49.4 +/- 8.7% of the intravenous and 35.7 +/- 13.0% of the oral dose.,"Pharmacokinetics of clavulanic acid, given in combination with amoxycillin, in volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4066561/),%,35.7,133498,DB00501,Cimetidine
,4066561,bioavailability,"The bioavailability of the oral dose averaged 60.0 +/- 23.1% but varied considerably (range 31.4-98.8%), indicating very variable absorption from the gastrointestinal tract.","Pharmacokinetics of clavulanic acid, given in combination with amoxycillin, in volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4066561/),%,60.0,133499,DB00501,Cimetidine
greater,3042243,plasma protein binding,Three of the 8 dihydropyridines have been reported to have plasma protein binding greater than 90%.,Pharmacokinetics of calcium antagonists under development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042243/),%,90,134432,DB00501,Cimetidine
,6786672,bioavailability,"The mean increase in bioavailability was 136.5 +/- 57.6%, and the results were consistent in each subject.",Influence of cimetidine on pharmacokinetics of propranolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786672/),%,136.5,135115,DB00501,Cimetidine
,21053991,elimination half-life,"Consistent with an elimination half-life of ∼24 hours, steady-state conditions are reached within 4 days of repeat dosing.",A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21053991/),h,∼24,138379,DB00501,Cimetidine
,1988238,systemic clearance,"The data on intravenous administration indicated that cimetidine produced a statistically significant alteration in the following disposition parameters (mean values for control versus cimetidine): systemic clearance, 46.6 versus 28.3 L/hr; mean residence time, 2.1 versus 3.2 hours; elimination half-life, 1.6 versus 2.3 hours.",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),[l] / [h],46.6,138863,DB00501,Cimetidine
,1988238,systemic clearance,"The data on intravenous administration indicated that cimetidine produced a statistically significant alteration in the following disposition parameters (mean values for control versus cimetidine): systemic clearance, 46.6 versus 28.3 L/hr; mean residence time, 2.1 versus 3.2 hours; elimination half-life, 1.6 versus 2.3 hours.",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),[l] / [h],28.3,138864,DB00501,Cimetidine
,1988238,mean residence time,"The data on intravenous administration indicated that cimetidine produced a statistically significant alteration in the following disposition parameters (mean values for control versus cimetidine): systemic clearance, 46.6 versus 28.3 L/hr; mean residence time, 2.1 versus 3.2 hours; elimination half-life, 1.6 versus 2.3 hours.",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),h,2.1,138865,DB00501,Cimetidine
,1988238,mean residence time,"The data on intravenous administration indicated that cimetidine produced a statistically significant alteration in the following disposition parameters (mean values for control versus cimetidine): systemic clearance, 46.6 versus 28.3 L/hr; mean residence time, 2.1 versus 3.2 hours; elimination half-life, 1.6 versus 2.3 hours.",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),h,3.2,138866,DB00501,Cimetidine
,1988238,elimination half-life,"The data on intravenous administration indicated that cimetidine produced a statistically significant alteration in the following disposition parameters (mean values for control versus cimetidine): systemic clearance, 46.6 versus 28.3 L/hr; mean residence time, 2.1 versus 3.2 hours; elimination half-life, 1.6 versus 2.3 hours.",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),h,1.6,138867,DB00501,Cimetidine
,1988238,elimination half-life,"The data on intravenous administration indicated that cimetidine produced a statistically significant alteration in the following disposition parameters (mean values for control versus cimetidine): systemic clearance, 46.6 versus 28.3 L/hr; mean residence time, 2.1 versus 3.2 hours; elimination half-life, 1.6 versus 2.3 hours.",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),h,2.3,138868,DB00501,Cimetidine
,1988238,absolute oral bioavailability,"The absolute oral bioavailability of moclobemide increased significantly after cimetidine administration (54% versus 68%), as did the maximum plasma concentration after a single oral dose (575 versus 787 ng/ml).",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),%,54,138869,DB00501,Cimetidine
,1988238,absolute oral bioavailability,"The absolute oral bioavailability of moclobemide increased significantly after cimetidine administration (54% versus 68%), as did the maximum plasma concentration after a single oral dose (575 versus 787 ng/ml).",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),%,68,138870,DB00501,Cimetidine
,1988238,maximum plasma concentration,"The absolute oral bioavailability of moclobemide increased significantly after cimetidine administration (54% versus 68%), as did the maximum plasma concentration after a single oral dose (575 versus 787 ng/ml).",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),[ng] / [ml],575,138871,DB00501,Cimetidine
,1988238,maximum plasma concentration,"The absolute oral bioavailability of moclobemide increased significantly after cimetidine administration (54% versus 68%), as did the maximum plasma concentration after a single oral dose (575 versus 787 ng/ml).",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),[ng] / [ml],787,138872,DB00501,Cimetidine
,8573949,times to maximum cy,"The average times to maximum cyclosporine concentrations were similar between baseline (3.2 h), cimetidine (2.9 h), and famotidine (3.6 h) dosing periods.",Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573949/),h,3.2,139511,DB00501,Cimetidine
,8573949,times to maximum cy,"The average times to maximum cyclosporine concentrations were similar between baseline (3.2 h), cimetidine (2.9 h), and famotidine (3.6 h) dosing periods.",Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573949/),h,2.9,139512,DB00501,Cimetidine
,8573949,times to maximum cy,"The average times to maximum cyclosporine concentrations were similar between baseline (3.2 h), cimetidine (2.9 h), and famotidine (3.6 h) dosing periods.",Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573949/),h,3.6,139513,DB00501,Cimetidine
,2530866,absolute bioavailability,A single intravenous dose of 10 mg resulted in an absolute bioavailability of 64% and a calculated elimination half-life of 34 hours.,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,64,140280,DB00501,Cimetidine
,2530866,elimination half-life,A single intravenous dose of 10 mg resulted in an absolute bioavailability of 64% and a calculated elimination half-life of 34 hours.,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,34,140281,DB00501,Cimetidine
,2530866,elimination half-life,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,3 to 10,140282,DB00501,Cimetidine
,2530866,absolute bioavailability,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,10,140283,DB00501,Cimetidine
,2530866,absolute bioavailability,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,30,140284,DB00501,Cimetidine
,2530866,elimination half-life,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,3 to 6,140285,DB00501,Cimetidine
,2530866,elimination half-life,"In the elderly population, elimination half-life of 5 mg oral doses is significantly prolonged (48 vs 35 hours; p less than 0.025) suggesting decreased oral clearance or increased bioavailability.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,48,140286,DB00501,Cimetidine
,2530866,elimination half-life,"In the elderly population, elimination half-life of 5 mg oral doses is significantly prolonged (48 vs 35 hours; p less than 0.025) suggesting decreased oral clearance or increased bioavailability.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,35,140287,DB00501,Cimetidine
,2530866,elimination half-life,"In patients with cirrhosis, elimination half-life is significantly prolonged (60 vs 34 hours; p less than 0.01) suggesting that there is a greater accumulation of amlodipine in patients with severe liver disease than in individuals with normal hepatic function.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,60,140288,DB00501,Cimetidine
,2530866,elimination half-life,"In patients with cirrhosis, elimination half-life is significantly prolonged (60 vs 34 hours; p less than 0.01) suggesting that there is a greater accumulation of amlodipine in patients with severe liver disease than in individuals with normal hepatic function.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,34,140289,DB00501,Cimetidine
,1685875,half-lives,half-lives of 30-40 min were determined for the beta-phase and 8-10 h for the terminal elimination phase (Table 2).,[The pharmacokinetics of lormetazepam following cimetidine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685875/),min,30-40,140482,DB00501,Cimetidine
,1685875,half-lives,half-lives of 30-40 min were determined for the beta-phase and 8-10 h for the terminal elimination phase (Table 2).,[The pharmacokinetics of lormetazepam following cimetidine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685875/),h,8-10,140483,DB00501,Cimetidine
,8229695,steady-state plasma concentrations (Css),The infusion of CM was conducted to achieve steady-state plasma concentrations (Css) of CM of 30 and 60 micrograms/mL.,Effect of cimetidine on the pharmacokinetics of fentiazac in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229695/),[μg] / [ml],30,140523,DB00501,Cimetidine
,8229695,steady-state plasma concentrations (Css),The infusion of CM was conducted to achieve steady-state plasma concentrations (Css) of CM of 30 and 60 micrograms/mL.,Effect of cimetidine on the pharmacokinetics of fentiazac in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229695/),[μg] / [ml],60,140524,DB00501,Cimetidine
,8229695,Css,The CLt values in rats with different Css of CM (30 and 60 micrograms/mL) were not significantly different from each other.,Effect of cimetidine on the pharmacokinetics of fentiazac in rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229695/),[μg] / [ml],30,140525,DB00501,Cimetidine
,8229695,Css,The CLt values in rats with different Css of CM (30 and 60 micrograms/mL) were not significantly different from each other.,Effect of cimetidine on the pharmacokinetics of fentiazac in rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229695/),[μg] / [ml],60,140526,DB00501,Cimetidine
,3327676,elimination half-life,The mean elimination half-life of felodipine is approximately 25h.,Clinical pharmacokinetics of felodipine. A summary. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327676/),h,25,140911,DB00501,Cimetidine
,3327676,volume of distribution,"The volume of distribution of felodipine is about 10 L/kg, implying that less than 1% of the amount of drug in the body is localised in the blood.",Clinical pharmacokinetics of felodipine. A summary. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327676/),[l] / [kg],10,140912,DB00501,Cimetidine
,3327676,total clearance from the blood,"Mean total clearance from the blood is 1 to 1.5 L/min and, therefore, felodipine is considered a high clearance drug.",Clinical pharmacokinetics of felodipine. A summary. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327676/),[l] / [min],1 to 1.5,140913,DB00501,Cimetidine
,18551044,renal tubular clearance (CLt),"The renal tubular clearance (CLt) of metformin averaged 8.78+/-1.75, 7.68+/-0.672, and 6.32+/-0.954 ml/min/kg for participants with GG (n=6), GT (n=5), and TT (n=4) genotypes, respectively (P=0.037, one-way analysis of variance).",OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18551044/),[ml] / [kg·min],8.78,142481,DB00501,Cimetidine
,18551044,renal tubular clearance (CLt),"The renal tubular clearance (CLt) of metformin averaged 8.78+/-1.75, 7.68+/-0.672, and 6.32+/-0.954 ml/min/kg for participants with GG (n=6), GT (n=5), and TT (n=4) genotypes, respectively (P=0.037, one-way analysis of variance).",OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18551044/),[ml] / [kg·min],7.68,142482,DB00501,Cimetidine
,18551044,renal tubular clearance (CLt),"The renal tubular clearance (CLt) of metformin averaged 8.78+/-1.75, 7.68+/-0.672, and 6.32+/-0.954 ml/min/kg for participants with GG (n=6), GT (n=5), and TT (n=4) genotypes, respectively (P=0.037, one-way analysis of variance).",OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18551044/),[ml] / [kg·min],6.32,142483,DB00501,Cimetidine
,8473547,maximum plasma concentration,"The maximum plasma concentration of ritanserin was decreased significantly (105.0 +/- 9.2 versus 125.0 +/- 13.8 ng/mL; P = .0039), whereas time to reach maximal concentration (tmax) of ritanserin was only slightly but not significantly increased, if the subjects were pretreated with cimetidine.",Effect of concomitantly administered cimetidine or ranitidine on the pharmacokinetics of the 5-HT2-receptor antagonist ritanserin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8473547/),[ng] / [ml],105.0,145022,DB00501,Cimetidine
,8473547,maximum plasma concentration,"The maximum plasma concentration of ritanserin was decreased significantly (105.0 +/- 9.2 versus 125.0 +/- 13.8 ng/mL; P = .0039), whereas time to reach maximal concentration (tmax) of ritanserin was only slightly but not significantly increased, if the subjects were pretreated with cimetidine.",Effect of concomitantly administered cimetidine or ranitidine on the pharmacokinetics of the 5-HT2-receptor antagonist ritanserin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8473547/),[ng] / [ml],125.0,145023,DB00501,Cimetidine
,3950073,time to peak doxepin plasma concentration,"Doxepin absorptive parameters--time to peak doxepin plasma concentration (2.3, control, vs. 2.4 hours during cimetidine co-administration) and peak concentration achieved (43.3. vs. 55.5 ng/ml)--were not changed during cimetidine administration.",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),h,2.3,145342,DB00501,Cimetidine
,3950073,time to peak doxepin plasma concentration,"Doxepin absorptive parameters--time to peak doxepin plasma concentration (2.3, control, vs. 2.4 hours during cimetidine co-administration) and peak concentration achieved (43.3. vs. 55.5 ng/ml)--were not changed during cimetidine administration.",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),h,2.4,145343,DB00501,Cimetidine
,3950073,peak concentration achieved,"Doxepin absorptive parameters--time to peak doxepin plasma concentration (2.3, control, vs. 2.4 hours during cimetidine co-administration) and peak concentration achieved (43.3. vs. 55.5 ng/ml)--were not changed during cimetidine administration.",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ng] / [ml],43.3,145344,DB00501,Cimetidine
,3950073,peak concentration achieved,"Doxepin absorptive parameters--time to peak doxepin plasma concentration (2.3, control, vs. 2.4 hours during cimetidine co-administration) and peak concentration achieved (43.3. vs. 55.5 ng/ml)--were not changed during cimetidine administration.",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ng] / [ml],55.5,145345,DB00501,Cimetidine
,3950073,elimination half-life,"Likewise, doxepin elimination half-life was similar in the control state (12.5 hours) and during cimetidine administration (13.2 hours).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),h,12.5,145346,DB00501,Cimetidine
,3950073,elimination half-life,"Likewise, doxepin elimination half-life was similar in the control state (12.5 hours) and during cimetidine administration (13.2 hours).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),h,13.2,145347,DB00501,Cimetidine
,3950073,area under the plasma concentration-time curve (AUC),"However, doxepin area under the plasma concentration-time curve (AUC) was increased during concurrent cimetidine administration (533 vs. 695 ng/ml . hour; p less than 0.05), resulting in a trend toward decreased doxepin oral clearance (4404 vs. 3278 ml/min; 0.05 less than p less than 0.1).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ng] / [h·ml],533,145348,DB00501,Cimetidine
,3950073,area under the plasma concentration-time curve (AUC),"However, doxepin area under the plasma concentration-time curve (AUC) was increased during concurrent cimetidine administration (533 vs. 695 ng/ml . hour; p less than 0.05), resulting in a trend toward decreased doxepin oral clearance (4404 vs. 3278 ml/min; 0.05 less than p less than 0.1).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ng] / [h·ml],695,145349,DB00501,Cimetidine
,3950073,oral clearance,"However, doxepin area under the plasma concentration-time curve (AUC) was increased during concurrent cimetidine administration (533 vs. 695 ng/ml . hour; p less than 0.05), resulting in a trend toward decreased doxepin oral clearance (4404 vs. 3278 ml/min; 0.05 less than p less than 0.1).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ml] / [min],4404,145350,DB00501,Cimetidine
,3950073,oral clearance,"However, doxepin area under the plasma concentration-time curve (AUC) was increased during concurrent cimetidine administration (533 vs. 695 ng/ml . hour; p less than 0.05), resulting in a trend toward decreased doxepin oral clearance (4404 vs. 3278 ml/min; 0.05 less than p less than 0.1).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ml] / [min],3278,145351,DB00501,Cimetidine
,3950073,Relative bioavailability,Relative bioavailability during concurrent cimetidine treatment was 123% of that during the control trial.,Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),%,123,145352,DB00501,Cimetidine
,3950073,AUC,"Desmethyldoxepin AUC was no different between trials (478, control, vs. 433 ng/ml . hour during cimetidine ingestion).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ng] / [h·ml],478,145353,DB00501,Cimetidine
,3950073,AUC,"Desmethyldoxepin AUC was no different between trials (478, control, vs. 433 ng/ml . hour during cimetidine ingestion).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ng] / [h·ml],433,145354,DB00501,Cimetidine
,3950073,percent unbound,"Plasma protein binding of doxepin was similar between trials (percent unbound; 10.5, control, vs. 11.2%) and therefore did not influence calculated AUC.",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),%,10.5,145355,DB00501,Cimetidine
,3950073,percent unbound,"Plasma protein binding of doxepin was similar between trials (percent unbound; 10.5, control, vs. 11.2%) and therefore did not influence calculated AUC.",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),%,11.2,145356,DB00501,Cimetidine
,12139218,maximum ABZSX concentration (Cmax),"In comparison to water, maximum ABZSX concentration (Cmax) was enhanced 6.5-fold by a fatty meal (from 0.24 +/- 0.09 mg/l to 1.55 +/- 0.30 mg/l; mean +/- SD; P < 0.001) and 3.2-fold by grapefruit juice (from 0.24 +/- 0.09 mg/l to 0.76 +/- 0.37 mg/L; P = 0.031).",Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139218/),[mg] / [l],0.24,145754,DB00501,Cimetidine
,12139218,maximum ABZSX concentration (Cmax),"In comparison to water, maximum ABZSX concentration (Cmax) was enhanced 6.5-fold by a fatty meal (from 0.24 +/- 0.09 mg/l to 1.55 +/- 0.30 mg/l; mean +/- SD; P < 0.001) and 3.2-fold by grapefruit juice (from 0.24 +/- 0.09 mg/l to 0.76 +/- 0.37 mg/L; P = 0.031).",Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139218/),[mg] / [l],1.55,145755,DB00501,Cimetidine
,12139218,maximum ABZSX concentration (Cmax),"In comparison to water, maximum ABZSX concentration (Cmax) was enhanced 6.5-fold by a fatty meal (from 0.24 +/- 0.09 mg/l to 1.55 +/- 0.30 mg/l; mean +/- SD; P < 0.001) and 3.2-fold by grapefruit juice (from 0.24 +/- 0.09 mg/l to 0.76 +/- 0.37 mg/L; P = 0.031).",Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139218/),[mg] / [l],0.76,145756,DB00501,Cimetidine
,12139218,Cmax,"When grapefruit juice was combined with cimetidine, Cmax was significantly lower than with grapefruit juice alone (0.41 +/- 0.29 mg/l and 0.76 +/- 0.37 mg/l, respectively; P = 0.022).",Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139218/),[mg] / [l],0.41,145757,DB00501,Cimetidine
,12139218,Cmax,"When grapefruit juice was combined with cimetidine, Cmax was significantly lower than with grapefruit juice alone (0.41 +/- 0.29 mg/l and 0.76 +/- 0.37 mg/l, respectively; P = 0.022).",Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139218/),[mg] / [l],0.76,145758,DB00501,Cimetidine
,12139218,Half-life (T(1/2)),Half-life (T(1/2)) was 8.8 +/- 4.2 hr and 8.2 +/- 4.3 hr after administration with water or a fatty meal (P = 1.000).,Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139218/),h,8.8,145759,DB00501,Cimetidine
,12139218,Half-life (T(1/2)),Half-life (T(1/2)) was 8.8 +/- 4.2 hr and 8.2 +/- 4.3 hr after administration with water or a fatty meal (P = 1.000).,Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139218/),h,8.2,145760,DB00501,Cimetidine
,10954343,clearance over bioavailability (CL/F),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[l] / [h],2.60,146191,DB00501,Cimetidine
,10954343,renal clearance (CLR),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[l] / [h],0.10,146192,DB00501,Cimetidine
,10954343,terminal half-life (t1/2),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),h,23.8,146193,DB00501,Cimetidine
,10954343,peak serum concentration (Cmax),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[μg] / [l],0.29,146194,DB00501,Cimetidine
,10954343,time to reach Cmax (tmax),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),h,1.6,146195,DB00501,Cimetidine
,10954343,total area under the serum concentration-time curve (AUC0-infinity),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[μg] / [min·ml],703.99,146196,DB00501,Cimetidine
,10954343,amount,The amount of lamotrigine excreted as glucuronide was 8.90+/-0.77 mg.,Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),mg,8.90,146197,DB00501,Cimetidine
,10954343,excreted,The amount of lamotrigine excreted as glucuronide was 8.90+/-0.77 mg.,Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),mg,8.90,146198,DB00501,Cimetidine
,10954343,CL/F,"Rifampicin significantly increased CL/F (5.13+/-1.05 l/h) and the amount of lamotrigine excreted as glucuronide (12.12+/-0.94 mg), whereas both t1/2 (14.1+/-1.7 h) and AUC(0-infinity) (396.24+/-60.18 microg/ml/min) were decreased (P<0.05).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[l] / [h],5.13,146199,DB00501,Cimetidine
,10954343,t1/2,"Rifampicin significantly increased CL/F (5.13+/-1.05 l/h) and the amount of lamotrigine excreted as glucuronide (12.12+/-0.94 mg), whereas both t1/2 (14.1+/-1.7 h) and AUC(0-infinity) (396.24+/-60.18 microg/ml/min) were decreased (P<0.05).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),h,14.1,146200,DB00501,Cimetidine
,10954343,AUC(0-infinity),"Rifampicin significantly increased CL/F (5.13+/-1.05 l/h) and the amount of lamotrigine excreted as glucuronide (12.12+/-0.94 mg), whereas both t1/2 (14.1+/-1.7 h) and AUC(0-infinity) (396.24+/-60.18 microg/ml/min) were decreased (P<0.05).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[μg] / [min·ml],396.24,146201,DB00501,Cimetidine
,3802377,AUC,Doxorubicin plasma pharmacokinetics were prolonged after cimetidine pretreatment [AUC 0.76 +/- 0.22 vs.,The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802377/),,0.76,146570,DB00501,Cimetidine
,3802377,half-life,"2.85 +/- 1.22 microM X h, no pretreatment vs pretreatment (p = 0.005), half-life = 11.7 +/- 6.55 vs 28.0 +/- 8.16 h (P = 0.0002), and clearance = 0.129 +/- 0.036 vs 0.036 +/- 0.011 l/min-1 kg-1 (P = 0.0007)].",The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802377/),h,11.7,146571,DB00501,Cimetidine
,3802377,half-life,"2.85 +/- 1.22 microM X h, no pretreatment vs pretreatment (p = 0.005), half-life = 11.7 +/- 6.55 vs 28.0 +/- 8.16 h (P = 0.0002), and clearance = 0.129 +/- 0.036 vs 0.036 +/- 0.011 l/min-1 kg-1 (P = 0.0007)].",The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802377/),h,28.0,146572,DB00501,Cimetidine
,3802377,clearance,"2.85 +/- 1.22 microM X h, no pretreatment vs pretreatment (p = 0.005), half-life = 11.7 +/- 6.55 vs 28.0 +/- 8.16 h (P = 0.0002), and clearance = 0.129 +/- 0.036 vs 0.036 +/- 0.011 l/min-1 kg-1 (P = 0.0007)].",The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802377/),[l] / [min],0.129,146573,DB00501,Cimetidine
,3802377,clearance,"2.85 +/- 1.22 microM X h, no pretreatment vs pretreatment (p = 0.005), half-life = 11.7 +/- 6.55 vs 28.0 +/- 8.16 h (P = 0.0002), and clearance = 0.129 +/- 0.036 vs 0.036 +/- 0.011 l/min-1 kg-1 (P = 0.0007)].",The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802377/),[l] / [min],0.036,146574,DB00501,Cimetidine
,8097364,durations of action,"The durations of action of cimetidine, ranitidine, and famotidine are similar to the dosage intervals usually chosen (6, 8, and 12 hours, respectively).",Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097364/),h,6,146832,DB00501,Cimetidine
,8097364,durations of action,"The durations of action of cimetidine, ranitidine, and famotidine are similar to the dosage intervals usually chosen (6, 8, and 12 hours, respectively).",Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097364/),h,8,146833,DB00501,Cimetidine
,8097364,durations of action,"The durations of action of cimetidine, ranitidine, and famotidine are similar to the dosage intervals usually chosen (6, 8, and 12 hours, respectively).",Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097364/),h,12,146834,DB00501,Cimetidine
,19853541,total run time,The total run time was 7 min per sample.,A single LC-tandem mass spectrometry method for the simultaneous determination of four H2 antagonists in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853541/),[min] / [sample],7,146976,DB00501,Cimetidine
,17375980,elimination half-life,The elimination half-life of escitalopram is about 27-33 hours and is consistent with once-daily administration.,The clinical pharmacokinetics of escitalopram. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17375980/),h,27-33,147053,DB00501,Cimetidine
,17375980,protein binding,Escitalopram has low protein binding (56%) and is not likely to cause interactions with highly protein-bound drugs.,The clinical pharmacokinetics of escitalopram. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17375980/),%,56,147054,DB00501,Cimetidine
,17375980,apparent volume of distribution during the terminal phase after oral administration (V(z)/F),"It is widely distributed throughout tissues, with an apparent volume of distribution during the terminal phase after oral administration (V(z)/F) of about 1100L.",The clinical pharmacokinetics of escitalopram. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17375980/),l,1100,147055,DB00501,Cimetidine
,8743335,absolute oral bioavailability,"Metformin has an absolute oral bioavailability of 40 to 60%, and gastrointestinal absorption is apparently complete within 6 hours of ingestion.",Clinical pharmacokinetics of metformin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8743335/),%,40 to 60,147787,DB00501,Cimetidine
,8743335,plasma elimination half-life,Metformin undergoes renal excretion and has a mean plasma elimination half-life after oral administration of between 4.0 and 8.7 hours.,Clinical pharmacokinetics of metformin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8743335/),h,4.0 and 8.7,147788,DB00501,Cimetidine
,7497581,AUC (AUC,"Specifically, metoclopramide had little effect on the etoposide absorption profile and did not significantly alter the AUC (AUC with etoposide alone, 68.4 +/- 20.3 micrograms ml-1 h, versus 74.3 +/- 25.9 micrograms ml-1 h with metoclopramide), suggesting that in most patients the drug is already emptied rapidly from the stomach.",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],68.4,148763,DB00501,Cimetidine
,7497581,AUC (AUC,"Specifically, metoclopramide had little effect on the etoposide absorption profile and did not significantly alter the AUC (AUC with etoposide alone, 68.4 +/- 20.3 micrograms ml-1 h, versus 74.3 +/- 25.9 micrograms ml-1 h with metoclopramide), suggesting that in most patients the drug is already emptied rapidly from the stomach.",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],74.3,148764,DB00501,Cimetidine
,7497581,time of maximal concentration tmax,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),h,1.1,148765,DB00501,Cimetidine
,7497581,time of maximal concentration tmax,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),h,3.5,148766,DB00501,Cimetidine
,7497581,AUC,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],78.3,148767,DB00501,Cimetidine
,7497581,AUC,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],88.1,148768,DB00501,Cimetidine
,7138754,elimination half-life,A significant increase in diazepam elimination half-life from (mean +/- s.e. mean) 66.9 +/- 21.4 to 89.6 +/- 22.5 h (P = 0.006) and area under the plasma concentration-time curve from 5.06 +/- 1.47 to 8.93 +/- 1.88 micrograms ml-1 h (P = 0.028) was observed indicating a probable cimetidine induced inhibition of diazepam hepatic metabolism.,Influence of cimetidine on oral diazepam elimination with measurement of subsequent cognitive change. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138754/),h,66.9,149087,DB00501,Cimetidine
,7138754,elimination half-life,A significant increase in diazepam elimination half-life from (mean +/- s.e. mean) 66.9 +/- 21.4 to 89.6 +/- 22.5 h (P = 0.006) and area under the plasma concentration-time curve from 5.06 +/- 1.47 to 8.93 +/- 1.88 micrograms ml-1 h (P = 0.028) was observed indicating a probable cimetidine induced inhibition of diazepam hepatic metabolism.,Influence of cimetidine on oral diazepam elimination with measurement of subsequent cognitive change. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138754/),h,89.6,149088,DB00501,Cimetidine
,7138754,area under the plasma concentration-time curve,A significant increase in diazepam elimination half-life from (mean +/- s.e. mean) 66.9 +/- 21.4 to 89.6 +/- 22.5 h (P = 0.006) and area under the plasma concentration-time curve from 5.06 +/- 1.47 to 8.93 +/- 1.88 micrograms ml-1 h (P = 0.028) was observed indicating a probable cimetidine induced inhibition of diazepam hepatic metabolism.,Influence of cimetidine on oral diazepam elimination with measurement of subsequent cognitive change. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138754/),[h·μg] / [ml],5.06,149089,DB00501,Cimetidine
,7138754,area under the plasma concentration-time curve,A significant increase in diazepam elimination half-life from (mean +/- s.e. mean) 66.9 +/- 21.4 to 89.6 +/- 22.5 h (P = 0.006) and area under the plasma concentration-time curve from 5.06 +/- 1.47 to 8.93 +/- 1.88 micrograms ml-1 h (P = 0.028) was observed indicating a probable cimetidine induced inhibition of diazepam hepatic metabolism.,Influence of cimetidine on oral diazepam elimination with measurement of subsequent cognitive change. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138754/),[h·μg] / [ml],8.93,149090,DB00501,Cimetidine
,6852412,half-life,No differences were observed in cimetidine half-life (2.53 +/- 0.63 and 2.33 +/- 0.40 h) between the two groups.,[Pharmacokinetics of cimetidine in ascitic cirrhotics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852412/),h,2.53,149860,DB00501,Cimetidine
,6852412,half-life,No differences were observed in cimetidine half-life (2.53 +/- 0.63 and 2.33 +/- 0.40 h) between the two groups.,[Pharmacokinetics of cimetidine in ascitic cirrhotics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852412/),h,2.33,149861,DB00501,Cimetidine
,6852412,clearance,Cimetidine clearance was diminished by about 30 p 100 in cirrhotic patients (0.426 +/- 0.138 vs. 0.649 +/- 0.163 l/h/kg).,[Pharmacokinetics of cimetidine in ascitic cirrhotics]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852412/),[l] / [h·kg],0.426,149862,DB00501,Cimetidine
,6852412,clearance,Cimetidine clearance was diminished by about 30 p 100 in cirrhotic patients (0.426 +/- 0.138 vs. 0.649 +/- 0.163 l/h/kg).,[Pharmacokinetics of cimetidine in ascitic cirrhotics]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852412/),[l] / [h·kg],0.649,149863,DB00501,Cimetidine
,6852412,apparent volume of distribution,The apparent volume of distribution was also significantly diminished (1.50 +/- 0.44 vs. 2.14 +/- 0.55 l/kg) in patients with cirrhosis and ascites.,[Pharmacokinetics of cimetidine in ascitic cirrhotics]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852412/),[l] / [kg],1.50,149864,DB00501,Cimetidine
,6852412,apparent volume of distribution,The apparent volume of distribution was also significantly diminished (1.50 +/- 0.44 vs. 2.14 +/- 0.55 l/kg) in patients with cirrhosis and ascites.,[Pharmacokinetics of cimetidine in ascitic cirrhotics]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852412/),[l] / [kg],2.14,149865,DB00501,Cimetidine
,1360044,ClC/Cll,"With cimetidine, ClC/Cll approached unity in 8 patients (mean 1.02 [SD 0.03]), but considerably exceeded unity in 8 others (1.33 [0.14]).",Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1360044/),,1.02,150411,DB00501,Cimetidine
,1360044,ClC/Cll,"With cimetidine, ClC/Cll approached unity in 8 patients (mean 1.02 [SD 0.03]), but considerably exceeded unity in 8 others (1.33 [0.14]).",Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1360044/),,1.33,150412,DB00501,Cimetidine
,1360044,renal clearance,"Plasma cimetidine/creatinine ratio was smaller in this second group, due to significantly higher renal clearance of cimetidine (333 [136] vs 165 [89] ml/min, p = 0.01).",Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1360044/),[ml] / [min],333,150413,DB00501,Cimetidine
,1360044,renal clearance,"Plasma cimetidine/creatinine ratio was smaller in this second group, due to significantly higher renal clearance of cimetidine (333 [136] vs 165 [89] ml/min, p = 0.01).",Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1360044/),[ml] / [min],165,150414,DB00501,Cimetidine
,1360044,clearance times,"However, because of the maximum daily dose of cimetidine that is advised, short clearance times (3 h) are recommended.",Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1360044/),h,3,150415,DB00501,Cimetidine
,24947923,intrinsic clearance,"In vitro intrinsic clearance of CYP2D6.1 and CYP2D6.10 for veliparib metabolism were 0.055 and 0.017 μL/min/pmol CYP, respectively.","Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24947923/),[μl] / [cyp·min·pM],0.055,150822,DB00501,Cimetidine
,24947923,intrinsic clearance,"In vitro intrinsic clearance of CYP2D6.1 and CYP2D6.10 for veliparib metabolism were 0.055 and 0.017 μL/min/pmol CYP, respectively.","Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24947923/),[μl] / [cyp·min·pM],0.017,150823,DB00501,Cimetidine
,24947923,oral clearance,"Population mean values for veliparib oral clearance and M8 clearance were 13.3 and 8.6 L/h, respectively.","Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24947923/),[l] / [h],13.3,150824,DB00501,Cimetidine
,24947923,M8 clearance,"Population mean values for veliparib oral clearance and M8 clearance were 13.3 and 8.6 L/h, respectively.","Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24947923/),[l] / [h],8.6,150825,DB00501,Cimetidine
,2598569,systemic clearance,"The three-compartment model analysis showed that systemic clearance (29.8 +/- 5.7 ml/min/kg), volume of distribution (16.6 +/- 4.1 L/kg), and terminal half-life (11.7 +/- 2.7 hours) were not altered by cimetidine.",Pharmacokinetics and pharmacodynamics of dilevalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598569/),[ml] / [kg·min],29.8,151422,DB00501,Cimetidine
,2598569,volume of distribution,"The three-compartment model analysis showed that systemic clearance (29.8 +/- 5.7 ml/min/kg), volume of distribution (16.6 +/- 4.1 L/kg), and terminal half-life (11.7 +/- 2.7 hours) were not altered by cimetidine.",Pharmacokinetics and pharmacodynamics of dilevalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598569/),[l] / [kg],16.6,151423,DB00501,Cimetidine
,2598569,terminal half-life,"The three-compartment model analysis showed that systemic clearance (29.8 +/- 5.7 ml/min/kg), volume of distribution (16.6 +/- 4.1 L/kg), and terminal half-life (11.7 +/- 2.7 hours) were not altered by cimetidine.",Pharmacokinetics and pharmacodynamics of dilevalol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598569/),h,11.7,151424,DB00501,Cimetidine
,6315329,plasma level peaks,"After treatment for one week with 4 X 10 mg nifedipine daily and 3 X 200 mg cimetidine daily and 400 mg at night plasma level peaks of nifedipine averaged 87.7 +/- 19.1 ng/ml, while after 4 X 10 mg nifedipine alone they were only 46.1 +/- 10.6 ng/ml.",[Effect of cimetidine and ranitidine on the pharmacokinetics and anti-hypertensive effect of nifedipine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6315329/),[ng] / [ml],87.7,151428,DB00501,Cimetidine
,6315329,plasma level peaks,"After treatment for one week with 4 X 10 mg nifedipine daily and 3 X 200 mg cimetidine daily and 400 mg at night plasma level peaks of nifedipine averaged 87.7 +/- 19.1 ng/ml, while after 4 X 10 mg nifedipine alone they were only 46.1 +/- 10.6 ng/ml.",[Effect of cimetidine and ranitidine on the pharmacokinetics and anti-hypertensive effect of nifedipine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6315329/),[ng] / [ml],46.1,151429,DB00501,Cimetidine
,6144488,total body clearance,"The dogs demonstrated metabolic and pharmacokinetic characteristics similar to human volunteers, as the total body clearance of cimetidine averaged 7.5 ml/min/kg in the dog as compared to 7.7 ml/min/kg in humans.",The partitioning of cimetidine into canine cerebrospinal fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144488/),[ml] / [kg·min],7.5,151860,DB00501,Cimetidine
,6144488,total body clearance,"The dogs demonstrated metabolic and pharmacokinetic characteristics similar to human volunteers, as the total body clearance of cimetidine averaged 7.5 ml/min/kg in the dog as compared to 7.7 ml/min/kg in humans.",The partitioning of cimetidine into canine cerebrospinal fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144488/),[ml] / [kg·min],7.7,151861,DB00501,Cimetidine
,4002755,half-life period of Antipyrine (t50),"In 14 male patients suffering from peptic ulcer the half-life period of Antipyrine (t50) was 8.6 +/- 0.6 h, whereas in the second test after 14 days it was 13 +/- 0.8 h.",[Effect of histamine H2 receptor blockers on hepatic elimination of drugs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002755/),h,8.6,153031,DB00501,Cimetidine
,4002755,half-life period of Antipyrine (t50),"In 14 male patients suffering from peptic ulcer the half-life period of Antipyrine (t50) was 8.6 +/- 0.6 h, whereas in the second test after 14 days it was 13 +/- 0.8 h.",[Effect of histamine H2 receptor blockers on hepatic elimination of drugs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002755/),h,13,153032,DB00501,Cimetidine
,4002755,systemic clearance (Cltot),The systemic clearance (Cltot) was estimated with 78 +/- 11.3 ml X min-1 before treatment and with 40.8 +/- 3.6 ml X min-1 after treatment.,[Effect of histamine H2 receptor blockers on hepatic elimination of drugs]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002755/),[ml] / [min],78,153033,DB00501,Cimetidine
,4002755,systemic clearance (Cltot),The systemic clearance (Cltot) was estimated with 78 +/- 11.3 ml X min-1 before treatment and with 40.8 +/- 3.6 ml X min-1 after treatment.,[Effect of histamine H2 receptor blockers on hepatic elimination of drugs]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002755/),[ml] / [min],40.8,153034,DB00501,Cimetidine
,3609545,total excretion,"Oral administration of 5 mg/kg of [14C]LY56110 (5-bis(4-chlorophenyl)methylpyrimidine) to the rat, monkey, and dog resulted in a total excretion of 68, 65, and 30% of the radioactivity within 5 days, respectively.","Disposition of the aromatase inhibitor LY56110 and associated induction and inhibition studies in rats, dogs, and monkeys. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609545/),%,68,154270,DB00501,Cimetidine
,3609545,total excretion,"Oral administration of 5 mg/kg of [14C]LY56110 (5-bis(4-chlorophenyl)methylpyrimidine) to the rat, monkey, and dog resulted in a total excretion of 68, 65, and 30% of the radioactivity within 5 days, respectively.","Disposition of the aromatase inhibitor LY56110 and associated induction and inhibition studies in rats, dogs, and monkeys. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609545/),%,65,154271,DB00501,Cimetidine
,3609545,total excretion,"Oral administration of 5 mg/kg of [14C]LY56110 (5-bis(4-chlorophenyl)methylpyrimidine) to the rat, monkey, and dog resulted in a total excretion of 68, 65, and 30% of the radioactivity within 5 days, respectively.","Disposition of the aromatase inhibitor LY56110 and associated induction and inhibition studies in rats, dogs, and monkeys. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609545/),%,30,154272,DB00501,Cimetidine
,3609545,urinary excretion,"Very low urinary excretion was observed in the rat and dog (2%), with fecal excretion being the predominant mode of elimination in all three species.","Disposition of the aromatase inhibitor LY56110 and associated induction and inhibition studies in rats, dogs, and monkeys. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609545/),%,2,154273,DB00501,Cimetidine
,3609545,plasma radioactivity half-life,"The plasma radioactivity half-life was 49, 41, and greater than 100 hr in the rat, monkey, and dog, respectively.","Disposition of the aromatase inhibitor LY56110 and associated induction and inhibition studies in rats, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609545/),h,49,154274,DB00501,Cimetidine
,3609545,plasma radioactivity half-life,"The plasma radioactivity half-life was 49, 41, and greater than 100 hr in the rat, monkey, and dog, respectively.","Disposition of the aromatase inhibitor LY56110 and associated induction and inhibition studies in rats, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609545/),h,41,154275,DB00501,Cimetidine
,3609545,plasma radioactivity half-life,"The plasma radioactivity half-life was 49, 41, and greater than 100 hr in the rat, monkey, and dog, respectively.","Disposition of the aromatase inhibitor LY56110 and associated induction and inhibition studies in rats, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609545/),h,greater,154276,DB00501,Cimetidine
,3609545,plasma radioactivity half-life,"The plasma radioactivity half-life was 49, 41, and greater than 100 hr in the rat, monkey, and dog, respectively.","Disposition of the aromatase inhibitor LY56110 and associated induction and inhibition studies in rats, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609545/),h,100,154277,DB00501,Cimetidine
,3609545,plasma half-life,The plasma half-life of parent compound was 18 hr in the rat and 10 hr in the dog.,"Disposition of the aromatase inhibitor LY56110 and associated induction and inhibition studies in rats, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609545/),h,18,154278,DB00501,Cimetidine
,3609545,plasma half-life,The plasma half-life of parent compound was 18 hr in the rat and 10 hr in the dog.,"Disposition of the aromatase inhibitor LY56110 and associated induction and inhibition studies in rats, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609545/),h,10,154279,DB00501,Cimetidine
,9784933,absolute bioavailability,"Although nisoldipine is almost completely absorbed, its absolute bioavailability from the CC tablet is only 5.5%, as a result of significant first-pass metabolism in the gut and liver.",Clinical pharmacokinetics of nisoldipine coat-core. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784933/),%,5.5,154456,DB00501,Cimetidine
,7222181,clearance,"Cimetidine clearance was lowest for peritoneal dialysis (5 ml/min), intermediate for hemodialysis (28 ml/min), and greatest for hemoperfusion (85 ml/min).","Removal of cimetidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7222181/),[ml] / [min],5,156936,DB00501,Cimetidine
,7222181,clearance,"Cimetidine clearance was lowest for peritoneal dialysis (5 ml/min), intermediate for hemodialysis (28 ml/min), and greatest for hemoperfusion (85 ml/min).","Removal of cimetidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7222181/),[ml] / [min],28,156937,DB00501,Cimetidine
,7222181,clearance,"Cimetidine clearance was lowest for peritoneal dialysis (5 ml/min), intermediate for hemodialysis (28 ml/min), and greatest for hemoperfusion (85 ml/min).","Removal of cimetidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7222181/),[ml] / [min],85,156938,DB00501,Cimetidine
,6875024,elimination half-life,"The following values were obtained: elimination half-life, 4.3 hours; systemic or total body clearance, 191 +/- 55 ml/min; and dialysis clearance, 4.2 +/- 3.1 ml/min.",Cimetidine disposition in patients undergoing continuous ambulatory peritoneal dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6875024/),h,4.3,157752,DB00501,Cimetidine
,6875024,systemic or,"The following values were obtained: elimination half-life, 4.3 hours; systemic or total body clearance, 191 +/- 55 ml/min; and dialysis clearance, 4.2 +/- 3.1 ml/min.",Cimetidine disposition in patients undergoing continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6875024/),[ml] / [min],191,157753,DB00501,Cimetidine
,6875024,total body clearance,"The following values were obtained: elimination half-life, 4.3 hours; systemic or total body clearance, 191 +/- 55 ml/min; and dialysis clearance, 4.2 +/- 3.1 ml/min.",Cimetidine disposition in patients undergoing continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6875024/),[ml] / [min],191,157754,DB00501,Cimetidine
,2882981,maximum rate of secretory transport (Tm),The maximum rate of secretory transport (Tm) of famotidine averaged 180 micrograms/min/kg.,Urinary excretion kinetics of famotidine in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882981/),[μg] / [kg·min],180,158928,DB00501,Cimetidine
,3770069,CLR,However mean renal clearance (CLR) and fe were significantly increased following 2 weeks of drug dosing (CLR 5.41 ml X min-1 X kg-1; fe 0.61) compared to control (CLR 4.00 ml X min-1 X kg-1; fe 0.48).,Pharmacokinetics of cimetidine after subchronic administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770069/),[ml] / [kg·min],5.41,160289,DB00501,Cimetidine
,3770069,CLR,However mean renal clearance (CLR) and fe were significantly increased following 2 weeks of drug dosing (CLR 5.41 ml X min-1 X kg-1; fe 0.61) compared to control (CLR 4.00 ml X min-1 X kg-1; fe 0.48).,Pharmacokinetics of cimetidine after subchronic administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770069/),[ml] / [kg·min],4.00,160290,DB00501,Cimetidine
,3770069,non renal clearance,Although the non renal clearance was reduced from control values of 4.29 to 3.51 ml X min-1 X kg-1 following 2 weeks of dosing the difference was not significant.,Pharmacokinetics of cimetidine after subchronic administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770069/),[ml] / [kg·min],4.29 to 3.51,160291,DB00501,Cimetidine
,4085354,area under the plasma concentration-time curve,"Ranitidine did not change the carbamazepine area under the plasma concentration-time curve (324.2 +/- 71.1 micrograms h/ml, placebo vs. 326.3 +/- 65.0 micrograms h/ml, ranitidine; p = 0.84) or the elimination half-life (32.2 +/- 6.4 h, placebo vs. 31.7 +/- 6.1 h, ranitidine; p = 0.62).",Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085354/),[h·μg] / [ml],324.2,161820,DB00501,Cimetidine
,4085354,area under the plasma concentration-time curve,"Ranitidine did not change the carbamazepine area under the plasma concentration-time curve (324.2 +/- 71.1 micrograms h/ml, placebo vs. 326.3 +/- 65.0 micrograms h/ml, ranitidine; p = 0.84) or the elimination half-life (32.2 +/- 6.4 h, placebo vs. 31.7 +/- 6.1 h, ranitidine; p = 0.62).",Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085354/),[h·μg] / [ml],326.3,161821,DB00501,Cimetidine
,4085354,elimination half-life,"Ranitidine did not change the carbamazepine area under the plasma concentration-time curve (324.2 +/- 71.1 micrograms h/ml, placebo vs. 326.3 +/- 65.0 micrograms h/ml, ranitidine; p = 0.84) or the elimination half-life (32.2 +/- 6.4 h, placebo vs. 31.7 +/- 6.1 h, ranitidine; p = 0.62).",Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085354/),h,32.2,161822,DB00501,Cimetidine
,4085354,elimination half-life,"Ranitidine did not change the carbamazepine area under the plasma concentration-time curve (324.2 +/- 71.1 micrograms h/ml, placebo vs. 326.3 +/- 65.0 micrograms h/ml, ranitidine; p = 0.84) or the elimination half-life (32.2 +/- 6.4 h, placebo vs. 31.7 +/- 6.1 h, ranitidine; p = 0.62).",Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085354/),h,31.7,161823,DB00501,Cimetidine
,6130952,concentrations causing 50% inhibition,"We analyzed sigmoid-shaped concentration-response curves to both agents; the concentrations causing 50% inhibition of meal-stimulated gastric acid secretion were 0.44 +/- 0.04 and 0.15 +/- 0.04 micrograms/ml for cimetidine and etintidine, respectively.",Clinical pharmacology of etintidine in patients with duodenal ulcer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6130952/),[μg] / [ml],0.44,163349,DB00501,Cimetidine
,6130952,concentrations causing 50% inhibition,"We analyzed sigmoid-shaped concentration-response curves to both agents; the concentrations causing 50% inhibition of meal-stimulated gastric acid secretion were 0.44 +/- 0.04 and 0.15 +/- 0.04 micrograms/ml for cimetidine and etintidine, respectively.",Clinical pharmacology of etintidine in patients with duodenal ulcer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6130952/),[μg] / [ml],0.15,163350,DB00501,Cimetidine
,7075114,total body clearance (TBC),"The total body clearance (TBC) of caffeine was higher (2.49 +/- 0.35 and 1.59 +/- 0.19 ml/kg/min, P less than 0.05) and the elimination half-life (t1/2) shorter (190 +/- 15 and 276 +/- 30 min, P less than 0.05) in smokers than nonsmokers, but Cmax, tmax, and the apparent volume of distribution (Vd, app) did not differ (P greater than 0.05).",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),[ml] / [kg·min],2.49,163735,DB00501,Cimetidine
,7075114,total body clearance (TBC),"The total body clearance (TBC) of caffeine was higher (2.49 +/- 0.35 and 1.59 +/- 0.19 ml/kg/min, P less than 0.05) and the elimination half-life (t1/2) shorter (190 +/- 15 and 276 +/- 30 min, P less than 0.05) in smokers than nonsmokers, but Cmax, tmax, and the apparent volume of distribution (Vd, app) did not differ (P greater than 0.05).",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),[ml] / [kg·min],1.59,163736,DB00501,Cimetidine
,7075114,elimination half-life (t1/2),"The total body clearance (TBC) of caffeine was higher (2.49 +/- 0.35 and 1.59 +/- 0.19 ml/kg/min, P less than 0.05) and the elimination half-life (t1/2) shorter (190 +/- 15 and 276 +/- 30 min, P less than 0.05) in smokers than nonsmokers, but Cmax, tmax, and the apparent volume of distribution (Vd, app) did not differ (P greater than 0.05).",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),min,190,163737,DB00501,Cimetidine
,7075114,elimination half-life (t1/2),"The total body clearance (TBC) of caffeine was higher (2.49 +/- 0.35 and 1.59 +/- 0.19 ml/kg/min, P less than 0.05) and the elimination half-life (t1/2) shorter (190 +/- 15 and 276 +/- 30 min, P less than 0.05) in smokers than nonsmokers, but Cmax, tmax, and the apparent volume of distribution (Vd, app) did not differ (P greater than 0.05).",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),min,276,163738,DB00501,Cimetidine
,7075114,TBC,"Cimetidine decreased the TBC of caffeine by 31% (to 1.73 +/- 0.28 ml/kg/min, P less than 0.05) and by 42% (to 0.92 +/- 0.11 ml/kg/min, P less than 0.01) in smokers and nonsmokers.",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),[ml] / [kg·min],1.73,163739,DB00501,Cimetidine
,7075114,TBC,"Cimetidine decreased the TBC of caffeine by 31% (to 1.73 +/- 0.28 ml/kg/min, P less than 0.05) and by 42% (to 0.92 +/- 0.11 ml/kg/min, P less than 0.01) in smokers and nonsmokers.",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),[ml] / [kg·min],0.92,163740,DB00501,Cimetidine
,7075114,t1/2,"The increases in t1/2 were 45% (to 276 +/- 25 min, P less than 0.05) and 96% (to 542 +/- 123 min, P less than 0.05).",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),min,276,163741,DB00501,Cimetidine
,7075114,t1/2,"The increases in t1/2 were 45% (to 276 +/- 25 min, P less than 0.05) and 96% (to 542 +/- 123 min, P less than 0.05).",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),min,542,163742,DB00501,Cimetidine
,3220613,apparent oral clearance,Cimetidine reduced the mean apparent oral clearance of quinidine (+/- s.e.m.) by 33% from 23.7 +/- 2.5 to 15.9 +/- 1.7 l/h (p less than 0.05).,Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220613/),[l] / [h],23.7,165148,DB00501,Cimetidine
,3220613,apparent oral clearance,Cimetidine reduced the mean apparent oral clearance of quinidine (+/- s.e.m.) by 33% from 23.7 +/- 2.5 to 15.9 +/- 1.7 l/h (p less than 0.05).,Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220613/),[l] / [h],15.9,165149,DB00501,Cimetidine
,3220613,renal clearance,This 33% decline in oral clearance paralleled the 33% decline in renal clearance of unchanged quinidine which decreased from 56.7 +/- 13.3 to 38.3 +/- 3.3 ml/min.,Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220613/),[ml] / [min],56.7,165150,DB00501,Cimetidine
,3220613,renal clearance,This 33% decline in oral clearance paralleled the 33% decline in renal clearance of unchanged quinidine which decreased from 56.7 +/- 13.3 to 38.3 +/- 3.3 ml/min.,Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220613/),[ml] / [min],38.3,165151,DB00501,Cimetidine
,3884305,steady-state peak,"After receiving cimetidine at a dose of 10 mg/kg/d in a full-term infant, the steady-state peak and four-hour concentrations were 3.5 and 1.8 micrograms/ml, respectively.",The pharmacokinetics of cimetidine and metabolites in a neonate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884305/),[μg] / [ml],3.5,166360,DB00501,Cimetidine
,3884305,four-hour concentrations,"After receiving cimetidine at a dose of 10 mg/kg/d in a full-term infant, the steady-state peak and four-hour concentrations were 3.5 and 1.8 micrograms/ml, respectively.",The pharmacokinetics of cimetidine and metabolites in a neonate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884305/),[μg] / [ml],1.8,166361,DB00501,Cimetidine
,3884305,half-life,A mean half-life of 3.6 h for cimetidine and 2.2 h for cimetidine sulfoxide were determined.,The pharmacokinetics of cimetidine and metabolites in a neonate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884305/),h,3.6,166362,DB00501,Cimetidine
,3884305,half-life,A mean half-life of 3.6 h for cimetidine and 2.2 h for cimetidine sulfoxide were determined.,The pharmacokinetics of cimetidine and metabolites in a neonate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884305/),h,2.2,166363,DB00501,Cimetidine
,7912279,cell-to-medium concentration ratios,"The uptakes of cimetidine and nizatidine achieved equilibrium in 5 min with cell-to-medium concentration ratios of 12.0 and 3.5, respectively.","Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912279/),,12.0,166574,DB00501,Cimetidine
,7912279,cell-to-medium concentration ratios,"The uptakes of cimetidine and nizatidine achieved equilibrium in 5 min with cell-to-medium concentration ratios of 12.0 and 3.5, respectively.","Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912279/),,3.5,166575,DB00501,Cimetidine
,6125199,elimination half-life,A slight but significant increase in the elimination half-life from 6.5 +/- 0.6 to 7.9 +/- 0.6 (P less than 0.05) was noted for atenolol after pretreatment with cimetidine.,The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125199/),,6.5,167150,DB00501,Cimetidine
,6125199,elimination half-life,A slight but significant increase in the elimination half-life from 6.5 +/- 0.6 to 7.9 +/- 0.6 (P less than 0.05) was noted for atenolol after pretreatment with cimetidine.,The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125199/),,7.9,167151,DB00501,Cimetidine
,3254976,plasma concentration,"The plasma concentration of lidocaine at the steady state, after a loading dose (7.62 mg/kg body weight) followed by an infusion (0.16 mg/min/kg), increased from 1.62 to 2.69 micrograms/ml after cimetidine treatment.",Effects of cimetidine on lidocaine distribution in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3254976/),[μg] / [ml],1.62,167755,DB00501,Cimetidine
,3254976,plasma concentration,"The plasma concentration of lidocaine at the steady state, after a loading dose (7.62 mg/kg body weight) followed by an infusion (0.16 mg/min/kg), increased from 1.62 to 2.69 micrograms/ml after cimetidine treatment.",Effects of cimetidine on lidocaine distribution in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3254976/),[μg] / [ml],2.69,167756,DB00501,Cimetidine
,3111514,AUC,"Compared with the control treatment, cimetidine increased the glibenclamide AUC (973 vs 710 ng ml-1 h), but during ranitidine dosing glibenclamide AUC (726 ng ml-1 h) was not significantly different from the control.",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·ng] / [ml],973,167821,DB00501,Cimetidine
,3111514,AUC,"Compared with the control treatment, cimetidine increased the glibenclamide AUC (973 vs 710 ng ml-1 h), but during ranitidine dosing glibenclamide AUC (726 ng ml-1 h) was not significantly different from the control.",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·ng] / [ml],710,167822,DB00501,Cimetidine
,3111514,AUC,"Compared with the control treatment, cimetidine increased the glibenclamide AUC (973 vs 710 ng ml-1 h), but during ranitidine dosing glibenclamide AUC (726 ng ml-1 h) was not significantly different from the control.",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·ng] / [ml],726,167823,DB00501,Cimetidine
,3111514,Apparent oral glibenclamide clearance,Apparent oral glibenclamide clearance decreased from 8.25 l h-1 under the control treatment to 6.0 l h-1 following cimetidine but was unchanged during ranitidine (7.97 l h-1).,The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[l] / [h],8.25,167824,DB00501,Cimetidine
,3111514,Apparent oral glibenclamide clearance,Apparent oral glibenclamide clearance decreased from 8.25 l h-1 under the control treatment to 6.0 l h-1 following cimetidine but was unchanged during ranitidine (7.97 l h-1).,The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[l] / [h],6.0,167825,DB00501,Cimetidine
,3111514,Apparent oral glibenclamide clearance,Apparent oral glibenclamide clearance decreased from 8.25 l h-1 under the control treatment to 6.0 l h-1 following cimetidine but was unchanged during ranitidine (7.97 l h-1).,The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[l] / [h],7.97,167826,DB00501,Cimetidine
,3111514,glucose,"Plasma glucose concentrations were unexpectedly higher when glibenclamide was administered with cimetidine or ranitidine (glucose AUC 237 mg dl-1 h, 228 mg dl-1 h) when compared with glibenclamide administered alone (195 mg dl-1 h, P less than 0.0001).",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·mg] / [dl],237,167827,DB00501,Cimetidine
,3111514,AUC,"Plasma glucose concentrations were unexpectedly higher when glibenclamide was administered with cimetidine or ranitidine (glucose AUC 237 mg dl-1 h, 228 mg dl-1 h) when compared with glibenclamide administered alone (195 mg dl-1 h, P less than 0.0001).",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·mg] / [dl],237,167828,DB00501,Cimetidine
,3111514,AUC,"Plasma glucose concentrations were unexpectedly higher when glibenclamide was administered with cimetidine or ranitidine (glucose AUC 237 mg dl-1 h, 228 mg dl-1 h) when compared with glibenclamide administered alone (195 mg dl-1 h, P less than 0.0001).",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·mg] / [dl],228,167829,DB00501,Cimetidine
,3111514,AUC,"Plasma glucose concentrations were unexpectedly higher when glibenclamide was administered with cimetidine or ranitidine (glucose AUC 237 mg dl-1 h, 228 mg dl-1 h) when compared with glibenclamide administered alone (195 mg dl-1 h, P less than 0.0001).",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·mg] / [dl],195,167830,DB00501,Cimetidine
,6437721,apparent volume of distribution,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),l,"1300 to 11,000",168376,DB00501,Cimetidine
,6437721,elimination half-life,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),d,53,168377,DB00501,Cimetidine
,6437721,elimination half-life,"Although it has a short elimination half-life (1 to 3h), 2 major metabolites with antiarrhythmic effects accumulate in the plasma of patients during long term therapy.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,1 to 3,168378,DB00501,Cimetidine
,6437721,elimination half-life,"Flecainide, another class Ic antiarrhythmic agent, has an elimination half-life of 14 hours which makes it suitable for twice daily dosing.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,14,168379,DB00501,Cimetidine
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,9,168380,DB00501,Cimetidine
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,28,168381,DB00501,Cimetidine
,6437721,apparent volume of distribution,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),[l] / [kg],5.0 to 6.6,168382,DB00501,Cimetidine
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,6 to 12,168383,DB00501,Cimetidine
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,11 to 17,168384,DB00501,Cimetidine
,2556239,plasma half-life,It has a plasma half-life of approximately 25-30 hr and approximately 70% of dose is excreted in the urine unchanged.,Review of fluconazole: a new triazole antifungal agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556239/),h,25-30,169591,DB00501,Cimetidine
,6749509,elimination half life,After oral administration elimination half life of atenolol is calculated from 6 to 9 h by different authors.,Clinical pharmacokinetics of atenolol--a review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6749509/),h,6 to 9,169734,DB00501,Cimetidine
,6749509,elimination half life,In patients with impaired renal function elimination half life of atenolol gradually increases to values of 36 h in uraemic patients (glomerular filtration rate (GFR) less than 10 ml/min).,Clinical pharmacokinetics of atenolol--a review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6749509/),h,36,169735,DB00501,Cimetidine
,6407848,plasma half-life,"In 9 with total renal failure, the plasma half-life ranged from 16.6 to 42.7 h and total plasma clearance from 35 to 94 ml/min.",Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,16.6 to 42.7,170295,DB00501,Cimetidine
,6407848,total plasma clearance,"In 9 with total renal failure, the plasma half-life ranged from 16.6 to 42.7 h and total plasma clearance from 35 to 94 ml/min.",Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),[ml] / [min],35 to 94,170296,DB00501,Cimetidine
,6407848,half-life,The mean half-life in the remaining patients was 22.3 +/- 4.8 h (+/- SD).,Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,22.3,170297,DB00501,Cimetidine
,6407848,half-life,"During a 4 h haemodialysis, the half-life in the 9 patients decreased to 8.5 +/- 4.6 h, which was calculated to correspond to removal of 25 +/- 14% of the drug from the body.",Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,8.5,170298,DB00501,Cimetidine
,6407848,half-life,In 6 patients with impaired renal function (creatinine clearance 10-55 ml/min) the tocainide half-life ranged from 13.2 to 22.0 h and total plasma clearance from 72 to 122 ml/min.,Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,13.2 to 22.0,170299,DB00501,Cimetidine
,6407848,total plasma clearance,In 6 patients with impaired renal function (creatinine clearance 10-55 ml/min) the tocainide half-life ranged from 13.2 to 22.0 h and total plasma clearance from 72 to 122 ml/min.,Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),[ml] / [min],72 to 122,170300,DB00501,Cimetidine
,6407848,half-life,"One patient was taking allopurinol and 1 dihydralazine, and the mean half-life in the others was 19.2 +/- 4.0 h.",Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,19.2,170301,DB00501,Cimetidine
,27885696,half-life,"The half-life (geometric mean) was 8.38 and 10.76 h, for p.o. alone and p.o. with cimetidine, respectively.",Pharmacokinetics of oral terbinafine in adult horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27885696/),h,8.38,171821,DB00501,Cimetidine
,27885696,half-life,"The half-life (geometric mean) was 8.38 and 10.76 h, for p.o. alone and p.o. with cimetidine, respectively.",Pharmacokinetics of oral terbinafine in adult horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27885696/),h,10.76,171822,DB00501,Cimetidine
,27885696,maximum plasma concentrations,"The mean maximum plasma concentrations were 0.291 μg/mL at 1.54 h and 0.418 μg/mL at 1.28 h for p.o. alone and p.o. with cimetidine, respectively.",Pharmacokinetics of oral terbinafine in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27885696/),[μg] / [ml],0.291,171823,DB00501,Cimetidine
,27885696,maximum plasma concentrations,"The mean maximum plasma concentrations were 0.291 μg/mL at 1.54 h and 0.418 μg/mL at 1.28 h for p.o. alone and p.o. with cimetidine, respectively.",Pharmacokinetics of oral terbinafine in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27885696/),[μg] / [ml],0.418,171824,DB00501,Cimetidine
,1764869,distribution half-life,"After intravenous administration the plasma famotidine concentration-time profile exhibits a biexponential decay, with a distribution half-life of about 0.18 to 0.5h and an elimination half-life of about 2 to 4h.",Clinical pharmacokinetics of famotidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),h,0.18 to 0.5,172321,DB00501,Cimetidine
,1764869,elimination half-life,"After intravenous administration the plasma famotidine concentration-time profile exhibits a biexponential decay, with a distribution half-life of about 0.18 to 0.5h and an elimination half-life of about 2 to 4h.",Clinical pharmacokinetics of famotidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),h,2 to 4,172322,DB00501,Cimetidine
,1764869,volume of distribution of the drug at steady-state,The volume of distribution of the drug at steady-state ranges from 1.0 to 1.3 L/kg; plasma protein binding is low (15 to 22%).,Clinical pharmacokinetics of famotidine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),[l] / [kg],1.0 to 1.3,172323,DB00501,Cimetidine
,1764869,plasma protein binding,The volume of distribution of the drug at steady-state ranges from 1.0 to 1.3 L/kg; plasma protein binding is low (15 to 22%).,Clinical pharmacokinetics of famotidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),%,15 to 22,172324,DB00501,Cimetidine
,1764869,renal clearance,"Because its renal clearance (15 L/h) far exceeds the glomerular filtration rate, famotidine is considered to be eliminated not only via glomerular filtration but also via renal tubular secretion.",Clinical pharmacokinetics of famotidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),[l] / [h],15,172325,DB00501,Cimetidine
,1764869,oral bioavailability,"After oral administration, peak plasma concentrations are attained within 2 to 4h; the oral bioavailability ranges from 40 to 50%, due mainly to incomplete absorption.",Clinical pharmacokinetics of famotidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),%,40 to 50,172326,DB00501,Cimetidine
,7863246,bioavailability,"Antacid ingestion decreased the bioavailability of famotidine, ranitidine and cimetidine by 20-25%, and the bioavailability of nizatidine by 12%.",Drug interactions of H2-receptor antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7863246/),,12,179873,DB00501,Cimetidine
,2488770,limit of detection,The limit of detection was 0.125 micrograms/ml for cimetidine and 1.00 micrograms/ml for cimetidine sulfoxide.,An improved high performance liquid chromatographic method for determination of cimetidine and its major metabolite in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2488770/),[μg] / [ml],0.125,180335,DB00501,Cimetidine
,2488770,limit of detection,The limit of detection was 0.125 micrograms/ml for cimetidine and 1.00 micrograms/ml for cimetidine sulfoxide.,An improved high performance liquid chromatographic method for determination of cimetidine and its major metabolite in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2488770/),[μg] / [ml],1.00,180336,DB00501,Cimetidine
,2488770,absolute recovery,The absolute recovery for cimetidine was 83% and 40% for its major metabolite; is greater than that reported by previous studies.,An improved high performance liquid chromatographic method for determination of cimetidine and its major metabolite in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2488770/),%,83,180337,DB00501,Cimetidine
,2488770,absolute recovery,The absolute recovery for cimetidine was 83% and 40% for its major metabolite; is greater than that reported by previous studies.,An improved high performance liquid chromatographic method for determination of cimetidine and its major metabolite in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2488770/),%,40,180338,DB00501,Cimetidine
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·min],5.70,180973,DB00501,Cimetidine
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·min],7.00,180974,DB00501,Cimetidine
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·ml],8.32,180975,DB00501,Cimetidine
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·ml],5.70,180976,DB00501,Cimetidine
less,2878729,pro,The preliminary data indicate that patients with a baseline prothrombin time ratio (PTR) of less than 2.0 would not be expected to exceed a PTR greater than 2.5 after two weeks of concomitant administration of cimetidine at either dosage.,Safety: cimetidine and concomitant theophylline or warfarin--drug interactions and their implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878729/),,2.0,182563,DB00501,Cimetidine
greater,2878729,PTR,The preliminary data indicate that patients with a baseline prothrombin time ratio (PTR) of less than 2.0 would not be expected to exceed a PTR greater than 2.5 after two weeks of concomitant administration of cimetidine at either dosage.,Safety: cimetidine and concomitant theophylline or warfarin--drug interactions and their implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878729/),,2.5,182564,DB00501,Cimetidine
,10320950,peak plasma concentration (Cmax),"The mean peak plasma concentration (Cmax) is approximately 2.5 micrograms/L, and the time to reach the peak is under 1 hour.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[μg] / [l],2.5,183615,DB00501,Cimetidine
under,10320950,time to reach the peak,"The mean peak plasma concentration (Cmax) is approximately 2.5 micrograms/L, and the time to reach the peak is under 1 hour.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),h,1,183616,DB00501,Cimetidine
,10320950,absolute bioavailability,The absolute bioavailability of buspirone is approximately 4%.,"Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),%,4,183617,DB00501,Cimetidine
,10320950,volume of distribution,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[l] / [kg],5.3,183618,DB00501,Cimetidine
,10320950,systemic clearance,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[l] / [h·kg],1.7,183619,DB00501,Cimetidine
,10320950,elimination half-life,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),h,2.5,183620,DB00501,Cimetidine
,3360971,peak plasma triazolam concentration (Cmax),"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],5.4,183829,DB00501,Cimetidine
,3360971,peak plasma triazolam concentration (Cmax),"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],3.9,183830,DB00501,Cimetidine
,3360971,total area under the plasma concentration curve (AUC),"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [h·ml],21.3,183831,DB00501,Cimetidine
,3360971,total area under the plasma concentration curve (AUC),"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [h·ml],16.1,183832,DB00501,Cimetidine
,3360971,oral clearance,"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ml] / [min],485,183833,DB00501,Cimetidine
,3360971,oral clearance,"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ml] / [min],668,183834,DB00501,Cimetidine
,3360971,Cmax,"During propranolol alone, triazolam Cmax (4.1 ng/mL), AUC (14.3 ng/mL X hr), and clearance (759 mL/min) did not differ significantly from control, whereas kinetic variables for triazolam with cimetidine plus propranolol were similar to those with cimetidine alone.","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],4.1,183835,DB00501,Cimetidine
,3360971,AUC,"During propranolol alone, triazolam Cmax (4.1 ng/mL), AUC (14.3 ng/mL X hr), and clearance (759 mL/min) did not differ significantly from control, whereas kinetic variables for triazolam with cimetidine plus propranolol were similar to those with cimetidine alone.","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [h·ml],14.3,183836,DB00501,Cimetidine
,3360971,clearance,"During propranolol alone, triazolam Cmax (4.1 ng/mL), AUC (14.3 ng/mL X hr), and clearance (759 mL/min) did not differ significantly from control, whereas kinetic variables for triazolam with cimetidine plus propranolol were similar to those with cimetidine alone.","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ml] / [min],759,183837,DB00501,Cimetidine
,3360971,Plasma free fraction,Plasma free fraction for triazolam (17 to 18% unbound) did not differ significantly among the four treatment conditions.,"Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),%·unbound,17 to 18,183838,DB00501,Cimetidine
,3360971,steady-state plasma cimetidine concentrations,"Mean steady-state plasma cimetidine concentrations during trials 2 and 4 were similar (1.04 versus .98 micrograms/mL), whereas plasma propranolol was significantly higher during cimetidine plus propranolol than with propranolol alone (47 versus 29 ng/ml, P less than .001).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[μg] / [ml],1.04,183839,DB00501,Cimetidine
,3360971,steady-state plasma cimetidine concentrations,"Mean steady-state plasma cimetidine concentrations during trials 2 and 4 were similar (1.04 versus .98 micrograms/mL), whereas plasma propranolol was significantly higher during cimetidine plus propranolol than with propranolol alone (47 versus 29 ng/ml, P less than .001).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[μg] / [ml],.98,183840,DB00501,Cimetidine
,3360971,steady-state plasma cimetidine concentrations,"Mean steady-state plasma cimetidine concentrations during trials 2 and 4 were similar (1.04 versus .98 micrograms/mL), whereas plasma propranolol was significantly higher during cimetidine plus propranolol than with propranolol alone (47 versus 29 ng/ml, P less than .001).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],47,183841,DB00501,Cimetidine
,3360971,steady-state plasma cimetidine concentrations,"Mean steady-state plasma cimetidine concentrations during trials 2 and 4 were similar (1.04 versus .98 micrograms/mL), whereas plasma propranolol was significantly higher during cimetidine plus propranolol than with propranolol alone (47 versus 29 ng/ml, P less than .001).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],29,183842,DB00501,Cimetidine
,3995530,Serum concentrations,"Serum concentrations 30 minutes after administration were 1.2 micrograms/ml, 5 micrograms/ml, and 4.2 micrograms/ml, respectively.",Pharmacokinetic evaluation of cimetidine in newborn infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3995530/),[μg] / [ml],1.2,184109,DB00501,Cimetidine
,3995530,Serum concentrations,"Serum concentrations 30 minutes after administration were 1.2 micrograms/ml, 5 micrograms/ml, and 4.2 micrograms/ml, respectively.",Pharmacokinetic evaluation of cimetidine in newborn infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3995530/),[μg] / [ml],5,184110,DB00501,Cimetidine
,3995530,Serum concentrations,"Serum concentrations 30 minutes after administration were 1.2 micrograms/ml, 5 micrograms/ml, and 4.2 micrograms/ml, respectively.",Pharmacokinetic evaluation of cimetidine in newborn infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3995530/),[μg] / [ml],4.2,184111,DB00501,Cimetidine
,3995530,half-life,The half-life of the drug ranged from 1.10 to 2.18 hours.,Pharmacokinetic evaluation of cimetidine in newborn infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3995530/),h,1.10 to 2.18,184112,DB00501,Cimetidine
,2582712,Ki,"Studies in microsomes prepared from two human organ donors indicated that cimetidine inhibited acetaminophen reactive metabolite formation noncompetitively, with Ki values of 0.35 mmol/L and 0.32 mmol/L for the respective livers, which is 5 to 10 times the putative cimetidine concentration required for therapeutic effect.",Lack of effect of cimetidine on acetaminophen disposition in humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2582712/),[mM] / [l],0.35,184247,DB00501,Cimetidine
,2582712,Ki,"Studies in microsomes prepared from two human organ donors indicated that cimetidine inhibited acetaminophen reactive metabolite formation noncompetitively, with Ki values of 0.35 mmol/L and 0.32 mmol/L for the respective livers, which is 5 to 10 times the putative cimetidine concentration required for therapeutic effect.",Lack of effect of cimetidine on acetaminophen disposition in humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2582712/),[mM] / [l],0.32,184248,DB00501,Cimetidine
,2391395,AUC0-1,"The AUC0-1 for the drug given alone was 80.5 +/- 15.8 micrograms.hr/mL, compared to 81.4 +/- 12.7 and 79.7 +/- 9.6 micrograms.hr/mL with concomitant antacid and cimetidine, respectively.",The effect of antacid and cimetidine on the oral absorption of the antifungal agent SCH 39304. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391395/),[h·μg] / [ml],80.5,184461,DB00501,Cimetidine
,2391395,AUC0-1,"The AUC0-1 for the drug given alone was 80.5 +/- 15.8 micrograms.hr/mL, compared to 81.4 +/- 12.7 and 79.7 +/- 9.6 micrograms.hr/mL with concomitant antacid and cimetidine, respectively.",The effect of antacid and cimetidine on the oral absorption of the antifungal agent SCH 39304. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391395/),[h·μg] / [ml],81.4,184462,DB00501,Cimetidine
,2391395,AUC0-1,"The AUC0-1 for the drug given alone was 80.5 +/- 15.8 micrograms.hr/mL, compared to 81.4 +/- 12.7 and 79.7 +/- 9.6 micrograms.hr/mL with concomitant antacid and cimetidine, respectively.",The effect of antacid and cimetidine on the oral absorption of the antifungal agent SCH 39304. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391395/),[h·μg] / [ml],79.7,184463,DB00501,Cimetidine
,2391395,amount of drug excreted in the urine (Ae0-1),"The amount of drug excreted in the urine (Ae0-1) was 22.7 +/- 5.1, 24.2 +/- 9.2, and 23.6 +/- 7.6 mg when the drug was given alone, with antacid, and with cimetidine, respectively.",The effect of antacid and cimetidine on the oral absorption of the antifungal agent SCH 39304. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391395/),mg,22.7,184464,DB00501,Cimetidine
,2391395,amount of drug excreted in the urine (Ae0-1),"The amount of drug excreted in the urine (Ae0-1) was 22.7 +/- 5.1, 24.2 +/- 9.2, and 23.6 +/- 7.6 mg when the drug was given alone, with antacid, and with cimetidine, respectively.",The effect of antacid and cimetidine on the oral absorption of the antifungal agent SCH 39304. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391395/),mg,24.2,184465,DB00501,Cimetidine
,2391395,amount of drug excreted in the urine (Ae0-1),"The amount of drug excreted in the urine (Ae0-1) was 22.7 +/- 5.1, 24.2 +/- 9.2, and 23.6 +/- 7.6 mg when the drug was given alone, with antacid, and with cimetidine, respectively.",The effect of antacid and cimetidine on the oral absorption of the antifungal agent SCH 39304. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391395/),mg,23.6,184466,DB00501,Cimetidine
,3266736,elimination half-life,The elimination half-life of the untreated control group (n = 27) was 4.62 h.,Effects of drugs on aminophylline elimination in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,4.62,184893,DB00501,Cimetidine
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.09,184894,DB00501,Cimetidine
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.47,184895,DB00501,Cimetidine
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.19,184896,DB00501,Cimetidine
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2,184897,DB00501,Cimetidine
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.85,184898,DB00501,Cimetidine
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.74,184899,DB00501,Cimetidine
,24820074,Km,"In vitro transporter studies revealed that M7 is a substrate for organic anion transporter 1 (OAT1) and OAT3 (Km = 28.6 and 54.0 μM, respectively).",Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24820074/),μM,28.6,185353,DB00501,Cimetidine
,24820074,Km,"In vitro transporter studies revealed that M7 is a substrate for organic anion transporter 1 (OAT1) and OAT3 (Km = 28.6 and 54.0 μM, respectively).",Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24820074/),μM,54.0,185354,DB00501,Cimetidine
,7550967,flow-rate,"The mobile phase was delivered at a flow-rate of 0.9 ml/min, detection was by ultraviolet absorption at 228 nm and concentrations were calculated on the basis of peak areas.",Determination of cimetidine in human plasma by high-performance liquid chromatography following liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550967/),[ml] / [min],0.9,185845,DB00501,Cimetidine
,2892545,apparent Cmax,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),[μg] / [ml],11.1,187483,DB00501,Cimetidine
,2892545,apparent Cmax,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),[μg] / [ml],10.0,187484,DB00501,Cimetidine
,2892545,Tmax,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),h,1.7,187485,DB00501,Cimetidine
,2892545,Tmax,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),h,1.4,187486,DB00501,Cimetidine
,2892545,oral clearance,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),[l] / [h·kg],0.0200,187487,DB00501,Cimetidine
,2892545,oral clearance,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),[l] / [h·kg],0.0564,187488,DB00501,Cimetidine
,2892545,elimination half-life,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),h,16.8,187489,DB00501,Cimetidine
,2892545,elimination half-life,"Comparison of the pharmacokinetic parameters of theophylline between the etintidine and the placebo groups indicates that while etintidine did not significantly (p greater than 0.05) affect the apparent Cmax (11.1 vs 10.0 micrograms ml-1) and Tmax (1.7 vs 1.4 h) values of theophylline, etintidine significantly reduced the oral clearance (0.0200 vs 0.0564 l kg-1 h-1, p = 0.000006) and prolonged the elimination half-life (16.8 vs 6.0 h) of theophylline.",Etintidine-theophylline interaction study in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892545/),h,6.0,187490,DB00501,Cimetidine
,9646011,elimination half-life,Peak concentration in serum is reached after 1 to 2 hours and the elimination half-life is between 1 and 3 hours.,Pharmacokinetic optimisation of the treatment of neurocysticercosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646011/),h,1 and 3,187764,DB00501,Cimetidine
,9646011,half-life,Concentrations of ALBSO are highly variable between individuals and it has a half-life of between 6 and 15 hours.,Pharmacokinetic optimisation of the treatment of neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646011/),h,6 and 15,187765,DB00501,Cimetidine
,15871634,terminal half-life,The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours.,"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871634/),h,22,188555,DB00501,Cimetidine
,1867965,Clearance,"Clearance and volume of distribution (Vz) of total drug were significantly (P less than 0.001) higher for the R-(-) enantiomer than the S-(+) enantiomer (7.9 vs 4.6 l h-1 and 89 vs 50 l, respectively), whereas no significant difference in half-life could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),[l] / [h],7.9,188565,DB00501,Cimetidine
,1867965,Clearance,"Clearance and volume of distribution (Vz) of total drug were significantly (P less than 0.001) higher for the R-(-) enantiomer than the S-(+) enantiomer (7.9 vs 4.6 l h-1 and 89 vs 50 l, respectively), whereas no significant difference in half-life could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),[l] / [h],4.6,188566,DB00501,Cimetidine
,1867965,volume of distribution (Vz),"Clearance and volume of distribution (Vz) of total drug were significantly (P less than 0.001) higher for the R-(-) enantiomer than the S-(+) enantiomer (7.9 vs 4.6 l h-1 and 89 vs 50 l, respectively), whereas no significant difference in half-life could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),l,89,188567,DB00501,Cimetidine
,1867965,volume of distribution (Vz),"Clearance and volume of distribution (Vz) of total drug were significantly (P less than 0.001) higher for the R-(-) enantiomer than the S-(+) enantiomer (7.9 vs 4.6 l h-1 and 89 vs 50 l, respectively), whereas no significant difference in half-life could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),l,50,188568,DB00501,Cimetidine
,1867965,clearance,"The clearance of free drug was significantly (P less than 0.05) higher for the S-(+) enantiomer than that of the R-(-) enantiomer (34.6 +/- 5.4 l h-1 vs 27.2 +/- 5.6 l h-1), whereas no significant enantioselective difference in unbound volumes of distribution (258 +/- 38 l vs 226 +/- 42 l) could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),[l] / [h],34.6,188569,DB00501,Cimetidine
,1867965,clearance,"The clearance of free drug was significantly (P less than 0.05) higher for the S-(+) enantiomer than that of the R-(-) enantiomer (34.6 +/- 5.4 l h-1 vs 27.2 +/- 5.6 l h-1), whereas no significant enantioselective difference in unbound volumes of distribution (258 +/- 38 l vs 226 +/- 42 l) could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),[l] / [h],27.2,188570,DB00501,Cimetidine
,1867965,unbound volumes of distribution,"The clearance of free drug was significantly (P less than 0.05) higher for the S-(+) enantiomer than that of the R-(-) enantiomer (34.6 +/- 5.4 l h-1 vs 27.2 +/- 5.6 l h-1), whereas no significant enantioselective difference in unbound volumes of distribution (258 +/- 38 l vs 226 +/- 42 l) could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),l,258,188571,DB00501,Cimetidine
,1867965,unbound volumes of distribution,"The clearance of free drug was significantly (P less than 0.05) higher for the S-(+) enantiomer than that of the R-(-) enantiomer (34.6 +/- 5.4 l h-1 vs 27.2 +/- 5.6 l h-1), whereas no significant enantioselective difference in unbound volumes of distribution (258 +/- 38 l vs 226 +/- 42 l) could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),l,226,188572,DB00501,Cimetidine
,3234462,AUC,AUC of ketoprofen was slightly but significantly larger following multiple (21.2 micrograms.h.ml-1) as compared to single dose administration (19.0 micrograms.h.ml-1).,Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),[h·μg] / [ml],21.2,188834,DB00501,Cimetidine
,3234462,AUC,AUC of ketoprofen was slightly but significantly larger following multiple (21.2 micrograms.h.ml-1) as compared to single dose administration (19.0 micrograms.h.ml-1).,Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),[h·μg] / [ml],19.0,188835,DB00501,Cimetidine
,3234462,plasma clearance,"As a result, plasma clearance of ketoprofen was slightly but significantly reduced following multiple dose administration (80.6 ml/min vs 89.3 ml/min).",Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),[ml] / [min],80.6,188836,DB00501,Cimetidine
,3234462,plasma clearance,"As a result, plasma clearance of ketoprofen was slightly but significantly reduced following multiple dose administration (80.6 ml/min vs 89.3 ml/min).",Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),[ml] / [min],89.3,188837,DB00501,Cimetidine
,3234462,Total 12-h,Total 12-h urinary recovery of ketoprofen (mostly in the form of ketoprofen glucuronide) was 83.5% of the dose following single dose administration and was significantly greater following multiple dose administration (93.1%).,Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),%,83.,188838,DB00501,Cimetidine
,3234462,Total 12-h,Total 12-h urinary recovery of ketoprofen (mostly in the form of ketoprofen glucuronide) was 83.5% of the dose following single dose administration and was significantly greater following multiple dose administration (93.1%).,Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),%,93.1,188839,DB00501,Cimetidine
,3234462,urinary recovery,Total 12-h urinary recovery of ketoprofen (mostly in the form of ketoprofen glucuronide) was 83.5% of the dose following single dose administration and was significantly greater following multiple dose administration (93.1%).,Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),%,83.,188840,DB00501,Cimetidine
,3234462,urinary recovery,Total 12-h urinary recovery of ketoprofen (mostly in the form of ketoprofen glucuronide) was 83.5% of the dose following single dose administration and was significantly greater following multiple dose administration (93.1%).,Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234462/),%,93.1,188841,DB00501,Cimetidine
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],15.3,189466,DB00501,Cimetidine
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],4.9,189467,DB00501,Cimetidine
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],2.5,189468,DB00501,Cimetidine
,7779153,elimination rate constant Ke,Significant differences were observed between the elimination rate constant Ke (h-1) for brand 2 (0.017 +/- 0.004) alone versus brand 2 plus cimetidine (0.006 +/- 0.001).,"Effect of cimetidine, bicarbonate and glucose on the bioavailability of different formulations of praziquantel. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779153/),,0.017,191000,DB00501,Cimetidine
,7779153,elimination rate constant Ke,Significant differences were observed between the elimination rate constant Ke (h-1) for brand 2 (0.017 +/- 0.004) alone versus brand 2 plus cimetidine (0.006 +/- 0.001).,"Effect of cimetidine, bicarbonate and glucose on the bioavailability of different formulations of praziquantel. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779153/),,0.006,191001,DB00501,Cimetidine
,2897213,volume of distribution,"When given alone, metronidazole had a mean volume of distribution of 0.667 +/- 0.15 lkg-1, a half-life of 9.7 +/- 3.1 h and an oral clearance of 0.852 +/- 0.23 (ml-1 min) kg-1.","Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897213/),1/[lkg],0.667,192515,DB00501,Cimetidine
,2897213,half-life,"When given alone, metronidazole had a mean volume of distribution of 0.667 +/- 0.15 lkg-1, a half-life of 9.7 +/- 3.1 h and an oral clearance of 0.852 +/- 0.23 (ml-1 min) kg-1.","Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897213/),h,9.7,192516,DB00501,Cimetidine
,2897213,oral clearance,"When given alone, metronidazole had a mean volume of distribution of 0.667 +/- 0.15 lkg-1, a half-life of 9.7 +/- 3.1 h and an oral clearance of 0.852 +/- 0.23 (ml-1 min) kg-1.","Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897213/),[min] / [kg·ml],0.852,192517,DB00501,Cimetidine
,2111245,systemic clearance,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),[ml] / [kg·min],9.1,192659,DB00501,Cimetidine
,2111245,systemic clearance,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),[ml] / [kg·min],7.6,192660,DB00501,Cimetidine
,2111245,elimination half-life,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),h,9.6,192661,DB00501,Cimetidine
,2111245,elimination half-life,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),h,11.5,192662,DB00501,Cimetidine
,7126415,volume of the central compartment,"2 In cirrhotic patients, the volume of the central compartment (0.41 +/- 0.06 v 0.19 +/- 0.09 1/kg) and the volume of distribution at steady-state (1.02 +/- 0.17 v 0.80 +/- 0.24 1/kg) were significantly increased.",Altered disposition and availability of cimetidine in liver cirrhotic patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7126415/),[1] / [kg],0.41,193854,DB00501,Cimetidine
,7126415,volume of the central compartment,"2 In cirrhotic patients, the volume of the central compartment (0.41 +/- 0.06 v 0.19 +/- 0.09 1/kg) and the volume of distribution at steady-state (1.02 +/- 0.17 v 0.80 +/- 0.24 1/kg) were significantly increased.",Altered disposition and availability of cimetidine in liver cirrhotic patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7126415/),[1] / [kg],0.19,193855,DB00501,Cimetidine
,7126415,volume of distribution at steady-state,"2 In cirrhotic patients, the volume of the central compartment (0.41 +/- 0.06 v 0.19 +/- 0.09 1/kg) and the volume of distribution at steady-state (1.02 +/- 0.17 v 0.80 +/- 0.24 1/kg) were significantly increased.",Altered disposition and availability of cimetidine in liver cirrhotic patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7126415/),[1] / [kg],1.02,193856,DB00501,Cimetidine
,7126415,volume of distribution at steady-state,"2 In cirrhotic patients, the volume of the central compartment (0.41 +/- 0.06 v 0.19 +/- 0.09 1/kg) and the volume of distribution at steady-state (1.02 +/- 0.17 v 0.80 +/- 0.24 1/kg) were significantly increased.",Altered disposition and availability of cimetidine in liver cirrhotic patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7126415/),[1] / [kg],0.80,193857,DB00501,Cimetidine
,7126415,non-renal clearance,The non-renal clearance was significantly decreased from 191 +/- 46 to 123 +/- 102 ml/min.,Altered disposition and availability of cimetidine in liver cirrhotic patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7126415/),[ml] / [min],191,193858,DB00501,Cimetidine
,7126415,non-renal clearance,The non-renal clearance was significantly decreased from 191 +/- 46 to 123 +/- 102 ml/min.,Altered disposition and availability of cimetidine in liver cirrhotic patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7126415/),[ml] / [min],123,193859,DB00501,Cimetidine
,7126415,bioavailability,3 The bioavailability of cimetidine (area method) was significantly increased from 60 +/- 23% to 77 /+- 18% in the cirrhotic patients.,Altered disposition and availability of cimetidine in liver cirrhotic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7126415/),%,60,193860,DB00501,Cimetidine
,7126415,bioavailability,3 The bioavailability of cimetidine (area method) was significantly increased from 60 +/- 23% to 77 /+- 18% in the cirrhotic patients.,Altered disposition and availability of cimetidine in liver cirrhotic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7126415/),%,77,193861,DB00501,Cimetidine
,7882634,elimination half-life,Its elimination half-life ranges from 6.2 to 12.4 hours.,Pefloxacin clinical pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7882634/),h,6.2 to 12.4,193898,DB00501,Cimetidine
,2905250,duration of effect,The duration of effect was approximately 12 hours.,"The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905250/),h,12,193937,DB00501,Cimetidine
,7023306,apparent volume of distribution,"The apparent volume of distribution was unchanged (p greater than 0.5), whereas the elimination rate constant was significantly decreased by a mean of 42% (control, 0.091 +/- 0.013 h-1 versus 0.053 +/- 0.007 h-1 with cimetidine treatment, p less than 0.005).",Cimetidine decreases theophylline clearance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023306/),1/[h],0.091,194021,DB00501,Cimetidine
,7023306,elimination rate constant,"The apparent volume of distribution was unchanged (p greater than 0.5), whereas the elimination rate constant was significantly decreased by a mean of 42% (control, 0.091 +/- 0.013 h-1 versus 0.053 +/- 0.007 h-1 with cimetidine treatment, p less than 0.005).",Cimetidine decreases theophylline clearance. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023306/),1/[h],0.091,194022,DB00501,Cimetidine
,7023306,elimination rate constant,"The apparent volume of distribution was unchanged (p greater than 0.5), whereas the elimination rate constant was significantly decreased by a mean of 42% (control, 0.091 +/- 0.013 h-1 versus 0.053 +/- 0.007 h-1 with cimetidine treatment, p less than 0.005).",Cimetidine decreases theophylline clearance. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023306/),1/[h],0.053,194023,DB00501,Cimetidine
,8803904,bioavailability,Hydroxychloroquine (HCQ) and chloroquine (CQ) are well absorbed (0.7-0.8 bioavailability) when given orally.,Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),,0.7-0.8,195382,DB00501,Cimetidine
,8803904,half-lives,"Both HCQ and CQ have prolonged half-lives, between 40 and 50 days, and low blood clearance (e.g. hydroxychloroquine's blood clearance is 96 ml/min).",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),d,40 and 50,195383,DB00501,Cimetidine
,8803904,blood clearance,"Both HCQ and CQ have prolonged half-lives, between 40 and 50 days, and low blood clearance (e.g. hydroxychloroquine's blood clearance is 96 ml/min).",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),[ml] / [min],96,195384,DB00501,Cimetidine
,8803904,Protein binding,"Protein binding ranges between 30 and 40% with binding to both albumin and alpha, glycoprotein.",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),%,30 and 40,195385,DB00501,Cimetidine
,2892249,plasma half-life,The plasma half-life in each of the animal species was between 1 and 2 h and no accumulation of nizatidine or its metabolites was seen in rats or dogs after daily oral administration for long periods.,Pharmacology and toxicology of nizatidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892249/),h,1 and 2,195724,DB00501,Cimetidine
,3956561,half-lives,The biphasic elimination kinetics of penbutolol (half-lives 0.8 and 17 h) was not affected by coadministration of cimetidine.,Penbutolol Pharmacokinetics: the influence of concomitant administration of cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956561/),h,0.8,195809,DB00501,Cimetidine
,3956561,half-lives,The biphasic elimination kinetics of penbutolol (half-lives 0.8 and 17 h) was not affected by coadministration of cimetidine.,Penbutolol Pharmacokinetics: the influence of concomitant administration of cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956561/),h,17,195810,DB00501,Cimetidine
,2892251,elimination half-life,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),h,35.3,195854,DB00501,Cimetidine
,2892251,elimination half-life,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),h,37.3,195855,DB00501,Cimetidine
,2892251,total plasma clearance,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),[ml] / [min],28.2,195856,DB00501,Cimetidine
,2892251,total plasma clearance,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),[ml] / [min],26.7,195857,DB00501,Cimetidine
,28971610,permeability,"Whilst all inhibited OCT1, none enhanced metformin's absorptive permeability (~0.5 × 10-6 cm/sec) suggesting that DDI AUC changes are not related to absorption.","Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28971610/),[cm] / [s],0.5 × 10-6,196647,DB00501,Cimetidine
,3562386,recoveries,"After tinidazole, the recoveries of the intact drug in urine and bile were 48.1% and 1.7%, respectively.",Effect of enzyme induction and inhibition on the fate of metronidazole and tinidazole in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3562386/),%,48.1,196658,DB00501,Cimetidine
,3562386,recoveries,"After tinidazole, the recoveries of the intact drug in urine and bile were 48.1% and 1.7%, respectively.",Effect of enzyme induction and inhibition on the fate of metronidazole and tinidazole in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3562386/),%,1.7,196659,DB00501,Cimetidine
,6628505,metabolic clearance,"The average metabolic clearance of cimetidine in these patients was 15 l/h, similar to values reported for normal subjects.",Cimetidine disposition in patients with Laennec's cirrhosis during multiple dosing therapy. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628505/),[l] / [h],15,196960,DB00501,Cimetidine
,6628505,metabolic clearance,"However, in 4 subjects with plasma prothrombin times above normal, the metabolic clearance was significantly decreased and ranged between 4.3 and 13.0 l/h.",Cimetidine disposition in patients with Laennec's cirrhosis during multiple dosing therapy. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628505/),[l] / [h],4.3 and 13.0,196961,DB00501,Cimetidine
,27292271,serum elimination half-life,"The serum elimination half-life was 7.05 ± 1.02, 7.43 ± 0.851 and 3.94 ± 1.04 h for cimetidine, ranitidine, and omeprazole, respectively.","Disposition of the anti-ulcer medications ranitidine, cimetidine, and omeprazole following administration of multiple doses to exercised Thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27292271/),h,7.05,198297,DB00501,Cimetidine
,27292271,serum elimination half-life,"The serum elimination half-life was 7.05 ± 1.02, 7.43 ± 0.851 and 3.94 ± 1.04 h for cimetidine, ranitidine, and omeprazole, respectively.","Disposition of the anti-ulcer medications ranitidine, cimetidine, and omeprazole following administration of multiple doses to exercised Thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27292271/),h,7.43,198298,DB00501,Cimetidine
,27292271,serum elimination half-life,"The serum elimination half-life was 7.05 ± 1.02, 7.43 ± 0.851 and 3.94 ± 1.04 h for cimetidine, ranitidine, and omeprazole, respectively.","Disposition of the anti-ulcer medications ranitidine, cimetidine, and omeprazole following administration of multiple doses to exercised Thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27292271/),h,3.94,198299,DB00501,Cimetidine
,2627821,overall healing rates,The overall healing rates after 8 weeks for the groups taking cimetidine alone and cimetidine plus antacid were 80.0% and 92.6% respectively with no significant difference.,[Effect of antacids on the bioavailability and therapeutic efficacy of cimetidine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2627821/),%,80.0,198599,DB00501,Cimetidine
,2627821,overall healing rates,The overall healing rates after 8 weeks for the groups taking cimetidine alone and cimetidine plus antacid were 80.0% and 92.6% respectively with no significant difference.,[Effect of antacids on the bioavailability and therapeutic efficacy of cimetidine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2627821/),%,92.6,198600,DB00501,Cimetidine
,2029717,peak cimetidine level,"After the oral administration of 10 mg/kg of cimetidine, the mean peak cimetidine level was 2.86 microgram/ml; the time to peak level was 1.3 hours; the area under the concentration-time curve was 9.74 microgram/ml.hr; the elimination half-life was 1.55 hours; and 56% of the drug was excreted unchanged in the urine.",Pharmacokinetic study of cimetidine in pediatric duodenal ulcer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029717/),[μg] / [ml],2.86,199666,DB00501,Cimetidine
,2029717,time to peak level,"After the oral administration of 10 mg/kg of cimetidine, the mean peak cimetidine level was 2.86 microgram/ml; the time to peak level was 1.3 hours; the area under the concentration-time curve was 9.74 microgram/ml.hr; the elimination half-life was 1.55 hours; and 56% of the drug was excreted unchanged in the urine.",Pharmacokinetic study of cimetidine in pediatric duodenal ulcer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029717/),h,1.3,199667,DB00501,Cimetidine
,2029717,area under the concentration-time curve,"After the oral administration of 10 mg/kg of cimetidine, the mean peak cimetidine level was 2.86 microgram/ml; the time to peak level was 1.3 hours; the area under the concentration-time curve was 9.74 microgram/ml.hr; the elimination half-life was 1.55 hours; and 56% of the drug was excreted unchanged in the urine.",Pharmacokinetic study of cimetidine in pediatric duodenal ulcer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029717/),[μg] / [h·ml],9.74,199668,DB00501,Cimetidine
,2029717,elimination half-life,"After the oral administration of 10 mg/kg of cimetidine, the mean peak cimetidine level was 2.86 microgram/ml; the time to peak level was 1.3 hours; the area under the concentration-time curve was 9.74 microgram/ml.hr; the elimination half-life was 1.55 hours; and 56% of the drug was excreted unchanged in the urine.",Pharmacokinetic study of cimetidine in pediatric duodenal ulcer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029717/),h,1.55,199669,DB00501,Cimetidine
,6487480,peak plasma concentration,The peak plasma concentration after oral 5FU was increased by 74% from 18.7 +/- 4.5 micrograms/ml (mean +/- s.e. mean) to 32.6 +/- 4.4 micrograms/ml (P less than 0.05) and AUC was increased by 72% from 528 +/- 133 micrograms/ml-1 min (mean +/- s.e. mean) to 911 +/- 152 micrograms ml-1 min (P less than 0.05).,The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[μg] / [ml],18.7,200235,DB00501,Cimetidine
,6487480,peak plasma concentration,The peak plasma concentration after oral 5FU was increased by 74% from 18.7 +/- 4.5 micrograms/ml (mean +/- s.e. mean) to 32.6 +/- 4.4 micrograms/ml (P less than 0.05) and AUC was increased by 72% from 528 +/- 133 micrograms/ml-1 min (mean +/- s.e. mean) to 911 +/- 152 micrograms ml-1 min (P less than 0.05).,The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[μg] / [ml],32.6,200236,DB00501,Cimetidine
,6487480,AUC,The peak plasma concentration after oral 5FU was increased by 74% from 18.7 +/- 4.5 micrograms/ml (mean +/- s.e. mean) to 32.6 +/- 4.4 micrograms/ml (P less than 0.05) and AUC was increased by 72% from 528 +/- 133 micrograms/ml-1 min (mean +/- s.e. mean) to 911 +/- 152 micrograms ml-1 min (P less than 0.05).,The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[μg] / [ml],528,200237,DB00501,Cimetidine
,6487480,AUC,The peak plasma concentration after oral 5FU was increased by 74% from 18.7 +/- 4.5 micrograms/ml (mean +/- s.e. mean) to 32.6 +/- 4.4 micrograms/ml (P less than 0.05) and AUC was increased by 72% from 528 +/- 133 micrograms/ml-1 min (mean +/- s.e. mean) to 911 +/- 152 micrograms ml-1 min (P less than 0.05).,The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[min·μg] / [ml],911,200238,DB00501,Cimetidine
,6487480,AUC,"After intravenous 5FU, AUC was increased by 27% from 977 +/- 96 micrograms ml-1 min (mean +/- s.e. mean) to 1353 +/- 124 micrograms ml-1 min (P less than 0.01).",The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[min·μg] / [ml],977,200239,DB00501,Cimetidine
,6487480,AUC,"After intravenous 5FU, AUC was increased by 27% from 977 +/- 96 micrograms ml-1 min (mean +/- s.e. mean) to 1353 +/- 124 micrograms ml-1 min (P less than 0.01).",The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[min·μg] / [ml],1353,200240,DB00501,Cimetidine
,6487480,Total body clearance,Total body clearance for 5FU following intravenous administration was decreased by 28% from 987 +/- 116 ml/min (mean +/- s.e. mean) to 711 +/- 87 ml/min (P less than 0.01).,The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[ml] / [min],987,200241,DB00501,Cimetidine
,6487480,Total body clearance,Total body clearance for 5FU following intravenous administration was decreased by 28% from 987 +/- 116 ml/min (mean +/- s.e. mean) to 711 +/- 87 ml/min (P less than 0.01).,The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[ml] / [min],711,200242,DB00501,Cimetidine
,2760260,clearance,"The mean (+/- SD) theophylline clearance for each of the treatment groups was: 1.4 +/- 0.4, 1.2 +/- 0.3, and 1.2 +/- 0.2 ml/min/kg for phases A, B and C, respectively.",The influence of intravenous cimetidine dosage regimens on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760260/),[ml] / [kg·min],1.4,200972,DB00501,Cimetidine
,2760260,clearance,"The mean (+/- SD) theophylline clearance for each of the treatment groups was: 1.4 +/- 0.4, 1.2 +/- 0.3, and 1.2 +/- 0.2 ml/min/kg for phases A, B and C, respectively.",The influence of intravenous cimetidine dosage regimens on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760260/),[ml] / [kg·min],1.2,200973,DB00501,Cimetidine
,2760260,clearance,"The mean (+/- SD) theophylline clearance for each of the treatment groups was: 1.4 +/- 0.4, 1.2 +/- 0.3, and 1.2 +/- 0.2 ml/min/kg for phases A, B and C, respectively.",The influence of intravenous cimetidine dosage regimens on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760260/),[ml] / [kg·min],1.2,200974,DB00501,Cimetidine
,2905709,area under the concentration-time curve,"After a 400-mg oral dose of tocainide, the area under the concentration-time curve decreased from (mean +/- SD) 31.64 +/- 14.16 micrograms.hr/mL during placebo, to 23.10 +/- 7.33 micrograms.hr/mL during cimetidine (P less than .05).",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),[h·μg] / [ml],31.64,201770,DB00501,Cimetidine
,2905709,area under the concentration-time curve,"After a 400-mg oral dose of tocainide, the area under the concentration-time curve decreased from (mean +/- SD) 31.64 +/- 14.16 micrograms.hr/mL during placebo, to 23.10 +/- 7.33 micrograms.hr/mL during cimetidine (P less than .05).",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),[h·μg] / [ml],23.10,201771,DB00501,Cimetidine
,2905709,peak tocainide concentrations,"Similarly, the peak tocainide concentrations were 2.81 +/- 0.89 micrograms/mL and 1.70 +/- 0.44 micrograms/mL with placebo and cimetidine, respectively (P less than .05).",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),[μg] / [ml],2.81,201772,DB00501,Cimetidine
,2905709,peak tocainide concentrations,"Similarly, the peak tocainide concentrations were 2.81 +/- 0.89 micrograms/mL and 1.70 +/- 0.44 micrograms/mL with placebo and cimetidine, respectively (P less than .05).",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),[μg] / [ml],1.70,201773,DB00501,Cimetidine
,2905709,total amount,"However, the total amount of tocainide excreted unchanged in the urine, decreased from 159.8 +/- 14.7 mg with placebo to 136.8 +/- 26.8 mg with cimetidine (P less than .05), whereas there was no change with ranitidine.",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),,159,201774,DB00501,Cimetidine
,2905709,total amount,"However, the total amount of tocainide excreted unchanged in the urine, decreased from 159.8 +/- 14.7 mg with placebo to 136.8 +/- 26.8 mg with cimetidine (P less than .05), whereas there was no change with ranitidine.",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),,136,201775,DB00501,Cimetidine
,3378388,apparent oral clearance (dose/AUC),"After single doses of nifedipine, cimetidine decreased apparent oral clearance (dose/AUC) from 66 +/- 32 L/hr to 33 +/- 14 L/hr (p less than 0.01); elimination half-life increased from 4.0 +/- 2.2 to 4.9 +/- 2.9 hours (p less than 0.07).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[l] / [h],66,201963,DB00501,Cimetidine
,3378388,apparent oral clearance (dose/AUC),"After single doses of nifedipine, cimetidine decreased apparent oral clearance (dose/AUC) from 66 +/- 32 L/hr to 33 +/- 14 L/hr (p less than 0.01); elimination half-life increased from 4.0 +/- 2.2 to 4.9 +/- 2.9 hours (p less than 0.07).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[l] / [h],33,201964,DB00501,Cimetidine
,3378388,elimination half-life,"After single doses of nifedipine, cimetidine decreased apparent oral clearance (dose/AUC) from 66 +/- 32 L/hr to 33 +/- 14 L/hr (p less than 0.01); elimination half-life increased from 4.0 +/- 2.2 to 4.9 +/- 2.9 hours (p less than 0.07).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),h,4.0,201965,DB00501,Cimetidine
,3378388,elimination half-life,"After single doses of nifedipine, cimetidine decreased apparent oral clearance (dose/AUC) from 66 +/- 32 L/hr to 33 +/- 14 L/hr (p less than 0.01); elimination half-life increased from 4.0 +/- 2.2 to 4.9 +/- 2.9 hours (p less than 0.07).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),h,4.9,201966,DB00501,Cimetidine
,3378388,apparent oral clearance,"During nifedipine multiple-dose administration, cimetidine decreased the apparent oral clearance from 76 +/- 39 to 43 +/- 20 L/hr (p less than 0.01).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[l] / [h],76,201967,DB00501,Cimetidine
,3378388,apparent oral clearance,"During nifedipine multiple-dose administration, cimetidine decreased the apparent oral clearance from 76 +/- 39 to 43 +/- 20 L/hr (p less than 0.01).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[l] / [h],43,201968,DB00501,Cimetidine
,3378388,heart rate,Blood pressure responses were not altered by cimetidine but heart rate increased more (18 +/- 9 vs 9 +/- 9 beats/min supine; 18 +/- 13 vs 13 +/- 14 beats/min standing).,Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[beats] / [min],18,201969,DB00501,Cimetidine
,3378388,heart rate,Blood pressure responses were not altered by cimetidine but heart rate increased more (18 +/- 9 vs 9 +/- 9 beats/min supine; 18 +/- 13 vs 13 +/- 14 beats/min standing).,Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[beats] / [min],9,201970,DB00501,Cimetidine
,3378388,heart rate,Blood pressure responses were not altered by cimetidine but heart rate increased more (18 +/- 9 vs 9 +/- 9 beats/min supine; 18 +/- 13 vs 13 +/- 14 beats/min standing).,Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[beats] / [min],18,201971,DB00501,Cimetidine
,3378388,heart rate,Blood pressure responses were not altered by cimetidine but heart rate increased more (18 +/- 9 vs 9 +/- 9 beats/min supine; 18 +/- 13 vs 13 +/- 14 beats/min standing).,Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[beats] / [min],13,201972,DB00501,Cimetidine
,2225711,Oral clearance,"Oral clearance of labetalol decreased with cimetidine administration (58.7 +/- 23.3 to 32.9 +/- 13.2 ml/min/kg; p less than 0.05), thereby causing a 79% increase in area under the curve.",Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225711/),[ml] / [kg·min],58.7,202610,DB00501,Cimetidine
,2225711,Oral clearance,"Oral clearance of labetalol decreased with cimetidine administration (58.7 +/- 23.3 to 32.9 +/- 13.2 ml/min/kg; p less than 0.05), thereby causing a 79% increase in area under the curve.",Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225711/),[ml] / [kg·min],32.9,202611,DB00501,Cimetidine
,2225711,systemic clearance,"Labetalol systemic clearance also decreased (23.2 +/- 5.3 to 17.7 +/- 3.7 ml/min/kg; p less than 0.05), but the volume of distribution was unchanged.",Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225711/),[ml] / [kg·min],23.2,202612,DB00501,Cimetidine
,2225711,systemic clearance,"Labetalol systemic clearance also decreased (23.2 +/- 5.3 to 17.7 +/- 3.7 ml/min/kg; p less than 0.05), but the volume of distribution was unchanged.",Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225711/),[ml] / [kg·min],17.7,202613,DB00501,Cimetidine
,6418428,total systemic clearance,The total systemic clearance is high (500 to 600 ml/min) and is mainly determined by renal clearance.,Clinical pharmacokinetics of cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418428/),[ml] / [min],500 to 600,203355,DB00501,Cimetidine
,6418428,volume of distribution (Vd beta,The volume of distribution (Vd beta or Vdss) is of the order of 1 L/kg and this about equals bodyweight.,Clinical pharmacokinetics of cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418428/),[l] / [kg],1,203356,DB00501,Cimetidine
,6418428,Vdss),The volume of distribution (Vd beta or Vdss) is of the order of 1 L/kg and this about equals bodyweight.,Clinical pharmacokinetics of cimetidine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418428/),[l] / [kg],1,203357,DB00501,Cimetidine
,6418428,Elimination half-life,Elimination half-life is approximately 2 hours.,Clinical pharmacokinetics of cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418428/),h,2,203358,DB00501,Cimetidine
,6418428,absolute bioavailability,The absolute bioavailability in healthy subjects is about 60%.,Clinical pharmacokinetics of cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418428/),%,60,203359,DB00501,Cimetidine
,6418428,bioavailability,"In patients with peptic ulcer disease, bioavailability is around 70%, but the variation is much greater than in healthy subjects.",Clinical pharmacokinetics of cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418428/),%,70,203360,DB00501,Cimetidine
,6418428,steady-state plasma concentrations,Mean steady-state plasma concentrations on a standard 1000mg daily dose are 1.0 microgram/ml (range 0.64-1.64 micrograms/ml) and are reproducible after treatment periods of up to 2 years.,Clinical pharmacokinetics of cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418428/),[μg] / [ml],1.0,203361,DB00501,Cimetidine
,6418428,saliva to plasma ratio,The mean saliva to plasma ratio is 0.2 (range 0.1-0.55).,Clinical pharmacokinetics of cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418428/),,0.2,203362,DB00501,Cimetidine
,6418428,Plasma protein binding,"Plasma protein binding is 20%, and there is no relevant effect of changes in binding on the pharmacokinetics of cimetidine.",Clinical pharmacokinetics of cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418428/),%,20,203363,DB00501,Cimetidine
,19801894,inhibitory constants (Ki),"The inhibitory constants (Ki) of KTZ were 2.80 +/- 0.70 and 115 +/- 28 microM for MDZ1'H and MDZ4H, respectively.","Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801894/),μM,2.80,203765,DB00501,Cimetidine
,19801894,inhibitory constants (Ki),"The inhibitory constants (Ki) of KTZ were 2.80 +/- 0.70 and 115 +/- 28 microM for MDZ1'H and MDZ4H, respectively.","Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801894/),μM,115,203766,DB00501,Cimetidine
,6726654,elimination half-life,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),h,22.1,206980,DB00501,Cimetidine
,6726654,elimination half-life,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),h,15.5,206981,DB00501,Cimetidine
,6726654,total metabolic clearance,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ml] / [min],623,206982,DB00501,Cimetidine
,6726654,total metabolic clearance,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ml] / [min],1048,206983,DB00501,Cimetidine
,6726654,volume of distribution,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[l] / [kg],17.2,206984,DB00501,Cimetidine
,6726654,volume of distribution,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[l] / [kg],19.8,206985,DB00501,Cimetidine
,6726654,unbound percent,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),%,17.7,206986,DB00501,Cimetidine
,6726654,unbound percent,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),%,16.5,206987,DB00501,Cimetidine
,6726654,peak imipramine blood levels,"After single p.o. imipramine doses, peak imipramine blood levels achieved were greater during cimetidine therapy (34.4 vs. 19.3 ng/ml, P less than .05) and area under the time/concentration curve was greatly increased (569 vs. 306 ng/ml X hr, P less than .05).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [ml],34.4,206988,DB00501,Cimetidine
,6726654,peak imipramine blood levels,"After single p.o. imipramine doses, peak imipramine blood levels achieved were greater during cimetidine therapy (34.4 vs. 19.3 ng/ml, P less than .05) and area under the time/concentration curve was greatly increased (569 vs. 306 ng/ml X hr, P less than .05).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [ml],19.3,206989,DB00501,Cimetidine
,6726654,area under the time/concentration curve,"After single p.o. imipramine doses, peak imipramine blood levels achieved were greater during cimetidine therapy (34.4 vs. 19.3 ng/ml, P less than .05) and area under the time/concentration curve was greatly increased (569 vs. 306 ng/ml X hr, P less than .05).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [h·ml],569,206990,DB00501,Cimetidine
,6726654,area under the time/concentration curve,"After single p.o. imipramine doses, peak imipramine blood levels achieved were greater during cimetidine therapy (34.4 vs. 19.3 ng/ml, P less than .05) and area under the time/concentration curve was greatly increased (569 vs. 306 ng/ml X hr, P less than .05).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [h·ml],306,206991,DB00501,Cimetidine
,6726654,area under the time/concentration curve,"Desipramine area under the time/concentration curve was increased during cimetidine therapy after p.o. imipramine doses (274 vs. 152 ng/ml X hr, P less than .05), suggesting that desipramine clearance was inhibited as well.",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [h·ml],274,206992,DB00501,Cimetidine
,6726654,area under the time/concentration curve,"Desipramine area under the time/concentration curve was increased during cimetidine therapy after p.o. imipramine doses (274 vs. 152 ng/ml X hr, P less than .05), suggesting that desipramine clearance was inhibited as well.",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [h·ml],152,206993,DB00501,Cimetidine
,6726654,absolute bioavailability,Comparison of i.v. and p.o. imipramine doses indicated absolute bioavailability was 40.2% in the control state and increased to 75.3% (P less than .05) during cimetidine treatment.,Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),%,40.2,206994,DB00501,Cimetidine
,6726654,absolute bioavailability,Comparison of i.v. and p.o. imipramine doses indicated absolute bioavailability was 40.2% in the control state and increased to 75.3% (P less than .05) during cimetidine treatment.,Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),%,75.3,206995,DB00501,Cimetidine
,7205631,Ccim/GFR,"Ccim was lower at higher concentrations, e.g., at ca. 200 micrograms/ml, Ccim/GFR was 1.24.",Renal excretion of cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205631/),,1.24,207058,DB00501,Cimetidine
,7205631,half-time,The half-time of cimetidine in plasma was 43 to 49 min.,Renal excretion of cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205631/),min,43 to 49,207059,DB00501,Cimetidine
,2895594,peak bupivacaine levels,"No significant difference was found between the peak bupivacaine levels: the mean (SD) values were 0.74 (0.17) microgram/ml, 0.81 (0.38) microgram/ml and 0.70 (0.24) microgram/ml in the control, cimetidine and ranitidine groups, respectively.",H2 antagonists and bupivacaine clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895594/),[μg] / [ml],0.74,209186,DB00501,Cimetidine
,2895594,peak bupivacaine levels,"No significant difference was found between the peak bupivacaine levels: the mean (SD) values were 0.74 (0.17) microgram/ml, 0.81 (0.38) microgram/ml and 0.70 (0.24) microgram/ml in the control, cimetidine and ranitidine groups, respectively.",H2 antagonists and bupivacaine clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895594/),[μg] / [ml],0.81,209187,DB00501,Cimetidine
,2895594,peak bupivacaine levels,"No significant difference was found between the peak bupivacaine levels: the mean (SD) values were 0.74 (0.17) microgram/ml, 0.81 (0.38) microgram/ml and 0.70 (0.24) microgram/ml in the control, cimetidine and ranitidine groups, respectively.",H2 antagonists and bupivacaine clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895594/),[μg] / [ml],0.70,209188,DB00501,Cimetidine
,25733012,AUC,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[h·ng] / [ml],6,209817,DB00501,Cimetidine
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[ng] / [ml],6,209818,DB00501,Cimetidine
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[h·ng] / [ml],541,209819,DB00501,Cimetidine
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[ng] / [ml],47.8,209820,DB00501,Cimetidine
,9758288,maximum observed serum trovafloxacin concentration,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),[μg] / [ml],2.4,210599,DB00501,Cimetidine
,9758288,area under the concentration-time curve,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),[h·μg] / [ml],27.8,210600,DB00501,Cimetidine
,9758288,area under the concentration-time curve,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),h,1.4,210601,DB00501,Cimetidine
,9758288,area under the concentration-time curve,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),[μg] / [ml],2.5,210602,DB00501,Cimetidine
,9758288,area under the concentration-time curve,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),[h·μg] / [ml],27.1,210603,DB00501,Cimetidine
,9758288,area under the concentration-time curve,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),h,1.5,210604,DB00501,Cimetidine
,9758288,earliest,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),[h·μg] / [ml],27.8,210605,DB00501,Cimetidine
,9758288,earliest,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),[h·μg] / [ml],27.1,210606,DB00501,Cimetidine
,9758288,time to the maximum serum concentration,"The maximum observed serum trovafloxacin concentration, the area under the concentration-time curve of trovafloxacin within the dosing interval of 24 h and the earliest time to the maximum serum concentration for trovafloxacin in volunteers receiving concomitant cimetidine were 2.4 microg/ml. 27.8 microg x h/ml and 1.4 h, respectively, compared with 2.5 microg/ml, 27.1 microg x h/ml and 1.5 h, respectively, in volunteers receiving concomitant placebo.","An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758288/),h,1.5,210607,DB00501,Cimetidine
,7363531,Bioavailability,"Bioavailability was not complete, but was about 60% based on the plasma concentration data.",Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363531/),%,60,211955,DB00501,Cimetidine
,7363531,plasma clearance,"The volume of distribution at steady-state was about 80% of body weight, and the plasma clearance value of 495 ml/min was mainly due to renal clearance (293 ml/min).",Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363531/),[ml] / [min],495,211956,DB00501,Cimetidine
,7363531,renal clearance,"The volume of distribution at steady-state was about 80% of body weight, and the plasma clearance value of 495 ml/min was mainly due to renal clearance (293 ml/min).",Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363531/),[ml] / [min],293,211957,DB00501,Cimetidine
,7363531,elimination half-life,The elimination half-life was approximately 2 hours.,Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363531/),h,2,211958,DB00501,Cimetidine
,3240766,oral clearance,"The oral clearance of theophylline after ranitidine pretreatment, 4.55 +/- 1.69 l/h (mean +/- SD) was indistinguishable from that after placebo, 4.78 +/- 1.96 l/h, but cimetidine was associated with a significant 21% reduction in theophylline clearance, 3.58 +/- 1.07 l/h (P = 0.006).",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),[l] / [h],4.55,212272,DB00501,Cimetidine
,3240766,oral clearance,"The oral clearance of theophylline after ranitidine pretreatment, 4.55 +/- 1.69 l/h (mean +/- SD) was indistinguishable from that after placebo, 4.78 +/- 1.96 l/h, but cimetidine was associated with a significant 21% reduction in theophylline clearance, 3.58 +/- 1.07 l/h (P = 0.006).",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),[l] / [h],4.78,212273,DB00501,Cimetidine
,3240766,oral clearance,"The oral clearance of theophylline after ranitidine pretreatment, 4.55 +/- 1.69 l/h (mean +/- SD) was indistinguishable from that after placebo, 4.78 +/- 1.96 l/h, but cimetidine was associated with a significant 21% reduction in theophylline clearance, 3.58 +/- 1.07 l/h (P = 0.006).",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),[l] / [h],3.58,212274,DB00501,Cimetidine
,3240766,clearance,"The oral clearance of theophylline after ranitidine pretreatment, 4.55 +/- 1.69 l/h (mean +/- SD) was indistinguishable from that after placebo, 4.78 +/- 1.96 l/h, but cimetidine was associated with a significant 21% reduction in theophylline clearance, 3.58 +/- 1.07 l/h (P = 0.006).",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),[l] / [h],3.58,212275,DB00501,Cimetidine
,3240766,terminal half-life,"There was a correspondingly significant increase in the terminal half-life of theophylline following cimetidine, 6.11 +/- 1.29 h (P = 0.017), compared with 5.05 +/- 1.43 h and 4.88 +/- 1.45 h for placebo and ranitidine, respectively.",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),h,6.11,212276,DB00501,Cimetidine
,3240766,terminal half-life,"There was a correspondingly significant increase in the terminal half-life of theophylline following cimetidine, 6.11 +/- 1.29 h (P = 0.017), compared with 5.05 +/- 1.43 h and 4.88 +/- 1.45 h for placebo and ranitidine, respectively.",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),h,5.05,212277,DB00501,Cimetidine
,3240766,terminal half-life,"There was a correspondingly significant increase in the terminal half-life of theophylline following cimetidine, 6.11 +/- 1.29 h (P = 0.017), compared with 5.05 +/- 1.43 h and 4.88 +/- 1.45 h for placebo and ranitidine, respectively.",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),h,4.88,212278,DB00501,Cimetidine
,6927127,elimination half-life,The mean elimination half-life of cimetidine was 1.44 +/- 0.41 hours.,Pharmacokinetics of cimetidine in critically ill children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6927127/),h,1.44,212926,DB00501,Cimetidine
,6927127,clearance,"Compared to adults, these children had a relatively faster clearance (14.21 +/- 2.85 ml/min/kg) of cimetidine and a larger apparent distribution volume (2.13 +/- 0.63 l/kg).",Pharmacokinetics of cimetidine in critically ill children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6927127/),[ml] / [kg·min],14.21,212927,DB00501,Cimetidine
,6927127,apparent distribution volume,"Compared to adults, these children had a relatively faster clearance (14.21 +/- 2.85 ml/min/kg) of cimetidine and a larger apparent distribution volume (2.13 +/- 0.63 l/kg).",Pharmacokinetics of cimetidine in critically ill children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6927127/),[l] / [kg],2.13,212928,DB00501,Cimetidine
,15372129,AUC(0-24),"Within-group comparisons, however, revealed a statistically significant increase in hypericin AUC(0-24) from a median of 119 (range 82-163 microg h/l) to 149 microg h/l (61-202 microg h/l) with cimetidine comedication and a decrease in pseudohypericin AUC(0-24) from a median of 51.0 (16.4-102.9 microg h/l) to 36.4 microg h/l (14.0-102.0 microg h/l) with carbamazepine comedication compared to the baseline pharmacokinetics in each group.",Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15372129/),[h·μg] / [l],119,214072,DB00501,Cimetidine
,15372129,AUC(0-24),"Within-group comparisons, however, revealed a statistically significant increase in hypericin AUC(0-24) from a median of 119 (range 82-163 microg h/l) to 149 microg h/l (61-202 microg h/l) with cimetidine comedication and a decrease in pseudohypericin AUC(0-24) from a median of 51.0 (16.4-102.9 microg h/l) to 36.4 microg h/l (14.0-102.0 microg h/l) with carbamazepine comedication compared to the baseline pharmacokinetics in each group.",Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15372129/),[h·μg] / [l],149,214073,DB00501,Cimetidine
,15372129,AUC(0-24),"Within-group comparisons, however, revealed a statistically significant increase in hypericin AUC(0-24) from a median of 119 (range 82-163 microg h/l) to 149 microg h/l (61-202 microg h/l) with cimetidine comedication and a decrease in pseudohypericin AUC(0-24) from a median of 51.0 (16.4-102.9 microg h/l) to 36.4 microg h/l (14.0-102.0 microg h/l) with carbamazepine comedication compared to the baseline pharmacokinetics in each group.",Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15372129/),,51.0,214074,DB00501,Cimetidine
,15372129,AUC(0-24),"Within-group comparisons, however, revealed a statistically significant increase in hypericin AUC(0-24) from a median of 119 (range 82-163 microg h/l) to 149 microg h/l (61-202 microg h/l) with cimetidine comedication and a decrease in pseudohypericin AUC(0-24) from a median of 51.0 (16.4-102.9 microg h/l) to 36.4 microg h/l (14.0-102.0 microg h/l) with carbamazepine comedication compared to the baseline pharmacokinetics in each group.",Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15372129/),[h·μg] / [l],36.4,214075,DB00501,Cimetidine
,6723756,total body clearance,"As compared to healthy adult volunteers, cystic fibrosis children had an elevated cimetidine total body clearance (474 vs 300 ml/min/m2) as well as renal clearance (293 vs 232 ml/min/m2) whether normalized for body weight or surface area differences.",The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis patients: age related differences as compared to adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723756/),[ml] / [m2·min],474,214419,DB00501,Cimetidine
,6723756,total body clearance,"As compared to healthy adult volunteers, cystic fibrosis children had an elevated cimetidine total body clearance (474 vs 300 ml/min/m2) as well as renal clearance (293 vs 232 ml/min/m2) whether normalized for body weight or surface area differences.",The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis patients: age related differences as compared to adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723756/),[ml] / [m2·min],300,214420,DB00501,Cimetidine
,6723756,renal clearance,"As compared to healthy adult volunteers, cystic fibrosis children had an elevated cimetidine total body clearance (474 vs 300 ml/min/m2) as well as renal clearance (293 vs 232 ml/min/m2) whether normalized for body weight or surface area differences.",The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis patients: age related differences as compared to adults. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723756/),[ml] / [m2·min],293,214421,DB00501,Cimetidine
,6723756,renal clearance,"As compared to healthy adult volunteers, cystic fibrosis children had an elevated cimetidine total body clearance (474 vs 300 ml/min/m2) as well as renal clearance (293 vs 232 ml/min/m2) whether normalized for body weight or surface area differences.",The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis patients: age related differences as compared to adults. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723756/),[ml] / [m2·min],232,214422,DB00501,Cimetidine
exceeded,2892261,absolute oral bioavailability,"The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively.",A pharmacokinetic profile of nizatidine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892261/),%,90,215101,DB00501,Cimetidine
,2892261,half-life (t1/2),"The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively.",A pharmacokinetic profile of nizatidine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892261/),h,1.3,215102,DB00501,Cimetidine
,2892261,plasma clearance (Clp),"The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively.",A pharmacokinetic profile of nizatidine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892261/),1/[h],461,215103,DB00501,Cimetidine
,2892261,volume of distribution (Vd),"The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively.",A pharmacokinetic profile of nizatidine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892261/),1/[kg],1.21,215104,DB00501,Cimetidine
up to,1743171,bioavailability,"Storage of carbamazepine (CBZ) and phenytoin (PHT) formulations in hot, humid conditions alters the dosage form and reduces bioavailability up to 50%.",Pharmacokinetic pitfalls of present antiepileptic medications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743171/),%,50,215613,DB00501,Cimetidine
,1687011,half-life,"However, with increasing dose, there was a progressive increase in EdUrd half-life from 18.9 to 36.4 min and decrease in total clearance from 5.5 to 2.5 ml/min, indicating dose-dependent elimination.",Elimination of the antiviral drug 5-ethyl-2'-deoxyuridine by the isolated perfused rat liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687011/),min,18.9 to 36.4,215814,DB00501,Cimetidine
,1687011,total clearance,"However, with increasing dose, there was a progressive increase in EdUrd half-life from 18.9 to 36.4 min and decrease in total clearance from 5.5 to 2.5 ml/min, indicating dose-dependent elimination.",Elimination of the antiviral drug 5-ethyl-2'-deoxyuridine by the isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687011/),[ml] / [min],5.5 to 2.5,215815,DB00501,Cimetidine
,7283113,half-life,"While duration and half-life of the alpha-phase are prolonged, the half-life of the beta-phase (150 min) remains almost unchanged.",[Prevention of fentanyl rebound by administration of cimetidine (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7283113/),min,150,216975,DB00501,Cimetidine
,10456491,apparent formation clearance,"The reduction of apparent clearance of R-warfarin by cimetidine was found to be the effect of inhibition of the formation of warfarin metabolites as determined by apparent formation clearance values (+/-SD) of R-6-hydroxywarfarin (31.1+/-7.4 ml/h baseline; 18.5+/-4.5 ml/h at end of cimetidine treatment; P < 0.01), and R-7-hydroxywarfarin (6.9+/-1.3 ml/h baseline; 4.3+/-1.1 ml/h at end of cimetidine treatment; P < 0.01).",The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456491/),[ml] / [h],31.1,217419,DB00501,Cimetidine
,10456491,apparent formation clearance,"The reduction of apparent clearance of R-warfarin by cimetidine was found to be the effect of inhibition of the formation of warfarin metabolites as determined by apparent formation clearance values (+/-SD) of R-6-hydroxywarfarin (31.1+/-7.4 ml/h baseline; 18.5+/-4.5 ml/h at end of cimetidine treatment; P < 0.01), and R-7-hydroxywarfarin (6.9+/-1.3 ml/h baseline; 4.3+/-1.1 ml/h at end of cimetidine treatment; P < 0.01).",The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456491/),[ml] / [h],18.5,217420,DB00501,Cimetidine
,10456491,apparent formation clearance,"The reduction of apparent clearance of R-warfarin by cimetidine was found to be the effect of inhibition of the formation of warfarin metabolites as determined by apparent formation clearance values (+/-SD) of R-6-hydroxywarfarin (31.1+/-7.4 ml/h baseline; 18.5+/-4.5 ml/h at end of cimetidine treatment; P < 0.01), and R-7-hydroxywarfarin (6.9+/-1.3 ml/h baseline; 4.3+/-1.1 ml/h at end of cimetidine treatment; P < 0.01).",The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456491/),[ml] / [h],6.9,217421,DB00501,Cimetidine
,10456491,apparent formation clearance,"The reduction of apparent clearance of R-warfarin by cimetidine was found to be the effect of inhibition of the formation of warfarin metabolites as determined by apparent formation clearance values (+/-SD) of R-6-hydroxywarfarin (31.1+/-7.4 ml/h baseline; 18.5+/-4.5 ml/h at end of cimetidine treatment; P < 0.01), and R-7-hydroxywarfarin (6.9+/-1.3 ml/h baseline; 4.3+/-1.1 ml/h at end of cimetidine treatment; P < 0.01).",The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456491/),[ml] / [h],4.3,217422,DB00501,Cimetidine
,3758150,mean residence time (MRT),"The mean residence time (MRT) of R-AC was about 10 times longer than that of S-AC, 15 h vs 1.2 h.",Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3758150/),h,15,218411,DB00501,Cimetidine
,3758150,mean residence time (MRT),"The mean residence time (MRT) of R-AC was about 10 times longer than that of S-AC, 15 h vs 1.2 h.",Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3758150/),h,1.2,218412,DB00501,Cimetidine
,18443035,inhibition constant (K(i)),"Zonampanel inhibited the uptake of typical substrates by Oat1, Oat2, and Oat3 with inhibition constant (K(i)) values of 7.02 to 10.4 microM.","Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443035/),μM,7.02 to 10.4,218835,DB00501,Cimetidine
,18443035,Michaelis-Menten constant (K(m)),A time- and saturable concentration-dependent increase in [14C]zonampanel uptake was observed in these cells [Michaelis-Menten constant (K(m)) values: 13.4 to 53.6 microM].,"Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443035/),μM,13.4 to 53.6,218836,DB00501,Cimetidine
,7657856,CL,"In contrast, cimetidine treatment significantly altered every pharmacokinetic parameter of theophylline as follows: Cimetidine decreased theophylline geometric mean CL from 2.74 L/h to 2.07 L/h (P < .001), and prolonged theophylline harmonic mean half-life from 6.6 to 9.6 hours (P < .001) and mean residence time from 10.8 to 15.0 hours (P < .001).",Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657856/),[l] / [h],2.74,220019,DB00501,Cimetidine
,7657856,CL,"In contrast, cimetidine treatment significantly altered every pharmacokinetic parameter of theophylline as follows: Cimetidine decreased theophylline geometric mean CL from 2.74 L/h to 2.07 L/h (P < .001), and prolonged theophylline harmonic mean half-life from 6.6 to 9.6 hours (P < .001) and mean residence time from 10.8 to 15.0 hours (P < .001).",Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657856/),[l] / [h],2.07,220020,DB00501,Cimetidine
,7657856,half-life,"In contrast, cimetidine treatment significantly altered every pharmacokinetic parameter of theophylline as follows: Cimetidine decreased theophylline geometric mean CL from 2.74 L/h to 2.07 L/h (P < .001), and prolonged theophylline harmonic mean half-life from 6.6 to 9.6 hours (P < .001) and mean residence time from 10.8 to 15.0 hours (P < .001).",Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657856/),h,6.6 to 9.6,220021,DB00501,Cimetidine
,7657856,mean residence time,"In contrast, cimetidine treatment significantly altered every pharmacokinetic parameter of theophylline as follows: Cimetidine decreased theophylline geometric mean CL from 2.74 L/h to 2.07 L/h (P < .001), and prolonged theophylline harmonic mean half-life from 6.6 to 9.6 hours (P < .001) and mean residence time from 10.8 to 15.0 hours (P < .001).",Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657856/),h,10.8 to 15.0,220022,DB00501,Cimetidine
,27469324,Systemic plasma clearance,"Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine).",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[ml] / [kg·min],1.1,220371,DB00501,Cimetidine
,27469324,Systemic plasma clearance,"Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine).",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[ml] / [kg·min],37.4,220372,DB00501,Cimetidine
,27469324,Volume of distribution,Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide.,Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[l] / [kg],0.7,220373,DB00501,Cimetidine
,27469324,Volume of distribution,Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide.,Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[l] / [kg],3.2,220374,DB00501,Cimetidine
,27469324,hepatocellularity,"The hepatocellularity for minipig was determined as 124 Mcells/g liver, similar to the values reported for human.",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[Mcells] / [g],124,220375,DB00501,Cimetidine
,7073151,systemic clearance,Cimetidine reduced the systemic clearance of lidocaine from 766 +/- 50 mL/min to 576 +/- 47 mL/min (p less than 0.05); the apparent volume of distribution at steady-state and the degree of plasma protein binding of lidocaine also were decreased.,Increased toxicity and reduced clearance of lidocaine by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7073151/),[ml] / [min],766,220871,DB00501,Cimetidine
,7073151,systemic clearance,Cimetidine reduced the systemic clearance of lidocaine from 766 +/- 50 mL/min to 576 +/- 47 mL/min (p less than 0.05); the apparent volume of distribution at steady-state and the degree of plasma protein binding of lidocaine also were decreased.,Increased toxicity and reduced clearance of lidocaine by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7073151/),[ml] / [min],576,220872,DB00501,Cimetidine
,6822105,apparent total body clearance,Cimetidine decreased the apparent total body clearance of theophylline an average of 29 percent (range: 18-47 percent) from 39.5 +/- 11.7 to 28.1 +/- 3.4 ml/hr/kg (p less than 0.02).,The effects of cimetidine on theophylline pharmacokinetics at steady state. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6822105/),[ml] / [h·kg],39.5,221491,DB00501,Cimetidine
,6822105,apparent total body clearance,Cimetidine decreased the apparent total body clearance of theophylline an average of 29 percent (range: 18-47 percent) from 39.5 +/- 11.7 to 28.1 +/- 3.4 ml/hr/kg (p less than 0.02).,The effects of cimetidine on theophylline pharmacokinetics at steady state. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6822105/),[ml] / [h·kg],28.1,221492,DB00501,Cimetidine
,6822105,terminal half-life,"There was no significant change in the volume of distribution; however, the terminal half-life increased from 7.3 +/- 1.5 to 10.1 +/- 2.1 hr (p less than 0.01) during A and A-C, respectively.",The effects of cimetidine on theophylline pharmacokinetics at steady state. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6822105/),h,7.3,221493,DB00501,Cimetidine
,6822105,terminal half-life,"There was no significant change in the volume of distribution; however, the terminal half-life increased from 7.3 +/- 1.5 to 10.1 +/- 2.1 hr (p less than 0.01) during A and A-C, respectively.",The effects of cimetidine on theophylline pharmacokinetics at steady state. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6822105/),h,10.1,221494,DB00501,Cimetidine
,2893637,total body clearance,The mean total body clearance of theophylline was reduced from 57.6 ml min-1 before cimetidine to 39.5 ml min-1 during cimetidine; and the half-life was prolonged from 8.7 h before cimetidine to 12 h during cimetidine.,Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893637/),[ml] / [min],57.6,224781,DB00501,Cimetidine
,2893637,total body clearance,The mean total body clearance of theophylline was reduced from 57.6 ml min-1 before cimetidine to 39.5 ml min-1 during cimetidine; and the half-life was prolonged from 8.7 h before cimetidine to 12 h during cimetidine.,Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893637/),[ml] / [min],39.5,224782,DB00501,Cimetidine
,2893637,half-life,The mean total body clearance of theophylline was reduced from 57.6 ml min-1 before cimetidine to 39.5 ml min-1 during cimetidine; and the half-life was prolonged from 8.7 h before cimetidine to 12 h during cimetidine.,Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893637/),h,8.7,224783,DB00501,Cimetidine
,2893637,half-life,The mean total body clearance of theophylline was reduced from 57.6 ml min-1 before cimetidine to 39.5 ml min-1 during cimetidine; and the half-life was prolonged from 8.7 h before cimetidine to 12 h during cimetidine.,Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893637/),h,12,224784,DB00501,Cimetidine
,2923963,half-life,"The control mean theophylline half-life and clearance were 7.32 h and 0.86 ml min-1 kg-1, respectively.",Effects of equimolar doses of cimetidine and ranitidine on theophylline elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2923963/),h,7.32,225219,DB00501,Cimetidine
,2923963,clearance,"The control mean theophylline half-life and clearance were 7.32 h and 0.86 ml min-1 kg-1, respectively.",Effects of equimolar doses of cimetidine and ranitidine on theophylline elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2923963/),[ml] / [kg·min],0.86,225220,DB00501,Cimetidine
,3604263,total plasma clearance,The total plasma clearance of cimetidine decreased as the dose increased (4.11 to 2.21 l/h per kg) with a consequent increase in half-life (24.0 to 37.9 min) but no change in volume of distribution (mean 2.31 l/kg).,Dose-dependent pharmacokinetics of cimetidine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604263/),[l] / [h·kg],4.11 to 2.21,225797,DB00501,Cimetidine
,3604263,half-life,The total plasma clearance of cimetidine decreased as the dose increased (4.11 to 2.21 l/h per kg) with a consequent increase in half-life (24.0 to 37.9 min) but no change in volume of distribution (mean 2.31 l/kg).,Dose-dependent pharmacokinetics of cimetidine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604263/),min,24.0 to 37.9,225798,DB00501,Cimetidine
,3604263,volume of distribution,The total plasma clearance of cimetidine decreased as the dose increased (4.11 to 2.21 l/h per kg) with a consequent increase in half-life (24.0 to 37.9 min) but no change in volume of distribution (mean 2.31 l/kg).,Dose-dependent pharmacokinetics of cimetidine in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604263/),[l] / [kg],2.31,225799,DB00501,Cimetidine
,3604263,renal clearance,Both the renal clearance (1.52 to 0.99 l/h per kg) and the formation clearance of the sulphoxide metabolite (1.45 to 0.30 l/h per kg) decreased with increasing dose.,Dose-dependent pharmacokinetics of cimetidine in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604263/),[l] / [h·kg],1.52 to 0.99,225800,DB00501,Cimetidine
,3604263,formation clearance,Both the renal clearance (1.52 to 0.99 l/h per kg) and the formation clearance of the sulphoxide metabolite (1.45 to 0.30 l/h per kg) decreased with increasing dose.,Dose-dependent pharmacokinetics of cimetidine in the rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604263/),[l] / [h·kg],1.45 to 0.30,225801,DB00501,Cimetidine
,3604263,Residual clearance,"Residual clearance, calculated as the difference between total clearance and the sum of renal and metabolic clearance, did not change with dose (mean 1.08 l/h per kg).",Dose-dependent pharmacokinetics of cimetidine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604263/),[l] / [h·kg],1.08,225802,DB00501,Cimetidine
,1563208,area under the plasma concentration-time curve,The area under the plasma concentration-time curve of both R-(+)- and S-(-)-pindolol were significantly (p less than 0.01) increased by cimetidine from 234 +/- 90 (mean +/- SD) to 344 +/- 78 ng/ml.hr for R-(+)-pindolol and from 209 +/- 73 to 288 +/- 69 ng/ml.hr for S-(-)-pindolol.,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ng] / [h·ml],234,226210,DB00501,Cimetidine
,1563208,area under the plasma concentration-time curve,The area under the plasma concentration-time curve of both R-(+)- and S-(-)-pindolol were significantly (p less than 0.01) increased by cimetidine from 234 +/- 90 (mean +/- SD) to 344 +/- 78 ng/ml.hr for R-(+)-pindolol and from 209 +/- 73 to 288 +/- 69 ng/ml.hr for S-(-)-pindolol.,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ng] / [h·ml],344,226211,DB00501,Cimetidine
,1563208,area under the plasma concentration-time curve,The area under the plasma concentration-time curve of both R-(+)- and S-(-)-pindolol were significantly (p less than 0.01) increased by cimetidine from 234 +/- 90 (mean +/- SD) to 344 +/- 78 ng/ml.hr for R-(+)-pindolol and from 209 +/- 73 to 288 +/- 69 ng/ml.hr for S-(-)-pindolol.,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ng] / [h·ml],209,226212,DB00501,Cimetidine
,1563208,area under the plasma concentration-time curve,The area under the plasma concentration-time curve of both R-(+)- and S-(-)-pindolol were significantly (p less than 0.01) increased by cimetidine from 234 +/- 90 (mean +/- SD) to 344 +/- 78 ng/ml.hr for R-(+)-pindolol and from 209 +/- 73 to 288 +/- 69 ng/ml.hr for S-(-)-pindolol.,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ng] / [h·ml],288,226213,DB00501,Cimetidine
,1563208,renal clearance,The renal clearance of R-(+)-pindolol (170 +/- 55 ml/min) was significantly (p less than 0.05) less than that for S-(-)-pindolol (222 +/- 66 ml/min).,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ml] / [min],170,226214,DB00501,Cimetidine
,1563208,renal clearance,The renal clearance of R-(+)-pindolol (170 +/- 55 ml/min) was significantly (p less than 0.05) less than that for S-(-)-pindolol (222 +/- 66 ml/min).,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ml] / [min],222,226215,DB00501,Cimetidine
,1563208,renal clearances,Cimetidine significantly (p less than 0.01) reduced the renal clearances of R-(+)-pindolol to 104 +/- 18 ml/min and for S-(-)-pindolol to 155 +/- 38 ml/min.,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ml] / [min],104,226216,DB00501,Cimetidine
,1563208,renal clearances,Cimetidine significantly (p less than 0.01) reduced the renal clearances of R-(+)-pindolol to 104 +/- 18 ml/min and for S-(-)-pindolol to 155 +/- 38 ml/min.,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ml] / [min],155,226217,DB00501,Cimetidine
,6697868,half-life,"The half-life of cimetidine ranged from 3.4 to 2.1 h, and decreased as total body clearance increased.",The pharmacokinetics and metabolism of cimetidine in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6697868/),h,3.4 to 2.1,227259,DB00501,Cimetidine
,25034211,IC50,"DA-9801 inhibited the in vitro transport activities of OCT1, OCT2, OAT3, and OATP1B1, with IC50 values of 106, 174, 48.1, and 273 μg/mL, respectively, while the other transporters were not inhibited by 300 μg/mL DA-9801.","Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034211/),[μg] / [ml],106,229770,DB00501,Cimetidine
,25034211,IC50,"DA-9801 inhibited the in vitro transport activities of OCT1, OCT2, OAT3, and OATP1B1, with IC50 values of 106, 174, 48.1, and 273 μg/mL, respectively, while the other transporters were not inhibited by 300 μg/mL DA-9801.","Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034211/),[μg] / [ml],174,229771,DB00501,Cimetidine
,25034211,IC50,"DA-9801 inhibited the in vitro transport activities of OCT1, OCT2, OAT3, and OATP1B1, with IC50 values of 106, 174, 48.1, and 273 μg/mL, respectively, while the other transporters were not inhibited by 300 μg/mL DA-9801.","Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034211/),[μg] / [ml],48.1,229772,DB00501,Cimetidine
,25034211,IC50,"DA-9801 inhibited the in vitro transport activities of OCT1, OCT2, OAT3, and OATP1B1, with IC50 values of 106, 174, 48.1, and 273 μg/mL, respectively, while the other transporters were not inhibited by 300 μg/mL DA-9801.","Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034211/),[μg] / [ml],273,229773,DB00501,Cimetidine
,7249489,bioavailability,The bioavailability of cimetidine measured as the ratio between the areas under the plasma concentration-time curves (AUC) after oral and intravenous administration was 76%.,Pharmacokinetics of cimetidine after single doses and during continuous treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249489/),%,76,230262,DB00501,Cimetidine
,7249489,excretion,"The mean excretion of cimetidine in the urine as unchanged drug, expressed as a percentage of administered dose, was 58% after 200mg intravenously and between 37 and 41% after single oral doses of 200, 400 and 800mg and during continuous treatment with 1.0g/day.",Pharmacokinetics of cimetidine after single doses and during continuous treatment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249489/),%,58,230263,DB00501,Cimetidine
,7249489,excretion,"The mean excretion of cimetidine in the urine as unchanged drug, expressed as a percentage of administered dose, was 58% after 200mg intravenously and between 37 and 41% after single oral doses of 200, 400 and 800mg and during continuous treatment with 1.0g/day.",Pharmacokinetics of cimetidine after single doses and during continuous treatment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249489/),%,37 and 41,230264,DB00501,Cimetidine
,7249489,volume of distribution,"Following intravenous administration, the mean volume of distribution was 1.39L/kg and the mean total body clearance and the mean plasma renal clearance of cimetidine were 655 and 375ml/min, respectively.",Pharmacokinetics of cimetidine after single doses and during continuous treatment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249489/),[l] / [kg],1.39,230265,DB00501,Cimetidine
,7249489,total body clearance,"Following intravenous administration, the mean volume of distribution was 1.39L/kg and the mean total body clearance and the mean plasma renal clearance of cimetidine were 655 and 375ml/min, respectively.",Pharmacokinetics of cimetidine after single doses and during continuous treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249489/),[ml] / [min],655,230266,DB00501,Cimetidine
,7249489,plasma renal clearance,"Following intravenous administration, the mean volume of distribution was 1.39L/kg and the mean total body clearance and the mean plasma renal clearance of cimetidine were 655 and 375ml/min, respectively.",Pharmacokinetics of cimetidine after single doses and during continuous treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249489/),[ml] / [min],375,230267,DB00501,Cimetidine
above,7249489,morning plasma concentration,A morning plasma concentration above 0.6 microgram/ml before the next morning dose has been taken during treatment with cimetidine 1.0g/day is only seen in patients with some degree of renal failure.,Pharmacokinetics of cimetidine after single doses and during continuous treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249489/),[μg] / [ml],0.6,230268,DB00501,Cimetidine
,7249489,plasma half-life,Measurement of plasma half-life during continuous treatment shows that the plasma half-life is longer than the mean 1.79 hours estimated after intravenous administration of a single dose.,Pharmacokinetics of cimetidine after single doses and during continuous treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249489/),h,1.79,230269,DB00501,Cimetidine
,9923817,tmax,"Small differences were found in mean tmax (0.7 to 0.8 h), CLr (2.0 to 2.6 ml/min per kg), and t1/2 (7.4 to 8.8 h) for hydrodolasetron between treatment periods.",Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923817/),h,0.7 to 0.8,231686,DB00501,Cimetidine
,9923817,CLr,"Small differences were found in mean tmax (0.7 to 0.8 h), CLr (2.0 to 2.6 ml/min per kg), and t1/2 (7.4 to 8.8 h) for hydrodolasetron between treatment periods.",Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923817/),[ml] / [kg·min],2.0 to 2.6,231687,DB00501,Cimetidine
,9923817,t1/2,"Small differences were found in mean tmax (0.7 to 0.8 h), CLr (2.0 to 2.6 ml/min per kg), and t1/2 (7.4 to 8.8 h) for hydrodolasetron between treatment periods.",Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923817/),h,7.4 to 8.8,231688,DB00501,Cimetidine
,19646084,t(max),Cimetidine was absorbed rapidly post-treatment (t(max) = 0.5 h).,Pharmacokinetics of cimetidine in dogs after oral administration of cimetidine tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646084/),h,0.5,232024,DB00501,Cimetidine
,19646084,absolute bioavailability,A mean absolute bioavailability of 75% was calculated following a single oral administration of 5 mg cimetidine/kg body weight.,Pharmacokinetics of cimetidine in dogs after oral administration of cimetidine tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646084/),%,75,232025,DB00501,Cimetidine
,19646084,plasma half-life,"After intravenous administration, a plasma half-life of 1.6 h was calculated.",Pharmacokinetics of cimetidine in dogs after oral administration of cimetidine tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646084/),h,1.6,232026,DB00501,Cimetidine
,19646084,t(max),Food intake concomitant with oral administration of cimetidine delayed (t(max) = 2.25 h) and decreased the rate and extent of absorption (AUC) by about 40%.,Pharmacokinetics of cimetidine in dogs after oral administration of cimetidine tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646084/),h,2.25,232027,DB00501,Cimetidine
,9642517,C0,"After the first visit, patients were randomized to Group I (C0: 100-200 ng/ml) or Group II (C2: 200-400 ng/ml).",Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9642517/),[ng] / [ml],100-200,233140,DB00501,Cimetidine
,9642517,C2,"After the first visit, patients were randomized to Group I (C0: 100-200 ng/ml) or Group II (C2: 200-400 ng/ml).",Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9642517/),[ng] / [ml],200-400,233141,DB00501,Cimetidine
,9642517,C2 levels,"C2 levels decreased in Group II from 912 +/- 438 to 555 +/- 271 ng/ml (p = 0.01), without evidence of acute rejection on endomyocardial biopsies.",Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9642517/),[ng] / [ml],912,233142,DB00501,Cimetidine
,9642517,C2 levels,"C2 levels decreased in Group II from 912 +/- 438 to 555 +/- 271 ng/ml (p = 0.01), without evidence of acute rejection on endomyocardial biopsies.",Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9642517/),[ng] / [ml],555,233143,DB00501,Cimetidine
,6507464,bioavailability,Assessment of methylprednisolone disposition following oral and intravenous doses revealed no effect of cimetidine on the bioavailability (74 to 81 percent absorption) or plasma clearance (22 to 24 liters per hour) of the steroid.,Cimetidine-methylprednisolone-theophylline metabolic interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6507464/),%,74 to 81,233352,DB00501,Cimetidine
,6507464,plasma clearance,Assessment of methylprednisolone disposition following oral and intravenous doses revealed no effect of cimetidine on the bioavailability (74 to 81 percent absorption) or plasma clearance (22 to 24 liters per hour) of the steroid.,Cimetidine-methylprednisolone-theophylline metabolic interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6507464/),[l] / [h],22 to 24,233353,DB00501,Cimetidine
,27019345,AUC ratio,"Assuming competitive inhibition and using cimetidine Ki values determined in vitro, the predicted metformin AUC ratio was 1.0 compared to an observed value of 1.46.",Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27019345/),,1.0,233900,DB00501,Cimetidine
,27019345,AUC ratio,"Assuming competitive inhibition and using cimetidine Ki values determined in vitro, the predicted metformin AUC ratio was 1.0 compared to an observed value of 1.46.",Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27019345/),,1.46,233901,DB00501,Cimetidine
,3975263,Clearance,"Clearance decreased as the dose of theophylline increased going from 0.064 +/- 0.016 to 0.052 +/- 0.011 1.h-1.kg-1 at the 2 and 6 mg/kg doses, respectively (p less than 0.02).",Theophylline kinetics: dose dependency and single sample prediction of clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975263/),[1] / [h·kg],0.064,233988,DB00501,Cimetidine
,3975263,Clearance,"Clearance decreased as the dose of theophylline increased going from 0.064 +/- 0.016 to 0.052 +/- 0.011 1.h-1.kg-1 at the 2 and 6 mg/kg doses, respectively (p less than 0.02).",Theophylline kinetics: dose dependency and single sample prediction of clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975263/),[1] / [h·kg],0.052,233989,DB00501,Cimetidine
,3216031,area under the curve at steady state,Cimetidine significantly increased (P less than .05) pentoxifylline area under the curve at steady state 26.2% from 675 +/- 97 (mean +/- SEM) to 852 +/- 108 ng.,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),ng,675,235228,DB00501,Cimetidine
,3216031,area under the curve at steady state,Cimetidine significantly increased (P less than .05) pentoxifylline area under the curve at steady state 26.2% from 675 +/- 97 (mean +/- SEM) to 852 +/- 108 ng.,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),ng,852,235229,DB00501,Cimetidine
,3216031,steady-state plasma concentration,The average steady-state plasma concentration increased 27.4% from 84 +/- 12 to 107 +/- 14 ng/mL (P less than .05).,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),[ng] / [ml],84,235230,DB00501,Cimetidine
,3216031,steady-state plasma concentration,The average steady-state plasma concentration increased 27.4% from 84 +/- 12 to 107 +/- 14 ng/mL (P less than .05).,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),[ng] / [ml],107,235231,DB00501,Cimetidine
,3216031,Apparent oral clearance,Apparent oral clearance decreased 21.5% from 1309 +/- 304 to 1027 +/- 244 mL/min (P less than .02).,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),[ml] / [min],1309,235232,DB00501,Cimetidine
,3216031,Apparent oral clearance,Apparent oral clearance decreased 21.5% from 1309 +/- 304 to 1027 +/- 244 mL/min (P less than .02).,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),[ml] / [min],1027,235233,DB00501,Cimetidine
,6827475,elimination T1/2,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,16.7,235671,DB00501,Cimetidine
,6827475,elimination T1/2,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,10.9,235672,DB00501,Cimetidine
,6827475,total metabolic clearance,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.46,235673,DB00501,Cimetidine
,6827475,total metabolic clearance,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.72,235674,DB00501,Cimetidine
,6827475,T1/2,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,58,235675,DB00501,Cimetidine
,6827475,T1/2,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,39,235676,DB00501,Cimetidine
,6827475,total metabolic clearance,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.42,235677,DB00501,Cimetidine
,6827475,total metabolic clearance,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.30,235678,DB00501,Cimetidine
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,16.8,235679,DB00501,Cimetidine
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,15.3,235680,DB00501,Cimetidine
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],1.03,235681,DB00501,Cimetidine
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],1.07,235682,DB00501,Cimetidine
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,2.66,235683,DB00501,Cimetidine
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,2.60,235684,DB00501,Cimetidine
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],4.8,235685,DB00501,Cimetidine
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],4.5,235686,DB00501,Cimetidine
,6827475,LD50,"In an animal model used to assess the effect of cimetidine on acetaminophen toxicity, the LD50 of acetaminophen alone in Charles River CD-1 mice was 480 mg/kg (95% confidence interval: 436-528 mg/kg).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[mg] / [kg],480,235687,DB00501,Cimetidine
,2520367,CCr,The initial CCr of 65 ml/min (median) was reduced to a nadir of 46 ml/min (p less than 0.01) during the first 2 h after infusion of cimetidine.,"The effects of cimetidine on creatinine excretion, glomerular filtration rate and tubular function in renal transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2520367/),[ml] / [min],65,236064,DB00501,Cimetidine
,2520367,CCr,The initial CCr of 65 ml/min (median) was reduced to a nadir of 46 ml/min (p less than 0.01) during the first 2 h after infusion of cimetidine.,"The effects of cimetidine on creatinine excretion, glomerular filtration rate and tubular function in renal transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2520367/),[ml] / [min],46,236065,DB00501,Cimetidine
,2520367,fractional clearance of c,"GFR remained unchanged, and thus the fractional clearance of creatinine (CCr/CTh) was reduced from 1.43 (median) to 1.03 (p less than 0.01).","The effects of cimetidine on creatinine excretion, glomerular filtration rate and tubular function in renal transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2520367/),,1.43,236066,DB00501,Cimetidine
,2520367,fractional clearance of c,"GFR remained unchanged, and thus the fractional clearance of creatinine (CCr/CTh) was reduced from 1.43 (median) to 1.03 (p less than 0.01).","The effects of cimetidine on creatinine excretion, glomerular filtration rate and tubular function in renal transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2520367/),,1.03,236067,DB00501,Cimetidine
,7056278,clearance (ClHDa),The average haemodialysis clearance (ClHDa) of cimetidine during dialysis was 46-92 ml/min at a dialysate flow rate of 320 ml/min and blood flow rates in the 6 patients between 160-240 ml/min.,Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056278/),[ml] / [min],46-92,237257,DB00501,Cimetidine
,7056278,flow rate,The average haemodialysis clearance (ClHDa) of cimetidine during dialysis was 46-92 ml/min at a dialysate flow rate of 320 ml/min and blood flow rates in the 6 patients between 160-240 ml/min.,Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056278/),[ml] / [min],320,237258,DB00501,Cimetidine
,7056278,blood flow rates,The average haemodialysis clearance (ClHDa) of cimetidine during dialysis was 46-92 ml/min at a dialysate flow rate of 320 ml/min and blood flow rates in the 6 patients between 160-240 ml/min.,Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056278/),[ml] / [min],160-240,237259,DB00501,Cimetidine
,7056278,ClHDa,"The mean ClHDa of the sulphoxide metabolite was 44% higher than that of cimetidine, and ranged between 49-148 ml/min.",Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056278/),[ml] / [min],49-148,237260,DB00501,Cimetidine
,7056278,plasma elimination half-life (t 1/2),During haemodialysis the mean plasma elimination half-life (t 1/2) of cimetidine was 3.24h (range 2.08-5.08) and of the sulphoxide metabolite 9.49h (range 4.70-14.39).,Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056278/),h,3.24,237261,DB00501,Cimetidine
,7056278,plasma elimination half-life (t 1/2),During haemodialysis the mean plasma elimination half-life (t 1/2) of cimetidine was 3.24h (range 2.08-5.08) and of the sulphoxide metabolite 9.49h (range 4.70-14.39).,Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056278/),h,9.49,237262,DB00501,Cimetidine
,7056278,total amount of cimetidine eliminated,"The mean total amount of cimetidine eliminated during dialysis was 27.3mg (range 17.9-31.8), which was 9.0-15.9% of the given dose.",Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056278/),mg,27.3,237263,DB00501,Cimetidine
,1352810,elimination half-life,"The elimination half-life of dapsone (814 +/- 351 min) was more than doubled in the presence of trimethoprim and cimetidine compared with control (355 +/- 160 min, P less than 0.05).",Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),min,814,238476,DB00501,Cimetidine
,1352810,elimination half-life,"The elimination half-life of dapsone (814 +/- 351 min) was more than doubled in the presence of trimethoprim and cimetidine compared with control (355 +/- 160 min, P less than 0.05).",Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),min,355,238477,DB00501,Cimetidine
,1352810,AUC,There was a threefold increase in the AUC of trimethoprim (6296 +/- 2249 micrograms min mL-1) in the presence of dapsone compared with trimethoprim alone (2122 +/- 552 micrograms min mL-1).,Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),[min·μg] / [ml],6296,238478,DB00501,Cimetidine
,1352810,AUC,There was a threefold increase in the AUC of trimethoprim (6296 +/- 2249 micrograms min mL-1) in the presence of dapsone compared with trimethoprim alone (2122 +/- 552 micrograms min mL-1).,Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),[min·μg] / [ml],2122,238479,DB00501,Cimetidine
,1352810,clearance,There was also a corresponding decrease in the clearance of trimethoprim in the presence of dapsone compared with control (19.1 +/- 6.9 vs 60.8 +/- 21.0 mL min-1).,Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),[ml] / [min],19.1,238480,DB00501,Cimetidine
,1352810,clearance,There was also a corresponding decrease in the clearance of trimethoprim in the presence of dapsone compared with control (19.1 +/- 6.9 vs 60.8 +/- 21.0 mL min-1).,Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),[ml] / [min],60.8,238481,DB00501,Cimetidine
,1352810,elimination half-life,"However, there was no change in the elimination half-life of trimethoprim between the two experimental groups (273 +/- 120 vs 292 +/- 54 min).",Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),min,273,238482,DB00501,Cimetidine
,1352810,elimination half-life,"However, there was no change in the elimination half-life of trimethoprim between the two experimental groups (273 +/- 120 vs 292 +/- 54 min).",Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),min,292,238483,DB00501,Cimetidine
,1352810,AUC,The AUC of trimethoprim increased more than threefold in the presence of cimetidine (7100 +/- 1501 micrograms min mL-1) compared with trimethoprim alone (2122 +/- 552 micrograms min mL-1).,Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),[min·μg] / [ml],7100,238484,DB00501,Cimetidine
,1352810,AUC,The AUC of trimethoprim increased more than threefold in the presence of cimetidine (7100 +/- 1501 micrograms min mL-1) compared with trimethoprim alone (2122 +/- 552 micrograms min mL-1).,Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),[min·μg] / [ml],2122,238485,DB00501,Cimetidine
,8158054,maximum concentration,"Before addition of cimetidine, the maximum concentration of praziquantel was 350 ng/mL; concurrent cimetidine administration increased the maximum concentration to 826 ng/mL.",Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8158054/),[ng] / [ml],350,238576,DB00501,Cimetidine
,8158054,maximum concentration,"Before addition of cimetidine, the maximum concentration of praziquantel was 350 ng/mL; concurrent cimetidine administration increased the maximum concentration to 826 ng/mL.",Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8158054/),[ng] / [ml],826,238577,DB00501,Cimetidine
,8158054,elimination half-life,The elimination half-life increased from 1.7 h without cimetidine to 3.3 h with cimetidine and the area under the curve for the 12-h sampling period rose from 754 ng.h/mL to 3050 ng.h/mL.,Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8158054/),h,1.7,238578,DB00501,Cimetidine
,8158054,elimination half-life,The elimination half-life increased from 1.7 h without cimetidine to 3.3 h with cimetidine and the area under the curve for the 12-h sampling period rose from 754 ng.h/mL to 3050 ng.h/mL.,Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8158054/),h,3.3,238579,DB00501,Cimetidine
,8158054,area under the curve,The elimination half-life increased from 1.7 h without cimetidine to 3.3 h with cimetidine and the area under the curve for the 12-h sampling period rose from 754 ng.h/mL to 3050 ng.h/mL.,Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8158054/),[h·ng] / [ml],754,238580,DB00501,Cimetidine
,8158054,area under the curve,The elimination half-life increased from 1.7 h without cimetidine to 3.3 h with cimetidine and the area under the curve for the 12-h sampling period rose from 754 ng.h/mL to 3050 ng.h/mL.,Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8158054/),[h·ng] / [ml],3050,238581,DB00501,Cimetidine
,2393206,-to-CCr ratio,"Use of cimetidine improved the accuracy of CCr, as measured by the CDTPA-to-CCr ratio (1.07 [cimetidine] compared with 1.33 [placebo]; P less than 0.05).",Oral cimetidine improves the accuracy and precision of creatinine clearance in lupus nephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393206/),,1.07,238965,DB00501,Cimetidine
,2393206,-to-CCr ratio,"Use of cimetidine improved the accuracy of CCr, as measured by the CDTPA-to-CCr ratio (1.07 [cimetidine] compared with 1.33 [placebo]; P less than 0.05).",Oral cimetidine improves the accuracy and precision of creatinine clearance in lupus nephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393206/),,1.33,238966,DB00501,Cimetidine
,2271376,AUC,2. The AUC of dapsone (31.0 +/- 7.2 micrograms ml-1 h) was significantly increased (P less than 0.001) in the presence of cimetidine (43.3 +/- 8.8 micrograms ml-1 h).,The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271376/),[h·μg] / [ml],31.0,242614,DB00501,Cimetidine
,2271376,AUC,2. The AUC of dapsone (31.0 +/- 7.2 micrograms ml-1 h) was significantly increased (P less than 0.001) in the presence of cimetidine (43.3 +/- 8.8 micrograms ml-1 h).,The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271376/),[h·μg] / [ml],43.3,242615,DB00501,Cimetidine
,2271376,Peak,3. Peak methaemoglobin levels observed after dapsone administration (2.5 +/- 0.6%) were significantly (P less than 0.05) reduced in the presence of cimetidine (0.98 +/- 0.35%).,The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271376/),%,2.,242616,DB00501,Cimetidine
,3383988,half-life,Sulphaphenazole produced a significant increase in the half-life of tolbutamide (7.10 to 21.50 h) and a corresponding decrease in its clearance (0.260 to 0.084 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,7.10 to 21.50,243330,DB00501,Cimetidine
,3383988,clearance,Sulphaphenazole produced a significant increase in the half-life of tolbutamide (7.10 to 21.50 h) and a corresponding decrease in its clearance (0.260 to 0.084 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.260 to 0.084,243331,DB00501,Cimetidine
,3383988,half lives,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,6.21 to 9.04,243332,DB00501,Cimetidine
,3383988,half lives,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,14.2 to 19.2,243333,DB00501,Cimetidine
,3383988,clearance,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.226 to 0.148,243334,DB00501,Cimetidine
,3383988,clearance,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.50 to 0.31,243335,DB00501,Cimetidine
,3383988,half-life,A single dose of primaquine had no demonstrable effect on tolbutamide disposition whereas the half-life of antipyrine was increased (12.1 to 15.0 h) and its clearance decreased (0.63 to 0.38 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,12.1 to 15.0,243336,DB00501,Cimetidine
,3383988,clearance,A single dose of primaquine had no demonstrable effect on tolbutamide disposition whereas the half-life of antipyrine was increased (12.1 to 15.0 h) and its clearance decreased (0.63 to 0.38 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.63 to 0.38,243337,DB00501,Cimetidine
,3803421,unbound hydroxylation clearance rate,"Cimetidine had no effect on the disposition of tolbutamide, including the unbound hydroxylation clearance rate (324 ml X min-1, tolbutamide alone; 316 ml X min-1, tolbutamide plus cimetidine).",Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803421/),[ml] / [min],324,245126,DB00501,Cimetidine
,3803421,unbound hydroxylation clearance rate,"Cimetidine had no effect on the disposition of tolbutamide, including the unbound hydroxylation clearance rate (324 ml X min-1, tolbutamide alone; 316 ml X min-1, tolbutamide plus cimetidine).",Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803421/),[ml] / [min],316,245127,DB00501,Cimetidine
,3803421,total urinary recovery,The total urinary recovery of carboxy- and hydroxy-tolbutamide metabolites was 85.7 +/- 20.3% of the dose when tolbutamide was given alone and 78.9 +/- 14.3% when given with cimetidine.,Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803421/),%,85.7,245128,DB00501,Cimetidine
,3803421,total urinary recovery,The total urinary recovery of carboxy- and hydroxy-tolbutamide metabolites was 85.7 +/- 20.3% of the dose when tolbutamide was given alone and 78.9 +/- 14.3% when given with cimetidine.,Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803421/),%,78.9,245129,DB00501,Cimetidine
,2783182,plasma half-life (1/2),The plasma half-life (1/2) of piroxicam in male rats was about 8.3 h and it was increased to 20.74 h by cimetidine pretreatment.,Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783182/),h,8.3,245393,DB00501,Cimetidine
,2783182,plasma half-life (1/2),The plasma half-life (1/2) of piroxicam in male rats was about 8.3 h and it was increased to 20.74 h by cimetidine pretreatment.,Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783182/),h,20.74,245394,DB00501,Cimetidine
,2783182,t1/2,The t1/2 of piroxicam was increased from 37.36 to 52.86 h with cimetidine administration.,Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783182/),h,37.36,245395,DB00501,Cimetidine
,2783182,t1/2,The t1/2 of piroxicam was increased from 37.36 to 52.86 h with cimetidine administration.,Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783182/),h,52.86,245396,DB00501,Cimetidine
,2979257,half life,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),h,7.7,245443,DB00501,Cimetidine
,2979257,half life,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),h,9.8,245444,DB00501,Cimetidine
,2979257,clearance,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),[ml] / [kg·min],0.8,245445,DB00501,Cimetidine
,2979257,clearance,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),[ml] / [kg·min],0.60,245446,DB00501,Cimetidine
,2298190,t1/2,"Following 3.3 mg/kg iv, cimetidine displayed two-compartment characteristics with a t1/2 of 0.083 +/- 0.039 h and t1/2 of 2.23 +/- 0.64 h.",Pharmacokinetic studies of cimetidine hydrochloride in adult horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298190/),h,0.083,246220,DB00501,Cimetidine
,2298190,t1/2,"Following 3.3 mg/kg iv, cimetidine displayed two-compartment characteristics with a t1/2 of 0.083 +/- 0.039 h and t1/2 of 2.23 +/- 0.64 h.",Pharmacokinetic studies of cimetidine hydrochloride in adult horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298190/),h,2.23,246221,DB00501,Cimetidine
,2298190,total body clearance,The total body clearance was 0.443 +/- 0.160 litre/h/kg and the mean residence time was 2.74 +/- 1.11 h.,Pharmacokinetic studies of cimetidine hydrochloride in adult horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298190/),[l] / [h·kg],0.443,246222,DB00501,Cimetidine
,2298190,mean residence time,The total body clearance was 0.443 +/- 0.160 litre/h/kg and the mean residence time was 2.74 +/- 1.11 h.,Pharmacokinetic studies of cimetidine hydrochloride in adult horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298190/),h,2.74,246223,DB00501,Cimetidine
,2298190,volume of distribution (Vss),"The volume of distribution (Vss) and volume of the central compartment (Vc) were 1.138 +/- 0.230 and 0.276 +/- 0.102 litre/kg, respectively.",Pharmacokinetic studies of cimetidine hydrochloride in adult horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298190/),[l] / [kg],1.138,246224,DB00501,Cimetidine
,2298190,volume of the central compartment (Vc),"The volume of distribution (Vss) and volume of the central compartment (Vc) were 1.138 +/- 0.230 and 0.276 +/- 0.102 litre/kg, respectively.",Pharmacokinetic studies of cimetidine hydrochloride in adult horses. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298190/),[l] / [kg],0.276,246225,DB00501,Cimetidine
,2298190,peak plasma concentration,"After a single oral dose of 10 mg/kg as crushed tablets, peak plasma concentration of 1.81 +/- 0.82 micrograms/ml occurred at approximately 1.4 h.",Pharmacokinetic studies of cimetidine hydrochloride in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298190/),[μg] / [ml],1.81,246226,DB00501,Cimetidine
,2298190,extent of absorption,Oral absorption of cimetidine appeared variable and slow with an extent of absorption of 0.296 +/- 0.183 and a mean residence time for absorption of 1.99 +/- 0.79 h.,Pharmacokinetic studies of cimetidine hydrochloride in adult horses. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298190/),,0.296,246227,DB00501,Cimetidine
,2298190,mean residence time for absorption,Oral absorption of cimetidine appeared variable and slow with an extent of absorption of 0.296 +/- 0.183 and a mean residence time for absorption of 1.99 +/- 0.79 h.,Pharmacokinetic studies of cimetidine hydrochloride in adult horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298190/),h,1.99,246228,DB00501,Cimetidine
,2298190,steady state plasma concentration,"Based on a desired average steady state plasma concentration of 1.0 microgram/ml, 11.0 mg/kg/day iv and 48 mg/kg/day orally can be recommended in adult horses.",Pharmacokinetic studies of cimetidine hydrochloride in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298190/),[μg] / [ml],1.0,246229,DB00501,Cimetidine
,8519046,apparent oral clearance,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[l] / [h],2.47,246341,DB00501,Cimetidine
,8519046,apparent oral clearance,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[l] / [h],1.85,246342,DB00501,Cimetidine
,8519046,area under the curve,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [h·l],233.48,246343,DB00501,Cimetidine
,8519046,area under the curve,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [h·l],307.43,246344,DB00501,Cimetidine
,8519046,peak concentration,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [l],13.2,246345,DB00501,Cimetidine
,8519046,peak concentration,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [l],16.7,246346,DB00501,Cimetidine
,8519046,trough concentration,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [l],6.4,246347,DB00501,Cimetidine
,8519046,trough concentration,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [l],9.0,246348,DB00501,Cimetidine
,8148224,Cmax,"Cmax was increased significantly when tenoxicam was given with probenecid (2.8 micrograms ml-1 alone, 3.5 micrograms ml-1 after probenecid; P < 0.005).",Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148224/),[μg] / [ml],2.8,246855,DB00501,Cimetidine
,8148224,Cmax,"Cmax was increased significantly when tenoxicam was given with probenecid (2.8 micrograms ml-1 alone, 3.5 micrograms ml-1 after probenecid; P < 0.005).",Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148224/),[μg] / [ml],3.5,246856,DB00501,Cimetidine
,3770173,t1/2 beta,"The main pharmacokinetic parameters of cimetidine were calculated as follows: t1/2 beta = 1.7 h, t1/2 alpha = 0.12 h, Vd = 1.0 1/kg, Cis = 0.43 1/kg/h, Cior = 1.2 1/kg/h, bioavailability 36%.",[Cimetidine pharmacokinetics]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770173/),h,1.7,249682,DB00501,Cimetidine
,3770173,t1/2 alpha,"The main pharmacokinetic parameters of cimetidine were calculated as follows: t1/2 beta = 1.7 h, t1/2 alpha = 0.12 h, Vd = 1.0 1/kg, Cis = 0.43 1/kg/h, Cior = 1.2 1/kg/h, bioavailability 36%.",[Cimetidine pharmacokinetics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770173/),h,0.12,249683,DB00501,Cimetidine
,3770173,Vd,"The main pharmacokinetic parameters of cimetidine were calculated as follows: t1/2 beta = 1.7 h, t1/2 alpha = 0.12 h, Vd = 1.0 1/kg, Cis = 0.43 1/kg/h, Cior = 1.2 1/kg/h, bioavailability 36%.",[Cimetidine pharmacokinetics]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770173/),[1] / [kg],1.0,249684,DB00501,Cimetidine
,3770173,Cis,"The main pharmacokinetic parameters of cimetidine were calculated as follows: t1/2 beta = 1.7 h, t1/2 alpha = 0.12 h, Vd = 1.0 1/kg, Cis = 0.43 1/kg/h, Cior = 1.2 1/kg/h, bioavailability 36%.",[Cimetidine pharmacokinetics]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770173/),[1] / [h·kg],0.43,249685,DB00501,Cimetidine
,3770173,Cior,"The main pharmacokinetic parameters of cimetidine were calculated as follows: t1/2 beta = 1.7 h, t1/2 alpha = 0.12 h, Vd = 1.0 1/kg, Cis = 0.43 1/kg/h, Cior = 1.2 1/kg/h, bioavailability 36%.",[Cimetidine pharmacokinetics]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770173/),[1] / [h·kg],1.2,249686,DB00501,Cimetidine
,3770173,bioavailability,"The main pharmacokinetic parameters of cimetidine were calculated as follows: t1/2 beta = 1.7 h, t1/2 alpha = 0.12 h, Vd = 1.0 1/kg, Cis = 0.43 1/kg/h, Cior = 1.2 1/kg/h, bioavailability 36%.",[Cimetidine pharmacokinetics]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770173/),%,36,249687,DB00501,Cimetidine
,6487478,AUC,"After glutethimide there was a significant reduction in the AUC after the oral dose of labetalol, from 40,596 +/- 11,534 (mean +/- s.e. mean) to 22,057 +/- 6,276 ng ml-1 min (2P less than 0.05), and systemic bioavailability was reduced from 30.3 +/- 2.8 to 17.0 +/- 3.5% (2P less than 0.001).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),[min·ng] / [ml],"40,596",253780,DB00501,Cimetidine
,6487478,AUC,"After glutethimide there was a significant reduction in the AUC after the oral dose of labetalol, from 40,596 +/- 11,534 (mean +/- s.e. mean) to 22,057 +/- 6,276 ng ml-1 min (2P less than 0.05), and systemic bioavailability was reduced from 30.3 +/- 2.8 to 17.0 +/- 3.5% (2P less than 0.001).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),[min·ng] / [ml],"22,057",253781,DB00501,Cimetidine
,6487478,systemic bioavailability,"After glutethimide there was a significant reduction in the AUC after the oral dose of labetalol, from 40,596 +/- 11,534 (mean +/- s.e. mean) to 22,057 +/- 6,276 ng ml-1 min (2P less than 0.05), and systemic bioavailability was reduced from 30.3 +/- 2.8 to 17.0 +/- 3.5% (2P less than 0.001).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),%,30.3,253782,DB00501,Cimetidine
,6487478,systemic bioavailability,"After glutethimide there was a significant reduction in the AUC after the oral dose of labetalol, from 40,596 +/- 11,534 (mean +/- s.e. mean) to 22,057 +/- 6,276 ng ml-1 min (2P less than 0.05), and systemic bioavailability was reduced from 30.3 +/- 2.8 to 17.0 +/- 3.5% (2P less than 0.001).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),%,17.0,253783,DB00501,Cimetidine
,6487478,volume of distribution,"After cimetidine there was a significant reduction in the volume of distribution of labetalol, from 520 +/- 51 to 445 +/- 24 1 (2P less than 0.05).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),1,520,253784,DB00501,Cimetidine
,6487478,volume of distribution,"After cimetidine there was a significant reduction in the volume of distribution of labetalol, from 520 +/- 51 to 445 +/- 24 1 (2P less than 0.05).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),1,445,253785,DB00501,Cimetidine
,6487478,AUC,"The AUC of labetalol after the oral dose increased by 66%, from 51,029 +/- 7,950 to 84,772 +/- 19,444 ng ml-1 min (2P = 0.06).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),[min·ng] / [ml],"51,029",253786,DB00501,Cimetidine
,6487478,AUC,"The AUC of labetalol after the oral dose increased by 66%, from 51,029 +/- 7,950 to 84,772 +/- 19,444 ng ml-1 min (2P = 0.06).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),[min·ng] / [ml],"84,772",253787,DB00501,Cimetidine
,6487478,systemic bioavailability,The systemic bioavailability of labetalol increased from 25.1 +/- 2.4 to 39.0 +/- 7.6% (2P = 0.06).,The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),%,25.1,253788,DB00501,Cimetidine
,6487478,systemic bioavailability,The systemic bioavailability of labetalol increased from 25.1 +/- 2.4 to 39.0 +/- 7.6% (2P = 0.06).,The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),%,39.0,253789,DB00501,Cimetidine
,1618254,peak blood ethanol concentration,The peak blood ethanol concentration of 21.9 to 22.8 mmol.l-1 occurred at 64 to 70 min after the end of drinking.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[mM] / [l],21.9 to 22.8,255086,DB00501,Cimetidine
,1618254,rate of disappearance,The rate of disappearance of ethanol from the blood ranged from 3.0 to 3.3 mmol.l-1.h-1 and the rate of removal from the whole body ranged from 8.0 to 8.5 g.h-1.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[mM] / [h·l],3.0 to 3.3,255087,DB00501,Cimetidine
,1618254,rate of removal,The rate of disappearance of ethanol from the blood ranged from 3.0 to 3.3 mmol.l-1.h-1 and the rate of removal from the whole body ranged from 8.0 to 8.5 g.h-1.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[g] / [h],8.0 to 8.5,255088,DB00501,Cimetidine
,1618254,apparent volume of distribution,"The apparent volume of distribution of ethanol was almost the same for all four treatments: mean 0.68 l.kg-1, corresponding to a mean total body water of 44 l (59% body weight).","Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[l] / [kg],0.68,255089,DB00501,Cimetidine
,1618254,areas under the concentration-time profiles,Mean areas under the concentration-time profiles of ethanol ranged from 83 to 87 mmol.l-1.h for the four treatments.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[h·mM] / [l],83 to 87,255090,DB00501,Cimetidine
,16387482,F-value,The low F-value (approximately 0.136%) of DA-6034 at a dose of 50mg/kg in rats could be due to considerable intestinal first-pass effect (approximately 69% of oral dose) and unabsorbed fraction from the gastrointestinal tract (approximately 30.5%).,"Pharmacokinetics of DA-6034, an agent for inflammatory bowel disease, in rats and dogs: Contribution of intestinal first-pass effect to low bioavailability in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387482/),%,0.136,255561,DB00501,Cimetidine
,3063727,maximum concentration,The maximum concentration of propafenone in plasma was 993 +/- 532 ng/mL when propafenone was given alone compared with 1230 +/- 591 ng/mL when propafenone was given with cimetidine (P = .0622).,Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063727/),[ng] / [ml],993,256130,DB00501,Cimetidine
,3063727,maximum concentration,The maximum concentration of propafenone in plasma was 993 +/- 532 ng/mL when propafenone was given alone compared with 1230 +/- 591 ng/mL when propafenone was given with cimetidine (P = .0622).,Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063727/),[ng] / [ml],1230,256131,DB00501,Cimetidine
,3063727,PR interval,"When compared with cimetidine, propafenone significantly increased the PR interval from 161 +/- 5 msec to 192 +/- 6 msec (P less than .01) and the QRS duration from 89 +/- 3 msec to 98 +/- 4 msec (P less than .01).",Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063727/),ms,161,256132,DB00501,Cimetidine
,3063727,PR interval,"When compared with cimetidine, propafenone significantly increased the PR interval from 161 +/- 5 msec to 192 +/- 6 msec (P less than .01) and the QRS duration from 89 +/- 3 msec to 98 +/- 4 msec (P less than .01).",Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063727/),ms,192,256133,DB00501,Cimetidine
,6713782,Vdss,"Women had larger Vdss (64% +/- 19%), longer t 1/2 (50% +/- 18%), and greater oral lidocaine bioavailability (63% +/- 29%) than did men.",Lidocaine disposition--sex differences and effects of cimetidine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713782/),%,64,258546,DB00501,Cimetidine
,6713782,t 1/2,"Women had larger Vdss (64% +/- 19%), longer t 1/2 (50% +/- 18%), and greater oral lidocaine bioavailability (63% +/- 29%) than did men.",Lidocaine disposition--sex differences and effects of cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713782/),%,50,258547,DB00501,Cimetidine
,6713782,bioavailability,"Women had larger Vdss (64% +/- 19%), longer t 1/2 (50% +/- 18%), and greater oral lidocaine bioavailability (63% +/- 29%) than did men.",Lidocaine disposition--sex differences and effects of cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713782/),%,63,258548,DB00501,Cimetidine
,1282174,bioavailability,"Thus, it easily enters the systemic blood flow, resulting in almost complete bioavailability (75-100%).",Pharmacokinetic profile of nicorandil in humans: an overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),%,75-100,258555,DB00501,Cimetidine
,1282174,Cmax,"On average, the Cmax then is approximately 300 ng/ml, which is achieved rapidly within 30 min after drug intake.",Pharmacokinetic profile of nicorandil in humans: an overview. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),[ng] / [ml],300,258556,DB00501,Cimetidine
,1282174,apparent volume of distribution,"After oral (and i.v.) administration of the drug, the apparent volume of distribution is approximately 1.0 L/kg body weight.",Pharmacokinetic profile of nicorandil in humans: an overview. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),[l] / [body·kg·weight],1.0,258557,DB00501,Cimetidine
,1282174,apparent elimination half-life,"The apparent elimination half-life is short (approximately 1 h), and total body clearance is close to 1.15 L/min, which is lower than the liver blood flow.",Pharmacokinetic profile of nicorandil in humans: an overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),h,1,258558,DB00501,Cimetidine
,1282174,total body clearance,"The apparent elimination half-life is short (approximately 1 h), and total body clearance is close to 1.15 L/min, which is lower than the liver blood flow.",Pharmacokinetic profile of nicorandil in humans: an overview. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),[l] / [min],1.15,258559,DB00501,Cimetidine
,25115365,apparent Km,"The apparent Km and Vmax values of guanfacine uptake by hOCT2 were 96.19 ± 7.49 μM and 13.03 ± 0.49 nmol/mg protein/min, respectively.","Investigation of the role of organic cation transporter 2 (OCT2) in the renal transport of guanfacine, a selective α2A-adrenoreceptor agonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25115365/),μM,96.19,259892,DB00501,Cimetidine
,25115365,Vmax,"The apparent Km and Vmax values of guanfacine uptake by hOCT2 were 96.19 ± 7.49 μM and 13.03 ± 0.49 nmol/mg protein/min, respectively.","Investigation of the role of organic cation transporter 2 (OCT2) in the renal transport of guanfacine, a selective α2A-adrenoreceptor agonist. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25115365/),[nM] / [·mg·min],13.03,259893,DB00501,Cimetidine
,25115365,IC50,Guanfacine transport mediated by hOCT2 was significantly inhibited by a typical OCT2 inhibitor cimetidine with an IC50 value of 93.82 ± 1.13 μM.,"Investigation of the role of organic cation transporter 2 (OCT2) in the renal transport of guanfacine, a selective α2A-adrenoreceptor agonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25115365/),μM,93.82,259894,DB00501,Cimetidine
,3370741,area under the curve,High-dose ranitidine increased the total exposure to doxorubicin (area under the curve of doxorubicin alone = 1.44 +/- 0.88 microM.h/ml vs 4.49 +/- 2.35 microM.hr/ml for doxorubicin given with high-dose ranitidine; P = 0.06).,The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370741/),[h·μM] / [ml],1.44,259895,DB00501,Cimetidine
,3370741,area under the curve,High-dose ranitidine increased the total exposure to doxorubicin (area under the curve of doxorubicin alone = 1.44 +/- 0.88 microM.h/ml vs 4.49 +/- 2.35 microM.hr/ml for doxorubicin given with high-dose ranitidine; P = 0.06).,The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370741/),[h·μM] / [ml],4.49,259896,DB00501,Cimetidine
,3370741,half-life,14C-Aminopyrine half-life was altered by a ranitidine dose of 25 mg/kg (aminopyrine half-life after placebo control = 97 +/- 6 min as against aminopyrine half-life after ranitidine = 121 +/- 7 min; mean +/- SEM; P less than 0.02).,The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370741/),min,97,259897,DB00501,Cimetidine
,3370741,half-life,14C-Aminopyrine half-life was altered by a ranitidine dose of 25 mg/kg (aminopyrine half-life after placebo control = 97 +/- 6 min as against aminopyrine half-life after ranitidine = 121 +/- 7 min; mean +/- SEM; P less than 0.02).,The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370741/),min,121,259898,DB00501,Cimetidine
,2741189,peak plasma concentration,Cimetidine increased the cisapride peak plasma concentration from 58 +/- 25 ng/ml to 84 +/- 19 ng/ml (p = 0.01) and AUC0-24 from 509 +/- 289 ng/ml.h to 738 +/- 148 ng/ml.h (p = 0.02).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),[ng] / [ml],58,260864,DB00501,Cimetidine
,2741189,peak plasma concentration,Cimetidine increased the cisapride peak plasma concentration from 58 +/- 25 ng/ml to 84 +/- 19 ng/ml (p = 0.01) and AUC0-24 from 509 +/- 289 ng/ml.h to 738 +/- 148 ng/ml.h (p = 0.02).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),[ng] / [ml],84,260865,DB00501,Cimetidine
,2741189,AUC0-24,Cimetidine increased the cisapride peak plasma concentration from 58 +/- 25 ng/ml to 84 +/- 19 ng/ml (p = 0.01) and AUC0-24 from 509 +/- 289 ng/ml.h to 738 +/- 148 ng/ml.h (p = 0.02).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),[ng] / [h·ml],509,260866,DB00501,Cimetidine
,2741189,AUC0-24,Cimetidine increased the cisapride peak plasma concentration from 58 +/- 25 ng/ml to 84 +/- 19 ng/ml (p = 0.01) and AUC0-24 from 509 +/- 289 ng/ml.h to 738 +/- 148 ng/ml.h (p = 0.02).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),[ng] / [h·ml],738,260867,DB00501,Cimetidine
,2741189,time to the peak concentration,Cisapride shortened the time to the peak concentration of cimetidine from 1.3 +/- 0.6 h to 0.6 +/- 0.2 h (p = 0.005) and reduced the cimetidine AUC0-24 from 11.0 +/- 2.3 micrograms/ml.h to 9.0 +/- 2.0 micrograms/ml.h (p = 0.05).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),h,1.3,260868,DB00501,Cimetidine
,2741189,time to the peak concentration,Cisapride shortened the time to the peak concentration of cimetidine from 1.3 +/- 0.6 h to 0.6 +/- 0.2 h (p = 0.005) and reduced the cimetidine AUC0-24 from 11.0 +/- 2.3 micrograms/ml.h to 9.0 +/- 2.0 micrograms/ml.h (p = 0.05).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),h,0.6,260869,DB00501,Cimetidine
,2741189,AUC0-24,Cisapride shortened the time to the peak concentration of cimetidine from 1.3 +/- 0.6 h to 0.6 +/- 0.2 h (p = 0.005) and reduced the cimetidine AUC0-24 from 11.0 +/- 2.3 micrograms/ml.h to 9.0 +/- 2.0 micrograms/ml.h (p = 0.05).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),[μg] / [h·ml],11.0,260870,DB00501,Cimetidine
,2741189,AUC0-24,Cisapride shortened the time to the peak concentration of cimetidine from 1.3 +/- 0.6 h to 0.6 +/- 0.2 h (p = 0.005) and reduced the cimetidine AUC0-24 from 11.0 +/- 2.3 micrograms/ml.h to 9.0 +/- 2.0 micrograms/ml.h (p = 0.05).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),[μg] / [h·ml],9.0,260871,DB00501,Cimetidine
,2935051,elimination half-life,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,2.25,261184,DB00501,Cimetidine
,2935051,elimination half-life,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,2.02,261185,DB00501,Cimetidine
,2935051,elimination half-life,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,2.05,261186,DB00501,Cimetidine
,2935051,volume of distribution,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[l] / [kg],2.13,261187,DB00501,Cimetidine
,2935051,volume of distribution,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[l] / [kg],2.14,261188,DB00501,Cimetidine
,2935051,volume of distribution,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[l] / [kg],2.16,261189,DB00501,Cimetidine
,2935051,total clearance,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],10.8,261190,DB00501,Cimetidine
,2935051,total clearance,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],12.2,261191,DB00501,Cimetidine
,2935051,total clearance,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],12.3,261192,DB00501,Cimetidine
,2935051,peak plasma level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ng] / [ml],90,261193,DB00501,Cimetidine
,2935051,peak plasma level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ng] / [ml],95,261194,DB00501,Cimetidine
,2935051,peak plasma level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ng] / [ml],117,261195,DB00501,Cimetidine
,2935051,time of peak level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,0.65,261196,DB00501,Cimetidine
,2935051,time of peak level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,1.45,261197,DB00501,Cimetidine
,2935051,time of peak level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,0.90,261198,DB00501,Cimetidine
,2935051,elimination half-life,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,3.04,261199,DB00501,Cimetidine
,2935051,elimination half-life,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,3.38,261200,DB00501,Cimetidine
,2935051,elimination half-life,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,3.30,261201,DB00501,Cimetidine
,2935051,apparent oral clearance,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],16.2,261202,DB00501,Cimetidine
,2935051,apparent oral clearance,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],14.3,261203,DB00501,Cimetidine
,2935051,apparent oral clearance,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],13.8,261204,DB00501,Cimetidine
,1765572,clearance,"When the entire patient population was dichotomized by age, patients less than 50 years old had a significantly greater mean clearance (48.2 +/- 37.8 liters/min) versus those greater than or equal to 50 (20.0 +/- 12.6 liters/min).","Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1765572/),[l] / [min],48.2,261688,DB00501,Cimetidine
,1765572,clearance,"When the entire patient population was dichotomized by age, patients less than 50 years old had a significantly greater mean clearance (48.2 +/- 37.8 liters/min) versus those greater than or equal to 50 (20.0 +/- 12.6 liters/min).","Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1765572/),[l] / [min],20.0,261689,DB00501,Cimetidine
,1765572,clearance,Men in this cohort exhibited a significantly higher clearance (49.2 +/- 38.7 liters/min) than did the women (22.0 +/- 13.5 liters/min).,"Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1765572/),[l] / [min],49.2,261690,DB00501,Cimetidine
,1765572,clearance,Men in this cohort exhibited a significantly higher clearance (49.2 +/- 38.7 liters/min) than did the women (22.0 +/- 13.5 liters/min).,"Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1765572/),[l] / [min],22.0,261691,DB00501,Cimetidine
,1894763,half-life,Only a minor difference in theophylline half-life between control and continuous cimetidine infusion (7.59 +/- 2.52 vs. 9.05 +/- 3.17 hr; P less than .05) was observed.,Theophylline pharmacokinetics: effect of continuous versus intermittent cimetidine i.v. infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1894763/),h,7.59,262576,DB00501,Cimetidine
,1894763,half-life,Only a minor difference in theophylline half-life between control and continuous cimetidine infusion (7.59 +/- 2.52 vs. 9.05 +/- 3.17 hr; P less than .05) was observed.,Theophylline pharmacokinetics: effect of continuous versus intermittent cimetidine i.v. infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1894763/),h,9.05,262577,DB00501,Cimetidine
,7097510,plasma elimination half-life,Cimetidine was substantially absorbed and rapidly eliminated (plasma elimination half-life of 112-130 min).,High-pressure liquid chromatographic determination of cimetidine in plasma and urine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7097510/),min,112-130,262716,DB00501,Cimetidine
,2775619,total area under the plasma concentration-time curve,"Following alkaline hydrolysis of glucuronide conjugates, the urinary recoveries of ibuprofen and its major metabolites were measured by h.p.l.c. 3. There was no difference (P greater than 0.05, two-tailed Student's t-test; data expressed as mean +/- s.d.) between C and T phases in the total area under the plasma concentration-time curve of R(-)-ibuprofen (C 4514 +/- 1063 mg 1(-1) min vs T 4665 +/- 1435 mg 1(-1) min) and S(+)-ibuprofen (C 6460 +/- 1063 mg 1(-1) min vs T 6886 +/- 1207 mg 1(-1) min).",Lack of effect of cimetidine on the pharmacokinetics of R(-)- and S(+)-ibuprofen. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775619/),mg·min,4514,262798,DB00501,Cimetidine
,2775619,total area under the plasma concentration-time curve,"Following alkaline hydrolysis of glucuronide conjugates, the urinary recoveries of ibuprofen and its major metabolites were measured by h.p.l.c. 3. There was no difference (P greater than 0.05, two-tailed Student's t-test; data expressed as mean +/- s.d.) between C and T phases in the total area under the plasma concentration-time curve of R(-)-ibuprofen (C 4514 +/- 1063 mg 1(-1) min vs T 4665 +/- 1435 mg 1(-1) min) and S(+)-ibuprofen (C 6460 +/- 1063 mg 1(-1) min vs T 6886 +/- 1207 mg 1(-1) min).",Lack of effect of cimetidine on the pharmacokinetics of R(-)- and S(+)-ibuprofen. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775619/),mg·min,4665,262799,DB00501,Cimetidine
,2775619,total area under the plasma concentration-time curve,"Following alkaline hydrolysis of glucuronide conjugates, the urinary recoveries of ibuprofen and its major metabolites were measured by h.p.l.c. 3. There was no difference (P greater than 0.05, two-tailed Student's t-test; data expressed as mean +/- s.d.) between C and T phases in the total area under the plasma concentration-time curve of R(-)-ibuprofen (C 4514 +/- 1063 mg 1(-1) min vs T 4665 +/- 1435 mg 1(-1) min) and S(+)-ibuprofen (C 6460 +/- 1063 mg 1(-1) min vs T 6886 +/- 1207 mg 1(-1) min).",Lack of effect of cimetidine on the pharmacokinetics of R(-)- and S(+)-ibuprofen. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775619/),mg·min,6460,262800,DB00501,Cimetidine
,2775619,total area under the plasma concentration-time curve,"Following alkaline hydrolysis of glucuronide conjugates, the urinary recoveries of ibuprofen and its major metabolites were measured by h.p.l.c. 3. There was no difference (P greater than 0.05, two-tailed Student's t-test; data expressed as mean +/- s.d.) between C and T phases in the total area under the plasma concentration-time curve of R(-)-ibuprofen (C 4514 +/- 1063 mg 1(-1) min vs T 4665 +/- 1435 mg 1(-1) min) and S(+)-ibuprofen (C 6460 +/- 1063 mg 1(-1) min vs T 6886 +/- 1207 mg 1(-1) min).",Lack of effect of cimetidine on the pharmacokinetics of R(-)- and S(+)-ibuprofen. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775619/),mg·min,6886,262801,DB00501,Cimetidine
,4030163,total body clearance,The mean total body clearance in patients with cirrhosis (414.3 +/- 69.7 ml/min) was significantly less than that of subjects without liver dysfunction (501.1 +/- 37.9 ml/min) (p less than 0.01).,Pharmacokinetics of cimetidine in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030163/),[ml] / [min],414.3,263928,DB00501,Cimetidine
,4030163,total body clearance,The mean total body clearance in patients with cirrhosis (414.3 +/- 69.7 ml/min) was significantly less than that of subjects without liver dysfunction (501.1 +/- 37.9 ml/min) (p less than 0.01).,Pharmacokinetics of cimetidine in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030163/),[ml] / [min],501.1,263929,DB00501,Cimetidine
,4030163,steady-state volume of distribution,"However, the mean steady-state volume of distribution (1.34 +/- 0.41 l/kg vs 1.40 +/- 0.24 l/kg), volume of central compartment (0.51 +/- 0.11 l/kg vs. 0.45 +/- 0.05 l/kg), area volume of distribution (1.69 +/- 0.46 l/kg vs. 1.81 +/- 0.43 l/kg) and mean half-life (2.56 +/- 0.58 h vs. 2.68 +/- 0.43 h) did not demonstrate any significant changes.",Pharmacokinetics of cimetidine in patients with liver disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030163/),[l] / [kg],1.34,263930,DB00501,Cimetidine
,4030163,steady-state volume of distribution,"However, the mean steady-state volume of distribution (1.34 +/- 0.41 l/kg vs 1.40 +/- 0.24 l/kg), volume of central compartment (0.51 +/- 0.11 l/kg vs. 0.45 +/- 0.05 l/kg), area volume of distribution (1.69 +/- 0.46 l/kg vs. 1.81 +/- 0.43 l/kg) and mean half-life (2.56 +/- 0.58 h vs. 2.68 +/- 0.43 h) did not demonstrate any significant changes.",Pharmacokinetics of cimetidine in patients with liver disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030163/),[l] / [kg],1.40,263931,DB00501,Cimetidine
,4030163,volume of central compartment,"However, the mean steady-state volume of distribution (1.34 +/- 0.41 l/kg vs 1.40 +/- 0.24 l/kg), volume of central compartment (0.51 +/- 0.11 l/kg vs. 0.45 +/- 0.05 l/kg), area volume of distribution (1.69 +/- 0.46 l/kg vs. 1.81 +/- 0.43 l/kg) and mean half-life (2.56 +/- 0.58 h vs. 2.68 +/- 0.43 h) did not demonstrate any significant changes.",Pharmacokinetics of cimetidine in patients with liver disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030163/),[l] / [kg],0.51,263932,DB00501,Cimetidine
,4030163,volume of central compartment,"However, the mean steady-state volume of distribution (1.34 +/- 0.41 l/kg vs 1.40 +/- 0.24 l/kg), volume of central compartment (0.51 +/- 0.11 l/kg vs. 0.45 +/- 0.05 l/kg), area volume of distribution (1.69 +/- 0.46 l/kg vs. 1.81 +/- 0.43 l/kg) and mean half-life (2.56 +/- 0.58 h vs. 2.68 +/- 0.43 h) did not demonstrate any significant changes.",Pharmacokinetics of cimetidine in patients with liver disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030163/),[l] / [kg],0.45,263933,DB00501,Cimetidine
,4030163,area volume of distribution,"However, the mean steady-state volume of distribution (1.34 +/- 0.41 l/kg vs 1.40 +/- 0.24 l/kg), volume of central compartment (0.51 +/- 0.11 l/kg vs. 0.45 +/- 0.05 l/kg), area volume of distribution (1.69 +/- 0.46 l/kg vs. 1.81 +/- 0.43 l/kg) and mean half-life (2.56 +/- 0.58 h vs. 2.68 +/- 0.43 h) did not demonstrate any significant changes.",Pharmacokinetics of cimetidine in patients with liver disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030163/),[l] / [kg],1.69,263934,DB00501,Cimetidine
,4030163,area volume of distribution,"However, the mean steady-state volume of distribution (1.34 +/- 0.41 l/kg vs 1.40 +/- 0.24 l/kg), volume of central compartment (0.51 +/- 0.11 l/kg vs. 0.45 +/- 0.05 l/kg), area volume of distribution (1.69 +/- 0.46 l/kg vs. 1.81 +/- 0.43 l/kg) and mean half-life (2.56 +/- 0.58 h vs. 2.68 +/- 0.43 h) did not demonstrate any significant changes.",Pharmacokinetics of cimetidine in patients with liver disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030163/),[l] / [kg],1.81,263935,DB00501,Cimetidine
,4030163,half-life,"However, the mean steady-state volume of distribution (1.34 +/- 0.41 l/kg vs 1.40 +/- 0.24 l/kg), volume of central compartment (0.51 +/- 0.11 l/kg vs. 0.45 +/- 0.05 l/kg), area volume of distribution (1.69 +/- 0.46 l/kg vs. 1.81 +/- 0.43 l/kg) and mean half-life (2.56 +/- 0.58 h vs. 2.68 +/- 0.43 h) did not demonstrate any significant changes.",Pharmacokinetics of cimetidine in patients with liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030163/),h,2.56,263936,DB00501,Cimetidine
,4030163,half-life,"However, the mean steady-state volume of distribution (1.34 +/- 0.41 l/kg vs 1.40 +/- 0.24 l/kg), volume of central compartment (0.51 +/- 0.11 l/kg vs. 0.45 +/- 0.05 l/kg), area volume of distribution (1.69 +/- 0.46 l/kg vs. 1.81 +/- 0.43 l/kg) and mean half-life (2.56 +/- 0.58 h vs. 2.68 +/- 0.43 h) did not demonstrate any significant changes.",Pharmacokinetics of cimetidine in patients with liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030163/),h,2.68,263937,DB00501,Cimetidine
,4030163,Renal clearance,Renal clearance was significantly decreased from 389.5 +/- 41.9 ml/min in healthy subjects to 279.1 +/- 57.8 ml/min in cirrhotic patients (p less than 0.01).,Pharmacokinetics of cimetidine in patients with liver disease. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030163/),[ml] / [min],389.5,263938,DB00501,Cimetidine
,4030163,Renal clearance,Renal clearance was significantly decreased from 389.5 +/- 41.9 ml/min in healthy subjects to 279.1 +/- 57.8 ml/min in cirrhotic patients (p less than 0.01).,Pharmacokinetics of cimetidine in patients with liver disease. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030163/),[ml] / [min],279.1,263939,DB00501,Cimetidine
,3451957,plasma concentration,"The plasma concentration of quinidine at steady state, after an intravenous injection (20 mg/kg body weight) followed by a constant rate infusion (0.2 mg/min/kg), increased from 3.02 to 5.11 micrograms/ml after cimetidine treatment.",Effects of cimetidine on quinidine distribution in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3451957/),[μg] / [ml],3.02,264199,DB00501,Cimetidine
,3451957,plasma concentration,"The plasma concentration of quinidine at steady state, after an intravenous injection (20 mg/kg body weight) followed by a constant rate infusion (0.2 mg/min/kg), increased from 3.02 to 5.11 micrograms/ml after cimetidine treatment.",Effects of cimetidine on quinidine distribution in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3451957/),[μg] / [ml],5.11,264200,DB00501,Cimetidine
,2869002,apparent volume of distribution,The drug was widely distributed with an apparent volume of distribution between 140 and 200 l.,"Pharmacokinetics of CM 57755, a new histamine H2-receptor antagonist, after single oral doses in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869002/),l,140 and 200,264365,DB00501,Cimetidine
,2869002,plasma clearance,The plasma clearance was between 56 and 69 L/h.,"Pharmacokinetics of CM 57755, a new histamine H2-receptor antagonist, after single oral doses in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869002/),[l] / [h],56 and 69,264366,DB00501,Cimetidine
,2869002,elimination half-life,The plasma concentrations declined following a monoexponential function with an elimination half-life of 2 h.,"Pharmacokinetics of CM 57755, a new histamine H2-receptor antagonist, after single oral doses in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869002/),h,2,264367,DB00501,Cimetidine
,7059413,plasma elimination half-life (T1/2),The mean plasma elimination half-life (T1/2) of cimetidine was 2.0 h and of cimetidine sulphoxide 1.7 h.,The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059413/),h,2.0,267879,DB00501,Cimetidine
,7059413,plasma elimination half-life (T1/2),The mean plasma elimination half-life (T1/2) of cimetidine was 2.0 h and of cimetidine sulphoxide 1.7 h.,The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059413/),h,1.7,267880,DB00501,Cimetidine
,7059413,plasma T1/2,The mean plasma T1/2 of cimetidine was 3.9 h.,The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059413/),h,3.9,267881,DB00501,Cimetidine
,7059413,non-renal clearance,"The mean non-renal clearance of cimetidine was 210 ml/min and lower than in normal renal function, suggesting decreased metabolism of cimetidine in uraemia.",The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059413/),[ml] / [min],210,267882,DB00501,Cimetidine
,7059413,non-renal clearance,"The mean non-renal clearance of cimetidine was 210 ml/min and lower than in normal renal function, suggesting decreased metabolism of cimetidine in uraemia.",The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059413/),[ml] / [min],210,267883,DB00501,Cimetidine
,7059413,non-renal clearance,"The mean non-renal clearance of cimetidine was 210 ml/min and lower than in normal renal function, suggesting decreased metabolism of cimetidine in uraemia.",The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059413/),[ml] / [min],210,267884,DB00501,Cimetidine
,7059413,plasma T1/2,The mean plasma T1/2 of cimetidine was 3.1 h in mild renal dysfunction (creatinine clearance 50-75 ml/min) and 4.5 h in severe renal failure (creatinine clearance 5-15 ml/min) and of cimetidine sulphoxide 5.3 and 14.4 h respectively.,The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059413/),h,3.1,267885,DB00501,Cimetidine
,7059413,plasma T1/2,The mean plasma T1/2 of cimetidine was 3.1 h in mild renal dysfunction (creatinine clearance 50-75 ml/min) and 4.5 h in severe renal failure (creatinine clearance 5-15 ml/min) and of cimetidine sulphoxide 5.3 and 14.4 h respectively.,The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059413/),h,4.5,267886,DB00501,Cimetidine
,7059413,plasma T1/2,The mean plasma T1/2 of cimetidine was 3.1 h in mild renal dysfunction (creatinine clearance 50-75 ml/min) and 4.5 h in severe renal failure (creatinine clearance 5-15 ml/min) and of cimetidine sulphoxide 5.3 and 14.4 h respectively.,The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059413/),h,5.3,267887,DB00501,Cimetidine
,7059413,plasma T1/2,The mean plasma T1/2 of cimetidine was 3.1 h in mild renal dysfunction (creatinine clearance 50-75 ml/min) and 4.5 h in severe renal failure (creatinine clearance 5-15 ml/min) and of cimetidine sulphoxide 5.3 and 14.4 h respectively.,The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059413/),h,14.4,267888,DB00501,Cimetidine
,8630630,elimination half-life (t1/2),The elimination half-life (t1/2) of meloxicam is approximately 20 h.,A review of the clinical pharmacokinetics of meloxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630630/),h,20,268516,DB00501,Cimetidine
,8630630,total plasma clearance (CL),This is reflected in a total plasma clearance (CL) of 0.42-0.48 1/h.,A review of the clinical pharmacokinetics of meloxicam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630630/),[1] / [h],0.42-0.48,268517,DB00501,Cimetidine
,6317740,Systemic bioavailability,Systemic bioavailability is approximately 70% with cimetidine and 50% with ranitidine.,Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),%,70,269860,DB00501,Cimetidine
,6317740,Systemic bioavailability,Systemic bioavailability is approximately 70% with cimetidine and 50% with ranitidine.,Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),%,50,269861,DB00501,Cimetidine
,6317740,elimination half-lives,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),h,1.7-2.1,269862,DB00501,Cimetidine
,6317740,elimination half-lives,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),h,2.1-3.1,269863,DB00501,Cimetidine
,6317740,apparent volumes of distribution,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),l,50,269864,DB00501,Cimetidine
,6317740,apparent volumes of distribution,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),l,75,269865,DB00501,Cimetidine
,8751032,maximum mean increases,"The increase in plasma renin activity following losartan was not affected by cimetidine (maximum mean increases 12.6 and 12.1 ng Ang I.ml-1.h-1 without and with cimetidine, respectively).","Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751032/),[ang·i·ng] / [h·ml],12.6,270809,DB00501,Cimetidine
,8751032,maximum mean increases,"The increase in plasma renin activity following losartan was not affected by cimetidine (maximum mean increases 12.6 and 12.1 ng Ang I.ml-1.h-1 without and with cimetidine, respectively).","Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751032/),[ang·i·ng] / [h·ml],12.1,270810,DB00501,Cimetidine
,2737801,terminal elimination rate constant,"Cimetidine reduced the terminal elimination rate constant and the total body clearance of theophylline from 0.119 to 0.101 h-1 (p less than 0.05) and from 31.2 to 26.5 ml/min (p less than 0.05), respectively, in comparison with those of placebo.",Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),1/[h],0.119 to 0.101,271508,DB00501,Cimetidine
,2737801,total body clearance,"Cimetidine reduced the terminal elimination rate constant and the total body clearance of theophylline from 0.119 to 0.101 h-1 (p less than 0.05) and from 31.2 to 26.5 ml/min (p less than 0.05), respectively, in comparison with those of placebo.",Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),[ml] / [min],31.2 to 26.5,271509,DB00501,Cimetidine
,2737801,volume of distribution,There was no significant change in the volume of distribution (16.3 l for placebo and 15.5 l for cimetidine) and the renal clearance (4.5 ml/min for placebo and 3.9 ml/min for cimetidine).,Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),l,16.3,271510,DB00501,Cimetidine
,2737801,volume of distribution,There was no significant change in the volume of distribution (16.3 l for placebo and 15.5 l for cimetidine) and the renal clearance (4.5 ml/min for placebo and 3.9 ml/min for cimetidine).,Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),l,15.5,271511,DB00501,Cimetidine
,2737801,renal clearance,There was no significant change in the volume of distribution (16.3 l for placebo and 15.5 l for cimetidine) and the renal clearance (4.5 ml/min for placebo and 3.9 ml/min for cimetidine).,Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),[ml] / [min],4.5,271512,DB00501,Cimetidine
,2737801,renal clearance,There was no significant change in the volume of distribution (16.3 l for placebo and 15.5 l for cimetidine) and the renal clearance (4.5 ml/min for placebo and 3.9 ml/min for cimetidine).,Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737801/),[ml] / [min],3.9,271513,DB00501,Cimetidine
<,7888602,t1/2,The double peak frequency in simulated curves was considerably higher for t1/2 < 30 min.,Variable gastric emptying and discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption on motility phase and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888602/),min,30,271535,DB00501,Cimetidine
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],2.8,273446,DB00501,Cimetidine
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],5.2,273447,DB00501,Cimetidine
,9068926,bioavailability,The bioavailability of oral levofloxacin approaches 100% and is little affected by the administration with food.,The clinical pharmacokinetics of levofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),%,100,273448,DB00501,Cimetidine
,9068926,Cmax,"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],0.6 to 9.4,273449,DB00501,Cimetidine
,9068926,area under the concentration-time curve (AUC),"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[h·mg] / [l],4.7 to 108,273450,DB00501,Cimetidine
,9068926,volume of distribution,"Levofloxacin is widely distributed throughout the body, with a mean volume of distribution of 1.1 L/kg, and penetrates well into most body tissues and fluids.",The clinical pharmacokinetics of levofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[l] / [kg],1.1,273451,DB00501,Cimetidine
,9068926,plasma elimination half-life (t1/2 beta),The plasma elimination half-life (t1/2 beta) ranges from 6 to 8 hours in individuals with normal renal function.,The clinical pharmacokinetics of levofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),h,6 to 8,273452,DB00501,Cimetidine
